Apoptosis inducing agents for treating malignant new growth, and immune and autoimmune diseases

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula

wherein A1 represents N or C (A2); A2 represents H, F, Cl or CN; B1 represents H, OR1, SO2R1, NHR1, NHC(O)R1, F or Cl; D1 and E1 represents H or Cl; Y1 represents H, CN, NO2, F, Cl, Br, CF3, R17, OR17, SO2R17 or C(O)NH2; or Y1 and B1 together with atoms to which they are attached, represent 5- or 6-merous heteroarene having 2-3 nitrogen atoms, wherein heteroarene rings are unsubstituted or substituted by (O); G1 represents H; Z1 represents uncondensed phenylene substituted by OR41; R41 represents 6-merous heteroaryl having 1 N atom, wherein heteroaryl is condensed with R43A, R43A represents 5-merous heteroarene having 1 N atom; Z2 represents monocyclic 6-merous heterocycloalkylene having 1-2 N atoms and 0 double bonds; Z1A and Z2A are both absent; L1 represents -CH2-; Z3 represents R38 or R40; R38 represents uncondensed phenyl; R40 represents cycloalkyl, wherein cycloalkyl represents a monocyclic ring system having 3 to10 C atoms and 0 double bonds, cycloalkenyl, wherein cycloalkenyl represents monocyclic 6-merous ring having 1 heteroatom specified in a group consisting of O and N, and 1 double bond, wherein cycloalkenyl is uncondensed or condensed with R40A; R40A represents cycloalkane, wherein cycloalkane represents a monocyclic ring having 3-10 C atoms and 0 double bonds, or heterocycloalkane, wherein heterocycloalkane represents monocyclic 6-merous ring having 1 N atom and 0 double bonds (the rest substitutes are those as specified in cl. 1 of the patent claim). The invention also refers to compounds of formula

and a pharmaceutical composition containing an effective amount of the compound of formula (I) or (II) or its pharmaceutically acceptable salt.

EFFECT: compounds of formula (I) or (II) inhibiting the activity of anti-apoptotic Bcl-2 proteins.

6 cl, 5 tbl, 378 ex

 

This application claims the priority of provisional application U.S. serial No. 61/181203, filed may 26, 2009, which is incorporated herein by reference in full.

The SCOPE of the INVENTION

This invention relates to compounds that inhibit the activity of anti-apoptotic proteins Bcl-2, to compositions containing the compounds, and to methods of treating diseases during which is expressed anti-apoptotic proteins Bcl-2.

BACKGROUND of the INVENTION

Antiapoptotic proteins Bcl-2 is associated with a number of diseases. Thus, in the field of therapy there is a need for compounds that inhibit the activity of anti-apoptotic proteins Bcl-2.

Overexpression of proteins Bcl-2 correlates with resistance to chemotherapy and clinical outcome, disease progression, General forecast or their combination in various malignant tumors and disorders of the immune system.

The involvement of the protein Bcl-2 in bladder cancer, malignant brain tumor, breast cancer, cancer of the bone marrow, cervical cancer, chronic lymphocytic leukemia, cancer of the colon, rectum, esophagus cancer, liver cell cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or b-cell origin,melanoma, myelogenous leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, cancer of the spleen, etc., described in PCT US 2004/36770, published as WO 2005/049593, and PCT US 2004/37911, published as WO 2005/024636, of the same applicant.

The involvement of the protein Bcl-2 in immune and autoimmune diseases described in Current Allergy and Astma Reports 2003, 3, 378-384; British Journal of Haematology 2000, 110(3), 584-90; Blood 2000, 95(4), 1283-92; and New England Journal of Medicine 2004, 351(14), 1409-1418. The involvement of the protein Bcl-2 in arthritis are described in provisional patent application U.S. the same applicant with the serial number # 60/988479. The involvement of the protein Bcl-2 in the rejection of bone marrow transplant is described in patent application U.S. the same applicant, serial No. 11/941196.

The INVENTION

Thus, one of the embodiments of this invention refers to compounds or therapeutically acceptable salts, are useful as inhibitors of anti-apoptotic proteins Bcl-2, to compounds having formula (I)

where

A1represents N or C(A2);

A2represents H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1 C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A;

B1represents H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3 R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A;

D1represents H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A;

E1represents H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)NH 1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A; and

Y1represents H, CN, NO2C(O)OH, F, Cl, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17C(O)R17C(O)OR17, SR17, SO2R17, NH2, Other17N(R17)2, NHC(O)R17C(O)NH2C(O)other17C(O)N(R17)2NHS(O)R17or NHSO2R17; or

E1and Y1together with the atoms to which they are attached, are benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

A2B1and D1independently selected from H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1 1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A; or

Y1and B1together with the atoms to which they are attached, are benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

A2D1and E1independently selected from H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R )2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A; or

A2and B1together with the atoms to which they are attached, are benzene, naftilan, heteroaryl cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

D1, Ε1and Y1independently selected from H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1(CO)NC(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, , Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A; or

A2and D1together with the atoms to which they are attached, are benzene, naphthalene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

In1E1and Y1independently selected from H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NRSO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A;

G1represents H or C(O)OR;

R represents alkyl;

R1is an R2, R3, R4or R5;

R1Apre is is cycloalkyl, cycloalkenyl or cycloalkenyl;

R2represents phenyl, which is unfused or fused with R2A; R2Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R3is heteroaryl, which is unfused or fused with R3A; R3Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R4is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R4A; R4Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R5represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R6, NC(R6A)(R6B), R7, OR7, SR7, S(O)R7, SO2R7, Other7N(R7)2C(O)R7C(O)NH2C(O)other7C(O)N(R7)2, NHC(O)R7, NR7C(O)R7, NHSO2R7, NHC(O)OR7, SO2NH2, SO2Other7, SO2N(R7)2, NHC(O)NH2, NHC(O)other7, NHC(O)CH(CH3)NHC(O)CH(CH3)NH2, NHC(O)CH(CH 3)NHC(O)CH(CH3)Other7, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;

R6represents a C2-C5-spiralcell, each of which is unsubstituted or substituted by OH, (O), N3CN, CF3, CF2CF3, F, Cl, Br, I, NH2, NH(CH3) or N(CH3)2;

R6Aand R6Bindependently selected from alkyl or together with N to which they are attached, R6C;

R6Cis aziridine-1-yl, azetidin-1-yl, pyrrolidin-1-yl or piperidine-1-yl, each of which has one group CH2, unsubstituted or substituted by O, C(O), CNOH, CNOCH3, S, S(O), SO2or NH;

R7is an R8, R9, R10or R11;

R8represents phenyl, which is unfused or fused with R8A; R8Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R9is heteroaryl, which is unfused or fused with R9A; R9Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or the outdoor the IAOD with R 10A; R10Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R11represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R12, OR12, SR12, S(O)R12, SO2R12C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, Other12N(R12)2, NHC(O)R12, NR12C(O)R12NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)other12, NHC(O)N(R12)2, NR12C(O)other12, NR12C(O)N(R12)2C(O)NH2C(O)other12C(O)N(R12)2C(O)NHOH, C(O)NHOR12C(O)NHSO2R12C(O)NR12SO2R12, SO2NH2, SO2Other12, SO2N(R12)2C(O)H, C(O)OH, C(N)NH2C(N)other12C(N)N(R12)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R12is an R13, R14, R15or R16;

R13represents phenyl, which is unfused or fused with R13A; R13Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R 14is heteroaryl, which is unfused or fused with R14A; R14Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R15is cycloalkane, cycloalkene, geteroseksualen or geteroseksualen, each of which is unfused or fused with R15A; R15Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R16represents alkyl, alkenyl or quinil;

R17is an R18, R19, R20or R21;

R18represents phenyl, which is unfused or fused with R18A; R18Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R19is heteroaryl, which is unfused or fused with R19A; R19Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R20is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R20A; R20Arepresents a benzene,heteroaryl, cycloalkane, cycloalkene, geteroseksualen or geteroseksualen;

R21represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R22, OR22, SR22, S(O)R22, SO2R22C(O)R22, CO(O)R22, OC(O)R22, OC(O)OR22, NH2, Other22N(R22)2, NHC(O)R22, NR22C(O)R22NHS(O)2R22, NR22S(O)2R22, NHC(O)OR22, NR22C(O)OR22, NHC(O)NH2, NHC(O)other22, NHC(O)N(R22)2, NR22C(O)other22, NR22C(O)N(R22)2C(O)NH2C(O)other22C(O)N(R22)2C(O)NHOH, C(O)NHOR22C(O)NHSO2R22C(O)NR22SO2R22, SO2NH2, SO2Other22, SO2N(R22)2C(O)H, C(O)OH, C(N)NH2C(N)other22C(N)N(R22)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R22is an R23, R24or R25;

R23represents phenyl, which is unfused or fused with R23A; R23Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R24represents heteroaryl, which is seconden the new or fused with R 24A; R24Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R25is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R25A; R25Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

Z1is an R26or R27;

Z2is an R28, R29or R30;

Z1Aand Z2Aboth were missing or taken together form CH2CH2CH2or Z12A;

Z12Arepresents a C2-C6-alkylen with one or two groups CH2replaced by NH, N(CH3), S, S(O) or SO2;

L1is an R37, OR37, SR37, S(O)R37, SO2R37C(O)R37, CO(O)R37, OC(O)R37, OC(O)OR37, Other37C(O)NH, C(O)NR37C(O)NHOR37C(O)NHSO2R37, SO2NH, SO2Other37C(N)NH, C(N)other37;

R26represents a phenylene, which is unfused or fused with R26A; R26Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R27is heteroa the flax, which is unfused or fused with R27A; R27Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R28represents a phenylene, which is unfused or fused with R28A; R28Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R29represents heteroaryl, which is unfused or fused with R29A; R29Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R30is cycloalkyl, cycloalkenyl, heterocyclochain or heterocyclization, each of which is unfused or fused with R30A; R30Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R37represents a bond, or R37A;

R37Ais alkylen, albaniles or akinyan, each of which is unsubstituted or substituted one, or two, or three independently selected substituents of R37B, OR37B, SR37B, S(O)R37B, SO2R37BC(O)R37B, CO(O)R37B, OC(O)R37B, OC(O)OR37B, NH2, Other3B N(R37B)2, NHC(O)R37B, NR37BC(O)R37BNHS(O)2R37B, NR37BS(O)2R37B, NHC(O)OR37B, NR37BC(O)OR37B, NHC(O)NH2, NHC(O)other37B, NHC(O)N(R37B)2, NR37BC(O)other37B, NR37BC(O)N(R37B)2C(O)NH2C(O)other37BC(O)N(R37B)2C(O)NHOH, C(O)NHOR37BC(O)NHSO2R37BC(O)NR37BSO2R37B, SO2NH2, SO2Other37B, SO2N(R37B)2C(O)H, C(O)OH, C(N)NH2C(N)other37BC(N)N(R37B)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br and I;

R37Brepresents alkyl, alkenyl, quinil or R37C;

R37Crepresents phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen;

Z3is an R38, R39or R40;

R38represents phenyl, which is unfused or fused with R38A; R38Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R39is heteroaryl, which is unfused or fused with R39A; R39Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R40is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R40A; R40Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

where the group corresponding to R26and R27substituted (i.e., if Ζ1Aand Z2Aare absent) or further substituted (i.e., if Z1Aand Z2Apresent) by R41, OR41, SR41, S(O)R41, SO2R41C(O)R41, CO(O)R41, OC(O)R41, OC(O)OR41, Other41N(R41)2, NHC(O)R41, NR41C(O)R41NHS(O)2R41, NR41S(O)2R41, NHC(O)OR41, NR41C(O)OR41, NHC(O)other41, NHC(O)N(R41)2, NR41C(O)other41, NR41C(O)N(R41)2C(O)other41C(O)N(R41)2C(O)NHOR41C(O)NHSO2R41C(O)NR41SO2R41, SO2Other41, SO2N(R41)2C(N)other41or C(N)N(R41)2;

R41is heteroaryl, which is condensed with R43A; R43Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen, which is unfused or fused with benzene, heteroatom or R43B; R43 is cycloalkane, cycloalkene, geteroseksualen or geteroseksualen;

where the cyclic group corresponding to E1and Y1together, Y1and B1together, A2and B1together, A2and D1together, R1A, R2, R2A, R3, R3A, R4, R4A, R6, R6C, R8, R8A, R9, R9A, R10, R10A, R13, R13A, R14, R14A, R15, R15A, R18, R18A, R19, R19A, R20, R20A, R23, R23A, R24, R24A, R25, R25A, R26, R26A, R27, R27A, R28, R28A, R29, R29A, R30, R30A, R37B, R38, R38A, R39, R39A, R40and R40Ano not substituted, is not further substituted, substituted or optionally substituted with one, or two, or three, or four, or five of independently selected R57A, R57, OR57, SR57, S(O)R57, SO2R57C(O)R57, CO(O)R57, OC(O)R57, OC(O)OR57, NH2, Other57N(R57)2, NHC(O)R57, NR57C(O)R57NHS(O)2R57, NR57S(O)2R57, NHC(O)OR57, NR57C(O)OR57, NHC(O)NH2, NHC(O)other57, NHC(O)N(R57)2, NR57C(O)other57, NR57C(O)N(R57)2C(O)NH2C(O)other57C(ON(R 57)2C(O)NHOH, C(O)NHOR57C(O)NHSO2R57C(O)NR57SO2R57, SO2NH2, SO2Other57, SO2N(R57)2C(O)H, C(O)OH, C(N)NH2C(N)other57C(N)N(R57)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R57Ais spiralcell or spiroheterocyclic;

R57is an R58, R59, R60or R61;

R58represents phenyl, which is unfused or fused with R58A; R58Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R59is heteroaryl, which is unfused or fused with R59A; R59Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R60is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R60A; R60Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R61represents alkyl, alkenyl or quinil, each of which is unsubstituted or replacement of the puppy one, or two, or three of independently selected R62, OR62, SR62, S(O)R62, SO2R62C(O)R62, CO(O)R62, OC(O)R62, OC(O)OR62, NH2, Other62N(R62)2, NHC(O)R62, NR62C(O)R62NHS(O)2R62, NR62S(O)2R62, NHC(O)OR62, NR62C(O)OR62, NHC(O)NH2, NHC(O)other62, NHC(O)N(R62)2, NR62C(O)other62, NR62C(O)N(R62)2C(O)NH2C(O)other62C(O)N(R62)2C(O)NHOH, C(O)NHOR62C(O)NHSO2R62C(O)NR62SO2R62, SO2NH2, SO2Other62, SO2N(R62)2C(O)H, C(O)OH, C(N)NH2C(N)other62C(N)N(R62)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R62is an R63, R64, R65or R66;

R63represents phenyl, which is unfused or fused with R63A; R63Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R64is heteroaryl, which is unfused or fused with R64A; R64Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R65depict is to place cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R65A; R65Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R66represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected substituents R67, OR67, SR67, S(O)R67, SO2R67C(O)R67, CO(O)R67, OC(O)R67, OC(O)OR67, NH2, Other67N(R67)2, NHC(O)R67, NR67C(O)R67NHS(O)2R67, NR67S(O)2R67, NHC(O)OR67, NR67C(O) OR67, NHC(O)NH2, NHC(O)other67, NHC(O)N(R67)2, NR67C(O)other67, NR67C(O)N(R67)2C(O)NH2C(O)other67C(O)N(R67)2C(O)NHOH, C(O)NHOR67, C(O)NHSO2R67With(O)NR67SO2R67, SO2NH2, SO2Other67, SO2N(R67)2C(O)H, C(O)OH, C(N)NH2With(N)other67C(N)N(R67)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R67represents alkyl, alkenyl, quinil, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen;

where cilice is the cue group, the corresponding R57A, R58, R59, R60, R63, R64, R65and R67are unsubstituted or substituted one, or two, or three, or four of independently selected R68, OR68, SR68, S(O)R68, SO2R68C(O)R68, CO(O)R68, OC(O)R68, OC(O)OR68, NH2, Other68N(R68)2, NHC(O)R68, NR68C(O)R68NHS(O)2R68, NR68S(O)2R68, NHC(O)OR68, NR68C(O)OR68, NHC(O)NH2, NHC(O)other68, NHC(O)N(R68)2, NR68C(O)other68, NR68C(O)N (R68)2C(O)NH2C(O)other68C(O)N(R68)2C(O)NHOH, C(O)NHOR68, C(O)NHSO2R68With(O)NR68SO2R68, SO2NH2, SO2Other68, SO2N(R68)2C(O)H, C(O)OH, C(N)NH2With(N)other68C(N)N(R68)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R68is an R69, R70, R71or R72;

R69represents phenyl, which is unfused or fused with R69A; R69Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R70is heteroaryl, which is unfused or con is antiroman with R 70A; R70Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R71is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R71A; R71Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R72represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R73, OR73, SR73, S(O)R73, SO2R73C(O)R73, CO(O)R73, OC(O)R73, OC(O)OR73, NH2, Other73N(R73)2, NHC(O)R73, NR73C(O)R73, NHSO2R73, NR73S(O)2R73, NHC(O)OR73, NR73C(O)OR73, NHC(O)NH2, NHC(O)other73, NHC(O)N(R73)2, NR73C(O)other73, NR73C(O)N(R73)2C(O)NH2C(O)other73C(O)N(R73)2C(O)NHOH, C(O)NHOR73, C(O)NHSO2R73With(O)NR73SO2R73, SO2NH2, SO2Other73, SO2N(R73)2C(O)H, C(O)OH, C(N)NH2With(N)other73C(N)N(R73)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R73 represents alkyl, alkenyl, quinil, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen; and

where the group corresponding to R69, R70and R71are unsubstituted or substituted one, or two, or three, or four of independently selected NH2C(O)NH2C(O)NHOH, SO2NH2, CF3, CF2CF3C(O)H, C(O)OH, C(N)NH2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I.

Another variant implementation of the invention pertains to compounds or therapeutically acceptable salts, are useful as inhibitors of anti-apoptotic proteins Bcl-2, having the formula (II)

where

R100is as described for substituents on R26;

n is 0, 1, 2 or 3;

A1represents N or C(A2);

A2represents H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R 1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A;

B1represents H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A;

D1represents H, R1OR 1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A;

E1represents H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1) 2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A; and

Y1represents H, CN, NO2C(O)OH, F, Cl, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17C(O)R17C(O)OR17, SR17, SO2R17, NH2, Other17N(R17)2, NHC(O)R17C(O)NH2C(O)other17C(O)N(R17)2NHS(O)R17or NHSO2R17; or

E1and Y1together with the atoms to which they are attached, are benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

A2B1and D1independently selected from H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R 1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A; or

Y1and B1together with the atoms to which they are attached, are benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

A2D1and E1independently selected from H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1 , NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A; or

A2and B1together with the atoms to which they are attached, are benzene, naftilan, heteroaryl cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

D1, Ε1and Y1independently selected from H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)NC(R1)2, SO2NH2, SO2Other1, SO2N(R1)2NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A; or

A2and D1together with the atoms to which they are attached, represent the Wallpaper benzene, naphthalene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

In1E1and Y1independently selected from H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A;

R1is an R2, R3, R4or R5;

R1Ais cycloalkyl, cycloalkenyl or cycloalkenyl;

R2represents phenyl, which is unfused or fused with R2A; R2Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen and the and geteroseksualen;

R3is heteroaryl, which is unfused or fused with R3A; R3Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R4is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R4A; R4Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R5represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R6, NC(R6A)(R6B), R7, OR7, SR7, S(O)R7, SO2R7, Other7N(R7)2C(O)R7C(O)NH2C(O)other7C(O)N(R7)2, NHC(O)R7, NR7C(O)R7, NHSO2R7, NHC(O)OR7, SO2NH2, SO2Other7, SO2N(R7)2, NHC(O)NH2, NHC(O)other7, NHC(O)CH(CH3)NHC(O)CH(CH3)NH2, NHC(O)CH(CH3)NHC(O)CH(CH3)Other7, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;

R6represents a C2-C5-spiralcell, each of which is unsubstituted or substituted by OH, (O), N3CN, CF3, CF2 3, F, Cl, Br, I, NH2, NH(CH3) or N(CH3)2;

R6Aand R6Bindependently selected from alkyl or together with N to which they are attached, R6C;

R6Cis aziridine-1-yl, azetidin-1-yl, pyrrolidin-1-yl or piperidine-1-yl, each of which has one group CH2, unsubstituted or substituted by O, C(O), CNOH, CNOCH3, S, S(O), SO2or NH;

R7is an R8, R9, R10or R11;

R8represents phenyl, which is unfused or fused with R8A; R8Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R9is heteroaryl, which is unfused or fused with R9A; R9Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R10A; R10Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R11represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, the sludge is two, or three of independently selected R12, OR12, SR12, S(O)R12, SO2R12C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, Other12N(R12)2, NHC(O)R12, NR12C(O)R12NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)other12, NHC(O)N(R12)2, NR12C(O)other12, NR12C(O)N(R12)2C(O)NH2C(O)other12C(O)N(R12)2C(O)NHOH, C(O)NHOR12C(O)NHSO2R12C(O)NR12SO2R12, SO2NH2, SO2Other12, SO2N(R12)2C(O)H, C(O)OH, C(N)NH2C(N)other12C(N)N(R12)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R12is an R13, R14, R15or R16;

R13represents phenyl, which is unfused or fused with R13A; R13Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R14is heteroaryl, which is unfused or fused with R14A; R14Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R15is what my cycloalkane, cycloalken, geteroseksualen or geteroseksualen, each of which is unfused or fused with R15A; R15Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R16represents alkyl, alkenyl or quinil;

R17is an R18, R19, R20or R21;

R18represents phenyl, which is unfused or fused with R18A; R18Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R19is heteroaryl, which is unfused or fused with R19A; R19Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R20is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R20A; R20Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R21represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R22, OR22, SR 22, S(O)R22, SO2R22C(O)R22, CO(O)R22, OC(O)R22, OC(O)OR22, NH2, Other22N(R22)2, NHC(O)R22, NR22C(O)R22NHS(O)2R22, NR22S(O)2R22, NHC(O)OR22, NR22C(O)OR22, NHC(O)NH2, NHC(O)other22, NHC(O)N(R22)2, NR22C(O)other22, NR22C(O)N(R22)2C(O)NH2C(O)other22C(O)N(R22)2C(O)NHOH, C(O)NHOR22C(O)NHSO2R22C(O)NR22SO2R22, SO2NH2, SO2Other22, SO2N(R22)2C(O)H, C(O)OH, C(N)NH2C(N)other22C(N)N(R22)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R22is an R23, R24or R25;

R23represents phenyl, which is unfused or fused with R23A; R23Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R24represents heteroaryl, which is unfused or fused with R24A; R24Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R25is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen is l, each of which is unfused or fused with R25A; R25Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

Z2is an R28, R29or R30;

L1is an R37, OR37, SR37, S(O)R37, SO2R37C(O)R37, CO(O)R37, OC(O)R37, OC(O)OR37, Other37C(O)NH, C(O)NR37C(O)NHOR37C(O)NHSO2R37, SO2NH, SO2Other37C(N)NH, C(N)other37;

R28represents a phenylene, which is unfused or fused with R28A; R28Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R29represents heteroaryl, which is unfused or fused with R29A; R29Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R30is cycloalkyl, cycloalkenyl, heterocyclochain or heterocyclization, each of which is unfused or fused with R30A; R30Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R37that is the link Il is R 37A;

R37Ais alkylen, albaniles or akinyan, each of which is unsubstituted or substituted one, or two, or three independently selected substituents of R37B, OR37B, SR37B, S(O)R37B, SO2R37BC(O)R37B, CO(O)R37B, OC(O)R37B, OC(O)OR37B, NH2, Other37BN(R37B)2, NHC(O)R37B, NR37BC(O)R37BNHS(O)2R37B, NR37BS(O)2R37B, NHC(O)OR37B, NR37BC(O)OR37B, NHC(O)NH2, NHC(O)other37B, NHC(O)N(R37B)2, NR37BC(O)other37B, NR37BC(O)N(R37B)2C(O)NH2C(O)other37BC(O)N(R37B)2C(O)NHOH, C(O)NHOR37BC(O)NHSO2R37BC(O)NR37BSO2R37B, SO2NH2, SO2Other37B, SO2N(R37B)2C(O)H, C(O)OH, C(N)NH2C(N)other37BC(N)N(R37B)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br and I;

R37Brepresents alkyl, alkenyl, quinil or R37C;

R37Crepresents phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen;

Z3is an R38, R39or R40;

R38represents phenyl, which is unfused or fused with R38A; R38Ap is ecstasy a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R39is heteroaryl, which is unfused or fused with R39A; R39Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R40is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R40A; R40Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

where the cyclic group corresponding to E1and Y1together, Y1and B1together, A2and B1together, A2and D1together, R1A, R2, R2A, R3, R3A, R4, R4A, R6, R6C, R8, R8A, R9, R9A, R10, R10A, R13, R13A, R14, R14A, R15, R15A, R18, R18A, R19, R19A, R20, R20A, R23, R23A, R24, R24A, R25, R25A, R26, R26A, R27, R27A, R28, R28A, R29, R29A, R30, R30A, R37B, R38, R38A, R39, R39A, R40and R40Ano not substituted, is not further substituted, and substituted and optionally substituted with one, or two, or three, or four, or five of independently selected R57A, R57, OR57, SR57, S(O)R57, SO2R57C(O)R57, CO(O)R57, OC(O)R57, OC(O)OR57, NH2, Other57N(R57)2, NHC(O)R57, NR57C(O)R57NHS(O)2R57, NR57S(O)2R57, NHC(O)OR57, NR57C(O)OR57, NHC(O)NH2, NHC(O)other57, NHC(O)N(R57)2, NR57C(O)other57, NR57C(O)N(R57)2C(O)NH2C(O)other57C(O)N(R57)2C(O)NHOH, C(O)NHOR57C(O)NHSO2R57C(O)NR57SO2R57, SO2NH2, SO2Other57, SO2N(R57)2C(O)H, C(O)OH, C(N)NH2C(N)other57C(N)N(R57)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R57Ais spiralcell or spiroheterocyclic;

R57is an R58, R59, R60or R61;

R58represents phenyl, which is unfused or fused with R58A; R58Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R59is heteroaryl, which is unfused or fused with R59A; R59Ais a b is Sol, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R60is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R60A; R60Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R61represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R62, OR62, SR62, S(O)R62, SO2R62C(O)R62, CO(O)R62, OC(O)R62, OC(O)OR62, NH2, Other62N(R62)2, NHC(O)R62, NR62C(O)R62NHS(O)2R62, NR62S(O)2R62, NHC(O)OR62, NR62C(O)OR62, NHC(O)NH2, NHC(O)other62, NHC(O)N(R62)2, NR62C(O)other62, NR62C(O)N(R62)2C(O)NH2C(O)other62C(O)N(R62)2C(O)NHOH, C(O)NHOR62, C(O)NHSO2R62With(O)NR62SO2R62, SO2NH2, SO2Other62, SO2N(R62)2C(O)H, C(O)OH, C(N)NH2With(N)other62C(N)N(R62)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R62is an R63, R64,R 65or R66;

R63represents phenyl, which is unfused or fused with R63A; R63Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R64is heteroaryl, which is unfused or fused with R64A; R64Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R65is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R65A; R65Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R66represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected substituents R67, OR67, SR67, S(O)R67, SO2R67C(O)R67, CO(O)R67, OC(O)R67, OC(O)OR67, NH2, Other67N(R67)2, NHC(O)R67, NR67C(O)R67NHS(O)2R67, NR67S(O)2R67, NHC(O)OR67, NR67C(O)OR67, NHC(O)NH2, NHC(O)other67, NHC(O)N(R67)2, NR67C(O)other67, NR67C(O)N(R67)2 C(O)NH2C(O)other67C(O)N(R67)2C(O)NHOH, C(O)NHOR67C(O)NHSO2R67C(O)NR67SO2R67, SO2NH2, SO2Other67, SO2N(R67)2C(O)H, C(O)OH, C(N)NH2C(N)other67C(N)N(R67)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R67represents alkyl, alkenyl, quinil, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen;

where the cyclic group corresponding to R57A, R58, R59, R60, R63, R64, R65and R67are unsubstituted or substituted one, or two, or three, or four of independently selected R68, OR68, SR68, S(O)R68, SO2R68C(O)R68, CO(O)R68, OC(O)R68, OC(O)OR68, NH2, Other68N(R68)2, NHC(O)R68, NR68C(O)R68NHS(O)2R68, NR68S(O)2R68, NHC(O)OR68, NR68C(O)OR68, NHC(O)NH2, NHC(O)other68, NHC(O)N(R68)2, NR68C(O)other68, NR68C(O)N(R68)2C(O)NH2C(O)other68C(O)N(R68)2C(O)NHOH, C(O)NHOR68C(O)NHSO2R68C(O)NR68SO2R68, SO2NH2, SO2Other68, SO2N(R68)2C(O)H, C(O)OH, C(N)NH2C(N)other68C(N)N(R 68)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R68is an R69, R70, R71or R72;

R69represents phenyl, which is unfused or fused with R69A; R69Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R70is heteroaryl, which is unfused or fused with R70A; R70Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or heterocyclic;

R71is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R71A; R71Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R72represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R73, OR73, SR73, S(O)R73, SO2R73C(O)R73, CO(O)R73, OC(O)R73, OS(O)OR73, NH2, Other73N(R73)2, NHC(O)R73, NR73C(O)R73NHS(O)2R73 , NR73S(O)2R73, NHC(O)OR73, NR73C(O)OR73, NHC(O)NH2, NHC(O)other73, NHC(O)N(R73)2, NR73C(O)other73, NR73C(O)N(R73)2C(O)NH2C(O)other73C(O)N(R73)2C(O)NHOH, C(O)NHOR73, C(O)NHSO2R73With(O)NR73SO2R73, SO2NH2, SO2Other73, SO2N(R73)2C(O)H, C(O)OH, C(N)NH2With(N)other73C(N)N(R73)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R73represents alkyl, alkenyl, quinil, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen; and

where the group corresponding to R69, R70and R71are unsubstituted or substituted one, or two, or three, or four of independently selected NH2C(O)NH2C(O)NHOH, SO2NH2, CF3, CF2CF3C(O)H, C(O)OH, C(N)NH2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I.

Another variant of implementation relates to compounds of formula (I), where a1represents N or C (A2); And2represents H, and G1represents H.

Another variant of implementation relates to compounds of formula (I), where A1represents N or C(A 2); A2represents H; G1represents H and B1represents other1.

Another variant of implementation relates to compounds of formula (I), where A1represents N or C(A2); A2represents H; G1represents Η, B1represents other1; and D1represents H.

Another variant of implementation relates to compounds of formula (I), where A1represents N or C(A2); A2represents H; G1represents Η, B1represents other1; D1represents H; and E1represents H.

Another variant of implementation relates to compounds of formula (I), where A1represents N or C(A2); A2represents H; G1represents Η, B1represents other1; D1represents Η; E1represents H; and Y1represents NO2.

Another variant of implementation relates to compounds of formula (I) or formula (II), which are

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({4-[(3-morpholine-4-ylpropyl)amino]-3-nitrofen the l}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitro the Nile]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-(2-naphthylmethyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(2,2,2-triptorelin)amino]phenyl}Sul is of IMT-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3,3,3-cryptochromes)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2S)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2R)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitro the Nile)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[3-(aminocarbonyl)-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperaz the n-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-{[4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-(trifluoromethyl)phenyl]sulfonyl}benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;

TRANS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(1-methylpiperidin-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

5-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-(tetrahydro-2H-Piran-4-ylethoxy)nicotinamide;

N-({5-bromo-6-[(1-methylpiperidin-4-yl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-methylpiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(1,4-dioxane-2-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-bromo-6-(1,4-dioxane-2-illcox is)pyridine-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2,2-dimethylether-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-5-cyano-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-acetylpiperidine-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({2-chloro-5-fluoro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-morpholine-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(2-morpholine-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dim testicles-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)oxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-bromo-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-cyanoethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-{[4-({4-[bis(cyclopropylmethyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-methylpiperidin-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-the l)-N-({4-[(morpholine-3-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-albut-2-inyl)oxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-ethinyl-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-oxo-3,4-dihydroquinazolin-6-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)with Lionel]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl-3-{[4-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-nitrophenoxy]methyl}morpholine-4-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(morpholine-3-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(methylsulphonyl)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,1-dissidocerida-2H-thiopyran-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-chloro-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl} is piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[1-(2,2,2-triptorelin)piperidine-4-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)oxy]pyridin-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-isopropyl-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-5-fluoro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

and their therapeutically acceptable salts, and metabolites.

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(2,2-dottorati)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-ylox is)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropylidene-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-morpholine-4-illlogical)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(dicyclopropyl)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-6,6-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-bromo-6-[(4-ethylmorpholine-3-yl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-ethylmorpholine-3-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(4-tetrahydro-2H-Piran-4-Immortalis-3-yl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-n the tro-4-{[(3S)-1-tetrahydro-2H-Piran-4-reparacin-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(tetrahydro-2H-Piran-4-ylmethyl)amino]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,1-diocletianopolis-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(4-aminotetraline-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(4-morpholine-4-illlogical)amino]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-cyano-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1S,3R)-3-morpholine-4-enciclopedie]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,3S)-3-morpholine-4-enciclopedie]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperaz the n-1-yl)-N-({4-[(morpholine-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydrofuran-3-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[CIS-3-Porterage-2H-Piran-4-yl]piperidine-4-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydro-2H-Piran-4-ilisation-3-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydrofuran-3-ilisation-3-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-tetrahydro-2H-Piran-4-iparralde-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)-N-(4-((TRANS-4-hydroxycyclohexyl)methoxy)-3-nitrophenylarsonic)benzamide;

2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-(-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)-N-(4-((CIS-4-methoxycyclohexyl)methoxy)-3-nitrophenylarsonic)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(cyclopropylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(tetrahydro-2H-Piran-4-ylamino)cyclohexyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-({5-bromo-6-[(4-morpholine-4-illlogical)oxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl-4-{[4-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-nitrophenoxy]methyl}-4-foreperiod-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-foreperiod-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(4-tetrahydro-2H-Piran-4-reparation-1-yl)cyclohexyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-�lorgeril)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}methoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-1-tetrahydro-2H-Piran-4-iparralde-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2,2-dimethylether-2H-Piran-4-yl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-tetrahydro-2H-Piran-4-iparralde-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2,2-dimethylether-2H-Piran-4-yl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2-methoxyethyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(4-acetylmorpholine-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-PI is henyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[TRANS-4-(permitil)-1-oxetan-3-iparralde-3-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-Porterage-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-oxetan-3-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclobutylmethyl-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(2,2-dimethylether-2H-Piran-4-yl)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-cyclopropylboronic-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydrofuran-3-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-cyclopropylboronic-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methylpiperazin-1-yl)-N-{[3-nitro-4-({[(3S)-1-tetrahydro-2H-Piran-4-iparralde-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-hydroxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(methylsulphonyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(1-acetylpiperidine-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(methylsulphonyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-3,3-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]azetidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(methylsulphonyl)pyrrolidin-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(1-acetylpyrrolidine-3-yl)methyl]amino}-3-nitrofen the l)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(3R)-1-acetylpyrrolidine-3-yl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-methoxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1R,3R)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1S,3S)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1S,3R)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1R,3S)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-2-oxopiperidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({1-[2-FPO is-1-(permitil)ethyl]azetidin-3-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(1-oxetan-3-ilisation-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(1-oxetan-3-reparacin-4-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-cyclopropylidene-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2-foradil)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2,2-dottorati)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-oxetan-3-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(2S)-4,4-debtor-1-oxetan-3-iparralde-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(4-tetrahydro-2H-Piran-4-Immortalis-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclobutylmethyl-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(4-tetrahydrofuran-3-Immortalis-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropyl-4-foreperiod-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[3-(triptoreline)benzyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-methoxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(the WPPT is ormaetxe)benzyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxaspiro[4.5]Dec-8-ylamino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-[(4-{[4-(acetylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2,2-dottorati)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2-foradil)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2,2-dottorati)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2-foradil)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-oxetan-3-iparralde-3-yl]methoxy}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-(4-hydroxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-hydroxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[3-(deformedarse)benzyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[CIS-3-morpholine-4-enciclopedie]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(methylsulphonyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropylidene-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-oxetan-3-reparacin-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-tetrahydro-2H-Piran-4-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-and the]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-tetrahydrofuran-3-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-fluoro-1-(methylsulphonyl)piperidine-4-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-oxetan-3-iparralde-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-hydroxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[3-(dimethylamino)propoxy]benzyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(2-morpholine-4-ylethoxy)benzyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(E)-4-hydroxy-1-substituted]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(Z)-4-hydroxy-1-substituted]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1S,4S)-bicyclo[2.2.1]hept-5-ene-2-ylethoxy]-3-nitrophenyl} is sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-methyl-5-oxopyrrolidin-3-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,4R,5R,6S)-5,6-dihydroxybutyl[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,4R,5S,6R)-5,6-dihydroxybutyl[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3-oxocyclohexyl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohexane-1,3-Dien-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({(3R)-1-[2-fluoro-1-(permitil)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[6-[(4-Porterage-2H-Piran-4-yl)methoxy]-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethyl logex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3S)-1-oxetan-3-iparralde-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-oxetan-3-iparralde-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({4-[2-(2-methoxyethoxy)ethyl]morpholine-2-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(cyanomethyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

(2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}morpholine-4-yl)acetic acid;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex the-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-(methylsulphonyl)-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methyltetrahydro-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

ethyl-4-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)piperazine-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[4-(morpholine-4-yl)piperidine-1-yl]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-1-(oxetan-3-yl)pyrrolidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}PI is erasin-1-yl)-N-[(4-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamid;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-isopropylpiperazine-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-tert-butylpiperazine-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(2-methoxyethyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(cyanomethyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-methylpiperidin-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]amino}pyridine-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl-4-[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]piperazine-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-EN-1-yl]methyl}piperazine-1-yl)-N-({3-(pendaftar-λ 6-sulfanyl)-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1Η-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxytyramine-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]oxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(oxetan-3-yl)piperazine-1-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(tetrahydro-2H-Piran-4-yl)piperazine-1-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3R)-tetrahydrofuran-3-ylamino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4,4-diverticulosis)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-tert-butylpiperazine-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl} is piperazin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-({[4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(4-Porterage-2H-Piran-4-yl)methyl]amino}pyridine-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(1-cyclopropylidene-4-yl)amino]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-(cyanomethyl)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-(N,N-dimethylglycine)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2R)-4-(cyanomethyl)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2R)-4-(N,N-dimethylglycine)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-fluoro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[3-hydroxy-2-(hydroxymethyl)-2-methylpropoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(1,3-ditropan-2-yl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(cyanomethyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({(3R)-1-[2-(2-methoxyethoxy)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(N,N-dimethylglycine)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[1-(oxetan-3-yl)azetidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(cyanomethyl)-4-tochip ridin-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2R)-4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2S)-4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(N,N-dimethylphenyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(2,2-dottorati)pyrrolidin-3-yl]oxy}pyridine-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(cyanomethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-methoxypiperidine-1-yl}-N-({5-chloro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-methoxypiperidine-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-(1,3-ditropan-2-yl)-3-azaspiro[5.5]undec-8-the h-8-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamid;

4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-(1,3-ditropan-2-yl)-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4-fluoro-1-methylpiperidin-4-yl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(N,N-dimethylphenyl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-foreperiod-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-foreperiod-1-yl}-N-({5-chloro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8 is-8-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-(trifluoromethyl)phenyl}sulfonyl)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]oxy}pyridine-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[2-(tetrahydrofuran-3-yloxy)ethoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-cyanocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[2-(tetrahydro-2H-Piran-4-yl)ethoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(3-FuelMAX)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(2,2-dottorati)pyrrolidin-3-yl]methoxy}Piri is INF-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(1,3-ditropan-2-yl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-fluoro-1-methylpiperidin-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-cyano-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(2,2-dottorati)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4,4-diverticulosis)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[6-{[1-(1,3-ditropan-2-yl)-4-foreperiod-4-yl]methoxy}-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dime cyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-chloro-6-[2-(tetrahydrofuran-2-yl)ethoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}-3-methylpiperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[3-(cyclopropylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-chloro-6-(2-methoxyethoxy)pyridine-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-fluoro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(methoxyacetyl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(N,N-dimethylphenyl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohexyl]methyl}piperidine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]Piri is in-5-yloxy)-N-{[6-(tetrahydro-2H-Piran-4-ylethoxy)-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxycyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-cyano-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(TRANS-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(CIS-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4,4-debtor-1-hydroxycyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperidine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[TRANS-4-(morpholine-4-yl)cyclohexyl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(1,3-thiazol-5-ylmethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(tra the p-4 hydroxycyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-chloro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-(trifluoromethyl)phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(2,2,2-triptorelin)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3,5-debtor-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(1-methyl-L-prolyl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-yl]methyl}piperazine-1-yl)-N-({3,4-debtor-5-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-cyclopropylmethyl-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperidine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperidine-1-yl)-N-{[3-chloro-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

methyl-2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}morpholine-4-carboxylate;

2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(methylsulphonyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclobutyl(cyclopropyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-diverticulosis-1-EN-1-yl] ethyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-chloro-4-(tetrahydrofuran-3-ylethoxy)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-diverticulosis-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[9-(4-chlorophenyl)-3-(oxetan-3-yl)-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2R)-4-cyclopropylmethyl-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2S)-4-cyclopropylmethyl-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-chloro-6-({4-[cyclopropyl(oxetan-3-yl)amino]cyclohexyl}methoxypyridine-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-cyclopropylmethyl-2-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

2-{[(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

(2S)-2-{[(3-chloro-5-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}pyridine-2-yl)oxy]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

N-[(5-chloro-6-{[(4-cyclopropylmethyl-2-yl)methyl]amino}pyridine-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

2-{[(3-chloro-5-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}pyridine-2-yl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethyl who ekloges-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(1R,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2-cyanoethyl)(cyclopropyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(1R,2S,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(CIS-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-use the si)benzamide;

N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(3,3-debtorprovidian-1-yl)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2,2-diversicolor)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-1-fluoro-4-hydroxycyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-(2-oxaspiro[3.5]non-7-ylethoxy)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethyl who ekloges-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-bis(permitil)cyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-cyclopropylmethyl-2-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-1-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-1-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-cyano-4-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorine is enyl)-5-(methoxymethyl)-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(2S)-4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2-cyanoethyl)(cyclopropyl)amino]-1-forcelogix}methoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-nitro-6-[(tetrahydro-2H-Piran-4-ylmethyl)amino]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(2-oxaspiro[3.5]non-7-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyano-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)amino}Metreveli;

{[4-(4-{[2-(4-chlorphen is)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)amino}methylbutyrate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-{[3-(tetrahydro-2H-Piran-4-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridine-6-yl]sulfonyl}benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(6-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridine-3-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(5-cyano-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)morpholine-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(5-chloro-6-{[1-(1,3-the thiazole-2-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(6-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridine-3-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5-methodology the C-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide; and therapeutically acceptable salts, and metabolites.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection of the TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection Cys-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection of the TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically pickup the integral of salt.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation refers to the compound N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation refers to the compound N-({5-bromo-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}the Pipera the Jn-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(methylsulphonyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation relates to compounds of formula (I) or formula (II), which are 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(methylsulphonyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(chlorphenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or their pharmaceutically acceptable salt.

Another variant of implementation relates to compounds of formula (I) or formula (II), which are N-[(5-chloro-6-{[1-(cyanomethyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or their pharmaceutically acceptable salt.

Another variant of implementation relates to compounds of formula (I) or formula (II), which are 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or their pharmaceutically acceptable salt.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

D. the natives an implementation option relates to compounds of formula (I) or formula (II), which are 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-tetrahydro-2H-Piran-4-iparralde-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or their pharmaceutically acceptable salt.

Another variant of implementation relates to compounds of formula (I) or formula (II), which are 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-bromo-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(4-aminotetraline-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl-N-{[3-nitro-4-({[(3R)-1-tetrahydro-2H-Piran-4-iparralde-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(methylsulphonyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxytyramine-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(cyanomethyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(1R,2S,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(6-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridine-3-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or their pharmaceutically acceptable salt.

Another variant of implementation refers to the compound N-[(5-chloro-6-{[1-(cyanomethyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation relates to compounds of formula (I) or formula (II), which are N-[(4-{[(4-aminotetraline-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxytyramine-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or their pharmaceutically acceptable salt.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxytyramine-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation relates to compositions for the treatment of bladder cancer, malignant brain tumors, breast cancer, malignant tumor of the bone marrow, cervical cancer, chronic lymphocytic leukemia, cancer of the colon and rectum, esophageal cancer, liver cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or b-cell origin, melanoma, myelogenous leukemia, myeloma, malignant tumors of the oral cavity, cancer of the ovary, lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small-cell lung cancer or cancer of the spleen, and this composition contains excipient and a therapeutically effective amount of the compounds of formula (I) or formula (II).

Another variant of implementation relates to a method for treating bladder cancer, malignant brain tumors, breast cancer, malignant tumor of the bone marrow, cervical cancer, chronic lymphocytic leukemia, cancer of the colon and rectum, esophagus cancer, liver cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or b-cell origin, melanoma, myelogenous leukemia, myeloma, malignant tumors of the oral cavity, cancer of the ovary, lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small-cell lung cancer or cancer of the spleen in a patient, and this method includes the introduction of the patient is therapeutically effective amount of the compounds of formula (I) or formula (II).

Another variant of implementation relates to a method for treating bladder cancer, malignant brain tumors, breast cancer, malignant tumor of the bone marrow, cervical cancer, chronic lymphocytic leukemia, cancer of the colon and rectum, esophagus cancer, liver cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or b-cell origin, melanoma, myelogenous leukemia, myeloma, malignant tumors of the oral cavity, cancer of the ovary, lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, small-cell lung cancer or cancer of the spleen in a patient, and this method includes the introduction to the patient a therapeutically effective amount of the compounds of formula (I) or formula (II) and a therapeutically effective amount of one additional drug or more than one additional drug.

DETAILED description of the INVENTION

Different groups in this document are presented using the identifiers (capital letters, numeric and/or alphabetic Superscript characters) and they can be specifically implemented.

Imply that it is clear that the proper valence saved for all groups and the combinations what a monovalent group, having more than one atom are depicted from left to right and join through their left ends, and that divalent group also depicted from left to right.

Also assume that it is clear that the particular implementation of the group variable in the present document can be the same or different relative to another particular variant of the implementation that has the same ID.

The term "alkenyl", as used herein, means a straight or branched hydrocarbon chain containing from 2 to 10 carbon atoms and containing at least one carbon-carbon double bond. The term "Cx-Cyalkenyl" means a straight or branched hydrocarbon chain containing at least one carbon-carbon double bond containing from x to y carbon atoms. The term "C3-C6alkenyl" means alkenylphenol group containing 3 to b carbon atoms. Typical examples of alkenyl include, but are not limited to, buta-2,3-dienyl, ethynyl, 2-propenyl, 2-methyl-2-propenyl, 3-butenyl, 4-pentenyl, 5-hexenyl, 2-heptenyl, 2-methyl-1-Heptene and 3-decenyl.

The term "albaniles" means a divalent group formed from a straight or branched hydrocarbon of 2-4 carbon atoms, and contains at least one carbon-carbon on aunuu communication. The term "Cx-Cyalbaniles" means a divalent group formed from straight or branched hydrocarbon chain containing at least one carbon-carbon double bond and containing from x to y carbon atoms. Typical examples of Alcanena include, but are not limited to, -CH=CH - and-CH2CH=CH-.

The term "alkyl", as used herein, means a straight or branched saturated hydrocarbon chain containing from 1 to 10 carbon atoms. The term "Cx-Cyalkyl" means straight or branched saturated hydrocarbon containing from x to y carbon atoms. For example, "C1-C6alkyl" means straight or branched saturated hydrocarbon containing from 2 to 6 carbon atoms. Typical examples of alkyl include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, n-hexyl, 3-etylhexyl, 2,2-dimethylpentyl, 2,3-dimethylpentyl, n-heptyl, n-octyl, n-nonyl and n-decyl.

The term "alkylene" means a divalent group formed from straight or branched saturated hydrocarbon chain of from 1 to 10 carbon atoms, for example, from 1 to 4 carbon atoms. The term "Cx-Cyalkylene" means a divalent group formed from a straight or branched saturated is about hydrocarbon, containing from x to y carbon atoms. For example, "C2-C6alkylene" means straight or branched saturated hydrocarbon containing from 2 to 6 carbon atoms. Typical examples of alkylene include, but are not limited to, -CH2-, -CH2CH2-, -CH2CH2CH2-, -CH2CH2CH2CH2- and-CH2CH(CH3)CH2-.

The term "quinil", as used herein, means a straight or branched hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond. The term "Cx-Cyquinil" means a straight or branched hydrocarbon group containing from x to y carbon atoms. For example, "C3-C6quinil" means a straight or branched hydrocarbon group containing from 3 to 6 carbon atoms and containing at least one carbon-carbon triple bond. Typical examples of quinil include, but are not limited to, acetylenyl, 1-PROPYNYL, 2-PROPYNYL, 3-butynyl, 2-pentenyl and 1-butynyl.

The term "akinyan", as used herein, means the divalent radical formed from straight or branched hydrocarbon group containing from 2 to 10 carbon atoms and containing at least one carbon-carbon triple bond.

The terminology is "aryl", as used herein, means phenyl.

The term "cyclic group", as used herein, means benzene, phenyl, phenylene, cycloalkane, cycloalkyl, cycloalkyl, cycloalkene, cycloalkenyl, cycloalkenyl, cycloalkyl, cycloalkenyl, cycloalkenyl, heteroaryl, heteroaryl, geteroseksualen, heteroseksualci, geteroseksualen, geteroseksualen and spiralcell.

The term "cycloalkyl" or cycloalkyl" or "cycloalkyl", as used herein, means a monocyclic or having a bridge connection hydrocarbon ring system. Monocyclic cycloalkyl is a carbocyclic ring system containing from three to ten carbon atoms, and zero heteroatoms and zero double bonds. Examples of monocyclic ring systems include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl. Monocyclic ring may contain one or two alkilinity bridge, each of which consists of one, two or three carbon atoms, each of which connects two lesosecnyh carbon atom of the ring system. Typical examples of such having a bridge connection cycloalkyl ring systems include, but are not limited to, bicyclo[3.1.1]heptane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonan, bicyclo[3.3.1]non is h, bicyclo[4.2.1]nonan, tricyclo[3.3.1.03,7]nonan (octahydro-2,5-methanoindene or noradsanta), and tricyclo[3.3.1.13,7]decane (adamantane). Monocyclic and having a bridge connection cycloalkyl can be linked to the original molecular group via any measurable substitution atom in the ring system.

The term "cycloalkenyl" or "cycloalkenyl" or "cycloalkyl", as used herein, means a monocyclic or having a bridge connection hydrocarbon ring system. Monocyclic cycloalkenyl has from four to ten carbon atoms and zero heteroatoms. Four-membered ring systems have one double bond, five - or six-membered ring systems have one or two double bonds, a seven - or eight-membered ring systems have one, two or three double bonds, and nine or desyatiletnie rings have one, two, three or four double bonds. Typical examples of monocyclic cycloalkenyl groups include, but are not limited to, cyclobutenyl, cyclopentenyl, cyclohexenyl, cycloheptenyl and cyclooctanol. Monocyclic cycloalkenyl ring may contain one or two alkilinity bridge, each of which consists of one, two or three carbon atoms, each of which connects two lesosecnyh carbon atom of the ring system. Tipi the examples having a bridge connection cycloalkenyl groups include, but not limited to, 4,5,6,7-tetrahydro-3aH-inden, octahydronaphthalene and 1,6-dihydro-pentalene. Monocyclic and having a bridge connection cycloalkenyl can be linked to the original molecular group via any measurable substitution atom contained within the ring systems.

The term "cycloalkyl" or "cycloalkenyl" or "cycloalkenyl", as used herein, means a monocyclic or having a bridge connection hydrocarbon ring system. Monocyclic cycloalkenyl has eight or more carbon atoms, and zero heteroatoms and one or more triple bonds. Monocyclic cycloalkenyl ring may contain one or two alkilinity bridge, each of which consists of one, two or three carbon atoms, each of which connects two lesosecnyh carbon atoms in the ring system. Monocyclic and having a bridge connection cycloalkenyl can be linked to the original molecular group via any measurable substitution atom contained within the ring systems.

The term "heteroaryl" or "heteroaryl" or "heteroaryl", as used herein, means a five-membered or six-membered aromatic ring having at least one carbon atom and one or more atoms independently selected from nitrogen atoms, oxygen or sulfur. G is teroare according to this invention are connected through any of the adjacent atoms in the ring, provided that these are appropriate valence. Typical examples of heteroaryl include, but are not limited to, furanyl (including, but not limited to, furan-2-yl), imidazolyl (including, but not limited to, 1Η-imidazol-1-yl), isoxazolyl, isothiazolin, oxadiazolyl, 1,3-oxazolyl, pyridinyl (e.g. pyridin-4-yl, pyridine-2-yl, pyridin-3-yl), pyridazinyl, pyrimidinyl, pyrazinyl, pyrazolyl, pyrrolyl, tetrazolyl, thiadiazolyl, 1,3-thiazolyl, thienyl (including, but not limited to, Tien-2-yl, Tien-3-yl), triazolyl and triazinyl.

The term "geteroseksualen" or "heteroseksualci" or "heterocyclochain", as used herein, means a monocyclic or having a bridge connection between the three-, four-, five-, six-, seven - or eight-membered ring containing at least one heteroatom independently selected from the group consisting of T, N and S and zero double bonds. Monocyclic and having a bridge connection geteroseksualen connected with a source of molecular group via any amenable to substitution of a carbon atom or any amenable to substitution of the nitrogen atom contained in the ring. The heteroatoms nitrogen and sulfur heterocyclic rings optionally may be oxidized and the nitrogen atoms may not necessarily be quaternidinum. Typical examples of groups geteroseksualen include, but are not limited to yaytsa them morpholinyl, tetrahydropyranyl, pyrrolidinyl, piperidinyl, DIOXOLANYL, tetrahydrofuranyl, thiomorpholine, 1,4-dioxane, tetrahydrothieno, tetrahydrothiopyran, oxetanyl, piperazinil, imidazolidinyl, azetidin, azepane, aziridinyl, diazepan, dithiolane, dithienyl, isoxazolidine, isothiazolinones, oxadiazolidine, oxazolidinyl, pyrazolidine, tetrahydrothieno, thiadiazolidine, diazolidinyl, thiomorpholine, tritional and tritional.

The term "geteroseksualen" or "geteroseksualen" or "heterocyclization", as used herein, means a monocyclic or having a bridge connection between the three-, four-, five-, six-, seven - or eight-membered ring containing at least one heteroatom independently selected from the group consisting of T, N and S, and one or more double bonds. Monocyclic and having a bridge connection geteroseksualen associated with the original molecular group via any amenable to substitution of a carbon atom or any amenable to substitution of the nitrogen atom contained in the ring. The heteroatoms nitrogen and sulfur heterocyclic rings optionally may be oxidized and the nitrogen atoms may not necessarily be quaternidinum. Typical examples geterotsiklicheskikh groups include, but are not limited to, 1,4,5,6-tetrahydropyridines, 1,2,3,6-tetrahydropyridine the sludge, dihydropyran, imidazolines, isothiazolines, oxadiazolyl, isoxazolyl, oxazolyl, pyranyl, pyrazolyl, pyrrolyl, thiadiazolyl, thiazolyl and tiopronin.

The term "phenyl", as used herein, means monovalent radical formed by removing a hydrogen atom from benzene.

The term "phenylene", as used herein, means the divalent radical formed by removal of a hydrogen atom of the phenyl.

The term "spirooli", as used herein, means alkylen, both ends of which are connected to the same carbon atom and its examples are C2-spiralcell,3-spiralcell, C4-spiralcell,5-spiralcell,6-spiralcell, C7-spiralcell, C8-spiralcell,9-spiralcell etc.

The term "spirolaterals", as used herein, means spiralcell with one or two groups CH2, replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2or NH and one or two CH group, is not replaced or replaced with N.

The term "spiroheterocyclic", as used herein, means serialkey with one or two groups CH2, replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2or NH and one or two CH group, nezamenennymi or replaced with N, andwell as means serialkeys, having one or two groups CH2, nezamenennymi or replaced with independently selected O, C(O), CNOH, CNOCH3, S, S(O), SO2or NH and one or two CH group, substituted n

The term "C2-C5spiralcell", as used herein, means C2-spiralcell,3-spiralcell, C4-spiralcell and C5-spiralcell.

The term "C2-spiralcell", as used herein, means et-1,2-ilen, both ends of which replace hydrogen atoms of one group CH2.

The term "C3-spiralcell", as used herein, means the prop-1,3-ilen, both ends of which replace hydrogen atoms of one group CH2.

The term "C4-spiralcell", as used herein, means buta-1,4-ilen, both ends of which replace hydrogen atoms of one group CH2.

The term "C5-spiralcell", as used herein, means the Penta-1,5-ilen, both ends of which replace hydrogen atoms of one group CH2.

The term "C6-spiralcell", as used herein, means Gex-1,6-ilen, both ends of which replace hydrogen atoms of one group CH2.

The term "NH-protective group" as used herein means trichlorocyanuric, tribromoethanol, benzyloxycarbonyl, para-nitroaniline is l, ortho-bromobenzyloxycarbonyl, chloroacetyl, dichloroacetyl, trichloroacetyl, TRIFLUOROACETYL, phenylacetyl, formyl, acetyl, benzoyl, tert-aryloxyalkyl, tert-butoxycarbonyl, para-methoxybenzeneboronic, 3,4-dimethoxyphenylacetone, 4-(phenylazo)benzyloxycarbonyl, 2-furfurylalcohol, diphenylcarbinol, 1,1-dimethylpropanolamine, isopropoxycarbonyl, phthaloyl, succinyl, alanyl, leucyl, 1-adamantanecarbonyl, 8-hinolincarbonova, benzyl, diphenylmethyl, triphenylmethyl, 2-nitrophenylthio, methanesulfonyl, para-toluensulfonyl, N,N-dimethylaminomethylene, benzylidene, 2-hydroxybenzylidene, 2-hydroxy-5-chlorobenzylidene, 2-hydroxy-1-naphthylmethyl, 3-hydroxy-4-pyridylmethylene, cyclohexylidene, 2-ethoxycarbonylphenyl, 2-ethoxycarbonylphenyl, 2-acetylcyclohexanone, 3,3-dimethyl-5-axillo-hexylidene, diphenylphosphoryl, dibenzoyltartaric, 5-methyl-2-oxo-2H-1,3-dioxol-4-yl-methyl, trimethylsilyl, triethylsilyl and triphenylsilane.

The term "C(O)OH-protective group" as used herein means methyl, ethyl, n-propyl, isopropyl, 1,1-dimethylpropyl, n-butyl, tert-butyl, phenyl, naphthyl, benzyl, diphenylmethyl, triphenylmethyl, para-nitrobenzyl, para-methoxybenzyl, bis(para-methoxyphenyl)methyl, acetylethyl, benzoylmethyl, para-nitrobenzoyl, para-bromobenzoyl, para-methanesulfonyl oilmeal, 2-tetrahydropyranyl 2-tetrahydropyranyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, acetoxymethyl, propionylacetate, pivaloyloxymethyl, phthalimidomethyl, Succinimidyl, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, methoxymethyl, methoxyethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, benzoyloxymethyl, methylthiomethyl, 2-methylthioethyl, phenylthiomethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, diethylenediamine, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, diphenylmethylsilane and tert-butylperoxyisopropyl.

The term "OH - or SH-protective group" as used herein means benzyloxycarbonyl, 4-nitrobenzenesulfonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzenesulfonyl, 3,4-dimethoxyphenylacetone, methoxycarbonyl, etoxycarbonyl, tert-butoxycarbonyl, 1,1-dimethylpropanolamine, isopropoxycarbonyl, isobutylacetate, diphenylcarbinol, 2,2,2-trichlorocyanuric, 2,2,2-tribromoethyl, 2-(trimethylsilyl)etoxycarbonyl, 2-(phenylsulfonyl)etoxycarbonyl, 2-(triphenylphosphonio)etoxycarbonyl, 2-furfurylalcohol, 1-adamantanecarbonyl, vinyloxycarbonyl, allyloxycarbonyl, S-benzyltoluene, 4 ethoxy-1-naphthaleneboronic, 8-hinolincarbonova, acetyl, formyl, chloroacetyl, dichloroacetyl, trichloro is cetil, TRIFLUOROACETYL, methoxyacetyl, phenoxyacetyl, pivaloyl, benzoyl, methyl, tert-butyl, 2,2,2-trichloroethyl, 2-trimethylsilylmethyl, 1,1-dimethyl-2-propenyl, 3-methyl-3-butenyl, allyl, benzyl (phenylmethyl), para-methoxybenzyl, 3,4-dimethoxybenzyl, diphenylmethyl, triphenylmethyl, tetrahydrofuryl, tetrahydropyranyl, tetrahydropyranyl, methoxymethyl, methylthiomethyl, benzoyloxymethyl, 2-methoxyethoxymethyl, 2,2,2-trichloro-ethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, 1-ethoxyethyl, methanesulfonyl, para-toluensulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, diethylenediamine, tert-butyldimethylsilyl, tert-butyldiphenylsilyl, diphenylmethylsilane and tert-butylperoxyisopropyl.

Connection

In the present compounds may exist as geometric isomers. Compounds according to this invention may contain carbon-carbon double bond or carbon-nitrogen double bond configuration, Ε or Ζ, where the term "E" represents substituents of higher order on opposite sides of the carbon-carbon or carbon-nitrogen double bond, and the term "Z" represents substituents of higher order on one side of the carbon-carbon or carbon-nitrogen double bond in the determination according to the rules of priority Cahn-Ingold-Prelog. Compounds according to this invention can also exist in ka is este mixture of E - and Z-isomers. Deputies around cycloalkyl or geterotsiklicheskie is designated as having a CIS - or TRANS-configuration. Moreover, the invention includes various isomers and mixtures thereof resulting from the placement of substituents around the ring system adamantane. Two Deputy around one ring in adamantanol ring system denoted as having a relative configuration or Ε Ζ.

For examples, see C. D. Jones, M. Kaselj, R. N. Salvatore, W. J. le Noble J. Org. Chem. 1998, 63, 2758-2760.

Compounds according to the invention can contain asymmetrically substituted carbon atoms in the R - or S-configuration, where the terms "R" and "S" are as defined in the IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. (1976) 45, 13-10. Compounds having asymmetrically substituted carbon atoms with equal amounts of R and S configurations are racemic these carbon atoms. Atoms with an excess of one configuration with respect to another attribute configuration present in a higher amount, preferably in excess of about 85%-90%, more preferably in excess of about 95%-99%, and even more preferably in excess of more than about 99%. Thus, this invention includes racemic mixtures, relative and absolute stereoisomers and a mixture of relative and absolute stereoisomers.

Isotopic enrichment of the military or labeled compounds

Compounds according to the invention can exist in isotope labeled or enriched form, containing one or more atoms having an atomic mass or mass number different from the atomic mass or mass number most common in nature. Isotopes can be a radioactive or non-radioactive isotopes. Isotopes of atoms such as hydrogen, carbon, phosphorus, sulfur, fluorine, chlorine, and iodine include, but are not limited to,2H,3H,13C,14C,15Ν,18O,32P,35S18F,36Cl125I. the scope of this invention include compounds that contain other isotopes of these and/or other atoms.

In another embodiment, isotope-labeled compounds contain isotopes deuterium (2H), tritium (3H) or14C. isotope-Labeled compounds of this invention can be obtained by General methods well known to the person skilled in the art. Such isotope-labeled compounds can conveniently be obtained by procedures described in the examples described in this document and in the diagrams by replacing unlabeled reagent well available isotope-labeled reagent. In some cases, the compounds can be processed isotope-labeled reagents to replace the normal atom by its isotope, for example, hydrogen is aterial can be replaced under the action of deuterated acid, such as D2SO4/D2O. In addition to the above, the relevant procedures and intermediate compounds described, for example, Lizondo, J et al., Drugs Fut, 21(11), 1116 (1996); Brickner, S J et al., J Med Chem, 39(3), 673 (1996); Mallesham, et al., Org Lett, 5(7), 963 (2003); the PCT publications W01997010223, W02005099353, W01995007271, W02006008754; U.S. patents№ 7538189; 7534814; 7531685; 7528131; 7521421; 7514068; 7511013; and publications of patent applications U.S.№ 20090137457; 20090131485; 20090131363; 20090118238; 20090111840; 20090105338; 20090105307; 20090105147; 20090093422; 20090088416 and 20090082471, these methods are incorporated herein as references.

Labeled isotope compounds according to the invention can be used as standards to determine the effectiveness of inhibitors of Bcl-2 in the analysis of binding. Containing the isotope compounds used in pharmaceutical research to study the metabolic fate of compoundsin vivoby evaluating the mechanism of action and metabolic cascade is not isotope-labeled parent compound (Blake et al. J. Pharm. Sci. 64, 3, 367-391 (1975)). Such metabolic studies are important for the development of safe, effective therapeutic drugs, becausein vivoor the active compound, administered to the patient, or the metabolites formed from the parent compound, are toxic or carcinogenic (Foster et al., Advances in Drug Research Vol. 14, pp. 2-36, Academic press, London, 1985; Kato et al., J. Labelled Comp.Radiopharmaceut., 36(10):927-932 (1995); Kusher et al., Can. J. Physiol. Pharmacol., 77, 79-88 (1999)).

In addition, for the treatment of diseases and conditions associated with the activity of Bcl-2, can be used not containing a radioactive isotope medicines, such as deuterated drugs called "hard drugs". Increasing the amount of isotope present in the compound above its natural content, called enrichment. Examples of the magnitude of enrichment include from about 0,5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 16, 21, 25, 29, 33, 37, 42, 46, 50, 54, 58, 63, 67, 71, 75, 79, 84, 88, 92, 96 to about 100 mol.%. Replacement of up to approximately 15% of normal heavy atom isotope is provided and maintained during the period of days to weeks in mammals, including rodents and dogs, with the lowest observed adverse effects (Czajka D Μ and A J Finkel, Ann. N. Y. Acad. Sci. 1960 84: 770; Thomson J F, Ann. New York Acad. Sci 1960 84: 736; Czakja D Μ et al., Am. J. Physiol. 1961 201: 357). It was found that the rapid replacement of up to 15%-23% in human body fluids by deuterium does not cause toxicity (Blagojevic N et al. in "Dosimetry &Treatment Planning for Neutron Capture Therapy", Zamenhof R, Solares G and Harling About Eds. 1994. Advanced Medical Publishing, Madison Wis. pp. 125-134; Diabetes Metab. 23: 251 (1997)).

Marking stable isotope drugs may alter its physico-chemical properties such as pKa and solubility in lipids. These effects and changes can influence n the pharmacodynamic response of the molecule drugs, if isotopic substitution affects the region involved in the interaction of the ligand-receptor. Although some of the physical properties of stable isotope-labeled molecules differ from unlabeled, chemical and biological properties are the same, with one important exception: due to the increased mass of the heavy isotope of any communication involving heavy isotope and the other atom is stronger than the same relationship between a light isotope, and this atom. Thus, the inclusion of isotope at the site of metabolism or enzymatic transformation slows down these reactions, potentially altering the pharmacokinetic profile or efficacy relative to non-isotropic connections.

Suitable groups for A1B1D1E1, G1, Y1L1, Z1A, Z2AΖ1, Z2and Z3in the compounds of formula (I) selected independently. Described embodiments of the present invention can be combined. Such combination is provided and included in the scope of the present invention. For example, it is envisaged that embodiments of any of the A1B1D1E1, G1, Y1L1, Z1A, Z2A, Z1, Z2and Z3can be combined with the variants of the implementation defined for any other of the A1B1 D1E1, G1, Y1L1, Z1A, Z2AΖ1, Z2and Z3.

Thus, one of the embodiments of this invention refers to compounds or therapeutically acceptable salts, are useful as inhibitors of anti-apoptotic proteins Bcl-2, and compounds have the formula (I)

where

A1represents N or C(A2);

A2represents H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A;

B1represents H, Rsup> 1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A;

D1represents H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N( 1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A;

E1represents H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A; and

Y1represents H, CN, NO2C(O)OH, F, Cl, Br, I, CF3, OCF3, CF2CF3, OCF2CF , R17, OR17C(O)R17C(O)OR17, SR17, SO2R17, NH2, Other17N(R17)2, NHC(O)R17C(O)NH2C(O)other17C(O)N(R17)2NHS(O)R17or NHSO2R17; or

E1and Y1together with the atoms to which they are attached, are benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

A2B1and D1independently selected from H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A; or

Y1and B1together with at the Mami, to which they are attached, are benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

A2D1and E1independently selected from H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A; or

A2and B1together with the atoms to which they are attached, are benzene, naftilan, heteroaryl cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

D1, Ε1and Y1independently selected from H, R1, OR1, SR1, S(O)R1, SO2R 1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1(CO)NC(R1)2, SO2NH2, SO2Other1, SO2N(R1)2NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A; or

A2and D1together with the atoms to which they are attached, are benzene, naphthalene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

In1E1and Y1independently selected from H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1CO)N(R 1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A;

G1represents H or C(O)OR;

R represents alkyl;

R1is an R2, R3, R4or R5;

R1Ais cycloalkyl, cycloalkenyl or cycloalkenyl;

R2represents phenyl, which is unfused or fused with R2A; R2Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R3is heteroaryl, which is unfused or fused with R3A; R3Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R4is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is some what generowanym or fused with R 4A; R4Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R5represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R6, NC(R6A)(R6B), R7, OR7, SR7, S(O)R7, SO2R7, Other7N(R7)2C(O)R7C(O)NH2C(O)other7C(O)N(R7)2, NHC(O)R7, NR7C(O)R7, NHSO2R7, NHC(O)OR7, SO2NH2, SO2Other7, SO2N(R7)2, NHC(O)NH2, NHC(O)other7, NHC(O)CH(CH3)NHC(O)CH(CH3)NH2, NHC(O)CH(CH3)NHC(O)CH(CH3)Other7, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;

R6represents a C2-C5-spiralcell, each of which is unsubstituted or substituted by OH, (O), N3CN, CF3, CF2CF3, F, Cl, Br, I, NH2, NH(CH3) or N(CH3)2;

R6Aand R6Bindependently selected from alkyl or together with N to which they are attached, R6C;

R6Cis aziridine-1-yl, azetidin-1-yl, pyrrolidin-1-yl or piperidine-1-yl, each of which has one group CH2, unsubstituted or substituted by O, C(O), CNOH, CNOCH3, S, S(O), SO2or NH;

R7the stand is made by a R 8, R9, R10or R11;

R8represents phenyl, which is unfused or fused with R8A; R8Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R9is heteroaryl, which is unfused or fused with R9A; R9Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R10A; R10Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R11represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R12, OR12, SR12, S(O)R12, SO2R12C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, Other12N(R12)2, NHC(O)R12, NR12C(O)R12NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)other12, NHC(O)N(R12)2, NR12C(O)other12, NR12C(O)N(R12)2/sub> C(O)NH2C(O)other12C(O)N(R12)2C(O)NHOH, C(O)NHOR12C(O)NHSO2R12C(O)NR12SO2R12, SO2NH2, SO2Other12, SO2N(R12)2C(O)H, C(O)OH, C(N)NH2C(N)other12C(N)N(R12)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R12is an R13, R14, R15or R16;

R13represents phenyl, which is unfused or fused with R13A; R13Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R14is heteroaryl, which is unfused or fused with R14A; R14Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R15is cycloalkane, cycloalkene, geteroseksualen or geteroseksualen, each of which is unfused or fused with R15A; R15Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R16represents alkyl, alkenyl or quinil;

R17is an R18, R19, R20or R21;

R18 represents phenyl, which is unfused or fused with R18A; R18Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R19is heteroaryl, which is unfused or fused with R19A; R19Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R20is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R20A; R20Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R21represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R22, OR22, SR22, S(O)R22, SO2R22C(O)R22, CO(O)R22, OC(O)R22, OC(O)OR22, NH2, Other22N(R22)2, NHC(O)R22, NR22C(O)R22NHS(O)2R22, NR22S(O)2R22, NHC(O)OR22, NR22C(O)OR22, NHC(O)NH2, NHC(O)other22, NHC(O)N(R22)2, NR22C(O)other22, NR22C(O)N(R22)2C(O)NH2C(O)other22C(O)N(R22)2 C(O)NHOH, C(O)NHOR22C(O)NHSO2R22C(O)NR22SO2R22, SO2NH2, SO2Other22, SO2N(R22)2C(O)H, C(O)OH, C(N)NH2C(N)other22C(N)N(R22)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R22is an R23, R24or R25;

R23represents phenyl, which is unfused or fused with R23A; R23Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R24represents heteroaryl, which is unfused or fused with R24A; R24Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R25is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R25A; R25Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

Z1is an R26or R27;

Z2is an R28, R29or R30;

Z1Aand Z2Aboth were missing or taken together form CH2CH 2CH2or Z12A;

Z12Arepresents a C2-C6-alkylen with one or two groups CH2replaced by NH, N(CH3), S, S(O) or SO2;

L1is an R37, OR37, SR37, S(O)R37, SO2R37C(O)R37, CO(O)R37, OC(O)R37, OC(O)OR37, Other37C(O)NH, C(O)NR37C(O)NHOR37C(O)NHSO2R37, SO2NH, SO2Other37C(N)NH, C(N)other37;

R26represents a phenylene, which is unfused or fused with R26A; R26Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R27represents heteroaryl, which is unfused or fused with R27A; R27Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R28represents a phenylene, which is unfused or fused with R28A; R28Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R29represents heteroaryl, which is unfused or fused with R29A; R29Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen and the and geteroseksualen;

R30is cycloalkyl, cycloalkenyl, heterocyclochain or heterocyclization, each of which is unfused or fused with R30A; R30Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R37represents a bond, or R37A;

R37Ais alkylen, albaniles or akinyan, each of which is unsubstituted or substituted one, or two, or three independently selected substituents of R37B, OR37B, SR37B, S(O)R37B, SO2R37BC(O)R37B, CO(O)R37B, OC(O)R37B, OC(O)OR37B, NH2, Other37BN(R37B)2, NHC(O)R37B, NR37BC(O)R37BNHS(O)2R37B, NR37BS(O)2R37B, NHC(O)OR37B, NR37BC(O)OR37B, NHC(O)NH2, NHC(O)other37B, NHC(O)N(R37B)2, NR37BC(O)other37B, NR37BC(O)N(R37B)2C(O)NH2C(O)other37BC(O)N(R37B)2C(O)NHOH, C(O)NHOR37BC(O)NHSO2R37BC(O)NR37BSO2R37B, SO2NH2, SO2Other37B, SO2N(R37B)2C(O)H, C(O)OH, C(N)NH2C(N)other37BC(N)N(R37B)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br and I;

R37Bisone alkyl, alkenyl, quinil or R37C;

R37Crepresents phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen;

Z3is an R38, R39or R40;

R38represents phenyl, which is unfused or fused with R38A; R38Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R39is heteroaryl, which is unfused or fused with R39A; R39Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R40is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R40A; R40Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

where the group corresponding to R26and R27substituted (i.e., if Ζ1Aand Z2Aare absent) or further substituted (i.e., if Z1Aand Z2Apresent) by R41, OR41, SR41, S(O)R41, SO2R41C(O)R41, CO(O)R41, OC(O)R41, OC(O)OR41, Other41N(R41)2, NHC(O)R41, NR1 C(O)R41NHS(O)2R41, NR41S(O)2R41, NHC(O)OR41, NR41C(O)OR41, NHC(O)other41, NHC(O)N(R41)2, NR41C(O)other41, NR41C(O)N(R41)2C(O)other41C(O)N(R41)2C(O)NHOR41C(O)NHSO2R41C(O)NR41SO2R41, SO2Other41, SO2N(R41)2C(N)other41or C(N)N(R41)2;

R41is heteroaryl, which is condensed with R43A; R43Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen, which is unfused or fused with benzene, heteroatom or R43B; R43Bis cycloalkane, cycloalkene, geteroseksualen or geteroseksualen;

where the cyclic group corresponding to E1and Y1together, Y1and B1together, A2and B1together, A2and D1together, R1A, R2, R2A, R3, R3A, R4, R4A, R6, R6C, R8, R8A, R9, R9A, R10, R10A, R13, R13A, R14, R14A, R15, R15A, R18, R18A, R19, R19A, R20, R20A, R23, R23A, R24, R24A, R25, R25A, R26, R26A, R27, R27A, R28, R28A, R29, R29A , R30, R30A, R37B, R38, R38A, R39, R39A, R40and R40Ano not substituted, is not further substituted, substituted or optionally substituted with one, or two, or three, or four, or five of independently selected R57A, R57, OR57, SR57, S(O)R57, SO2R57C(O)R57, CO(O)R57, OC(O)R57, OC(O)OR57, NH2, Other57N(R57)2, NHC(O)R57, NR57C(O)R57NHS(O)2R57, NR57S(O)2R57, NHC(O)OR57, NR57C(O)OR57, NHC(O)NH2, NHC(O)other57, NHC(O)N(R57)2, NR57C(O)other57, NR57C(O)N(R57)2C(O)NH2C(O)other57C(O)N(R57)2C(O)NHOH, C(O)NHOR57C(O)NHSO2R57C(O)NR57SO2R57, SO2NH2, SO2Other57, SO2N(R57)2C(O)H, C(O)OH, C(N)NH2C(N)other57C(N)N(R57)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R57Ais spiralcell or spiroheterocyclic;

R57is an R58, R59, R60or R61;

R58represents phenyl, which is unfused or fused with R58A; R58Arepresents a benzene, heteroaryl, cycloalkyl, recloak is h, geteroseksualen or geteroseksualen;

R59is heteroaryl, which is unfused or fused with R59A; R59Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R60is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R60A; R60Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R61represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R62, OR62, SR62, S(O)R62, SO2R62C(O)R62, CO(O)R62, OC(O)R62, OC(O)OR62, NH2, Other62N(R62)2, NHC(O)R62, NR62C(O)R62NHS(O)2R62, NR62S(O)2R62, NHC(O)OR62, NR62C(O)OR62, NHC(O)NH2, NHC(O)other62, NHC(O)N(R62)2, NR62C(O)other62, NR62C(O)N(R62)2C(O)NH2C(O)other62C(O)N(R62)2C(O)NHOH, C(O)NHOR62C(O)NHSO2R62C(O)NR62SO2R62, SO2NH2, SO2Other62, SO2N(R62)2C(O)H, C(O)HE, C(N)NH2With(N)other 62C(N)N(R62)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R62is an R63, R64, R65or R66;

R63represents phenyl, which is unfused or fused with R63A; R63Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R64is heteroaryl, which is unfused or fused with R64A; R64Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R65is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R65A; R65Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

Rr66represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected substituents R67, OR67, SR67, S(O)R67, SO2R67C(O)R67, CO(O)R67, OC(O)R67, OC(O)OR67, NH2, Other67N(R67)2, NHC(O)R67, NR67C(O)Rsup> 67NHS(O)2R67, NR67S(O)2R67, NHC(O)OR67, NR67C(O)OR67, NHC(O)NH2, NHC(O)other67, NHC(O)N(R67)2, NR67C(O)other67, NR67C(O)N(R67)2C(O)NH2C(O)other67C(O)N(R67)2C(O)NHOH, C(O)NHOR67, C(O)NHSO2R67With(O)NR67SO2R67, SO2NH2, SO2Other67, SO2N(R67)2C(O)H, C(O)OH, C(N)NH2With(N)other67C(N)N(R67)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R67represents alkyl, alkenyl, quinil, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen;

where the cyclic group corresponding to R57A, R58, R59, R60, R63, R64, R65and R67are unsubstituted or substituted one, or two, or three, or four of independently selected R68, OR68, SR68, S(O)R68, SO2R68C(O)R68, CO(O)R68, OC(O)R68, OC(O)OR68, NH2, Other68N(R68)2, NHC(O)R68, NR68C(O)R68NHS(O)2R68, NR68S(O)2R68, NHC(O)OR68, NR68C(O)OR68, NHC(O)NH2, NHC(O)other68, NHC(O)N(R68)2, NR68C(O)other68, NR68C(O)N(R68)2C(O)NH2C(O)other68 C(O)N(R68)2C(O)NHOH, C(O)NHOR68C(O)NHSO2R68C(O)NR68SO2R68, SO2NH2, SO2Other68, SO2N(R68)2C(O)H, C(O)OH, C(N)NH2C(N)other68C(N)N(R68)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R68is an R69, R70, R71or R72;

R69represents phenyl, which is unfused or fused with R69A; R69Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R70is heteroaryl, which is unfused or fused with R70A; R70Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R71is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R71A; R71Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R72represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R73 , OR73, SR73, S(O)R73, SO2R73C(O)R73, CO(O)R73, OC(O)R73, OC(O)OR73, NH2, Other73N(R73)2, NHC(O)R73, NR73C(O)R73NHS(O)2R73, NR73S(O)2R73, NHC(O)OR73, NR73C(O)OR73, NHC(O)NH2, NHC(O)other73, NHC(O)N(R73)2, NR73C(O)other73, NR73C(O)N(R73)2C(O)NH2C(O)other73C(O)N(R73)2C(O)NHOH, C(O)NHOR73, C(O)NHSO2R73With(O)NR73SO2R73, SO2NH2, SO2Other73, SO2N(R73)2C(O)H, C(O)OH, C(N)NH2With(N)other73C(N)N(R73)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R73represents alkyl, alkenyl, quinil, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen; and

where the group corresponding to R69, R70and R71are unsubstituted or substituted one, or two, or three, or four of independently selected NH2C(O)NH2C(O)NHOH, SO2NH2, CF3, CF2CF3C(O)H, C(O)OH, C(N)NH2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I.

Another variant implementation of the invention relates to compounds of formula (I), where

<> And1represents N or C(A2);

And2represents H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2With(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A;

B1represents H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1 2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A;

D1represents H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A;

E1isone H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A; and

Y1represents H, CN, NO2C(O)OH, F, Cl, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17C(O)R17C(O)OR17, SR17, SO2R17, NH2, Other17N(R17)2, NHC(O)R17C(O)NH2C(O)other17C(O)N(R17)2NHS(O)R17or NHSO2R17; or

E1and Y1together with the atoms to which they are attached, are benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen eleetrical; and

A2B1and D1independently selected from H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A; or

Y1and B1together with the atoms to which they are attached, are benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

A2D1and E1independently selected from H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHCO)OR 1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A; or

A2and B1together with the atoms to which they are attached, are benzene, naftilan, heteroaryl cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

D1, Ε1and Y1independently selected from H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1(CO)NC(R1)2, SO2NH2, SO2Other1, SO2N(R1)2NHSO2R1, NR1SO2R1, NHSO2Other , NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A; or

A2and D1together with the atoms to which they are attached, are benzene, naphthalene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

In1E1and Y1independently selected from H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2 3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A;

G1represents H or C(O)OR;

R represents alkyl;

R1is an R2, R3, R4or R5;

R1Ais cycloalkyl, cycloalkenyl or cycloalkenyl;

R2represents phenyl, which is unfused or fused with R2A; R2Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R3is heteroaryl, which is unfused or fused with R3A; R3Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R4is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R4A; R4Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R5represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R6, NC(R6A)(R6B), R7, OR7, SR7, S(O)R7, SO2/sub> R7, Other7N(R7)2C(O)R7C(O)NH2C(O)other7C(O)N(R7)2, NHC(O)R7, NR7C(O)R7, NHSO2R7, NHC(O)OR7, SO2NH2, SO2Other7, SO2N(R7)2, NHC(O)NH2, NHC(O)other7, NHC(O)CH(CH3)NHC(O)CH(CH3)NH2, NHC(O)CH(CH3)NHC(O)CH(CH3)Other7, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;

R6represents a C2-C5-spiralcell, each of which is unsubstituted or substituted by OH, (O), N3CN, CF3, CF2CF3, F, Cl, Br, I, NH2, NH(CH3) or N(CH3)2;

R6Aand R6Bindependently selected from alkyl or together with N to which they are attached, R6C;

R6Cis aziridine-1-yl, azetidin-1-yl, pyrrolidin-1-yl or piperidine-1-yl, each of which has one group CH2, unsubstituted or substituted by O, C(O), CNOH, CNOCH3, S, S(O), SO2or NH;

R7is an R8, R9, R10or R11;

R8represents phenyl, which is unfused or fused with R8A; R8Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R9is heteroaryl, which is unfused or to desirous with R 9A; R9Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R10A; R10Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R11represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R12, OR12, SR12, S(O)R12, SO2R12C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, Other12N(R12)2, NHC(O)R12, NR12C(O)R12NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)other12, NHC(O)N(R12)2, NR12C(O)other12, NR12C(O)N(R12)2C(O)NH2C(O)other12C(O)N(R12)2C(O)NHOH, C(O)NHOR12C(O)NHSO2R12C(O)NR12SO2R12, SO2NH2, SO2Other12, SO2N(R12)2C(O)H, C(O)OH, C(N)NH2C(N)other12C(N)N(R12)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R12 is an R13, R14, R15or R16;

R13represents phenyl, which is unfused or fused with R13A; R13Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R14is heteroaryl, which is unfused or fused with R14A; R14Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R15is cycloalkane, cycloalkene, geteroseksualen or geteroseksualen, each of which is unfused or fused with R15A; R15Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R16represents alkyl, alkenyl or quinil;

R17is an R18, R19, R20or R21;

R18represents phenyl, which is unfused or fused with R18A; R18Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R19is heteroaryl, which is not condensed or fused with R19A; R19Arepresents a benzene, euroart, cycloalkane, cycloalkene, geteroseksualen or geteroseksualen;

R20is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R20A; R20Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R21represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R22, OR22, SR22, S(O)R22, SO2R22C(O)R22, CO(O)R22, OC(O)R22, OC(O)OR22, NH2, Other22N(R22)2, NHC(O)R22, NR22C(O)R22NHS(O)2R22, NR22S(O)2R22, NHC(O)OR22, NR22C(O)OR22, NHC(O)NH2, NHC(O)other22, NHC(O)N(R22)2, NR22C(O)other22, NR22C(O)N(R22)2C(O)NH2C(O)other22C(O)N(R22)2C(O)NHOH, C(O)NHOR22C(O)NHSO2R22C(O)NR22SO2R22, SO2NH2, SO2Other22, SO2N(R22)2C(O)H, C(O)OH, C(N)NH2C(N)other22C(N)N(R22)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R22is an R23, R24or R25;

R23represents phenyl, which is unfused or fused with R23A; R23Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R24represents heteroaryl, which is unfused or fused with R24A; R24Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R25is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R25A; R25Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

Z1is an R26or R27;

Z2is an R28, R29or R30;

Z1Aand Z2Aboth were missing or taken together form CH2CH2CH2or Z12A;

Z12Arepresents a C2-C6-alkylen with one or two groups CH2replaced by NH, N(CH3), S, S(O) or SO2;

L1is an R37, OR37, SR37, S(O)R37, SO2R37C(O)R37, CO(O)R37, OC(O)R37, OC(O)OR37, Other37C(O)NH, C(O)NR37C(O)NHOR37C(O)NHSO2 R37, SO2NH, SO2Other37C(N)NH, C(N)other37;

R26represents a phenylene, which is unfused or fused with R26A; R26Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R27represents heteroaryl, which is unfused or fused with R27A; R27Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R28represents a phenylene, which is unfused or fused with R28A; R28Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R29represents heteroaryl, which is not condensed or fused with R29A; R29Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R30is cycloalkyl, cycloalkenyl, heterocyclochain or heterocyclization, each of which is unfused or fused with R30A; R30Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R37represents the relationship or 37A;

R37Ais alkylen, albaniles or akinyan, each of which is unsubstituted or substituted one, or two, or three independently selected substituents of R37B, OR37B, SR37B, S(O)R37B, SO2R37BC(O)R37B, CO(O)R37B, OC(O)R37B, OC(O)OR37B, NH2, Other37BN(R37B)2, NHC(O)R37B, NR37BC(O)R37BNHS(O)2R37B, NR37BS(O)2R37B, NHC(O)OR37B, NR37BC(O)OR37B, NHC(O)NH2, NHC(O)other37B, NHC(O)N(R37B)2, NR37BC(O)other37B, NR37BC(O)N(R37B)2C(O)NH2C(O)other37BC(O)N(R37B)2C(O)NHOH, C(O)NHOR37BC(O)NHSO2R37BC(O)NR37BSO2R37B, SO2NH2, SO2Other37B, SO2N(R37B)2C(O)H, C(O)OH, C(N)NH2C(N)other37BC(N)N(R37B)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br and I;

R37Brepresents alkyl, alkenyl, quinil or R37C;

R37Crepresents phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen;

Z3is an R38, R39or R40;

R38represents phenyl, which is unfused or fused with R38A; R38Ap is ecstasy a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R39is heteroaryl, which is unfused or fused with R39A; R39Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R40is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R40A; R40Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

where the group corresponding to R26and R27substituted (i.e., if Ζ1Aand Z2Aare absent) or further substituted (i.e., if Z1Aand Z2Apresent) by R41, OR41, SR41, S(O)R41, SO2R41C(O)R41, CO(O)R41, OC(O)R41, OC(O)OR41, Other41N(R41)2, NHC(O)R41, NR41C(O)R41NHS(O)2R41, NR41S(O)2R41, NHC(O)OR41, NR41C(O)OR41, NHC(O)other41, NHC(O)N(R41)2, NR41C(O)other41, NR41C(O)N(R41)2C(O)other41C(O)N(R41)2C(O)NHOR41C(O)NHSO2R41C(O)NR41SO2R41, SO2Other41, SO2N(R41)2C(N)other41or C(N)N(R4 )2;

R41is heteroaryl, which is condensed with R43A; R43Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen, which is unfused;

where the cyclic group corresponding to E1and Y1together, Y1and B1together, A2and B1together, A2and D1together, R1A, R2, R2A, R3, R3A, R4, R4A, R6, R6C, R8, R8A, R9, R9A, R10, R10A, R13, R13A, R14, R14A, R15, R15A, R18, R18A, R19, R19A, R20, R20A, R23, R23A, R24, R24A, R25, R25A, R26, R26A, R27, R27A, R28, R28A, R29, R29A, R30, R30A, R37B, R38, R38A, R39, R39A, R40and R40Ano not substituted, is not further substituted, substituted or optionally substituted with one, or two, or three, or four, or five of independently selected R57A, R57, OR57, SR57, S(O)R57, SO2R57C(O)R57, CO(O)R57, OC(O)R57, OC(O)OR57, NH2, Other57N(R57)2, NHC(O)R57, NR57C(O)R57NHS(O)2R57, NR57S(O)2R57, NHC(O)OR5 , NR57C(O)OR57, NHC(O)NH2, NHC(O)other57, NHC(O)N(R57)2, NR57C(O)other57, NR57C(O)N(R57)2C(O)NH2C(O)other57C(O)N(R57)2C(O)NHOH, C(O)NHOR57C(O)NHSO2R57C(O)NR57SO2R57, SO2NH2, SO2Other57, SO2N(R57)2C(O)H, C(O)OH, C(N)NH2C(N)other57C(N)N(R57)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R57Ais spiralcell or spiroheterocyclic;

R57is an R58, R59, R60or R61;

R58represents phenyl, which is unfused or fused with R58A; R58Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R59is heteroaryl, which is unfused or fused with R59A; R59Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R60is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R60A; R60Arepresents a benzene, heteroaryl, cycloalkyl, the CEC is olken, geteroseksualen or geteroseksualen;

R61represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R62, OR62, SR62, S(O)R62, SO2R62C(O)R62, CO(O)R62, OC(O)R62, OC(O)OR62, NH2, Other62N(R62)2, NHC(O)R62, NR62C(O)R62NHS(O)2R62, NR62S(O)2R62, NHC(O)OR62, NR62C(O)OR62, NHC(O)NH2, NHC(O)other62, NHC(O)N(R62)2, NR62C(O)other62, NR62C(O)N(R62)2C(O)NH2C(O)other62C(O)N(R62)2C(O)NHOH, C(O)NHOR62, C(O)NHSO2R62With(O)NR62SO2R62, SO2NH2, SO2Other62, SO2N(R62)2C(O)H, C(O)OH, C(N)NH2With(N)other62C(N)N(R62)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R62is an R63, R64, R65or R66;

R63represents phenyl, which is unfused or fused with R63A; R63Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R64is heteroaryl, which is unfused and the and fused with R 64A; R64Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R65is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R65A; R65Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R66represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected substituents R67, OR67, SR67, S(O)R67, SO2R67C(O)R67, CO(O)R67, OC(O)R67, OC(O)OR67, NH2, Other67N(R67)2, NHC(O)R67, NR67C(O)R67NHS(O)2R67, NR67S(O)2R67, NHC(O)OR67, NR67C(O)OR67, NHC(O)NH2, NHC(O)other67, NHC(O)N(R67)2, NR67C(O)other67, NR67C(O)N(R67)2C(O)NH2C(O)other67C(O)N(R67)2C(O)NHOH, C(O)NHOR67C(O)NHSO2R67C(O)NR67SO2R67, SO2NH2, SO2Other67, SO2N(R67)2C(O)H, C(O)OH, C(N)NH2C(N)other67C(N)N(R67)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br Il is I;

R67represents alkyl, alkenyl, quinil, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen;

where the cyclic group corresponding to R57A, R58, R59, R60, R63, R64, R65and R67are unsubstituted or substituted one, or two, or three, or four of independently selected R68, OR68, SR68, S(O)R68, SO2R68C(O)R68, CO(O)R68, OC(O)R68, OC(O)OR68, NH2, Other68N(R68)2, NHC(O)R68, NR68C(O)R68NHS(O)2R68, NR68S(O)2R68, NHC(O)OR68, NR68C(O)OR68, NHC(O)NH2, NHC(O)other68, NHC(O)N(R68)2, NR68C(O)other68, NR68C(O)N(R68)2C(O)NH2C(O)other68C(O)N(R68)2C(O)NHOH, C(O)NHOR68C(O)NHSO2R68C(O)NR68SO2R68, SO2NH2, SO2Other68, SO2N(R68)2C(O)H, C(O)OH, C(N)NH2C(N)other68C(N)N(R68)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R68is an R69, R70, R71or R72;

R69represents phenyl, which is unfused or fused with R69A; R69Ais a be the angry heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R70is heteroaryl, which is unfused or fused with R70A; R70Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R71is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R71A; R71Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R72represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R73, OR73, SR73, S(o)R73, SO2R73C(O)R73, CO(O)R73, OC(O)R73, OC(O)OR73, NH2, Other73N(R73)2, NHC(O)R73, NR73C(O)R73NHS(O)2R73, NR73S(O)2R73, NHC(O)OR73, NR73C(O)OR73, NHC(O)NH2, NHC(O)other73, NHC(O)N(R73)2, NR73C(O)other73, NR73C(O)N(R73)2C(O)NH2C(O)other73C(O)N(R73)2C(O)NHOH, C(O)NHOR73, C(O)NHSO2R73With(O)NR73SO2R73, SO2NH2, SO2Other73, SO2N(R73 2C(O)H, C(O)OH, C(N)NH2With(N)other73C(N)N(R73)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R73represents alkyl, alkenyl, quinil, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen; and

where the group corresponding to R69, R70and R71are unsubstituted or substituted one, or two, or three, or four of independently selected NH2C(O)NH2C(O)NHOH, SO2NH2, CF3, CF2CF3C(O)H, C(O)OH, C(N)NH2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I.

Another variant implementation of the invention relates to compounds of formula (I), where

A1represents N or C(A2);

A2represents H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2NR 1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A;

B1represents H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A;

D1represents H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1 , OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A;

E1represents H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2 C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A; and

Y1represents H, CN, NO2C(O)OH, F, Cl, Br, I, CF3, OCF3, CF2CF3, OCF2CF3, R17, OR17C(O)R17C(O)OR17, SR17, SO2R17, NH2, Other17N(R17)2, NHC(O)R17C(O)NH2C(O)other17C(O)N(R17)2NHS(O)R17or NHSO2R17; or

E1and Y1together with the atoms to which they are attached, are benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

A2B1and D1independently selected from H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R )2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A; or

Y1and B1together with the atoms to which they are attached, are benzene, naftilan, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

A2D1and E1independently selected from H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, , Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A; or

A2and B1together with the atoms to which they are attached, are benzene, naftilan, heteroaryl cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen; and

D1, Ε1and Y1independently selected from H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1(CO)NC(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A; or

A2and D1together with the atoms to which they are attached, are benzene, naphthalene, heteroaryl, cycloalkyl, cycloalkene, the heterocycle is alkane or geteroseksualen; and

In1E1and Y1independently selected from H, R1, OR1, SR1, S(O)R1, SO2R1C(O)R1C(O)OR1, OC(O)R1, Other1N(R1)2C(O)other1C(O)N(R1)2, NHC(O)R1, NR1C(O)R1, NHC(O)OR1, NR1C(O)OR1, NHC(O)NH2, NHC(O)other1, NHC(O)N(R1)2, NR1C(O)other1, NR1C(O)N(R1)2, SO2NH2, SO2Other1, SO2N(R1)2, NHSO2R1, NR1SO2R1, NHSO2Other1, NHSO2N(R1)2, NR1SO2Other1, NR1SO2N(R1)2C(O)NHNOH, C(O)NHNOR1C(O)NHSO2R1C(NH)NH2C(NH)other1C(NH)N(R1)2, NHSO2Other1, NHSO2N(CH3R1N(CH3)SO2N(CH3R1, F, Cl, Br, I, CN, NO2N3, OH, C(O)H, CHNOH, CH(NOCH3), CF3C(O)OH, C(O)NH2or C(O)OR1A;

G1represents H or C(O)OR;

R represents alkyl;

R1is an R2, R3, R4or R5;

R1Ais cycloalkyl, cycloalkenyl or cycloalkenyl;

R2represents phenyl, which is unfused or fused with R2A; R2Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or heterotic Walken;

R3is heteroaryl, which is unfused or fused with R3A; R3Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R4is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R4A; R4Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R5represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R6, NC(R6A)(R6B), R7, OR7, SR7, S(O)R7, SO2R7, Other7N(R7)2C(O)R7C(O)NH2C(O)other7C(O)N(R7)2, NHC(O)R7, NR7C(O)R7, NHSO2R7, NHC(O)OR7, SO2NH2, SO2Other7, SO2N(R7)2, NHC(O)NH2, NHC(O)other7, NHC(O)CH(CH3)NHC(O)CH(CH3)NH2, NHC(O)CH(CH3)NHC(O)CH(CH3)Other7, OH, (O), C(O)OH, N3, CN, NH2, CF3, CF2CF3, F, Cl, Br or I;

R6represents a C2-C5-spiralcell, each of which is unsubstituted or substituted by OH, (O), N3CN, CF3, CF2 3, F, Cl, Br, I, NH2, NH(CH3) or N(CH3)2;

R6Aand R6Bindependently selected from alkyl or together with N to which they are attached, R6C;

R6Cis aziridine-1-yl, azetidin-1-yl, pyrrolidin-1-yl or piperidine-1-yl, each of which has one group CH2, unsubstituted or substituted by O, C(O), CNOH, CNOCH3, S, S(O), SO2or NH;

R7is an R8, R9, R10or R11;

R8represents phenyl, which is unfused or fused with R8A; R8Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R9is heteroaryl, which is unfused or fused with R9A; R9Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R10A; R10Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R11represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, the sludge is two, or three of independently selected R12, OR12, SR12, S(O)R12, SO2R12C(O)R12, CO(O)R12, OC(O)R12, OC(O)OR12, NH2, Other12N(R12)2, NHC(O)R12, NR12C(O)R12NHS(O)2R12, NR12S(O)2R12, NHC(O)OR12, NR12C(O)OR12, NHC(O)NH2, NHC(O)other12, NHC(O)N(R12)2, NR12C(O)other12, NR12C(O)N(R12)2C(O)NH2C(O)other12C(O)N(R12)2C(O)NHOH, C(O)NHOR12C(O)NHSO2R12C(O)NR12SO2R12, SO2NH2, SO2Other12, SO2N(R12)2C(O)H, C(O)OH, C(N)NH2C(N)other12C(N)N(R12)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R12is an R13, R14, R15or R16;

R13represents phenyl, which is unfused or fused with R13A; R13Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R14is heteroaryl, which is unfused or fused with R14A; R14Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R15is what my cycloalkane, cycloalken, geteroseksualen or geteroseksualen, each of which is unfused or fused with R15A; R15Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R16represents alkyl, alkenyl or quinil;

R17is an R18, R19, R20or R21;

R18represents phenyl, which is unfused or fused with R18A; R18Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R19is heteroaryl, which is unfused or fused with R19A; R19Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R20is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R20A; R20Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R21represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R22, OR22, SR 22, S(O)R22, SO2R22C(O)R22, CO(O)R22, OC(O)R22, OC(O)OR22, NH2, Other22N(R22)2, NHC(O)R22, NR22C(O)R22NHS(O)2R22, NR22S(O)2R22, NHC(O)OR22, NR22C(O)OR22, NHC(O)NH2, NHC(O)other22, NHC(O)N(R22)2, NR22C(O)other22, NR22C(O)N(R22)2C(O)NH2C(O)other22C(O)N(R22)2C(O)NHOH, C(O)NHOR22C(O)NHSO2R22C(O)NR22SO2R22, SO2NH2, SO2Other22, SO2N(R22)2C(O)H, C(O)OH, C(N)NH2C(N)other22C(N)N(R22)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R22is an R23, R24or R25;

R23represents phenyl, which is not condensed or fused with R23A; R23Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R24represents heteroaryl, which is unfused or fused with R24A; R24Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R25is cycloalkyl, cycloalkenyl, heteroseksualci or heterocyclic the sludge, each of which is unfused or fused with R25A; R25Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

Z1is an R26or R27;

Z2is an R28, R29or R30;

Z1Aand Z2Aboth were missing or taken together form CH2CH2CH2or Z12A;

Z12Arepresents a C2-C6-alkylen with one or two groups CH2replaced by NH, N(CH3), S, S(O) or SO2;

L1is an R37, OR37, SR37, S(O)R37, SO2R37C(O)R37, CO(O)R37, OC(O)R37, OC(O)OR37, Other37C(O)NH, C(O)NR37C(O)NHOR37C(O)NHSO2R37, SO2NH, SO2Other37C(N)NH, C(N)other37;

R26represents a phenylene, which is unfused or fused with R26A; R26Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R27represents heteroaryl, which is unfused or fused with R27A; R27Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R28represents Fe which ilen, which is unfused or fused with R28A; R28Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R29represents heteroaryl, which is unfused or fused with R29A; R29Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R30is cycloalkyl, cycloalkenyl, heterocyclochain or heterocyclization, each of which is unfused or fused with R30A; R30Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R37represents a bond, or R37A;

R37Ais alkylen, albaniles or akinyan, each of which is unsubstituted or substituted one, or two, or three independently selected substituents of R37B, OR37B, SR37B, S(O)R37B, SO2R37BC(O)R37B, CO(O)R37B, OC(O)R37B, OC(O)OR37B, NH2, Other37BN(R37B)2, NHC(O)R37B, NR37BC(O)R37BNHS(O)2R37B, NR37BSO2R37B, NHC(O)OR37B, NR37BC(O)OR37B, NHC(O)NH2, NHC(O)other37B, NHC(O)N(R37B)2, NR37BC(O)other37BN 37BC(O)N(R37B)2C(O)NH2C(O)other37BC(O)N(R37B)2C(O)NHOH, C(O)NHOR37BC(O)NHSO2R37BC(O)NR37BSO2R37B, SO2NH2, SO2Other37B, SO2N(R37B)2C(O)H, C(O)OH, C(N)NH2C(N)other37BC(N)N(R37B)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br and I;

R37Brepresents alkyl, alkenyl, quinil or R37C;

R37Crepresents phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen;

Z3is an R38, R39or R40;

R38represents phenyl, which is unfused or fused with R38A; R38Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R39is heteroaryl, which is unfused or fused with R39A; R39Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R40is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R40A; R40Arepresents a benzene, heteroa the Yong, cycloalkane, cycloalkene, geteroseksualen or geteroseksualen;

where the group corresponding to R26and R27substituted (i.e., if Ζ1Aand Z2Aare absent) or further substituted (i.e., if Z1Aand Z2Apresent) by R41, OR41, SR41, S(O)R41, SO2R41C(O)R41, CO(O)R41, OC(O)R41, OC(O)OR41, Other41N(R41)2, NHC(O)R41, NR41C(O)R41NHS(O)2R41, NR41S(O)2R41, NHC(O)OR41, NR41C(O)OR41, NHC(O)other41, NHC(O)N(R41)2, NR41C(O)other41, NR41C(O)N(R41)2C(O)other41C(O)N(R41)2C(O)NHOR41C(O)NHSO2R41C(O)NR41SO2R41, SO2Other41, SO2N(R41)2C(N)other41or C(N)N(R41)2;

R41is heteroaryl, which is condensed with R43A; R43Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen, which is condensed with benzene, heteroatom or R43B; R43Bis cycloalkane, cycloalkene, geteroseksualen or geteroseksualen;

where the cyclic group corresponding to E1and Y1together, Y1and B1together, A2and B1together, A2and D1together, R1A, R22A, R3, R3A, R4, R4A, R6, R6C, R8, R8A, R9, R9A, R10, R10A, R13, R13A, R14, R14A, R15, R15A, R18, R18A, R19, R19A, R20, R20A, R23, R23A, R24, R24A, R25, R25A, R26, R26A, R27, R27A, R28, R28A, R29, R29A, R30, R30A, R37B, R38, R38A, R39, R39A, R40and R40Ano not substituted, is not further substituted, substituted or optionally substituted with one, or two, or three, or four, or five of independently selected R57A, R57, OR57, SR57, S(O)R57, SO2R57C(O)R57, CO(O)R57, OC(O)R57, OC(O)OR57, NH2, Other57N(R57)2, NHC(O)R57, NR57C(O)R57NHS(O)2R57, NR57S(O)2R57, NHC(O)OR57, NR57C(O)OR57, NHC(O)NH2, NHC(O)other57, NHC(O)N(R57)2, NR57C(O)other57, NR57C(O)N(R57)2C(O)NH2C(O)other57C(O)N(R57)2C(O)NHOH, C(O)NHOR57C(O)NHSO2R57C(O)NR57SO2R57, SO2NH2, SO2Other57, SO2N(R57)2C(O)H, C(O)OH, C(N)NH2C(N)other57C(N)N(R57)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3 , CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R57Ais spiralcell or spiroheterocyclic;

R57is an R58, R59, R60or R61;

R58represents phenyl, which is unfused or fused with R58A; R58Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R59is heteroaryl, which is not condensed or fused with R59A; R59Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R60is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R60A; R60Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R61represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R62, OR62, SR62, S(O)R62, SO2R62C(O)R62, CO(O)R62, OC(O)R62, OC(O)OR62, NH2, Other62N(R62)2, NHC(O)R62, NR62C(O)R62NHS(O)2R 62, NR62S(O)2R62, NHC(O)OR62, NR62C(O)OR62, NHC(O)NH2, NHC(O)other62, NHC(O)N(R62)2, NR62C(O)other62, NR62C(O)N(R62)2C(O)NH2C(O)other62C(O)N(R62)2C(O)NHOH, C(O)NHOR62C(O)NHSO2R62C(O)NR62SO2R62, SO2NH2, SO2Other62, SO2N(R62)2C(O)H, C(O)OH, C(N)NH2C(N)other62C(N)N(R62)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R62is an R63, R64, R65or R66;

R63represents phenyl, which is unfused or fused with R63A; R63Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R64is heteroaryl, which is unfused or fused with R64A; R64Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R65is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, each of which is unfused or fused with R65A; R65Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, heterocycle is lcan or geteroseksualen;

R66represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected substituents R67, OR67, SR67, S(O)R67, SO2R67C(O)R67, CO(O)R67, OC(O)R67, OC(O)OR67, NH2, Other67N(R67)2, NHC(O)R67, NR67C(O)R67NHS(O)2R67, NR67S(O)2R67, NHC(O)OR67, NR67C(O)OR67, NHC(O)NH2, NHC(O)other67, NHC(O)N(R67)2, NR67C(O)other67, NR67C(O)N(R67)2C(O)NH2C(O)other67C(O)N(R67)2C()NHOH, C(O)NHOR67, C(O) NHSO2R67With(O)NR67SO2R67, SO2NH2, SO2Other67, SO2N(R67)2C(O)H, C(O)OH, C(N)NH2With(N)other67C(N)N(R67)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R67represents alkyl, alkenyl, quinil, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen;

where the cyclic group corresponding to R57A, R58, R59, R60, R63, R64, R65and R67are unsubstituted or substituted one, or two, or three, or four of independently selected R68, OR68, SR68, S(O)R68 , SO2R68C(O)R68, CO(O)R68, OC(O)R68, OC(O)OR68, NH2, Other68N(R68)2, NHC(O)R68, NR68C(O)R68NHS(O)2R68, NR68S(O)2R68, NHC(O)OR68, NR68C(O)OR68, NHC(O)NH2, NHC(O)other68, NHC(O)N(R68)2, NR68C(O)other68, NR68C(O)N(R68)2C(O)NH2C(O)other68C(O)N(R68)2C(O)NHOH, C(O)NHOR68, C (O)NHSO2R68With(O)NR68SO2R68, SO2NH2, SO2Other68, SO2N(R68)2C(O)H, C(O)OH, C(N)NH2With(N)other68C(N)N(R68)2, CNOH, CNOCH3HE, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R68is an R69, R70, R71or R72;

R69represents phenyl, which is unfused or fused with R69A; R69Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R70is heteroaryl, which is unfused or fused with R70A; R70Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R71is cycloalkyl, cycloalkenyl,

heteroseksualci or heterocyclic the sludge, each of which is unfused or fused with R7lA; R71Arepresents a benzene, heteroaryl, cycloalkyl, cycloalkene, geteroseksualen or geteroseksualen;

R72represents alkyl, alkenyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R73, OR73, SR73, S(O)R73, SO2R73C(O)R73, CO(O)R73, OC(O)R73, OC(O)OR73, NH2, Other73N(R73)2, NHC(O)R73, NR73C(O)R73NHS(O)2R73, NR73S(O)2R73, NHC(O)OR73, NR73C(O)OR73, NHC(O)NH2, NHC(O)other73, NHC(O)N(R73)2, NR73C(O)other73, NR73C(O)N(R73)2C(O)NH2C(O)other73C(O)N(R73)2C(O)NHOH, C(O)NHOR73, C(O)NHSO2R73With(O)NR73SO2R73, SO2NH2, SO2Other73, SO2N(R73)2C(O)H, C(O)OH, C(N)NH2With(N)other73C(N)N(R73)2, CNOH, CNOCH3, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I;

R73represents alkyl, alkenyl, quinil, phenyl, heteroaryl, cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen; and

where the group corresponding to R69, R70and R71are unsubstituted who or substituted by one, or two, or three, or four of independently selected NH2C(O)NH2C(O)NHOH, SO2NH2, CF3, CF2CF3C(O)H, C(O)OH, C(N)NH2, OH, (O), CN, N3, NO2, CF3, CF2CF3, OCF3, OCF2CF3, F, Cl, Br or I.

In one embodiment, formula (I), A1represents N, and G1represents H. In another embodiment of formula (I), A1represents a C(A2and G1represents H. In another embodiment of formula (I), A1represents a C(A2); A2represents H, F, Cl, Br or I; and G1represents H. In another embodiment of formula (I), A1represents a C(A2); A2represents H; and G1represents H.

In one embodiment, formula (I), B1is an R1, OR1, Other1, NHC(O)R1, F, Cl, Br or I. In another embodiment of formula (I), A1represents a C(A2); A2represents Η; B1represents other1and G1represents H. In another embodiment of formula (I), A1represents a C(A2); A2represents Η; B1is a OR1and G1represents H. In another embodiment of formula (I), 1represents a C(A2); A2represents Η; B1represents Cl; and G1represents H. In another embodiment of formula (I), A1represents a C(A2); A2represents Η; B1is an R1; and G1represents H. In another embodiment of formula (I), A1is a Ν;1represents other1; and G1represents H. In another embodiment of formula (I), A1is a Ν;1is a OR1; and G1represents H. In another embodiment of formula (I), A1represents N;1represents Cl; and G1represents H. In another embodiment of formula (I), A1is a Ν;1is an R1; and G1represents H.

In one embodiment, formula (I) D1represents Η or Cl. In another embodiment of formula (I) A1represents a C(A2); A2represents Η; B1represents other1; D1represents H; and G1represents H. In another embodiment of formula (I) A1represents a C(A2); A2represents Η; B1represents the t a other 1; D1represents Cl; and G1represents H. In another embodiment of formula (I) A1represents a C(A2); A2represents Η; B1is a OR1; D1represents H; and G1represents H. In another embodiment of formula (I) A1represents a C(A2); A2represents Η; B1represents Cl; D1represents H; and G1represents H. In another embodiment of formula (I), A1represents a C(A2); A2represents Η; B1is an R1; D1represents H; and G1represents H. In another embodiment of formula (I), A1is a Ν;1represents other1; D1represents H; and G1represents H. In another embodiment of formula (I) A1is a Ν;1represents other1; D1represents Cl; and G1represents H. In another embodiment of formula (I), A1is a Ν; B1is a OR1; D1represents H; and G1represents H. In another embodiment of formula (I) A1represents N; B1before the hat is Cl; D1represents H; and G1represents H. In another embodiment of formula (I), A1is a Ν; B1is an R1; D1represents H; and G1represents H.

In one embodiment, formula (I) E1represents H. In another embodiment of formula (I) A1represents a C(A2); A2represents Η; B1represents other1; D1represents Η; E1represents H; and G1represents H. In another embodiment of formula (I) A1represents a C(A2); A2represents Η; B1represents other1; E1represents H; D1represents Cl; and G1represents H. In another embodiment of formula (I) A1represents a C(A2); A2represents Η; B1is a OR1; D1represents Η; E1represents H; and G1represents H. In another embodiment of formula (I) A1represents a C(A2); A2represents Η; B1represents Cl; D1represents Η; E1represents H; and G1represents H. In another embodiment, implemented the formula I (I) A 1represents a C(A2); A2represents Η; B1is an R1; D1represents Η; E1represents H; and G1represents H. In another embodiment of formula (I) A1is a Ν; B1represents other1; D1represents Η; E1represents H; and G1represents H. In another embodiment of formula (I) A1is a Ν; B1represents other1; E1represents H; D1represents Cl, and G1represents H. In another embodiment of formula (I) A1is a Ν;1is a OR1; D1represents Η; Ε represents H; and G1represents H. In another embodiment of formula (I) A1is a Ν; B1represents Cl; D1represents Η; E1represents H; and G1represents H. In another embodiment of formula (I) A1is a Ν;1is an R1; D1represents Η; Ε represents H; and G1represents H.

In one embodiment, formula (I) Y1represents H, CN, NO2, F, Cl, Br, I, CF3, R1717, SR17, SO2R17or C(O)NH2. In another embodiment of formula (I) Y1represents H. In another embodiment of formula (I) Y1represents CN. In another embodiment of formula (I) Y1represents F, Cl, Br or I. In another embodiment of formula (I) Y1is a CF3. In another embodiment of formula (I) Y1represents SR17. In another embodiment of formula (I) Y1is a OR17. In another embodiment of formula (I) Y1represents NO2. In another embodiment of formula (I) Y1represents the SO2R17; where R17are as defined herein. In another embodiment of formula (I) Y1represents the SO2R17; where R17represents alkyl. In another embodiment of formula (I) Y1is an R17; where R17represents quinil. In another embodiment of formula (I) A1represents a C(A2); A2represents Η; B1represents other1; D1represents Η; E1represents H; G1represents H; and Y1represents NO2or SO2 R17; where R17represents an alkyl or quinil. In another embodiment of formula (I) A1represents a C(A2); A2represents Η; B1represents other1; D1represents Η; E1represents H; G1represents H; and Y1represents NO2. In another embodiment of formula (I) A1represents a C(A2); A2represents Η; B1represents other1; D1represents Η; E1represents H; G1represents H; and Y1represents the SO2R17; where R17represents alkyl, substituted with three F. In another embodiment of formula (I) A1is a Ν; B1represents other1; D1represents Η; E1represents H; G1represents H; and Y1represents NO2or SO2R17; where R17represents an alkyl or quinil. In another embodiment of formula (I) A1is a Ν; B1represents other1; D1represents Η; E1represents H; G1represents H; and Y1represents NO2. In another embodiment of formula (I) A1the stand is made by a Ν; B1represents other1; D1represents Η; E1represents H; G1represents H; and Y1represents the SO2R17; where R17represents alkyl, substituted with three F.

In one embodiment, formula (I) G1represents H; A1represents N or C(A2); and A2represents H. In another embodiment of formula (I) G1represents H; A1represents N or C(A2); A2represents H; and B1represents other1. In another embodiment of formula (I) G1represents H; A1represents N or C(A2); A2represents Η; B1represents other1; and D1represents H. In another embodiment of formula (I) G1represents H; A1represents N or C(A2); A2represents Η; B1represents other1; D1represents H; and Ε1represents H. In another embodiment of formula (I) G1represents H; A1represents N or C(A2); A2represents Η;1represents other1; D1represents Η; E1represents H; and Y1the present is the focus of a NO 2.

In one embodiment, formula (I) Y1and B1together with the atoms to which they are attached, are benzene. In another embodiment of formula (I) Y1and B1together with the atoms to which they are attached, represent heteroaryl. In another embodiment of formula (I) A1represents a C(A2); A2, G1E1and D1independently selected from H; and Y1and B1together with the atoms to which they are attached, are benzene. In another embodiment of formula (I) A1represents a C(A2); A2, G1E1and D1independently selected from H; and Y1and B1together with the atoms to which they are attached, represent heteroaryl.

In one embodiment, formula (I) R1is an R4or R5. In one embodiment, formula (I) R1is an R4. In one embodiment, formula (I) R1is an R5. In one embodiment, formula (I) R1is an R4; and R4is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen. In one embodiment, formula (I) R1is an R4; and R4represents C is cloacal or heteroseksualci. In one embodiment, formula (I) R1is an R4; and R4is cycloalkyl. In one embodiment, formula (I) R1is an R4; and R4is heteroseksualci.

In one embodiment, formula (I) R1is an R4; and R4is cycloalkyl; where R4is unsubstituted or substituted as defined herein. In another embodiment of formula (I) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring substituted as defined herein. In another embodiment of formula (I) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring substituted R57or N(R57)2. In another embodiment of formula (I) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; and R57is an R60. In another embodiment of formula (I) R1is an R4; R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where C is chlorexidine ring substituted R 57; R57is an R60; and R60is heteroseksualci. In another embodiment of formula (I) R1is an R4; R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R60; R60is heteroseksualci; where geteroseksualnoe ring is morpholinyl. In another embodiment of formula (I) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring substituted N(R57)2. In another embodiment of formula (I), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted N(R57)2. In another embodiment of formula (I) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted N(R57)2; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted R62. In another embodiment of formula (I) R1 is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted R62; R62is an R65; and R65is cycloalkyl. In another embodiment of formula (I) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R61; and R61represents alkyl, which is substituted by an R62; R62is an R65; and R65is cyclopropyl.

In one embodiment, formula (I) R1is an R4; and R4is heteroseksualci; where R4is unsubstituted or substituted as defined herein. In another embodiment of formula (I) R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring substituted as defined herein. In another embodiment of formula (I) R1is an R ; and R4is heteroseksualci; where geteroseksualnoe ring substituted R57. In another embodiment of formula (I) R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where geteroseksualnoe ring substituted R57; and R57is an R60or R61. In another embodiment of formula (I) R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted R57; R57is an R60or R61; R60is heteroseksualci; and R61represents alkyl. In another embodiment of formula (I) R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted R57; R57is an R60; R60is heteroseksualci; where heteroseksualci is tetrahydropyranyl. In another embodiment of formula (I) R is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted R57; R57is an R61; R61represents alkyl; and the alkyl is a methyl. In another embodiment of formula (I) R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted C(O)OR57; R57is an R61; R61represents alkyl; and the alkyl is a methyl.

In one embodiment, formula (I) R1is an R5; and R5represents alkyl, which is unsubstituted or substituted. In one embodiment, formula (I) R1is an R5; and R5represents alkyl, which is unsubstituted or substituted R7, OR7, OH, CN or F. In another embodiment of formula (I) R1is an R5; and R5represents alkyl, which is substituted by an R7, OR7, Other7or N(R7)2.

In one embodiment, formula (I) 7is an R8, R9, R10or R11which are unsubstituted or substituted as defined herein. In another embodiment of formula (I) R7is an R8which is unsubstituted or substituted as defined herein. In another embodiment of formula (I) R7is an R9which is unsubstituted or substituted as defined herein. In another embodiment of formula (I), R7is an R10which is unsubstituted or substituted as defined herein. In another embodiment of formula (I) R7is an R11which is unsubstituted or substituted as defined herein.

In one embodiment, formula (I) R8represents phenyl, which is unsubstituted or substituted as defined herein.

In one embodiment, formula (I) R9is heteroaryl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (I) R9is furanyl, which is unsubstituted or substituted as defined herein. In another variant is nThe implementation of the formula (I) R 9is furanyl, which is unsubstituted.

In one embodiment, formula (I) R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, heteroseksualci, which are unsubstituted or substituted as defined herein. In another embodiment of formula (I) R10is heteroseksualci, which is unsubstituted or substituted as defined herein. In another embodiment of formula (I) R10is tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, dioxane, oxetanyl, piperidinyl or pyrrolidinyl, which are unsubstituted or substituted as defined herein. In another embodiment of formula (I) R10is tetrahydropyranyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (I) R10is morpholinyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (I) R10is cycloalkyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (I) R10the present is the focus of cycloalkyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (I) R10represents cyclohexyl, cyclopropyl, cyclobutyl or bicyclo[2.2.1]heptenyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (I) R10is heteroseksualci, which is condensed with R10A; and R10Arepresents heteroaryl. In another embodiment of formula (I) R10is a 5,6,7,8-tetrahydroimidazo[1,2-a]pyridinyl.

In one embodiment, formula (I) R11represents alkyl, alkenyl or quinil, which are unsubstituted or substituted as defined herein. In another embodiment of formula (I) R11represents alkyl. In another embodiment of formula (I) R11represents methyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (I) R11represents alkyl, which is substituted as defined herein. In another embodiment of formula (I) R11represents alkyl, which is substituted by an R12, OR12or CF3. In another embodiment, the OS is the hope of the formula (I) R 11represents alkyl, which is substituted OR12, R12is an R16; and R16represents alkyl. In another embodiment of formula (I) R11represents alkyl, which is substituted CF3. In another embodiment of formula (I) R11represents alkyl, which is substituted by an R12; R12is an R14; and R14is heteroaryl.

In one embodiment, formula (I) A1represents N or C(A2);

A2represents H, F, Br, I or Cl;

B1is an R1, OR1, Other1, NHC(O)R1, F, Br, I or Cl;

D1represents H, F, Br, I or Cl;

E1represents H; and

Y1represents H, CN, NO2, F, Cl, Br, I, CF3, R17, OR17, SR17, SO2R17or C(O)NH2; or

Y1and B1together with the atoms to which they are attached, are benzene, heteroaryl or geteroseksualen; and

A2D1and E1independently selected from H;

G1represents H or C(O)OR;

R represents alkyl;

R1is an R4or R5;

R4is cycloalkyl or heteroseksualci;

R5represents an alkyl or quinil, each of which is s is unsubstituted or substituted one, or two, or three of independently selected R7, OR7, Other7N(R7)2, CN, OH, F, Cl, Br or I;

R7is an R8, R9, R10or R11;

R8represents phenyl;

R9is heteroaryl;

R10is cycloalkyl, cycloalkenyl or heteroseksualci; each of which is unfused or fused with R10A, R10arepresents heteroaryl;

R11represents alkyl, each of which is unsubstituted or substituted one, or two, or three of independently selected R12, OR12or CF3;

R12is an R14or R16;

R14is heteroaryl;

R16represents alkyl;

R17is an R21;

R21represents an alkyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R22, F, Cl, Br or I;

R22is an R25;

R25is heteroseksualci;

Z1is an R26;

Z2is an R30;

Z1Aand Z2Aboth are absent;

L1is an R37;

R26represents the phenyl is;

R30is heterocyclochain;

R37is an R37A;

R37Ais alkylene;

Z3is an R38or R40;

R38represents phenyl;

R40is cycloalkyl, cycloalkenyl or geteroseksualen;

where the group corresponding to R26substituted OR41;

R41is heteroaryl, which is condensed with R43A; R43Arepresents heteroaryl, which is unfused or fused with benzene;

where the cyclic group corresponding to Y1and B1together, R4, R8, R10, R25, R30, R38and R40, are independently unsubstituted, further unsubstituted, substituted or further substituted with one, or two, or three, or four, or five of independently selected R57A, R57, OR57, SO2R57C(O)R57, CO(O)R57C(O)N(R57)2, NH2, Other57N(R57)2, NHC(O)R57, NHSO2R57, OH, CN, (O), F, Cl, Br or I;

R57Ais spiralcell or spiroheterocyclic;

R57is an R58, R59, R60or R61;

R58represents phenyl;

R59is own the th heteroaryl;

R60is cycloalkyl or heteroseksualci;

R61represents alkyl which is unsubstituted or substituted one, or two, or three of independently selected R62, OR62N(R62)2C(O)OH, CN, F, Cl, Br or I;

R62is an R65or R66;

R65is cycloalkyl or heteroseksualci;

R66represents alkyl, which is unsubstituted or substituted OR67;

R67represents alkyl;

where the cyclic group corresponding to R57A, R58and R60are unsubstituted or substituted one, or two, or three, or four of independently selected R68, F, Cl, Br or I;

R68is an R71or R72;

R71is heteroseksualci; and

R72represents alkyl, which is unsubstituted or substituted by one or two f

Another variant of implementation relates to compounds of formula (I), which are

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({4-[(3-morpholine-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-ilok and)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

2-(9H-carbazole-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide;

2-(9H-carbazole-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3-pyrrolidin-1-ylpropyl)amino]phenyl}sulfonyl)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-Pierre is lo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-(2-naphthylmethyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-(tetrahydro-2H-Piran-4-ylethoxy) is enyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(2,2,2-triptorelin)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3,3,3-cryptochromes)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2S)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2R)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]Piri is in-5-yloxy)benzamide;

TRANS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[3-(aminocarbonyl)-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}Pipa is Azin-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-{[4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-(trifluoromethyl)phenyl]sulfonyl}benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;

TRANS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(1-methylpiperidin-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

5-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-(tetrahydro-2H-Piran-4-ylethoxy)nicotinamide;

N-({5-bromo-6-[(1-methylpiperidin-4-yl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-methylpiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(1,4-dioxane-2-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-bromo-6-(1,4-dioxane-2-ylethoxy)pyridine-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2,2-dimethylether-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-5-cyano-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-acetylpiperidine-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({2-chloro-5-fluoro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-morpholine-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(4-Porterage-2H-PI is an-4-yl)methoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(2-morpholine-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)oxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-bromo-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-cyanoethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-{[4-({4-[bis(cyclopropylmethyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-4-(4-{[2-(4-chlorine is phenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-methylpiperidin-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(morpholine-3-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-albut-2-inyl)oxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-ethinyl-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-oxo-3,4-dihydroquinazolin-6-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)su is hanil]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl-3-{[4-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-nitrophenoxy]methyl}morpholine-4-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(morpholine-3-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(methylsulphonyl)piperidine-4-yl]am is but}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,1-dissidocerida-2H-thiopyran-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-chloro-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[1-(2,2,2-triptorelin)piperidine-4-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)oxy]pyridin-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-isopropyl-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-5-fluoro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

and their therapeutically acceptable salts, and metabolites.

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4-FPO is tetrahydro-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(2,2-dottorati)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropylidene-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-morpholine-4-illlogical)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(dicyclopropyl)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-6,6-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-bromo-6-[(4-ethylmorpholine-3-yl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-ethylmorpholine-3-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(4-t is trihydro-2H-Piran-4-Immortalis-3-yl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-tetrahydro-2H-Piran-4-reparacin-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(tetrahydro-2H-Piran-4-ylmethyl)amino]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,1-diocletianopolis-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(4-aminotetraline-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(4-morpholine-4-illlogical)amino]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-cyano-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1S,3R)-3-morpholine-4-enciclopedie]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]METI the}piperazine-1-yl)-N-[(4-{[(1R,3S)-3-morpholine-4-enciclopedie]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(morpholine-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydrofuran-3-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[CIS-3-Porterage-2H-Piran-4-yl]piperidine-4-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydro-2H-Piran-4-ilisation-3-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydrofuran-3-ilisation-3-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-tetrahydro-2H-Piran-4-iparralde-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorine is enyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)-N-(4-((TRANS-4-hydroxycyclohexyl)methoxy)-3-nitrophenylarsonic)benzamide;

2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)-N-(4-((CIS-4-methoxycyclohexyl)methoxy)-3-nitrophenylarsonic)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(cyclopropylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(tetrahydro-2H-Piran-4-ylamino)cyclohexyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-({5-bromo-6-[(4-morpholine-4-illlogical)oxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl-4-{[4-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-nitrophenoxy]methyl}-4-foreperiod-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-foreperiod-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclo the KS-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(4-tetrahydro-2H-Piran-4-reparation-1-yl)cyclohexyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}methoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-1-tetrahydro-2H-Piran-4-iparralde-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2,2-dimethylether-2H-Piran-4-yl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-tetrahydro-2H-Piran-4-iparralde-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2,2-dimethylether-2H-Piran-4-yl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2-methoxyethyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;/p>

N-[(4-{[(4-acetylmorpholine-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[TRANS-4-(permitil)-1-oxetan-3-iparralde-3-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-Porterage-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-oxetan-3-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclobutylmethyl-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(2,2-dimethylether-2H-Piran-4-yl)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-cyclopropylboronic-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-and the]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydrofuran-3-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-cyclopropylboronic-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3S)-1-tetrahydro-2H-Piran-4-iparralde-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-hydroxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(methylsulphonyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(1-acetylpiperidine-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(methylsulphonyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-3,3-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]IU the Il}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]azetidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(methylsulphonyl)pyrrolidin-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(1-acetylpyrrolidine-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(3R)-1-acetylpyrrolidine-3-yl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-methoxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1R,3R)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1S,3S)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1S,3R)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-is)-N-{[4-({[(1R,3S)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-2-oxopiperidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({1-[2-fluoro-1-(permitil)ethyl]azetidin-3-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(1-oxetan-3-ilisation-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(1-oxetan-3-reparacin-4-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-cyclopropylidene-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2-foradil)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2,2-dottorati)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}p is perazin-1-yl)-N-({4-[(4-fluoro-1-oxetan-3-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(2S)-4,4-debtor-1-oxetan-3-iparralde-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(4-tetrahydro-2H-Piran-4-Immortalis-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclobutylmethyl-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(4-tetrahydrofuran-3-Immortalis-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropyl-4-foreperiod-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimetallic ohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[3-(triptoreline)benzyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-methoxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(deformedarse)benzyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxaspiro[4.5]Dec-8-ylamino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-[(4-{[4-(acetylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2,2-dottorati)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2-foradil)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2,2-dottorati)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2-foradil)pyrrole the Jn-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-oxetan-3-iparralde-3-yl]methoxy}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-hydroxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-hydroxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[3-(deformedarse)benzyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[CIS-3-morpholine-4-enciclopedie]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(methylsulphonyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropylidene-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({nitro-4-[(1-oxetan-3-reparacin-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-tetrahydro-2H-Piran-4-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-tetrahydrofuran-3-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-fluoro-1-(methylsulphonyl)piperidine-4-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-oxetan-3-iparralde-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-hydroxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[3-(dimethylamino)propoxy]benzyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(2-morpholine-4-ylethoxy)benzyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dime cyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(E)-4-hydroxy-1-substituted]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(Z)-4-hydroxy-1-substituted]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1S,4S)-bicyclo[2.2.1]hept-5-ene-2-ylethoxy]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-methyl-5-oxopyrrolidin-3-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,4R,5R,6S)-5,6-dihydroxybutyl[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,4R,5S,6R)-5,6-dihydroxybutyl[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3-oxocyclohexyl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohexane-1,3-Dien-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}the Pipera the Jn-1-yl)-N-{[4-({(3R)-1-[2-fluoro-1-(permitil)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[6-[(4-Porterage-2H-Piran-4-yl)methoxy]-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3S)-1-oxetan-3-iparralde-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-oxetan-3-iparralde-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({4-[2-(2-methoxyethoxy)ethyl]morpholine-2-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(cyanomethyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethyl logex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

(2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}morpholine-4-yl)acetic acid;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-(methylsulphonyl)-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methyltetrahydro-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

ethyl-4-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)piperazine-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[4-(morpholine-4-yl)piperidine-1-yl]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-1-(oxetan-3-yl)pyrrolidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-isopropylpiperazine-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-tert-butylpiperazine-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(2-methoxyethyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(cyanomethyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-methylpiperidin-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-debtor is opan-2-yl)pyrrolidin-3-yl]amino}pyridine-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamid;

tert-butyl-4-[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]piperazine-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-(pendaftar-λ6-sulfanyl)-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxytyramine-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]oxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(oxetan-3-yl)piperazine-1-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(tetrahydro-2H-Piran-4-yl)piperazine-1-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3R)-tetrahydrofuran-3-ylamino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex the-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4,4-diverticulosis)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-tert-butylpiperazine-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-({[4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(4-Porterage-2H-Piran-4-yl)methyl]amino}pyridine-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(1-cyclopropylidene-4-yl)amino]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-(cyanomethyl)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-(N,N-dimethylglycine)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2R)-4-(cyanomethyl)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-(5-chloro-6-{[(2R)-4-(N,N-dimethylglycine)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-fluoro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[3-hydroxy-2-(hydroxymethyl)-2-methylpropoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(1,3-ditropan-2-yl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(cyanomethyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({(3R)-1-[2-(2-methoxyethoxy)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(N,N-dimethylglycine)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dime icicles-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[1-(oxetan-3-yl)azetidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(cyanomethyl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2R)-4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2S)-4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(N,N-dimethylphenyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(2,2-dottorati)pyrrolidin-3-yl]oxy}pyridine-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(cyanomethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-methoxypiperidine-1-yl}-N-({5-chloro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-meth is keepered-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-(1,3-ditropan-2-yl)-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-(1,3-ditropan-2-yl)-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4-fluoro-1-methylpiperidin-4-yl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(N,N-dimethylphenyl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-foreperiod-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-the l)methyl]-4-foreperiod-1-yl}-N-({5-chloro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-(trifluoromethyl)phenyl}sulfonyl)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]oxy}pyridine-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[2-(tetrahydrofuran-3-yloxy)ethoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-cyanocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[2-(tetrahydro-2H-Piran-4-yl)ethoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(3-FuelMAX)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]labels and}pyridine-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamid;

N-[(5-chloro-6-{[(3R)-1-(2,2-dottorati)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(1,3-ditropan-2-yl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-fluoro-1-methylpiperidin-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-cyano-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(2,2-dottorati)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4,4-diverticulosis)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-and the]methyl}piperazine-1-yl)-N-{[6-{[1-(1,3-ditropan-2-yl)-4-foreperiod-4-yl]methoxy}-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b] pyridine-5-yloxy)benzamid;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-chloro-6-[2-(tetrahydrofuran-2-yl)ethoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}-3-methylpiperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[3-(cyclopropylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-chloro-6-(2-methoxyethoxy)pyridine-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-fluoro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(methoxyacetyl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(N,N-dimethylphenyl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohexyl]methyl}piperidine-1-yl)-N-({3-nitro-4-[(then it is carbonated the ro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-{[6-(tetrahydro-2H-Piran-4-ylethoxy)-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxycyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-cyano-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(TRANS-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(CIS-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4,4-debtor-1-hydroxycyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperidine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[TRANS-4-(morpholine-4-yl)cyclohexyl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-d is methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(1,3-thiazol-5-ylmethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(TRANS-4-hydroxycyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-chloro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-(trifluoromethyl)phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(2,2,2-triptorelin)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3,5-debtor-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(1-methyl-L-prolyl)piperidine-4-yl]meth is XI}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3,4-debtor-5-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-cyclopropylmethyl-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperidine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperidine-1-yl)-N-{[3-chloro-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

methyl-2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}morpholine-4-carboxylate;

2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(methylsulphonyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methylpiperazin-1-yl)-N-{[4-({3-[cyclobutyl(cyclopropyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-diverticulosis-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-chloro-4-(tetrahydrofuran-3-ylethoxy)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[9-(4-chlorophenyl)-3-(oxetan-3-yl)-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2R)-4-cyclopropylmethyl-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2S)-4-cyclopropylmethyl-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-the l)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-chloro-6-({4-[cyclopropyl(oxetan-3-yl)amino]cyclohexyl}methoxy)pyridine-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-cyclopropylmethyl-2-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

2-{[(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

(2S)-2-{[(3-chloro-5-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}pyridine-2-yl)oxy]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

N-[(5-chloro-6-{[(4-cyclopropylmethyl-2-yl)methyl]amino}pyridine-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

2-{[(3-chloro-5-{[4-(4-{[2-(4-chlorp the Nile)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}pyridine-2-yl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(1R,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2-cyanoethyl)(cyclopropyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(1R,2S,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyrid is n-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(CIS-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(3,3-debtorprovidian-1-yl)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2,2-diversicolor)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-1-fluoro-4-hydroxycyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorphen the l)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-(2-oxaspiro[3.5]non-7-ylethoxy)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-bis(permitil)cyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-cyclopropylmethyl-2-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-1-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-1-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-cyano-4-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorp the Nile)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5-(methoxymethyl)-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(2S)-4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2-cyanoethyl)(cyclopropyl)amino]-1-forcelogix}methoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-nitro-6-[(tetrahydro-2H-Piran-4-ylmethyl)amino]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(2-oxaspiro[3.5]non-7-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyano-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

{[4-(4-{[2-(4-chlorophenyl)-4,4-dim testicles-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)amino}Metreveli;

{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)amino}methylbutyrate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-{[3-(tetrahydro-2H-Piran-4-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridine-6-yl]sulfonyl}benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(6-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridine-3-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(5-cyano-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)morpholine-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(5-chloro-6-{[1-(1,3-the thiazole-2-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-d is methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(6-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridine-3-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide; and therapeutically acceptable salts, and metabolites.

Another variant of implementation refers to 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide; and therapeutically acceptable salts, and metabolites.

Another variant of implementation refers to the TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide and its therapeutically acceptable salts, and metabolites.

Another variant of implementation refers to CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide; and therapeutically acceptable salts, and metabolites.

Another variant of implementation refers to the TRANS-4-(4-{[2-(4-chlorphen is)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide and its therapeutically acceptable salts, and metabolites.

Another variant of implementation refers to 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide and its therapeutically acceptable salts, and metabolites.

Another variant of implementation refers to the compound N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection 4-[4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}(2H8)piperazine-1-yl]-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl} is sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation refers to the compound N-({5-bromo-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(methylsulphonyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation relates to compounds of formula (I) or formula (II), which are 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-HYDR the XI-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(methylsulphonyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide; or their pharmaceutically acceptable salts.

Another variant of implementation relates to compounds of formula (I) or formula (II), which are N-[(5-chloro-6-{[1-(cyanomethyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or their pharmaceutically acceptable salt.

Another variant of implementation relates to compounds of formula (I) or formula (II), which are 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-hydroxy-4-methylcyclohexyl)m is Tyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or their pharmaceutically acceptable salt.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation relates to compounds of formula (I) or formula (II), which are 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-tetrahydro-2H-Piran-4-iparralde-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or their pharmaceutically acceptable salt.

Another variant of implementation relates to compounds of formula (I) or formula (II), which are 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-bromo-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]pyridine-3-yl}solf the Nile)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(4-aminotetraline-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-tetrahydro-2H-Piran-4-iparralde-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(methylsulphonyl)pyrrolidin-3-yl]amino}-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxytyramine-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(cyanomethyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(1R,2S,4R,5R)-5-hydroxy-5-IU albicilla[2.2.1]hept-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(6-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridine-3-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or their pharmaceutically acceptable salt.

Another variant of implementation refers to the compound N-[(5-chloro-6-{[1-(cyanomethyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

Another variant of implementation relates to compounds of formula (I) or formula (II), which are N-[(4-{[(4-aminotetraline-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide; 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxytyramine-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or their pharmaceutically acceptable salt.

Another variant of implementation refers to the connection 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperaz the n-1-yl)-N-({4-[(4-methoxytyramine-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide or its pharmaceutically acceptable salt.

In another aspect, the present invention relates to compounds of the formula (II)

and their therapeutically acceptable salts, and metabolites,

where A1B1D1, Ε1, Υ1, Z2L1and Z3are as described herein for formula (II); n is 0, 1, 2 or 3 and describes the number of substituents on the Z1; and R100is as described for substituents on R26.

In one embodiment of formula (II), n is 0 or 1. In another embodiment of formula (II), n is 0.

In one embodiment of formula (II), A1represents N. In another embodiment of formula (II) A1represents a C(A2). In another embodiment of formula (II), A1represents a C(A2); and A2represents H, F, Cl, Br or I. In another embodiment of formula (II), A1represents a C(A2); and A2represents H.

In one embodiment of formula (II) B1is an R1, OR1, Other1, NHC(O)R1, F, Cl, Br, or I. In another embodiment of formula (II) A1represents a C(A2); A2represents H; and B1represents other1. In another embodiment of formula (II) A1the stand is made by a C(A 2); A2represents H; and B1is a OR1. In another embodiment of formula (II) A1represents a C(A2); A2represents H; and1represents Cl. In another embodiment of formula (II) A1represents a C(A2); A2represents H; and B1is an R1. In another embodiment of formula (II) A1represents N; and B1represents other1. In another embodiment of formula (II) A1represents N; and B1is a OR1. In another embodiment of formula (II) A1represents N; and B1represents Cl. In another embodiment of formula (II) A1represents N; and B1is an R1.

In one embodiment of formula (II) D1represents Η or Cl. In another embodiment of formula (II) A1represents a C(A2); A2represents Η; B1represents other1; and D1represents H. In another embodiment of formula (II) A1represents a C(A2); A2represents Η; B1represents other1; and D1represents Cl. In another embodiment, the shape of the s (II) A 1represents a C(A2); A2represents Η; B1is a OR1; and D1represents H. In another embodiment of formula (II) A1represents a C(A2); A2represents Η; Β1represents Cl; and (D1represents H. In another embodiment of formula (II) A1represents a C(A2); A2represents H; B1is an R1; and D1represents H. In another embodiment of formula (II) A1is a Ν; B1represents other1; and D1represents H. In another embodiment of formula (II) A1is a Ν;1represents other1; and D1represents Cl. In another embodiment of formula (II) A1is a Ν;1is a OR1; and D1represents H. In another embodiment of formula (II) A1is a Ν; B1represents Cl; and (D1represents H. In another embodiment of formula (II) A1represents N; B1is an R1; and D1represents H.

In one embodiment of formula (II) E1represents H. In another embodiment, implementation is tvline formula (II) A 1represents a C(A2); A2represents Η; B1represents other1; D1represents H; and E1represents H. In another embodiment of formula (II) A1represents a C(A2); A2represents Η; B1represents other1; E1represents H; and D1represents Cl. In another embodiment of formula (II) A1represents a C(A2); A2represents Η; B1is a OR1; D1represents H; and E1represents H. In another embodiment of formula (II) A1represents a C(A2); A2represents Η; B1represents Cl; D1represents H and E1represents H. In another embodiment of formula (II) A1represents a C(A2); A2represents Η; B1is an R1; D1represents H; and E1represents H. In another embodiment of formula (II) A1is a Ν;1represents other1; D1represents H; and Ε1represents H. In another embodiment of formula (II) A1is a Ν; B1represents other1; E1predstavljaet a H; and D1represents Cl. In another embodiment of formula (II) A1is a Ν; B1is a OR1; D1represents H; and E1represents H. In another embodiment of formula (II) A1is a Ν; B1represents Cl; D1represents H; and E1represents H. In another embodiment of formula (II) A1is a Ν; B1is an R1; D1represents H and E1represents H.

In one embodiment of formula (II) Y1represents H, CN, NO2, F, Cl, Br, I, CF3, R17, OR17, SR17, SO2R17or C(O)NH2. In another embodiment of formula (II) Y1represents H. In another embodiment of formula (II) Y1represents CN. In another embodiment of formula (II) Y1represents F, Cl, Br or I. In another embodiment of formula (II) Y1is a CF3. In another embodiment of formula (II) Y1represents SR17. In another embodiment of formula (II) Y1is a OR17. In another embodiment of formula (II) Y1represents NO2. In another embodiment, the ormula (II) Y 1represents the SO2R17; where R17is as defined herein. In another embodiment of formula (II) Y1represents the SO2R17; where R17represents alkyl. In another embodiment of formula (II) Y1is an R17; where R17represents quinil. In another embodiment of formula (II) A1represents a C(A2); A2represents Η; B1represents other1; D1represents Η; Ε1represents H; and Y1represents NO2or SO2R17; where R17represents an alkyl or quinil. In another embodiment of formula (II) A1represents a C(A2); A2represents Η; B1represents other1; D1represents Η; E1represents H; and Y1represents NO2. In another embodiment of formula (II) A1represents a C(A2); A2represents Η; B1represents other1; D1represents Η; E1represents H; and Y1represents the SO2R17; where R17represents alkyl, substituted with three F. In another embodiment of formula (II) A is a Ν; B1represents other1; D1represents Η; E1represents H; and Y1represents NO2or SO2R17; where R17represents an alkyl or quinil. In another embodiment of formula (II) A1is a Ν;1represents other1; D1represents Η; Ε1represents H; and Y1represents NO2. In another embodiment of formula (II) A1is a Ν; B1represents other1; D1represents Η; E1represents H; and Y represents a SO2R17; where R17represents alkyl, substituted with three F.

In one embodiment of formula (II) G1represents H; A1represents N or C(A2); and A2represents H. In another embodiment of formula (II) G1represents H; A1represents N or C(A2); A2represents H; and B1represents other1. In another embodiment of formula (II) G1represents H; A1represents N or C(A2); A2represents Η; B1represents other1; and D1represents H. In another embodiment, assests is of formula (II) G 1represents H; A1represents N or C(A2); A2represents Η; B1represents other1; D1represents H; and E1represents H. In another embodiment of formula (II) G1represents H; A1represents N or C(A2); A2represents Η; B1represents other1; D1represents Η; E1represents H; and Y1represents NO2.

In one embodiment of formula (II) Y1and B1together with the atoms to which they are attached, are benzene. In another embodiment of formula (II) Y1and B1together with the atoms to which they are attached, represent heteroaryl. In another embodiment of formula (II) A1represents a C(A2); A2, G1E1and D1independently selected from H; and Y1and B1together with the atoms to which they are attached, are benzene. In another embodiment of formula (II) A1represents a C(A2); A2, G1E1and D1independently selected from H; and Y1and B1together with the atoms to which they are attached, represent heteroaryl.

In one embodiment of formula (II) R1depict is to place an R 4or R5. In one embodiment of formula (II) R1is an R4. In one embodiment of formula (II) R1is an R5. In one embodiment of formula (II) R1is an R4; and R4is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen. In one embodiment of formula (II) R1is an R4; and R4is cycloalkyl or heteroseksualci. In one embodiment of formula (II) R1is an R4; and R4is cycloalkyl. In one embodiment of formula (II) R1is an R4; and R4is heteroseksualci.

In one embodiment of formula (II) R1is an R4; and R4is cycloalkyl; where R4is unsubstituted or substituted as defined herein. In another embodiment of formula (II) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring substituted as defined herein. In another embodiment of formula (II) R1is an R4; and R4is cycloalkyl; where cycloalkyl number is CH substituted R 57or N(R57)2. In another embodiment of formula (II) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; and R57is an R60. In another embodiment of formula (II) R1is an R4; R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R60; and R60is heteroseksualci. In another embodiment of formula (II) R1is an R4; R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R60; R60is heteroseksualci; where geteroseksualnoe ring is morpholinyl. In another embodiment of formula (II) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring substituted N(R57)2. In another embodiment of formula (II) R1is an R4; and R4is cycloalkyl; where cyclo is lilinoe ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted N(R57)2. In another embodiment of formula (II), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted N(R57)2; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted R62. In another embodiment of formula (II) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted R62; R62is an R65; and R65is cycloalkyl. In another embodiment of formula (II) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R61; and R61represents alkyl, which is substituted by an R62; R62is an R65; and R65is cyclopropyl.

In one embodiment, the OS is supervising the formula (II) R 1is an R4; and R4is heteroseksualci; where R4is unsubstituted or substituted as defined herein. In another embodiment of formula (II) R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring substituted as defined herein. In another embodiment of formula (II) R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring substituted R57. In another embodiment of formula (II) R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where geteroseksualnoe ring substituted R57; and R57is an R60or R61. In another embodiment of formula (II) R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted R57; R57is an R60or R61; R60is heteroseksualci; and R61represents alkyl. In another VA who ianthe implementation of the formula (II) R 1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted R57; R57is an R60; R60is heteroseksualci; where heteroseksualci is tetrahydropyranyl. In another embodiment of formula (II) R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted R57; R57is an R61; R61represents alkyl; and the alkyl is a methyl. In another embodiment of formula (II) R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted C(O)OR57; R57is an R61; R61represents alkyl; and the alkyl is a methyl.

In one embodiment of formula (II) R1is an R5; and R5represents alkyl, which is nezameshchenny is or replaced. In one embodiment of formula (II) R1is an R5; and R5represents alkyl, which is unsubstituted or substituted R7, OR7, OH, CN or F. In another embodiment of formula (II) R1is an R5; and R5represents alkyl, kotoeri substituted R7, OR7, Other7or N(R7)2.

In one embodiment of formula (II) R7is an R8, R9, R10or R11which are unsubstituted or substituted as defined herein. In another embodiment of formula (II) R7is an R8which is unsubstituted or substituted as defined herein. In another embodiment of formula (II) R7is an R9which is unsubstituted or substituted as defined herein. In another embodiment of formula (II), R7is an R10which is unsubstituted or substituted as defined herein. In another embodiment of formula (II) R7is an R11which is unsubstituted or substituted as defined herein.

In one embodiment of formula (II) R8represents phenyl which is unsubstituted or substituted, as defined in this document.

In one embodiment of formula (II) R9is heteroaryl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (II) R9is furanyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (II) R9is furanyl, which is unsubstituted.

In one embodiment of formula (II) R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, heteroseksualci, which are unsubstituted or substituted as defined herein. In another embodiment of formula (II) R10is heteroseksualci, which is unsubstituted or substituted as defined herein. In another embodiment of formula (II) R10is tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, dioxane, oxetanyl, piperidinyl or pyrrolidinyl, which are unsubstituted or substituted as defined herein. In another embodiment of formula (II) R10is tetrahydropyranyl, which is unsubstituted or substituted as defined is prohibited in this document. In another embodiment of formula (II) R10is morpholinyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (II) R10is cycloalkyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (II) R10is cycloalkyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (II) R10represents cyclohexyl, cyclopropyl, cyclobutyl or bicyclo[2.2.1]heptenyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (II) R10is heteroseksualci, which is condensed with R10A; and R10Arepresents heteroaryl. In another embodiment of formula (II) R10is a 5,6,7,8-tetrahydroimidazo[1,2-a]pyridinyl.

In one embodiment of formula (II) R11represents alkyl, alkenyl or quinil, which are unsubstituted or substituted as defined herein. In another embodiment of formula (II) R11represents alkyl. In another embodiment of formula (II) R1 represents methyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (II) R11represents alkyl, which is substituted as defined herein. In another embodiment of formula (II) R11represents alkyl, which is substituted by an R12, OR12or CF3. In another embodiment of formula (II) R11represents alkyl, which is substituted OR12; R12is an R16; and R16represents alkyl. In another embodiment of formula (II), R11represents alkyl, which is substituted CF3. In another embodiment of formula (II) R11represents alkyl, which is substituted by an R12, R12is an R14and R14is heteroaryl.

In one embodiment of formula (II)

n is 0;

A1represents N or C(A2);

A2represents H, F, Br, I or Cl;

B1is an R1, OR1, Other1, NHC(O)R1, F, Br, I or Cl;

D1represents H, F, Br, I or Cl;

E1represents H; and

Y1represents H, CN, NO2, F, Cl, Br, I, CF3, R17, OR17, SR17, SO2R17or C(O)NH2; Il the

Y1and B1together with the atoms to which they are attached, are benzene, heteroaryl or geteroseksualen; and

A2D1and E1independently selected from H;

R1is an R4or R5;

R4is cycloalkyl or heteroseksualci;

R5represents an alkyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R7, OR7, Other7N(R7)2, CN, OH, F, Cl, Br or I;

R7is an R8, R9, R10or R11;

R8represents phenyl;

R9is heteroaryl;

R10is cycloalkyl, cycloalkenyl or heteroseksualci, each of which is unfused or fused with R10A, R10Arepresents heteroaryl;

R11represents alkyl, each of which is unsubstituted or substituted one, or two, or three of independently selected R12, OR12or CF3;

R12is an R14or R16;

R14is heteroaryl;

R16represents alkyl;

R17is an R21;

R21represents an alkyl or quinil, each of the which is unsubstituted or substituted one, or two, or three of independently selected R22, F, Cl, Br or I;

R22is an R25;

R25is heteroseksualci;

Z2is an R30;

Z1Aand Z2Aboth are absent;

L1is an R37;

R30is heterocyclochain;

R37is an R37A;

R37Ais alkylene;

Z3is an R38or R40;

R38represents phenyl;

R40is cycloalkyl, cycloalkenyl or geteroseksualen;

where the cyclic group corresponding to Y1and B1together, R4, R8, R10, R25, R30, R38and R40are independently unsubstituted, further unsubstituted, substituted or further substituted with one, or two, or three, or four, or five of independently selected R57A, R57, OR57, SO2R57C(O)R57, CO(O)R57C(O)N(R57)2, NH2, Other57N(R57)2, NHC(O)R57NHS(O)2R57, OH, CN, (O), F, Cl, Br or I;

R57Ais spiralcell or spiroheterocyclic;

R57is an R58, R60or R61;

R58represents phenyl;

R60pre is is cycloalkyl or heteroseksualci;

R61represents alkyl, which is unsubstituted or substituted one, or two, or three of independently selected R62, OR62N(R62)2C(O)OH, CN, F, Cl, Br or I;

R62is an R65or R66;

R65is cycloalkyl or heteroseksualci;

R66represents alkyl, which is unsubstituted or substituted OR67;

R67represents alkyl;

where the cyclic group corresponding to R57A, R58and R60are unsubstituted or substituted one, or two, or three, or four of independently selected R68, F, Cl, Br or I;

R68is an R71or R72;

R71is heteroseksualci; and

R72represents alkyl, which is unsubstituted or substituted by one or two f

Another variant of implementation relates to compounds of the formula (II), which are

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({4-[(3-morpholine-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]METI the}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)su is hanil]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-(2-naphthylmethyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(2,2,2-triptorelin)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3,3,3-cryptochromes)amino]phenyl}sulfonyl)-2-(1H-feast of the olo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2S)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2R)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-and the methoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[3-(aminocarbonyl)-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-{[4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-(trifluoromethyl)phenyl]sulfonyl}benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}PI is erasin-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;

TRANS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino}-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(1-methylpiperidin-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

5-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-(tetrahydro-2H-Piran-4-ylethoxy)nicotinamide;

N-({5-bromo-6-[(1-methylpiperidin-4-yl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-methylpiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(1,4-dioxane-2-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-bromo-6-(1,4-dioxane-2-ylethoxy)pyridine-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-the l)-N-({4-[(2,2-dimethylether-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-5-cyano-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-acetylpiperidine-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({2-chloro-5-fluoro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-morpholine-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(2-morpholine-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[2-(2-methoxyethoxy)ethylsulfanyl}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)oxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-bromo-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-cyanoethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-{[4-({4-[bis(cyclopropylmethyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-methylpiperidin-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-[(morpholine-3-ylmethyl)amino]-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-albut-2-inyl)oxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-ethinyl-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-oxo-3,4-dihydroquinazolin-6-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]FeNi is}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl-3-{[4-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-nitrophenoxy]methyl}morpholine-4-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(morpholine-3-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(methylsulphonyl)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,1-dissidocerida-2H-thiopyran-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-chloro-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[1-(2,2,2-triptorelin)piperidine-4-yl]amine is}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)oxy]pyridin-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-isopropyl-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-5-fluoro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

and their therapeutically acceptable salts, and metabolites.

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(2,2-dottorati)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropylidene-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)Ben is amide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-morpholine-4-illlogical)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(dicyclopropyl)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-6,6-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-bromo-6-[(4-ethylmorpholine-3-yl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-ethylmorpholine-3-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(4-tetrahydro-2H-Piran-4-Immortalis-3-yl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-tetrahydro-2H-Piran-4-reparacin-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}the Pipera the Jn-1-yl)-N-({5-cyano-6-[(tetrahydro-2H-Piran-4-ylmethyl)amino]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,1-diocletianopolis-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(4-aminotetraline-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(4-morpholine-4-illlogical)amino]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-cyano-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1S,3R)-3-morpholine-4-enciclopedie]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,3S)-3-morpholine-4-enciclopedie]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(morpholine-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro--[(tetrahydrofuran-3-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[CIS-3-Porterage-2H-Piran-4-yl]piperidine-4-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydro-2H-Piran-4-ilisation-3-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydrofuran-3-ilisation-3-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-tetrahydro-2H-Piran-4-iparralde-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)-N-(4-((TRANS-4-hydroxycyclohexyl)methoxy)-3-nitrophenylarsonic)benzamide;

2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)-N-(4-((CIS-4-methoxycyclohexyl)methoxy)-3-nitrophenylarsonic)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimetallic ohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(cyclopropylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(tetrahydro-2H-Piran-4-ylamino)cyclohexyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-({5-bromo-6-[(4-morpholine-4-illlogical)oxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl-4-{[4-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-nitrophenoxy]methyl}-4-foreperiod-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-foreperiod-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(4-tetrahydro-2H-Piran-4-reparation-1-yl)cyclohexyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}methoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-1-tetrahydro-2H-Piran-4-iparralde-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2,2-dimethylether-2H-Piran-4-yl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-tetrahydro-2H-Piran-4-iparralde-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2,2-dimethylether-2H-Piran-4-yl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2-methoxyethyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(4-acetylmorpholine-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[TRANS-4-(permitil)-1-oxetan-3-iparralde-3-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-Porterage-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-oxetan-3-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclobutylmethyl-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(2,2-dimethylether-2H-Piran-4-yl)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-cyclopropylboronic-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydrofuran-3-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-cyclopropylboronic-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3S)-1-tetrahydro-2H-Piran-4-iparralde-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex--EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-hydroxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(methylsulphonyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(1-acetylpiperidine-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(methylsulphonyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-3,3-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]azetidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(methylsulphonyl)pyrrolidin-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(1-acetylpyrrolidine-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(3R)-1-acetylpyrrolidine-3-yl]amino}-3-nitrophen is)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-methoxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1R,3R)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1S,3S)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1S,3R)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1R,3S)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-2-oxopiperidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({1-[2-fluoro-1-(permitil)ethyl]azetidin-3-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperaz the n-1-yl)-N-[(3-nitro-4-{[(1-oxetan-3-ilisation-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(1-oxetan-3-reparacin-4-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-cyclopropylidene-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2-foradil)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2,2-dottorati)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-oxetan-3-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(2S)-4,4-debtor-1-oxetan-3-iparralde-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(4-tetrahydro-2H-Piran-4-Immortalis-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimetallic ohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclobutylmethyl-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(4-tetrahydrofuran-3-Immortalis-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropyl-4-foreperiod-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[3-(triptoreline)benzyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-methoxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(deformedarse)benzyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxaspiro the[4.5]Dec-8-ylamino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-[(4-{[4-(acetylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2,2-dottorati)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2-foradil)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2,2-dottorati)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2-foradil)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-oxetan-3-iparralde-3-yl]methoxy}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-hydroxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-HYDR shall kribensis)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[3-(deformedarse)benzyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[CIS-3-morpholine-4-enciclopedie]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(methylsulphonyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropylidene-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-oxetan-3-reparacin-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-tetrahydro-2H-Piran-4-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-tetrahydrofuran-3-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-fluoro-1-(methylsulphonyl)piperidine-4-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-oxetan-3-iparralde-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-hydroxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[3-(dimethylamino)propoxy]benzyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(2-morpholine-4-ylethoxy)benzyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(E)-4-hydroxy-1-substituted]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(Z)-4-hydroxy-1-substituted]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1S,4S)-bicyclo[2.2.1]hept-5-ene-2-ylethoxy]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-is)-N-({4-[(1-methyl-5-oxopyrrolidin-3-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,4R,5R,6S)-5,6-dihydroxybutyl[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,4R,5S,6R)-5,6-dihydroxybutyl[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3-oxocyclohexyl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohexane-1,3-Dien-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({(3R)-1-[2-fluoro-1-(permitil)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[6-[(4-Porterage-2H-Piran-4-yl)methoxy]-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3S)-1-oxetan-3-iparralde-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-({5-chloro-6-[(4-meth is Csillaghegy)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-oxetan-3-iparralde-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({4-[2-(2-methoxyethoxy)ethyl]morpholine-2-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(cyanomethyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

(2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}morpholine-4-yl)acetic acid;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N - {[3-nitro-4-({[4-oxetan-3-yl)morpholine-2-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-(methylsulphonyl)-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methyltetrahydro-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

ethyl-4-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)piperazine-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[4-(morpholine-4-yl)piperidine-1-yl]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-1-(oxetan-3-yl)pyrrolidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethyl who ekloges-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-isopropylpiperazine-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-tert-butylpiperazine-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(2-methoxyethyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(cyanomethyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-methylpiperidin-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]amino}pyridine-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl-4-[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]piperazine-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-(pendaftar-λ6-sulfanyl)-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-PI is henyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxytyramine-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]oxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(oxetan-3-yl)piperazine-1-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(tetrahydro-2H-Piran-4-yl)piperazine-1-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3R)-tetrahydrofuran-3-ylamino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4,4-diverticulosis)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-tert-butylpiperazine-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-({[4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(4-Porterage-2H-PI is an-4-yl)methyl]amino}pyridine-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(1-cyclopropylidene-4-yl)amino]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-(cyanomethyl)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-(N,N-dimethylglycine)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2R)-4-(cyanomethyl)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2R)-4-(N,N-dimethylglycine)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-fluoro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[3-hydroxy-2-(hydroxymethyl)-2-methylpropoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-d is methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(1,3-ditropan-2-yl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(cyanomethyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({(3R)-1-[2-(2-methoxyethoxy)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(N,N-dimethylglycine)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[1-(oxetan-3-yl)azetidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(cyanomethyl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2R)-4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dim testicles-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2S)-4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(N,N-dimethylphenyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(2,2-dottorati)pyrrolidin-3-yl]oxy}pyridine-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(cyanomethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-methoxypiperidine-1-yl}-N-({5-chloro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-methoxypiperidine-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-(1,3-ditropan-2-yl)-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-(1,3-ditropan-2-yl)-3-azaspiro[5.5]of the University of the EC-8-EN-8-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4-fluoro-1-methylpiperidin-4-yl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(N,N-dimethylphenyl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-foreperiod-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-{4-[(4'-chlorobiphenyl-2-yl)methyl]-4-foreperiod-1-yl}-N-({5-chloro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[9-(4-chlorophenyl)-3-isopropyl-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-(trifluoromethyl)phenyl}sulfonyl)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]oxy}pyridine-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]IU the Il}piperazine-1-yl)-N-({3-nitro-4-[2-(tetrahydrofuran-3-yloxy)ethoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-cyanocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[2-(tetrahydro-2H-Piran-4-yl)ethoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(3-FuelMAX)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(2,2-dottorati)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(1,3-ditropan-2-yl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-fluoro-1-methylpiperidin-4-yl) is ethoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-cyano-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(2,2-dottorati)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4,4-diverticulosis)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[6-{[1-(1,3-ditropan-2-yl)-4-foreperiod-4-yl]methoxy}-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-chloro-6-[2-(tetrahydrofuran-2-yl)ethoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}-3-methylpiperazin-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1 is the n-1-yl]methyl}piperazine-1-yl)-N-[(4-{[3-(cyclopropylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-chloro-6-(2-methoxyethoxy)pyridine-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-fluoro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(methoxyacetyl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(N,N-dimethylphenyl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohexyl]methyl}piperidine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-{[6-(tetrahydro-2H-Piran-4-ylethoxy)-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxycyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-tzia is about-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(TRANS-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(CIS-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4,4-debtor-1-hydroxycyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperidine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[TRANS-4-(morpholine-4-yl)cyclohexyl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(1,3-thiazol-5-ylmethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(TRANS-4-hydroxycyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-chloro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dim testicles-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-(trifluoromethyl)phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(2,2,2-triptorelin)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3,5-debtor-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(1-methyl-L-prolyl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3,4-debtor-5-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-cyclopropylmethyl-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-s is-1-yl]methyl}piperidine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperidine-1-yl)-N-{[3-chloro-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

methyl-2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}morpholine-4-carboxylate;

2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(methylsulphonyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclobutyl(cyclopropyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-diverticulosis-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]m is Teal}piperazine-1-yl)-N-{[3-chloro-4-(tetrahydrofuran-3-ylethoxy)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-diverticulosis-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[9-(4-chlorophenyl)-3-(oxetan-3-yl)-3-azaspiro[5.5]undec-8-EN-8-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2R)-4-cyclopropylmethyl-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2S)-4-cyclopropylmethyl-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-chloro-6-({4-[cyclopropyl(oxetan-3-yl)amino]cyclohexyl}methoxy)pyridine-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-cyclopropylmethyl-2-yl)labels and]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

2-{[(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

(2S)-2-{[(3-chloro-5-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}pyridine-2-yl)oxy]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

N-[(5-chloro-6-{[(4-cyclopropylmethyl-2-yl)methyl]amino}pyridine-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

2-{[(3-chloro-5-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}pyridine-2-yl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(1R,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-ml]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2-cyanoethyl)(cyclopropyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1R,2S,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(CIS-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamid

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(3,3-debtorprovidian-1-yl)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2,2-diversicolor)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-1-fluoro-4-hydroxycyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-(2-oxaspiro[3.5]non-7-ylethoxy)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-bis(f is ormetal)cyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-cyclopropylmethyl-2-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-1-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-1-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-cyano-4-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5-(methoxymethyl)-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(2S)-4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2-cyanoethyl)(cyclopropyl)amino]-1-forcelogix}methoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-nitro-6-[(tetrahydro-2H-Piran-4-ylmethyl)amino]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(2-oxaspiro[3.5]non-7-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyano-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-{[3-(tetrahydro-2H-Piran-4-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridine-6-yl]sulfonyl}benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(6-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridine-3-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-harfe who yl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(5-cyano-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)morpholine-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(5-chloro-6-{[1-(1,3-the thiazole-2-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(6-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridine-3-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5-methoxy-5-methylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide; and therapeutically acceptable salts, and metabolites.

In another aspect, the present invention relates to compounds of the formula (III)

and their therapeutically acceptable salts, and metabolites,

where A 1B1D1E1and Y1are as described herein for formula (I); R100is as described for substituents on R26; n is 0, 1, 2 or 3; R101is as described for substituents on R30; p is 0, 1, 2, 3, 4, 5 or 6; R102is as described for substituents on R40; q is 0, 1, 2, 3, 4, 5 or 6; R103is as described for substituents on R58; and r is 0, 1, 2, 3, or 4.

In one embodiment of formula (III), each of n, p, r and q are equal to 0.

In one embodiment of formula (III), A1represents N. In another embodiment of formula (III), A1represents a C(A2). In another embodiment of formula (III), A1represents a C(A2); and A2represents H, F, Cl, Br or I. In another embodiment of formula (III), A1represents a C(A2); and A2represents H.

In one embodiment of formula (III) B1is an R1, OR1, Other1, NHC(O)R1, F, Cl, Br or I. In another embodiment of formula (III) (A1represents a C(A2); A2represents H; and B1represents other1. In another embodiment of formula (III) (A1represents a C(A2); A2 represents H; and B1is a OR1. In another embodiment of formula (III) (A1represents a C(A2); A2represents H; and1represents Cl. In another embodiment of formula (III) (A1represents a C(A2); A2represents H; and B1is an R1. In another embodiment of formula (III) (A1represents N; and B1represents other1. In another embodiment of formula (III) (A1represents N; and B1is a OR1. In another embodiment of formula (III) (A1represents N; and B1represents Cl. In another embodiment of formula (III) (A1represents N; and B1is an R1.

In one embodiment of formula (III) D1represents Η or Cl. In another embodiment of formula (III) (A1represents a C(A2); A2represents Η; B1represents other1; and D1represents H. In another embodiment of formula (III) (A1represents a C(A2); A2represents Η; B1represents other1; and D1represents Cl. In another embodiment of formula (III) (A1 represents a C(A2); A2represents Η; B1is a OR1; and D1represents H. In another embodiment of formula (III) (A1represents a C(A2); A2represents Η;1represents Cl; and (D1represents H. In another embodiment of formula (III) (A1represents a C(A2); A2represents Η; B1is an R1; and D1represents H. In another embodiment of formula (III) (A1is a Ν; B1represents other1; and D1represents H. In another embodiment of formula (III) (A1is a Ν; B1represents other1; and D1represents Cl. In another embodiment of formula (III) (A1is a Ν;1is a OR1; and D1represents H. In another embodiment of formula (III) (A1is a Ν; B1represents Cl; and (D1represents H. In another embodiment of formula (III) (A1is a Ν; B1is an R1and D1represents H.

In one embodiment of formula (III) E1represents H. In another embodiment, implementation is tvline formula (III) (A 1represents a C(A2); A2represents Η; B1represents other1; D1represents H; and E1represents H. In another embodiment of formula (III) (A1represents a C(A2); A2represents Η; B1represents other1; E1represents H; and D1represents Cl. In another embodiment of formula (III) (A1represents a C(A2); A2represents Η; B1is a OR1; D1represents H; and E1represents H. In another embodiment of formula (III) (A1represents a C(A2); A2represents Η; B1represents Cl; D1represents H; and E1represents H. In another embodiment of formula (III) (A1represents a C(A2); A2represents Η; B1is an R1; D1represents H; and E1represents H. In another embodiment of formula (III) (A1is a Ν;1represents other1; D1represents H; and Ε1represents H. In another embodiment of formula (III) (A1is a Ν; B1represents other1; E1 represents H; and D1represents Cl. In another embodiment of formula (III) (A1is a Ν;1is a OR1; D1represents H; and Ε1represents H. In another embodiment of formula (III) (A1is a Ν; B1represents Cl; D1represents H; and E1represents H. In another embodiment of formula (III) (A1is a Ν; B1is an R1; D1represents H; and E1represents H.

In one embodiment of formula (III) Y1represents H, CN, NO2, F, Cl, Br, I, CF3, R17, OR17, SR17, SO2R17or C(O)NH2. In another embodiment of formula (III) Y1represents H. In another embodiment of formula (III) Y1represents CN. In another embodiment of formula (III) Y1represents F, Cl, Br or I. In another embodiment of formula (III) Y1is a CF3. In another embodiment of formula (III) Y1represents SR17. In another embodiment of formula (III) Y1is a OR17. In another embodiment of formula (III) Y1represents ΝΟ2. In d the natives embodiment of formula (III) Y 1represents the SO2R17; where R17is as defined herein. In another embodiment of formula (III) Y1represents the SO2R17; where R17represents alkyl. In another embodiment of formula (III) Y1is an R17; where R17represents quinil. In another embodiment of formula (III) (A1represents a C(A2); A2represents Η; B1represents other1; D1represents Η; Ε1represents H; and Y1represents NO2or SO2R17; where R17represents an alkyl or quinil. In another embodiment of formula (III) (A1represents a C(A2); A2represents Η; B1represents other1; D1represents Η; E1represents H; and Y1represents NO2. In another embodiment of formula (III) (A1represents a C(A2); A2represents Η; B1represents other1; D1represents Η; E1represents H; and Y1represents the SO2R17; where R17represents alkyl, substituted with three F. In another embodiment of formula (III) Asup> 1is a Ν; B1represents other1; D1represents Η; E1represents H; and Y1represents NO2or SO2R17; where R17represents an alkyl or quinil. In another embodiment of formula (III) (A1is a Ν;1represents other1; D1represents Η; Ε1represents H; and Y1represents NO2. In another embodiment of formula (III) (A1is a Ν; B1represents other1; D1represents Η; E1represents H; and Y1represents the SO2R17; where R17represents alkyl, substituted with three F.

In one embodiment of formula (III) Y1and B1together with the atoms to which they are attached, are benzene. In another embodiment of formula (III) Y1and B1together with the atoms to which they are attached, represent heteroaryl. In another embodiment of formula (III) (A1represents a C(A2); A2, G1E1and D1independently selected from H; and Y1and B1together with the atoms to which they are attached, are benzene. In another embodiment of formula (III) (A1pre is is C(A 2); A2, G1E1and D1independently selected from H; and Y1and B1together with the atoms to which they are attached, represent heteroaryl.

In one embodiment of formula (III), R1is an R4or R5. In one embodiment of formula (III), R1is an R4. In one embodiment of formula (III), R1is an R5. In one embodiment of formula (III), R1is an R4; and R4is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen. In one embodiment of formula (III), R1is an R4; and R4is cycloalkyl or heteroseksualci. In one embodiment of formula (III), R1is an R4; and R4is cycloalkyl. In one embodiment of formula (III), R1is an R4; and R4is heteroseksualci.

In one embodiment of formula (III), R1is an R4; and R4is cycloalkyl; where R4is unsubstituted or substituted as defined herein. In another embodiment of formula (III), R1is an R4; and R4pre is is cycloalkyl; where cycloalkyl ring substituted as defined herein. In another embodiment of formula (III), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring substituted R57or N(R57)2. In another embodiment of formula (III), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; and R57is an R60. In another embodiment of formula (III), R1is an R4; R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R60; and R60is heteroseksualci. In another embodiment of formula (III), R1is an R4; R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R60; R60is heteroseksualci; where geteroseksualnoe ring is morpholinyl. In another embodiment of formula (III), R1represents the FDS is th R 4; and R4is cycloalkyl; where cycloalkyl ring substituted N(R57)2. In another embodiment of formula (III), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted N(R57)2. In another embodiment of formula (III), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted N(R57)2. R57is an R61; and R61represents alkyl, which is unsubstituted or substituted R62. In another embodiment of formula (III), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted R62; R62is an R65; and R65is cycloalkyl. In another embodiment of formula (III), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring before the hat is cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R61; and R61represents alkyl, which is substituted by an R62; R62is an R65; and R65is cyclopropyl.

In one embodiment of formula (III), R1is an R4; and R4is heteroseksualci; where R4is unsubstituted or substituted as defined herein. In another embodiment of formula (III), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring substituted as defined herein. In another embodiment of formula (III), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring substituted R57. In another embodiment of formula (III), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where geteroseksualnoe ring substituted R57; and R57is an R60or R61. In another embodiment of formula (III), R1is an R4; R4is heteroseksualci; where heterocy alkylene ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted R57; R57is an R60or R61; R60is heteroseksualci; and R61represents alkyl. In another embodiment of formula (III), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted R57; R57is an R60; R60is heteroseksualci; where heteroseksualci is tetrahydropyranyl. In another embodiment of formula (III), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted R57; R57is an R61; R61represents alkyl; and the alkyl is a methyl. In another embodiment of formula (III), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted C(O)OR57; R7 is an R61; R61represents alkyl; and the alkyl is a methyl.

In one embodiment of formula (III), R1is an R5; and R5represents alkyl, which is unsubstituted or substituted. In one embodiment of formula (III), R1is an R5; and R5represents alkyl, which is unsubstituted or substituted R7, OR7, OH, CN or F. In another embodiment of formula (III), R1is an R5; and R5represents alkyl, which is substituted by an R7, OR7, Other7or N(R7)2.

In one embodiment of formula (III), R7is an R8, R9, R10or R11which are unsubstituted or substituted as defined herein. In another embodiment of formula (III), R7is an R8which is unsubstituted or substituted as defined herein. In another embodiment of formula (III), R7is an R9which is unsubstituted or substituted as defined herein. In another embodiment of formula (III), R7is an R10which is unsubstituted or substituted as defined in the present document. In another embodiment of formula (III), R7is an R11which is unsubstituted or substituted as defined herein.

In one embodiment of formula (III), R8represents phenyl, which is unsubstituted or substituted as defined herein.

In one embodiment of formula (III), R9is heteroaryl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (III), R9is furanyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (III), R9is furanyl, which is unsubstituted.

In one embodiment of formula (III), R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, heteroseksualci, which are unsubstituted or substituted as defined herein. In another embodiment of formula (III), R10is heteroseksualci, which is unsubstituted or substituted as defined herein. In another embodiment of formula (III), R10is tetrahydrofuranyl, tetrahydropyranyl, m is holiner, dioxane, oxetanyl, piperidinyl or pyrrolidinyl, which are unsubstituted or substituted as defined herein. In another embodiment of formula (III), R10is tetrahydropyranyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (III), R10is morpholinyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (III), R10is cycloalkyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (III), R10is cycloalkyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (III), R10represents cyclohexyl, cyclopropyl, cyclobutyl or bicyclo[2.2.1]heptenyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (III), R10is heteroseksualci, which is fused with R10A; and R10Arepresents heteroaryl. In another embodiment of formula (III), R10is a 5,6,7,8-tetrahydroimidazo[1,2-a]pyridine is.

In one embodiment of formula (III), R11represents alkyl, alkenyl or quinil, which are unsubstituted or substituted as defined herein. In another embodiment of formula (III), R11represents alkyl. In another embodiment of formula (III), R11represents methyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (III), R11represents alkyl, which is substituted as defined herein. In another embodiment of formula (III), R11represents alkyl, which is substituted by an R12, OR12or CF3. In another embodiment of formula (III), R11represents alkyl, which is substituted OR12; R12is an R16; and R16represents alkyl. In another embodiment of formula (III), R11represents alkyl, which is substituted CF3. In another embodiment of formula (III), R11represents alkyl, which is substituted by an R12; R12is an R14; and R14is heteroaryl.

In one embodiment of formula (III)

each of n, p, r and q are 0;

A1represents N or C(A2);

A2before the hat is H, F, Br, I or Cl;

B1is an R1, OR1, Other1, NHC(O)R1, F, Br, I or Cl;

D1represents H, F, Br, I or Cl;

E1represents H; and

Y1represents H, CN, NO2, F, Cl, Br, I, CF3, R17, OR17, SR17, SO2R17or C(O)NH2; or

Y1and B1together with the atoms to which they are attached, are benzene, heteroaryl or geteroseksualen; and

A2D1and E1independently selected from H;

R1is an R4or R5;

R4is cycloalkyl or heteroseksualci;

R5represents an alkyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R7, OR7, Other7N(R7)2, CN, OH, F, Cl, Br or I;

R7is an R8, R9, R10or R11;

R8represents phenyl;

R9is heteroaryl;

R10is cycloalkyl, cycloalkenyl, or heteroseksualci, each of which is unfused or fused with R10A, R10Arepresents heteroaryl;

R11represents alkyl, each of which is unsubstituted or substituted one, or two, and the three of independently selected R 12, OR12or CF3;

R12is an R14or R16;

R14is heteroaryl;

R16represents alkyl;

R17is an R21;

R21represents an alkyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R22, F, Cl, Br or I;

R22is an R25;

R25is heteroseksualci;

where the cyclic group corresponding to Y1and B1together, R4, R8, R10and R25, are independently unsubstituted, further unsubstituted, substituted or further substituted with one, or two, or three, or four, or five of independently selected R57A, R57, OR57, SO2R57C(O)R57, CO(O)R57C(O)N(R57)2, NH2, Other57N(R57)2, NHC(O)R57, NHSO2R57, OH, CN, (O), F, Cl, Br or I;

R57Ais spiralcell or spiroheterocyclic;

R57is an R58, R60or R61;

R58represents phenyl;

R60is cycloalkyl or heteroseksualci;

R61represents alkyl, which is unsubstituted or substituted one, or two, and the three of independently selected R 62, OR62N(R62)2C(O)OH, CN, F, Cl, Br or I;

R62is an R65or R66;

R65is cycloalkyl or heteroseksualci;

R66represents alkyl, which is unsubstituted or substituted OR67;

R67represents alkyl;

where the cyclic group corresponding to R57A, R58and R60are unsubstituted or substituted one, or two, or three, or four of independently selected R68, F, Cl, Br or I;

R68is an R71or R72;

R71is heteroseksualci; and

R72represents alkyl, which is unsubstituted or substituted by one or two f

Another variant of implementation relates to compounds of the formula (III), which are

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrol the[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-(2-naphthylmethyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridi the-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(2,2,2-triptorelin)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3,3,3-cryptochromes)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2S)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2R)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}su is hanil)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[3-(aminocarbonyl)-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

5-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-(tetrahydro-2H-Piran-4-ylethoxy)nicotinamide;

N-({5-bromo-6-[(1-methylpiperidin-4-yl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-�lorgeril)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-methylpiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(1,4-dioxane-2-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-bromo-6-(1,4-dioxane-2-ylethoxy)pyridine-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2,2-dimethylether-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-5-cyano-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-acetylpiperidine-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({2-chloro-5-fluoro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-morpholine-4-ylpropyl)amine is]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(2-morpholine-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)oxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-bromo-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-cyanoethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[4-({4-[bis(cyclopropylmethyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-4-(4-{[2-(4-chlorphen the l)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-methylpiperidin-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(morpholine-3-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-albut-2-inyl)oxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-ethinyl-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-oxo-3,4-dihydroquinazolin-6-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl-3-{[4-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-nitrophenoxy]methyl}morpholine-4-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(morpholine-3-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(methylsulphonyl)piperidine-4-yl]amino}-3-nitrophenyl) is sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,1-dissidocerida-2H-thiopyran-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-chloro-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[1-(2,2,2-triptorelin)piperidine-4-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)oxy]pyridin-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-isopropyl-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-5-fluoro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)--(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(2,2-dottorati)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropylidene-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-morpholine-4-illlogical)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(dicyclopropyl)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-bromo-6-[(4-ethylmorpholine-3-yl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-ethylmorpholine-3-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(4-tetrahydro-2H-Piran-4-Immortalis-3-yl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-who and Jethro-4-{[(3S)-1-tetrahydro-2H-Piran-4-reparacin-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(tetrahydro-2H-Piran-4-ylmethyl)amino]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,1-diocletianopolis-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(4-aminotetraline-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(4-morpholine-4-illlogical)amino]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-cyano-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1S,3R)-3-morpholine-4-enciclopedie]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,3S)-3-morpholine-4-enciclopedie]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperaz the n-1-yl)-N-({4-[(morpholine-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydrofuran-3-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[CIS-3-Porterage-2H-Piran-4-yl]piperidine-4-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydro-2H-Piran-4-ilisation-3-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydrofuran-3-ilisation-3-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-tetrahydro-2H-Piran-4-iparralde-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)-N-(4-((TRANS-4-hydroxycyclohexyl)methoxy)-3-nitrophenylarsonic)benzamide;

2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)-N-(4-((CIS-4-methoxycyclohexyl)methoxy)-3-nitrophenylarsonic)benzamide;

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex the C-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(cyclopropylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(tetrahydro-2H-Piran-4-ylamino)cyclohexyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-({5-bromo-6-[(4-morpholine-4-illlogical)oxy]pyridin-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl-4-{[4-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-nitrophenoxy]methyl}-4-foreperiod-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-foreperiod-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(4-tetrahydro-2H-Piran-4-reparation-1-yl)cyclohexyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}methoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-1-tetrahydro-2H-Piran-4-iparralde-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2,2-dimethylether-2H-Piran-4-yl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-tetrahydro-2H-Piran-4-iparralde-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2,2-dimethylether-2H-Piran-4-yl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methylmorpholin-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2-methoxyethyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(4-acetylmorpholine-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[TRANS-4-(permitil)-1-oxetan-3-iparralde-3-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-Porterage-2H-Piran-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-oxetan-3-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclobutylmethyl-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(2,2-dimethylether-2H-Piran-4-yl)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-cyclopropylboronic-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydrofuran-3-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-cyclopropylboronic-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3S)-1-tetrahydro-2H-Piran-4-iparralde-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex--EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-hydroxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(methylsulphonyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(1-acetylpiperidine-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(methylsulphonyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({1-[2-fluoro-1-(permitil)ethyl]azetidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(methylsulphonyl)pyrrolidin-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(1-acetylpyrrolidine-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(4-{[(3R)-1-acetylpyrrolidine-3-yl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methylpiperazin-1-yl)-N-({4-[(3-methoxy-2,2-dimethylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1R,3R)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1S,3S)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1S,3R)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(1R,3S)-3-hydroxycyclopent]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-2-oxopiperidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({1-[2-fluoro-1-(permitil)ethyl]azetidin-3-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(1-oxetan-3-ilisation-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}p is perazin-1-yl)-N-[(3-nitro-4-{[(1-oxetan-3-reparacin-4-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-cyclopropylidene-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2-foradil)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(2,2-dottorati)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-oxetan-3-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(2S)-4,4-debtor-1-oxetan-3-iparralde-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(4-tetrahydro-2H-Piran-4-Immortalis-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclobutylmethyl-3-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclo the CEN-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(4-tetrahydrofuran-3-Immortalis-3-yl)methyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({1-[2-fluoro-1-(permitil)ethyl]piperidine-4-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropyl-4-foreperiod-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[3-(triptoreline)benzyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-methoxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(deformedarse)benzyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxaspiro[4.5]Dec-8-ylamino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-[(4-{[4-(acetylamino)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclo the KS-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2,2-dottorati)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2-foradil)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3S)-1-(2,2-dottorati)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(2-foradil)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-oxetan-3-iparralde-3-yl]methoxy}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-hydroxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-hydroxybenzyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[3-(deformedarse)benzo is l]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[CIS-3-morpholine-4-enciclopedie]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(methylsulphonyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-cyclopropylidene-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-oxetan-3-reparacin-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-tetrahydro-2H-Piran-4-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-tetrahydrofuran-3-reparacin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-fluoro-1-(methylsulphonyl)piperidine-4-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3R)-1-oxetan-3-iparralde-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-hydroxycyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[3-(dimethylamino)propoxy]benzyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(2-morpholine-4-ylethoxy)benzyl]amino}-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(E)-4-hydroxy-1-substituted]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(Z)-4-hydroxy-1-substituted]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1S,4S)-bicyclo[2.2.1]hept-5-ene-2-ylethoxy]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-methyl-5-oxopyrrolidin-3-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,4,5 R,6S)-5,6-dihydroxybutyl[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1R,4R,5S,6R)-5,6-dihydroxybutyl[2.2.1]hept-2-yl]methoxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3-oxocyclohexyl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({(3R)-1-[2-fluoro-1-(permitil)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[6-[(4-Porterage-2H-Piran-4-yl)methoxy]-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(3S)-1-oxetan-3-iparralde-3-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-N-({5-chloro-6-[(4-methoxycyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethyl logex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-1-oxetan-3-iparralde-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[({4-[2-(2-methoxyethoxy)ethyl]morpholine-2-yl}methyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(cyanomethyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

(2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}morpholine-4-yl)acetic acid;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-(methylsulphonyl)-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethy cyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methyltetrahydro-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

ethyl-4-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)piperazine-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[4-(morpholine-4-yl)piperidine-1-yl]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-1-(oxetan-3-yl)pyrrolidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]amino}-3-[(trifluoromethyl)sulfonyl]phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-isopropylpiperazine-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-tert-butylpiperazine-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{4-({[1-(2-methoxyethyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[1-(cyanomethyl)piperidine-3-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-fluoro-1-methylpiperidin-4-yl)methoxy]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]amino}pyridine-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

tert-butyl-4-[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]piperazine-1-carboxylate;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-(pendaftar-λ6-sulfanyl)-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methoxytyramine-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]oxy}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

<> 4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(oxetan-3-yl)piperazine-1-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[4-(tetrahydro-2H-Piran-4-yl)piperazine-1-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3R)-tetrahydrofuran-3-ylamino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4,4-diverticulosis)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({4-[(1-tert-butylpiperazine-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-({[4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(4-Porterage-2H-Piran-4-yl)methyl]amino}pyridine-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(1-cyclopropylidene-4-the l)amino]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-(cyanomethyl)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-(N,N-dimethylglycine)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2R)-4-(cyanomethyl)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2R)-4-(N,N-dimethylglycine)morpholine-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-fluoro-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[3-hydroxy-2-(hydroxymethyl)-2-methylpropoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dim testicles-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(1,3-ditropan-2-yl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(cyanomethyl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({(3R)-1-[2-(2-methoxyethoxy)ethyl]pyrrolidin-3-yl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(N,N-dimethylglycine)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[1-(oxetan-3-yl)azetidin-3-yl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(cyanomethyl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2R)-4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2S)-4-(N,N-dimethylglycine)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(N,N-dimethyl ITIL)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(2,2-dottorati)pyrrolidin-3-yl]oxy}pyridine-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(3R)-1-(cyanomethyl)pyrrolidin-3-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4-fluoro-1-methylpiperidin-4-yl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(N,N-dimethylphenyl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]oxy}pyridine-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[2-(tetrahydrofuran-3-yloxy)ethoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-cyanocyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)Pipa is one-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[2-(tetrahydro-2H-Piran-4-yl)ethoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(3-FuelMAX)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(1,3-ditropan-2-yl)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(3R)-1-(2,2-dottorati)pyrrolidin-3-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(1,3-ditropan-2-yl)-4-foreperiod-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-fluoro-1-methylpiperidin-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-cyano-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[1-(2,2-dottorati)-4-foreperiod-4-yl]methoxy}Piri is INF-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(4,4-diverticulosis)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[6-{[1-(1,3-ditropan-2-yl)-4-foreperiod-4-yl]methoxy}-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-chloro-6-[2-(tetrahydrofuran-2-yl)ethoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[3-(cyclopropylamino)propyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-chloro-6-(2-methoxyethoxy)pyridine-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-fluoro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(methoxyacetyl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(N,N-dimethylphenyl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-{[6-(tetrahydro-2H-Piran-4-ylethoxy)-5-(trifluoromethyl)pyridin-3-yl]sulfonyl}benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxycyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-cyano-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(TRANS-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({6-[(CIS-4-methoxycyclohexyl)methoxy]-5-(trifluoromethyl)pyridin-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[TRANS-4-(morpholine-4-yl)cyclohexyl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dime cyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(1,3-thiazol-5-ylmethyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(TRANS-4-hydroxycyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-chloro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-(trifluoromethyl)phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(2,2,2-triptorelin)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3,5-debtor-4-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclopropyl(oxetan-3-yl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[1-(1-methyl-L-prolyl)piperidine-4-yl]meth is XI}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3,4-debtor-5-[(4-Porterage-2H-Piran-4-yl)methoxy]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(2S)-4-cyclopropylmethyl-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

methyl-2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}morpholine-4-carboxylate;

2-{[(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(methylsulphonyl)morpholine-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({3-[cyclobutyl(cyclopropyl)amino]propyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethyl logex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-chloro-4-(tetrahydrofuran-3-ylethoxy)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2R)-4-cyclopropylmethyl-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[(2S)-4-cyclopropylmethyl-2-yl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-{[5-chloro-6-({4-[cyclopropyl(oxetan-3-yl)amino]cyclohexyl}methoxy)pyridine-3-yl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(4-cyclopropylmethyl-2-yl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(3-chloro-4-{[(4-cyclopropylmethyl-2-yl)methyl]amino}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

2-{[(2-chloro-4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]meth is l}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}phenyl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

(2S)-2-{[(3-chloro-5-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}pyridine-2-yl)oxy]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

N-[(5-chloro-6-{[(4-cyclopropylmethyl-2-yl)methyl]amino}pyridine-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

2-{[(3-chloro-5-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}pyridine-2-yl)amino]methyl}-N-ethyl-N-methylmorpholin-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(1R,2R,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2-cyanoethyl)(cyclopropyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]feast the DIN-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(5,6,7,8-tetrahydroimidazo[1,2-a]pyridine-6-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[(1R,2S,4R,5R)-5-hydroxy-5-methylbicyclo[2.2.1]hept-2-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(CIS-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-[(5-chloro-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-4-(4-{[5-(4-chlorophenyl)Spiro[2.5]Oct-5-EN-6-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[4-(3,3-debtorprovidian-1-yl)cyclohexyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-CHL is R-6-[(CIS-4-hydroxy-4-methylcyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2,2-diversicolor)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-1-fluoro-4-hydroxycyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-(2-oxaspiro[3.5]non-7-ylethoxy)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-cyclopropylmethyl-2-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(TRANS-1-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({5-chloro-6-[(CIS-1-fluoro-4-hydroxy-4-methylcyclohexyl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-immiscibles-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-cyano-4-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(TRANS-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(CIS-4-ethyl-4-hydroxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-({[(2S)-4-(oxetan-3-yl)morpholine-2-yl]methyl}amino)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-({3-chloro-4-[(TRANS-4-hydroxy-4-methylcyclohexyl)methoxy]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({4-[(2-cyanoethyl)(cyclopropyl)amino]-1-forcelogix}methoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-nitro-6-[(tetrahydro-2H-Piran-4-ylmethyl)amino]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(2-oxaspiro[3.5]non-7-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-44-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-cyano-4-methylcyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-{[3-(tetrahydro-2H-Piran-4-ylmethyl)-3H-[1,2,3]triazolo[4,5-b]pyridine-6-yl]sulfonyl}benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(6-{[(TRANS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridine-3-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(5-cyano-6-{[4-fluoro-1-(oxetan-3-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

N-(4-{[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]sulfamoyl}-2-nitrophenyl)morpholine-4-carboxamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-({[4-(methoxymethyl)cyclohexyl]methyl}amino)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(5-chloro-6-{[1-(1,3-the thiazole-2-yl)piperidine-4-yl]methoxy}pyridin-3-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(6-{[(CIS-4-hydroxy-4-methylcyclohexyl)methyl]amino}-5-nitropyridine-3-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide; and therapeutically acceptable is haunted salts and metabolites.

In another aspect, the present invention relates to compounds of the formula (IV)

and their therapeutically acceptable salts, and metabolites,

where A1B1D1E1and Y1are as described herein for formula (I); R100is as described for substituents on R26; n is 0, 1, 2 or 3; R101is as described for substituents on R30; p is 0, 1, 2, 3, 4, 5 or 6; R104is as described for substituents on R38; s is 0, 1, 2, 3, 4, 5 or 6; R103is as described for substituents on R58; and r is 0, 1, 2, 3, or 4.

In one embodiment of formula (IV), each of n, p, r and s is equal to 0.

In one embodiment of formula (IV), A1represents N. In another embodiment of formula (IV), A1represents a C(A2). In another embodiment of formula (IV), A1represents a C(A2); and A2represents H, F, Cl, Br or I. In another embodiment of formula (IV), A1represents a C(A2and A2represents H.

In one embodiment of formula (IV), B1is an R1, OR1, Other1, NHC(O)R1, F, Cl, Br, or I. In another embodiment of formula (IV), A1is the Wallpaper C(A 2); A2represents H; and B1represents other1. In another embodiment of formula (IV), A1represents a C(A2); A2represents H; and B1is a OR1. In another embodiment of formula (IV), A1represents a C(A2); A2represents H; and B1represents Cl. In another embodiment of formula (IV), A1represents a C(A2); A2represents H; and B1is an R1. In another embodiment of formula (IV), A1represents N; and B1represents other1. In another embodiment of formula (IV), A1represents N; and B1is a OR1. In another embodiment of formula (IV), A1represents N; and B1represents Cl. In another embodiment of formula (IV), A1represents N; and B1is an R1.

In one embodiment of formula (IV) D1represents Η or Cl. In another embodiment of formula (IV), A1represents a C(A2); A2represents Η; B1represents other1; and D1represents H. In another embodiment of formula (IV), A1is the Wallpaper C(A 2); A2represents Η; B1represents other1; and D1represents Cl. In another embodiment of formula (IV), A1represents a C(A2); A2represents Η; B1is a OR1; and D1represents H. In another embodiment of formula (IV), A1represents a C(A2); A2represents Η;1represents Cl; and (D1represents H. In another embodiment of formula (IV), A1represents a C(A2); A2represents Η; B1is an R1; and D1represents H. In another embodiment of formula (IV), A1is a Ν; B1represents other1; and D1represents H. In another embodiment of formula (IV), A1is a Ν; B1represents other1; and D1represents Cl. In another embodiment of formula (IV), A1is a Ν;1is a OR1; and D1represents H. In another embodiment of formula (IV), A1is a Ν; B1represents Cl; and (D1represents H. In another embodiment of formula (IV), A1is a Ν; B1depict is to place an R 1; and D1represents H.

In one embodiment of formula (IV) E1represents H. In another embodiment of formula (IV), A1represents a C(A2); A2represents Η; B1represents other1; D1represents H; and E1represents H. In another embodiment of formula (IV), A1represents a C(A2); A2represents Η; B1represents other1; E1represents H; and D1represents Cl. In another embodiment of formula (IV), A1represents a C(A2); A2represents Η; B1is a OR1; D1represents H; and E1represents H. In another embodiment of formula (IV), A1represents a C(A2); A2represents Η; B1represents Cl; D1represents H; and E1represents H. In another embodiment of formula (IV), A1represents a C(A2); A2represents Η; B1is an R1; D1represents H; and E1represents H. In another embodiment of formula (IV), A1is a Ν;1represents other1; D1isone H; and Ε1represents H. In another embodiment of formula (IV), A1is a Ν; B1represents other1; E1represents H; and D1represents Cl. In another embodiment of formula (IV), A1is a Ν;1is a OR1; D1represents H; and Ε1represents H. In another embodiment of formula (IV), A1is a Ν; B1represents Cl; D1represents H; and E1represents H. In another embodiment of formula (IV), A1is a Ν; B1is an R1; D1represents H; and E1represents H.

In one embodiment of formula (IV) Y1represents H, CN, NO2, F, Cl, Br, I, CF3, R17, OR17, SR17, SO2R17or C(O)NH2. In another embodiment of formula (IV) Y1represents H. In another embodiment of formula (IV) Y1represents CN. In another embodiment of formula (IV) Y1represents F, Cl, Br or I. In another embodiment of formula (IV) Y1is a CF3. In another embodiment of formula (IV) Y1represents SR17. In another embodiment, the OS is the hope of the formula (IV) Y 1is a OR17. In another embodiment of formula (IV) Y1represents NO2. In another embodiment of formula (IV) Y1represents the SO2R17; where R17is as defined herein. In another embodiment of formula (IV) Y1represents the SO2R17; where R17represents alkyl. In another embodiment of formula (IV) Y1is an R17; where R17represents quinil. In another embodiment of formula (IV), A1represents a C(A2); A2represents Η; B1represents other1; D1represents Η; Ε1represents H; and Y1represents NO2or SO2R17; where R17represents an alkyl or quinil. In another embodiment of formula (IV), A1represents a C(A2); A2represents Η; B1represents other1; D1represents Η; E1represents H; and Y1represents NO2. In another embodiment of formula (IV), A1represents a C(A2); A2represents Η; B1represents other1; D1represents Η; E1our opinion is t H a; and Y1represents the SO2R17; where R17represents alkyl, substituted with three F. In another embodiment of formula (IV), A1is a Ν; B1represents other1; D1represents Η; E1represents H; and Y1represents NO2or SO2R17; where R17represents an alkyl or quinil. In another embodiment of formula (IV), A1is a Ν;1represents other1; D1represents Η; Ε1represents H; and Y1represents NO2. In another embodiment of formula (IV), A1is a Ν; B1represents other1; D1represents Η; E1represents H; and Y1represents the SO2R17; where R17represents alkyl, substituted with three F.

In one embodiment of formula (IV) Y1and B1together with the atoms to which they are attached, are benzene. In another embodiment of formula (IV) Y1and B1together with the atoms to which they are attached, represent heteroaryl. In another embodiment of formula (IV), A1represents a C(A2); A2, G1E1and D1independently selected symptom; and Y1and B1together with the atoms to which they are attached, are benzene. In another embodiment of formula (IV), A1represents a C(A2); A2, G1E1and D1independently selected from H; and Y1and B1together with the atoms to which they are attached, represent heteroaryl.

In one embodiment of formula (IV) R1is an R4or R5. In one embodiment of formula (IV) R1is an R4. In one embodiment of formula (IV) R1is an R5. In one embodiment of formula (IV) R1is an R4; and R4is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen. In one embodiment of formula (IV) R1is an R4; and R4is cycloalkyl or heteroseksualci. In one embodiment of formula (IV) R1is an R4; and R4is cycloalkyl. In one embodiment of formula (IV) R1is an R4; and R4is heteroseksualci.

In one embodiment of formula (IV) R1is an R4; and R4is cycloalkyl; where R4JW is aetsa unsubstituted or substituted, as defined herein. In another embodiment of formula (IV) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring substituted as defined herein. In another embodiment of formula (IV) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring substituted R57or N(R57)2. In another embodiment of formula (IV) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; and R57is an R60. In another embodiment of formula (IV) R1is an R4; R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R60; and R60is heteroseksualci. In another embodiment of formula (IV) R1is an R4; R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R60; R60is the battle heteroseksualci; where geteroseksualnoe ring is morpholinyl. In another embodiment of formula (IV) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring substituted N(R57)2. In another embodiment of formula (IV) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted N(R57)2. In another embodiment of formula (IV) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted N(R57)2; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted R62. In another embodiment of formula (IV) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted R62, R62is an R65; and R65is cycloalkyl. In other variations is the implementation of the formula (IV) R 1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R61; and R61represents alkyl, which is substituted by an R62; R62is an R65; and R65is cyclopropyl.

In one embodiment of formula (IV) R1is an R4; and R4is heteroseksualci; where R4is unsubstituted or substituted as defined herein. In another embodiment of formula (IV) R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring substituted as defined herein. In another embodiment of formula (IV) R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring substituted R57. In another embodiment of formula (IV) R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where geteroseksualnoe ring substituted R57; and R57is an R60or R61. Another is ariante implementation of the formula (IV) R 1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted R57; R57is an R60or R61; R60is heteroseksualci; and R61represents alkyl. In another embodiment of formula (IV) R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted R57; R57is an R60; R60is heteroseksualci; where heteroseksualci is tetrahydropyranyl. In another embodiment of formula (IV) R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted R57; R57is an R61; R61represents alkyl; and the alkyl is a methyl. In another embodiment of formula (IV) R1is an R4; R4is heterocyclyl is l; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted C(O)OR57; R57is an R61; R61represents alkyl; and the alkyl is a methyl.

In one embodiment of formula (IV) R1is an R5; and R5represents alkyl, which is unsubstituted or substituted. In one embodiment of formula (IV) R1is an R5; and R5represents alkyl, which is unsubstituted or substituted R7, OR7, OH, CN or F. In another embodiment of formula (IV) R1is an R5; and R5represents alkyl, which is substituted by an R7, OR7, Other7or N(R7)2.

In one embodiment of formula (IV) R7is an R8, R9, R10or R11which are unsubstituted or substituted as defined herein. In another embodiment of formula (IV) R7is an R8which is unsubstituted or substituted as defined herein. In another embodiment of formula (IV) R7is an R9which is unsubstituted or substituted as defined in the present document. In another embodiment of formula (IV) R7is an R10which is unsubstituted or substituted as defined herein. In another embodiment of formula (IV) R7is an R11which is unsubstituted or substituted as defined herein.

In one embodiment of formula (IV) R8represents phenyl, which is unsubstituted or substituted as defined herein.

In one embodiment of formula (IV) R9is heteroaryl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (IV) R9is furanyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (IV) R9is furanyl, which is unsubstituted.

In one embodiment of formula (IV) R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, heteroseksualci, which are unsubstituted or substituted as defined herein. In another embodiment of formula (IV) R10is heteroseksualci, which is unsubstituted or C is substituted, as defined herein. In another embodiment of formula (IV) R10is tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, dioxane, oxetanyl, piperidinyl or pyrrolidinyl, which are unsubstituted or substituted as defined herein. In another embodiment of formula (IV) R10is tetrahydropyranyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (IV) R10is morpholinyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (IV) R10is cycloalkyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (IV) R10is cycloalkyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (IV) R10represents cyclohexyl, cyclopropyl, cyclobutyl or bicyclo[2.2.1]heptenyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (IV) R10is heteroseksualci, which is fused with R10A ; and R10Arepresents heteroaryl. In another embodiment of formula (IV) R10is a 5,6,7,8-tetrahydroimidazo[1,2-a]pyridinyl.

In one embodiment of formula (IV) R11represents alkyl, alkenyl or quinil, which are unsubstituted or substituted as defined herein. In another embodiment of formula (IV) R11represents alkyl. In another embodiment of formula (IV) R11represents methyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (IV) R11represents alkyl, which is substituted as defined herein. In another embodiment of formula (IV) R11represents alkyl, which is substituted by an R12, OR12or CF3. In another embodiment of formula (IV) R11represents alkyl, which is substituted OR12; R12is an R16; and R16represents alkyl. In another embodiment of formula (IV), R11represents alkyl, which is substituted CF3. In another embodiment of formula (IV) R11represents alkyl, which is substituted by an R12, R12is an R14and R14is a GE is Eroare.

In one embodiment of formula (IV)

each of n, p, r, and s is 0;

A1represents N or C(A2);

A2represents H, F, Br, I or Cl;

B1is an R1, OR1, Other1, NHC(O)R1, F, Br, I or Cl;

D1represents H, F, Br, I or Cl;

E1represents H; and

Y1represents H, CN, NO2, F, Cl, Br, I, CF3, R17, OR17, SR17, SO2R17or C(O)NH2; or

Y1and B1together with the atoms to which they are attached, are benzene, heteroaryl or geteroseksualen; and

A2D1and E1independently selected from H;

R1is an R4or R5;

R4is cycloalkyl or heteroseksualci;

R5represents an alkyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R7, OR7, Other7N(R7)2, CN, OH, F, Cl, Br or I;

R7is an R8, R9, R10or R11;

R8represents phenyl;

R9is heteroaryl;

R10is cycloalkyl, cycloalkenyl, or heteroseksualci; each of which is unfused or fused with R10A , R10Arepresents heteroaryl;

R11represents alkyl, each of which is unsubstituted or substituted one, or two, or three of independently selected R12, OR12or CF3;

R12is an R14or R16;

R14is heteroaryl;

R16represents alkyl;

R17is an R21;

R21represents an alkyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R22, F, Cl, Br or I;

R22is an R25;

R25is heteroseksualci;

where the cyclic group corresponding to Y1and B1together, R4, R8, R10and R25, are independently unsubstituted, further unsubstituted, substituted or further substituted with one, or two, or three, or four, or five of independently selected R57A, R57, OR57, SO2R57C(O)R57, CO(O)R57C(O)N(R57)2, NH2, Other57N(R57)2, NHC(O)R57, NHSO2R57, OH, CN, (O), F, Cl, Br or I;

R57Ais spiralcell or spiroheterocyclic;

R57is an R58, R60or R61;

R58before the hat is phenyl;

R60is cycloalkyl or heteroseksualci;

R61represents alkyl, which is unsubstituted or substituted one, or two, or three of independently selected R62, OR62N(R62)2C(O)OH, CN, F, Cl, Br or I;

R62is an R65or R66;

R65is cycloalkyl or heteroseksualci;

R66represents alkyl, which is unsubstituted or substituted OR67;

R67represents alkyl;

where the cyclic group corresponding to R57A, R58and R60are unsubstituted or substituted one, or two, or three, or four of independently selected R68, F, Cl, Br or I;

R68is an R71or R72;

R71is heteroseksualci; and

R72represents alkyl, which is unsubstituted or substituted by one or two f

Another variant of implementation relates to compounds of the formula (IV), which are 4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide; 4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({4-[(3-morpholine-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzo the ID; and their therapeutically acceptable salts, and metabolites.

In another aspect, the present invention relates to compounds of the formula (V)

and their therapeutically acceptable salts, and metabolites,

where A1B1D1E1and Y1are as described herein for formula (I); R100is as described for substituents on R26; n is 0, 1, 2 or 3; R101is the same as described for zamestitelei R30; p is 0, 1, 2, 3, 4, 5 or 6; R105is as described for substituents on R40; t is 0, 1, 2, 3 or 4; R103is as described for substituents on R58; and r is 0, 1, 2, 3, or 4.

In one embodiment of formula (V), each of n, p, r and t are equal to 0.

In one embodiment of formula (V), A1represents N. In another embodiment of formula (V), A1represents a C(A2). In another embodiment of formula (V), A1represents a C(A2); and A2represents H, F, Cl, Br or I. In another embodiment of formula (V), A1represents a C(A2); and A2represents H.

In one embodiment of formula (V), B1is an R1, OR1, Other1, NHC(O)R1, F, Cl, Br or I. In another embodiment, the OS is the hope of the formula (V), A1represents a C(A2); A2represents H; and B1represents other1. In another embodiment of formula (V), A1represents a C(A2); A2represents H; and B1is a OR1. In another embodiment of formula (V), A1represents a C(A2); A2represents H; and1represents Cl. In another embodiment of formula (V), A1represents a C(A2); A2represents H; and B1is an R1. In another embodiment of formula (V), A1represents N; and B1represents other1. In another embodiment of formula (V), A1represents N; and B1is a OR1. In another embodiment of formula (V), A1represents N; and B1represents Cl. In another embodiment of formula (V), A1represents N; and B1is an R1.

In one embodiment of formula (V), D1represents Η or Cl. In another embodiment of formula (V), A1represents a C(A2); A2represents Η; B1represents other1; and D1represents H. In another embodiment, Faure the uly (V), A1represents a C(A2); A2represents Η; B1represents other1; and D1represents Cl. In another embodiment of formula (V), A1represents a C(A2); A2represents Η; B1is a OR1; and D1represents H. In another embodiment of formula (V), A1represents a C(A2); A2represents Η; B1represents Cl; and (D1represents H. In another embodiment of formula (V), A1represents a C(A2); A2represents Η; B1is an R1; and D1represents H. In another embodiment of formula (V), A1is a Ν; B1represents other1; and D1represents H. In another embodiment of formula (V), A1is a Ν; B1represents other1; and D1represents Cl. In another embodiment of formula (V), A1is a Ν;1is a OR1; and D1represents H. In another embodiment of formula (V), A1is a Ν; B1represents Cl; and (D1represents H. In another embodiment of formula (V) A1before the hat is Ν; B1is an R1; and D1represents H.

In one embodiment of formula (V), E1represents H. In another embodiment of formula (V), A1represents a C(A2); A2represents Η; B1represents other1; D1represents H; and E1represents H. In another embodiment of formula (V), A1represents a C(A2); A2represents Η; B1represents other1; E1represents H; and D1represents Cl. In another embodiment of formula (V), A1represents a C(A2); A2represents Η; B1is a OR1; D1represents H; and E1represents H. In another embodiment of formula (V) A1represents a C(A2); A2represents Η; B1represents Cl; D1represents H; and E1represents H. In another embodiment of formula (V), A1represents a C(A2); A2represents Η; B1is an R1; D1represents H; and E1represents H. In another embodiment of formula (V), A1is a Ν;1is a HR 1; D1represents H; and Ε1represents H. In another embodiment of formula (V), A1is a Ν; B1represents other1; E1represents H; and D1represents Cl. In another embodiment of formula (V), A1is a Ν; B1is a OR1; D1represents H; and E1represents H. In another embodiment of formula (V), A1is a Ν; B1represents Cl; D1represents H; and E1represents H. In another embodiment of formula (V), A1is a Ν; B1is an R1; D1represents H; and E1represents H.

In one embodiment of formula (V) Y1represents H, CN, NO2, F, Cl, Br, I, CF3, R17, OR17, SR17, SO2R17or C(O)NH2. In another embodiment of formula (V) Y1represents H. In another embodiment of formula (V) Y1represents CN. In another embodiment of formula (V) Y1represents F, Cl, Br or I. In another embodiment of formula (V) Y1is a CF3. In another embodiment of formula (V) Y1is a S 17. In another embodiment of formula (V) Y1is a OR17. In another embodiment of formula (V) Y1represents NO2. In another embodiment of formula (V) Y1represents the SO2R17; where R17is as defined herein. In another embodiment of formula (V) Y1represents the SO2R17; where R17represents alkyl. In another embodiment of formula (V) Y1is an R17; where R17represents quinil. In another embodiment of formula (V) A1represents a C(A2); A2represents Η; B1represents other1; D1represents Η; Ε1represents H; and Y1represents NO2or SO2R17; where R17represents an alkyl or quinil. In another embodiment of formula (V) A1represents a C(A2); A2represents Η; B1represents other1; D1represents Η; E1represents H; and Y1represents NO2. In another embodiment of formula (V) A1represents a C(A2); A2represents Η; B1represents other1; D 1represents Η; E1represents H; and Y1represents the SO2R17; where R17represents alkyl, substituted with three F. In another embodiment of formula (V) A1is a Ν; B1represents other1; D1represents Η; E1represents H; and Y1represents NO2or SO2R17; where R17represents an alkyl or quinil. In another embodiment of formula (V) A1is a Ν;1represents other1; D1represents Η; Ε1represents H; and Y1represents ΝΟ2. In another embodiment of formula (V) A1is a Ν; B1represents other1; D1represents Η; E1represents H; and Y1represents the SO2R17; where R17represents alkyl, substituted with three F.

In one embodiment of formula (V) Y1and B1together with the atoms to which they are attached, are benzene. In another embodiment of formula (V) Y1and B1together with the atoms to which they are attached, represent heteroaryl. In another embodiment of formula (V) A1represents a C(A2); A2 , G1E1and D1independently selected from H; and Y1and B1together with the atoms to which they are attached, are benzene. In another embodiment of formula (V) A1represents a C(A2); A2, G1E1and D1independently selected from H; and Y1and B1together with the atoms to which they are attached, represent heteroaryl.

In one embodiment of formula (V) R1is an R4or R5. In one embodiment of formula (V) R1is an R4. In one embodiment of formula (V) R1is an R5. In one embodiment of formula (V) R1is an R4; and R4is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen. In one embodiment of formula (V) R1is an R4; and R4is cycloalkyl or heteroseksualci. In one embodiment of formula (V) R1is an R4; and R4is cycloalkyl. In one embodiment of formula (V) R1is an R4; and R4is heteroseksualci.

In one embodiment of formula (V) R1is an R4; and R4 represents cycloalkyl; where R4is unsubstituted or substituted as defined herein. In another embodiment of formula (V) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring substituted as defined herein. In another embodiment of formula (V) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring substituted R57or N(R57)2. In another embodiment of formula (V) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; and R57is an R60. In another embodiment of formula (V) R1is an R4; R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R60; and R60is heteroseksualci. In another embodiment of formula (V) R1is an R4; R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57made the focus of an R 60. R60is heteroseksualci; where geteroseksualnoe ring is morpholinyl. In another embodiment of formula (V) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring substituted N(R57)2. In another embodiment of formula (V) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted N(R57)2. In another embodiment of formula (V) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where cyclohexane ring substituted N(R57)2; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted R62. In another embodiment of formula (V) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted R62; R62is an R65; and R65 is cycloalkyl. In another embodiment of formula (V) R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R61; and R61represents alkyl, which is substituted by an R62; R62is an R65; and R65is cyclopropyl.

In one embodiment of formula (V) R1is an R4; and R4is heteroseksualci; where R4is unsubstituted or substituted as defined herein. In another embodiment of formula (V) R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring substituted as defined herein. In another embodiment of formula (V) R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring substituted R57. In another embodiment of formula (V) R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where geteroseksualnoe ring replacement is prohibited R 57; and R57is an R60or R61. In another embodiment of formula (V) R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted R57; R57is an R60or R61; R60is heteroseksualci; and R61represents alkyl. In another embodiment of formula (V) R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted R57; R57is an R60; R60is heteroseksualci; where heteroseksualci is tetrahydropyranyl. In another embodiment of formula (V) R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted R57; R57is an R61; R61represents alkyl; and the alkyl is a methyl. In another embodiment, the OS is the hope of the formula (V) R 1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted C(O)OR57; R57is an R61; R61represents alkyl; and the alkyl is a methyl.

In one embodiment of formula (V) R1is an R5; and R5represents alkyl, which is unsubstituted or substituted. In one embodiment of formula (V) R1is an R5; and R5represents alkyl, which is unsubstituted or substituted R7, OR7, OH, CN or F. In another embodiment of formula (V) R1is an R5; and R5represents alkyl, which is substituted by an R7, OR7, Other7or N(R7)2.

In one embodiment of formula (V) R7is an R8, R9, R10or R11which are unsubstituted or substituted as defined herein. In another embodiment of formula (V) R7is an R8which is unsubstituted or substituted as defined herein. In another embodiment of formula (V) R7is the battle R 9which is unsubstituted or substituted as defined herein. In another embodiment of formula (V), R7is an R10which is unsubstituted or substituted as defined herein. In another embodiment of formula (V) R7is an R11which is unsubstituted or substituted as defined herein.

In one embodiment of formula (V) R8represents phenyl, which is unsubstituted or substituted as defined herein.

In one embodiment of formula (V) R9is heteroaryl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (V) R9is furanyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (V) R9is furanyl, which is unsubstituted.

In one embodiment of formula (V) R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, heteroseksualci, which are unsubstituted or substituted as defined herein. In another embodiment of formula (V) 10is heteroseksualci, which is unsubstituted or substituted as defined herein. In another embodiment of formula (V) R10is tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, dioxane, oxetanyl, piperidinyl or pyrrolidinyl, which are unsubstituted or substituted as defined herein. In another embodiment of formula (V) R10is tetrahydropyranyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (V) R10is morpholinyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (V) R10is cycloalkyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (V) R10is cycloalkyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (V) R10represents cyclohexyl, cyclopropyl, cyclobutyl or bicyclo[2.2.1]heptenyl, which is unsubstituted or substituted as defined herein. In another embodiment, Faure the uly (V) R 10is heteroseksualci, which is fused with R10A; and R10Arepresents heteroaryl. In another embodiment of formula (V) R10is a 5,6,7,8-tetrahydroimidazo[1,2-a]pyridinyl.

In one embodiment of formula (V) R11represents alkyl, alkenyl or quinil, which are unsubstituted or substituted as defined herein. In another embodiment of formula (V) R11represents alkyl. In another embodiment of formula (V) R11represents methyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (V) R11represents alkyl, which is substituted as defined herein. In another embodiment of formula (V) R11represents alkyl, which is substituted by an R12, OR12or CF3. In another embodiment of formula (V) R11represents alkyl, which is substituted OR12; R12is an R16; and R16represents alkyl. In another embodiment of formula (V) R11represents alkyl, which is substituted CF3. In another embodiment of formula (V) R11represents alkyl, which is substituted by an R12; R12is an R14; and R14is heteroaryl.

In one embodiment of formula (V)

each of n, p, r and t are equal to 0;

A1represents N or C(A2);

A2represents Η, F, Br, I or Cl;

B1is an R1, OR1, Other1, NHC(O)R1, F, Br, I or Cl;

D1represents H, F, Br, I or Cl;

E1represents H; and

Y1represents H, CN, NO2, F, Cl, Br, I, CF3, R17, OR17, SR17, SO2R17or C(O)NH2; or

Y1and B1together with the atoms to which they are attached, are benzene, heteroaryl or geteroseksualen; and

A2D1and E1independently selected from H;

R1is an R4or R5;

R4is cycloalkyl or heteroseksualci;

R5represents an alkyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R7, OR7, Other7N(R7)2, CN, OH, F, Cl, Br or I;

R7is an R8, R9, R10or R11;

R8represents phenyl;

R9is heteroaryl;

R10is cycloalkyl, cycloalkenyl or heterotic alkyl, each of which is unfused or fused with R10A, R10Arepresents heteroaryl;

R11represents alkyl, each of which is unsubstituted or substituted one, or two, or three of independently selected R12, OR12or CF3;

R12is an R14or R16;

R14is heteroaryl;

R16represents alkyl;

R17is an R21;

R21represents an alkyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R22, F, Cl, Br or I;

R22is an R25;

R25is heteroseksualci;

where the cyclic group corresponding to Y1and B1together, R4, R8, R10and R25, are independently unsubstituted, further unsubstituted, substituted or further substituted with one, or two, or three, or four, or five of independently selected R57A, R57, OR57, SO2R57C(O)R57, CO(O)R57C(O)N(R57)2, NH2, Other57N(R57)2, NHC(O)R57NHS(O)2R57, OH, CN, (O), F, Cl, Br or I;

R57Ais spiralcell or spiroheterocyclic;

R 57is an R58, R60or R61;

R58represents phenyl;

R60is cycloalkyl or heteroseksualci;

R61represents alkyl, which is unsubstituted or substituted one, or two, or three of independently selected R62, OR62N(R62)2C(O)OH, CN, F, Cl, Br or I;

R62is an R65or R66;

R65is cycloalkyl or heteroseksualci;

R66represents alkyl, which is unsubstituted or substituted OR67;

R67represents alkyl;

where the cyclic group corresponding to R57A, R58and R60are unsubstituted or substituted one, or two, or three, or four of independently selected R68, F, Cl, Br or I;

R68is an R71or R72;

R71is heteroseksualci; and

R72represents alkyl, which is unsubstituted or substituted by one or two f

Another variant of implementation relates to the compound of formula (V), which is a

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-PI is henyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

TRANS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-{[4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-(trifluoromethyl)phenyl]sulfonyl}benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(1-methylpiperidin-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

CIS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

and their therapeutically acceptable salts, and metabolites.

In another aspect, the present invention relates to compounds of the formula (VI)

and their therapeutically acceptable salts, and metabolites,

where A1B1D1E1and Y1are as described herein for formula (I); R100is as described for substituents on R26; n is 0, 1, 2 or 3; R101is as described for substituents on R30; p is 0, 1, 2, 3, 4, 5 or 6; R102is as described for substituents on R40; q is 0, 1, 2, 3, 4, 5 or 6; R103is as described for substituents on R58; and r is 0, 1, 2, 3, or 4.

In one embodiment of formula (VI) each of n, p, r and q are equal to 0.

One is ariante implementation of the formula (VI), A 1represents N. In another embodiment of formula (VI), A1represents a C(A2). In another embodiment of formula (VI), A1represents a C(A2); and A2represents H, F, Cl, Br or I. In another embodiment of formula (VI), A1represents a C(A2); and A2represents H.

In one embodiment of formula (VI) B1is an R1, OR1, Other1, NHC(O)R1, F, Cl, Br or I. In another embodiment of formula (VI), A1represents a C(A2); A2represents H; and B1represents other1. In another embodiment of formula (VI), A1represents a C(A2); A2represents H; and B1is a OR1. In another embodiment of formula (VI), A1represents a C(A2); A2represents H; and1represents Cl. In another embodiment of formula (VI), A1represents a C(A2); A2represents H; and B1is an R1. In another embodiment of formula (VI), A1represents N; and B1represents other1. In another embodiment of formula (VI), A1represents N; and B1is a OR1In another embodiment of formula (VI), A 1represents N; and B1represents Cl. In another embodiment of formula (VI), A1represents N; and B1is an R1.

In one embodiment of formula (VI) D1represents Η or Cl. In another embodiment of formula (VI), A1represents a C(A2); A2represents Η; B1represents other1; and D1represents H. In another embodiment of formula (VI), A1represents a C(A2); A2represents Η; B1represents other1; and D1represents Cl. In another embodiment of formula (VI), A1represents a C(A2); A2represents Η; B1is a OR1; and D1represents H. In another embodiment of formula (VI), A1represents a C(A2); A2represents Η; B1represents Cl; and (D1represents H. In another embodiment of formula (VI), A1represents a C(A2); A2represents Η; B1is an R1; and D1represents H. In another embodiment of formula (VI), A1is a Ν; B1represents other1; and D1represents H. the another embodiment of formula (VI), A 1is a Ν; B1represents other1; and D1represents Cl. In another embodiment of formula (VI), A1is a Ν;1is a OR1; and D1represents H. In another embodiment of formula (VI), A1is a Ν; B1represents Cl; and (D1represents H. In another embodiment of formula (VI), A1is a Ν; B1is an R1; and D1represents H.

In one embodiment of formula (VI) E1represents H. In another embodiment of formula (VI), A1represents a C(A2); A2represents Η; B1represents other1; D1represents H; and E1represents H. In another embodiment of formula (VI), A1represents a C(A2); A2represents Η; B1represents other1; E1represents H; and D1represents Cl. In another embodiment of formula (VI), A1represents a C(A2); A2represents Η; B1is a OR1; D1represents H; and E1represents H. In another embodiment of formula (VI), A1is the th C(A 2); A2represents Η; B1represents Cl; D1represents H; and E1represents H. In another embodiment of formula (VI), A1represents a C(A2); A2represents Η; B1is an R1; D1represents H; and E1represents H. In another embodiment of formula (VI), A1is a Ν;1represents other1; D1represents H; and Ε1represents H. In another embodiment of formula (VI), A1is a Ν; B1represents other1; E1represents H; and D1represents Cl. In another embodiment of formula (VI), A1is a Ν;1is a OR1; D1represents H; and Ε1represents H. In another embodiment of formula (VI), A1is a Ν; B1represents Cl; D1represents H; and E1represents H. In another embodiment of formula (VI), A1is a Ν; B1is an R1; D1represents H; and E1represents H.

In one embodiment of formula (VI) Y1represents H, CN, NO2, F, Cl, Br, I, CF3 , R17, OR17, SR17, SO2R17or C(O)NH2. In another embodiment of formula (VI) Y1represents H. In another embodiment of formula (VI) Y1represents CN. In another embodiment of formula (VI) Y1represents F, Cl, Br or I. In another embodiment of formula (VI) Y1is a CF3. In another embodiment of formula (VI) Y1represents SR17. In another embodiment of formula (VI) Y1is a OR17. In another embodiment of formula (VI) Y1represents NO2. In another embodiment of formula (VI) Y1represents the SO2R17; where R17is as defined herein. In another embodiment of formula (VI) Y1represents the SO2R17; where R17represents alkyl. In another embodiment of formula (VI) Y1is an R17; where R17represents quinil. In another embodiment of formula (VI), A1represents a C(A2); A2represents Η; B1represents other1; D1represents Η; Ε1represents H; and Y1represents NO2or SO2R17; where R17represents an alkyl or quinil. In another embodiment of formula (VI), A1represents a C(A2); A2represents Η; B1represents other1; D1represents Η; E1represents H; and Y1represents NO2. In another embodiment of formula (VI), A1represents a C(A2); A2represents Η; B1represents other1; D1represents Η; E1represents H; and Y1represents the SO2R17; where R17represents alkyl, substituted with three F. In another embodiment of formula (VI), A1is a Ν; B1represents other1; D1represents Η; E1represents H; and Y1represents NO2or SO2R17; where R17represents an alkyl or quinil. In another embodiment of formula (VI), A1is a Ν;1represents other1; D1represents Η; Ε1represents Η; and Υ1represents ΝΟ2. In another embodiment of formula (VI), A1is a Ν; B1represents other1; D1represents Η; E1represents H; and Y1 2R17; where R17represents alkyl, substituted with three F.

In one embodiment of formula (VI) Y1and B1together with the atoms to which they are attached, are benzene. In another embodiment of formula (VI) Y1and B1together with the atoms to which they are attached, represent heteroaryl. In another embodiment of formula (VI), A1represents a C(A2); A2, G1E1and D1are independently selected H; and Y1and B1together with the atoms to which they are attached, are benzene. In another embodiment of formula (VI), A1represents a C(A2); A2, G1E1and D1are independently selected H; and Y1and B1together with the atoms to which they are attached, represent heteroaryl.

In one embodiment of formula (VI), R1is an R4or R5. In one embodiment of formula (VI), R1is an R4. In one embodiment of formula (VI), R1is an R5. In one embodiment of formula (VI), R1is an R4; and R4is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen. In od the om embodiment of formula (VI), R 1is an R4; and R4is cycloalkyl or heteroseksualci. In one embodiment of formula (VI), R1is an R4; and R4is cycloalkyl. In one embodiment of formula (VI), R1is an R4; and R4is heteroseksualci.

In one embodiment of formula (VI), R1is an R4; and R4is cycloalkyl; where R4is unsubstituted or substituted as defined herein. In another embodiment of formula (VI), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring substituted as defined herein. In another embodiment of formula (VI), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring substituted R57or N(R57)2. In another embodiment of formula (VI), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; and R57is an R60. In another embodiment of formula (VI), R1is an R4; R4 is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R60; and R60is heteroseksualci. In another embodiment of formula (VI), R1is an R4; R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R60. R60is heteroseksualci; where geteroseksualnoe ring is morpholinyl. In another embodiment of formula (VI), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring substituted N(R57)2. In another embodiment of formula (VI), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted N(R57)2. In another embodiment of formula (VI), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted N(R57)2; R57is an R61; and 61represents alkyl, which is unsubstituted or substituted R62. In another embodiment of formula (VI), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R61; and R61represents alkyl, which is unsubstituted or substituted R62; R62is an R65; and R65is cycloalkyl. In another embodiment of formula (VI), R1is an R4; and R4is cycloalkyl; where cycloalkyl ring is a cyclohexyl; and where tsiklogeksilnogo ring substituted R57; R57is an R61; and R61represents alkyl, which is substituted by an R62; R62is an R65; and R65is cyclopropyl.

In one embodiment of formula (VI), R1is an R4; and R4is heteroseksualci; where R4is unsubstituted or substituted as defined herein. In another embodiment of formula (VI), R1is an R4; and R4is heteroseksualci; where heterocycle kilroe ring substituted, as defined herein. In another embodiment of formula (VI), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring substituted R57. In another embodiment of formula (VI), R1is an R4; and R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where geteroseksualnoe ring substituted R57; and R57is an R60or R61. In another embodiment of formula (VI), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted R57; R57is an R60or R61; R60is heteroseksualci; and R61represents alkyl. In another embodiment of formula (VI), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted R57; R57is an R60; R60represents gets rocklouder; where heteroseksualci is tetrahydropyranyl. In another embodiment of formula (VI), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted R57; R57is an R61; R61represents alkyl; and the alkyl is a methyl. In another embodiment of formula (VI), R1is an R4; R4is heteroseksualci; where geteroseksualnoe ring is piperidinyl or piperazinyl; and where piperidinyl or piperazinyl ring substituted C(O)OR57; R57is an R61; R61represents alkyl; and the alkyl is a methyl.

In one embodiment of formula (VI), R1is an R5; and R5represents alkyl, which is unsubstituted or substituted. In one embodiment of formula (VI), R1is an R5; and R5represents alkyl, which is unsubstituted or substituted R7, OR7, OH, CN or F. In another embodiment of formula (VI), R1is an R5; and R5represents al the sludge, which is replaced by R7, OR7, Other7or N(R7)2.

In one embodiment of formula (VI), R7is an R8, R9, R10or R11which are unsubstituted or substituted as defined herein. In another embodiment of formula (VI), R7is an R8which is unsubstituted or substituted as defined herein. In another embodiment of formula (VI), R7is an R9which is unsubstituted or substituted as defined herein. In another embodiment of formula (VI), R7is an R10which is unsubstituted or substituted as defined herein. In another embodiment of formula (VI), R7is an R11which is unsubstituted or substituted as defined herein.

In one embodiment of formula (VI), R8represents phenyl, which is unsubstituted or substituted as defined herein.

In one embodiment of formula (VI), R9is heteroaryl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (VI), R9p is ecstasy furanyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (VI), R9is furanyl, which is unsubstituted.

In one embodiment of formula (VI), R10is cycloalkyl, cycloalkenyl, heteroseksualci or geteroseksualen, heteroseksualci, which are unsubstituted or substituted as defined herein. In another embodiment of formula (VI), R10is heteroseksualci, which is unsubstituted or substituted as defined herein. In another embodiment of formula (VI), R10is tetrahydrofuranyl, tetrahydropyranyl, morpholinyl, dioxane, oxetanyl, piperidinyl or pyrrolidinyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (VI), R10is tetrahydropyranyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (VI), R10is morpholinyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (VI), R10is cycloalkyl, which are the two which is unsubstituted or substituted, as defined herein. In another embodiment of formula (VI), R10is cycloalkyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (VI), R10represents cyclohexyl, cyclopropyl, cyclobutyl or bicyclo[2.2.1]heptenyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (VI), R10is heteroseksualci, which is condensed with R10A; and R10Arepresents heteroaryl. In another embodiment of formula (VI), R10is a 5,6,7,8-tetrahydroimidazo[1,2-a]pyridinyl.

In one embodiment of formula (VI), R11represents alkyl, alkenyl or quinil, which is unsubstituted or substituted as defined herein. In another embodiment of formula (VI), R11represents alkyl. In another embodiment of formula (VI), R11represents methyl, which is unsubstituted or substituted as defined herein. In another embodiment of formula (VI), R11represents alkyl, which is substituted as defined herein. In another embodiment of formula (VI), R11 represents alkyl, which is substituted by an R12, OR12or CF3. In another embodiment of formula (VI), R11represents alkyl, which is substituted OR12; R12is an R16; and R16represents alkyl. In another embodiment of formula (VI), R11represents alkyl, which is substituted CF3. In another embodiment of formula (VI), R11represents alkyl, which is substituted by an R12; R12is an R14; and R14is heteroaryl.

In one embodiment of formula (VI)

each of n, p, r and q are 0;

A1represents N or C(A2);

A2represents H, F, Br, I or Cl;

B1is an R1, OR1, Other1, NHC(O)R1, F, Br, I or Cl;

D1represents H, F, Br, I or Cl;

E1represents H; and

Y1represents H, CN, NO2, F, Cl, Br, I, CF3, R17, OR17, SR17, SO2R17or C(O)NH2; or

Y1and B1together with the atoms to which they are attached, are benzene, heteroaryl or geteroseksualen; and

A2D1and E1independently selected from H;

R1is an R4or R5;

R4is cycloalkyl eleetrical;

R5represents an alkyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R7, OR7, Other7N(R7)2, CN, OH, F, Cl, Br or I;

R7is an R8, R9, R10or R11;

R8represents phenyl;

R9is heteroaryl;

R10is cycloalkyl, cycloalkenyl or heteroseksualci, each of which is unfused or fused with R10A, R10Arepresents heteroaryl;

R11represents alkyl, each of which is unsubstituted or substituted one, or two, or three of independently selected R12, OR12or CF3;

R12is an R14or R16;

R14is heteroaryl;

R16represents alkyl;

R17is an R21;

R21represents an alkyl or quinil, each of which is unsubstituted or substituted one, or two, or three of independently selected R22, F, Cl, Br or I;

R22is an R25;

R25is heteroseksualci;

where the cyclic group corresponding to Y1and B1together, R4, R8, R10 and R25are independently unsubstituted, further unsubstituted, substituted or further substituted with one, or two, or three, or four, or five of independently selected R57A, R57, OR57, SO2R57C(O)R57, CO(O)R57C(O)N(R57)2, NH2, Other57N(R57)2, NHC(O)R57, NHSO2R57, OH, CN, (O), F, Cl, Br or I;

R57Ais spiralcell or spiroheterocyclic;

R57is an R58, R60or R61;

R58represents phenyl;

R60is cycloalkyl or heteroseksualci;

R61represents alkyl, which is unsubstituted or substituted one, or two, or three of independently selected R62, OR62N(R62)2C(O)OH, CN, F, Cl, Br or I;

R62is an R65or R66;

R65is cycloalkyl or heteroseksualci;

R66represents alkyl, which is unsubstituted or substituted OR67;

R67represents alkyl;

where the cyclic group corresponding to R57A, R58and R60are unsubstituted or substituted one, or two, or three, or four of independently selected R68, F, Cl, Br or I;

R68is an R71 or R72;

R71is heteroseksualci; and

R72represents alkyl, which is unsubstituted or substituted by one or two f

Another variant of implementation relates to the compound of formula (VI), which represents 4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide;

and their therapeutically acceptable salts, and metabolites.

The pharmaceutical compositions, combination therapy, treatment and introduction

Another variant implementation includes pharmaceutical compositions containing a compound of the formula (I) and excipient.

Another variant implementation includes methods of treating a malignant tumor in a mammal, comprising introducing him therapeutically acceptable amount of the compounds of formula (I).

Another variant implementation includes methods of treatment auto monogo disease in a mammal, includes introduction to him therapeutically acceptable amount of the compounds of formula (I).

Another variant of implementation relates to compositions for treating diseases during which is expressed anti-apoptotic proteins Bcl-2, and these compositions contain excipient and a therapeutically effective amount of the compounds of formula (I).

Another variant of implementation relates to methods for treating disease in a patient during which are expressed anti-apoptotic proteins Bcl-2, and these methods include the introduction to the patient a therapeutically effective amount of the compounds of formula (I).

Another variant of implementation relates to compositions for the treatment of bladder cancer, malignant brain tumors, breast cancer, malignant tumor of the bone marrow, cervical cancer, chronic lymphocytic leukemia, cancer of the colon and rectum, esophagus cancer, liver cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, malignant tumors of the oral cavity, cancer of the ovary, non-small cell lung cancer, prostate cancer, small-cell lung cancer or cancer of the spleen, moreover, these compositions contain the former is ipient and a therapeutically effective amount of the compounds of formula (I).

Another variant of implementation relates to methods of treating bladder cancer, malignant brain tumors, breast cancer, malignant tumor of the bone marrow, cervical cancer, chronic lymphocytic leukemia, cancer of the colon and rectum, esophagus cancer, liver cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, malignant tumors of the oral cavity, cancer of the ovary, non-small cell lung cancer, prostate cancer, small-cell lung cancer or cancer of the spleen in a patient, moreover, these methods include the introduction to the patient a therapeutically effective amount of the compounds of formula (I).

Another variant of implementation relates to compositions for treating diseases during which is expressed anti-apoptotic proteins Bcl-2, and these compositions contain excipient and a therapeutically effective amount of the compounds of formula (I) and a therapeutically effective amount of one additional drug or more than one additional drug.

Another variant of implementation relates to methods for treating disease in a patient, which expressed antiup pliticheskoe proteins Bcl-2, moreover, these methods include the introduction to the patient a therapeutically effective amount of the compounds of formula (I) and a therapeutically effective amount of one additional drug or more than one additional drug.

Another variant of implementation relates to compositions for the treatment of bladder cancer, malignant brain tumors, breast cancer, malignant tumor of the bone marrow, cervical cancer, chronic lymphocytic leukemia, cancer of the colon and rectum, esophagus cancer, liver cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, malignant tumors of the oral cavity, cancer of the ovary, non-small cell lung cancer, prostate cancer, small-cell lung cancer or cancer of the spleen, moreover, these compositions contain excipient and a therapeutically effective amount of the compounds of formula (I) and a therapeutically effective amount of one additional drug or more than one additional drug.

Another variant of implementation relates to methods of treating bladder cancer, malignant tumors of the hunter, breast cancer, a malignant tumor of the bone marrow, cervical cancer, chronic lymphocytic leukemia, cancer of the colon and rectum, esophagus cancer, liver cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, melanoma, myelogenous leukemia, myeloma, malignant tumors of the oral cavity, cancer of the ovary, non-small cell lung cancer, prostate cancer, small-cell lung cancer or cancer of the spleen in a patient, and these methods include the introduction to the patient a therapeutically effective amount of the compounds of formula (I) and a therapeutically effective amount of one additional drug or more than one additional drug.

Also for the treatment of diseases associated with anti-apoptotic proteins Bcl-2, can be applied metabolites of compounds of formula (I) produced by metabolic processesin vitroor processesin vivo.

Certain compounds precursor, which can be metabolisedin vitroorin vivowith the formation of compounds of formula (I), may also be applicable for the treatment of diseases associated with expression of the antiapoptotic proteins Bcl-2.

The compounds of formula (I) which may exist as acid additive salts, basically additive salts or zwitterions. Salts of the compounds produced by the process of isolation and subsequent purification of the compounds. Acid additive salts of the compounds are salts formed in the reaction of compounds with acid. For example, the following salts of the compounds are considered as covered by this invention: acetates, adipate, alginates, bicarbonates, citrates, aspartate, benzoate, bansilalpet, bisulfate, butyrate, camphorate, camphorsulfonate, digluconate, formate, fumarate, glycerophosphate, glutamate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactobionate, lactates, maleate, mesitylenesulfonic, methansulfonate, naphthalenesulfonate, nicotinate, oxalates, pamoate, pectinate, persulfates, phosphate, picrate, propionate, succinate, tartratami, thiocyanates, trichloracetate, triptoreline, para-toluensulfonate and undecanoate. Basically additive salts of the compounds are salts formed in the reaction of compounds with hydroxide, carbonate or bicarbonate of cations such as lithium, sodium, potassium, calcium and magnesium.

The compounds of formula (I) can be entered, for example, buccal, eyes, orally, osmotically, parenterally (intramuscularly, intraperitoneally, nutrigrain, intravenously, subcutaneously), rectally, topically, transdermally, or vaginally.

a Therapeutically effective amount of compounds of formula (I) depend on recipient of treatment, disorders, being treated and its severity, the compositions containing the compound, time of administration, route of administration, duration of treatment, the effectiveness of connection, speed of deducing and introduce to them jointly medicine. The number of compounds according to this invention of the formula (I) used to obtain the composition for introduction every day the patient in a single dose or in divided doses is from about 0.03 to about 200 mg/kg of body weight. Composition single doses contain these quantities, or a combination of their shares.

The compounds of formula (I) can be used to enter excipients or without him. Excipients include, for example, the encapsulating materials or additives such as substances that accelerate the absorption, antioxidants, binders, buffers, means for applying coatings, paints, thinners, dezintegriruetsja substances, emulsifiers, diluents, fillers, flavoring additives, wetting agents, lubricants, flavors, preservatives, propellants, releasing agents, sterilizing agents, sweeteners, soljubilizatory, wetting agents and mixtures thereof.

Excipients to obtain compositions containing the compound of formula (I), for oral administration in solid dosage form include, for example, agar, alginic to the slot, aluminum hydroxide, benzyl alcohol, benzyl benzoate, 1,3-butyleneglycol, carbomer, castor oil, cellulose, cellulose acetate, cocoa butter, corn starch, corn oil, cottonseed oil, crospovidon, diglycerides, ethanol, ethylcellulose, ailleret, etiloleat, esters of fatty acids, gelatin, oil seedlings, glucose, glycerin, oil of groundnuts, hypromellose, isopropanol, isotonic saline, lactose, magnesium hydroxide, magnesium stearate, malt, mannitol, monoglycerides, olive oil, peanut oil, potassium phosphate salt, potato starch, povidone, propylene glycol, ringer's solution, safflower oil, sesame oil, sodium carboxymethylcellulose, sodium phosphate salts, sodium lauryl sulfate, sorbitol, sodium, soy oil, stearic acid, fumarate, sucrose, surfactants, talc, tragakant, tetrahydrofurfuryl alcohol, triglycerides, water and their mixtures. Excipients to obtain compositions containing the compound according to this invention of the formula (I), for introduction into the eye or orally in liquid dosage forms include, for example, 1,3-butyleneglycol, castor oil, corn oil, cottonseed oil, ethanol, esters of fatty acids and sorbitan, butter germ, oil of groundnuts, glycerol, isopropanol, is Lugovoe oil, the polyethylene glycols, propylene glycol, sesame oil, water and mixtures thereof. Excipients to obtain compositions containing the compound according to this invention of the formula (I), for osmotic injection include, for example, chlorofluorocarbons, ethanol, water and mixtures thereof. Excipients to obtain compositions containing the compound according to this invention of the formula (I), for administration include parenteral, e.g., 1,3-butanediol, castor oil, corn oil, cottonseed oil, dextrose, butter germ, oil of groundnuts, liposomes, oleic acid, olive oil, peanut oil, ringer's solution, safflower oil, sesame oil, soybean oil, U. S. P. or isotonic sodium chloride solution, water and their mixtures. Excipients to obtain compositions comprising the compound according to this invention of the formula (I), for rectal or vaginal injection include, for example, cocoa butter, polyethylene glycol, wax and mixtures thereof.

It is expected that the compounds of formula (I) can be useful when used with alkylating agents, angiogenesis inhibitors, antibodies, antimetabolites, antimitoticescoy means, antiproliferative means, antiviral agents, inhibitors of aurora kinase and other stimulators of apoptosis (e.g., inhibitors of Bcl-xL, Bcl-w and Bfl-1), cascade activators of receptors death, and what hibitory kinase Bcr-Ab1, antibodies BiTE (bespecifically linking T-cell antibodies, conjugates of the antibody-drug, biological response modifiers, inhibitors of cyclin-dependent kinase inhibitors, cell cycle inhibitors, cyclooxygenase-2, DVD, inhibitors of receptor homologue of the oncogene leukosis virus (ErbB2), inhibitors of growth factors, inhibitors of heat shock protein (HSP)-90, inhibitors of histone deacetylase (HDAC), hormonal drugs, immunological agents, inhibitors of inhibitors of apoptosis proteins (IAP), intercalating antibiotics, kinase inhibitors, inhibitors of kinesin, Jak2 inhibitors, inhibitors target of rapamycin mammalian microRNA inhibitors of mitogen-activated extracellular regulated kinase signal, multivalent binding proteins, non-steroidal anti-inflammatory drugs (NSAID), inhibitors of poly-ADP (adenosine diphosphate)-robosapiens (PARP), chemotherapeutics platinum-based inhibitors of polo-like kinase (Plk) inhibitors phosphoinositide-3-kinase (PI3K), proteasome inhibitors, purine analogues, pyrimidine analogues, inhibitors of receptor tyrosinekinase, alkaloids of plants, retinoids/deltoids, small inhibitory ribonucleic acids (siRNAs), inhibitors that is isomers, inhibitors of ubiquitinate, etc. or in combination with one or more of these tools.

The BiTE antibodies are bespecifically antibodies that direct T cells to attack cancerous cells by simultaneous binding of the two cells. Then T-malignant cells attacking the target cell. Examples of BiTE antibodies include adecatumumab (Micromet MT201), blinatumomab (Micromet MT103), etc., Without communication with theory, one mechanism by which T cells induce apoptosis of malignant target cells, is the exocytosis of cytolytic components granules, which include perforin and Grasim B. In this regard, it has been shown that Bcl-2 attenuates the induction of apoptosis by both perforin and grannymom B. These data indicate that inhibition of Bcl-2 may enhance the cytotoxic effects induced T-cells, targeting malignant cells (V. R. Sutton, D. L. Vaux and J. A. Trapani, J. of Immunology 1997, 158 (12), 5783).

SiRNA represent molecules with endogenous reasons RNA or chemically modified nucleotides. Modifications do not eliminate cell activity, and instead give increased stability and/or increased efficiency in cells. Examples of chemical modifications include phosphorothioate group, 2'-deoxynucleotides, 2'-OCH3-containing ribonucleotides, 2'-F-ribonucleo the Chida, 2'-methoxyethylamine, combinations thereof, etc., siRNA can have a different length (e.g., 10-200 p. N.) and structure (e.g., studs, single/double chains, loops, breaks/gaps, incorrectly paired bases) and they are processed in cells, providing active gene silencing. Double-stranded siRNA (dsRNA) can have the same number of nucleotides on each chain (blunt ends) or asymmetric ends (lugs). Ledge of 1-2 nucleotides may be present on the sense and/or antisense chain, and it can also be present on the 5'- and/or 3'-ends of this chain. For example, it was shown that siRNA targeted to Mcl-1, enhanced the activity of ABT-263 (i.e., N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-EN-1-yl)methyl)piperazine-1-yl)benzoyl)-4-(((1R)-3-(morpholine-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzosulfimide) or ABT-737 (i.e., N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazine-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide) in many tumor cell lines (Tse et al., Cancer Research 2008, 68(9), 3421 and references therein).

Multivalent binding proteins are binding proteins that contain two or more antigenspecific center. Multivalent binding proteins are manufactured so that they had three or more antigenspecific centre and, as the government is about, they are not naturally occurring antibodies. The term "polyspecific binding protein" means a binding protein capable of binding two or more related or unrelated targets. Binding proteins with dual variable domain (DVD) represent a tetravalent or multivalent binding proteins containing two or more antigenspecific center. These DVDs can be monospecific (i.e., able to bind one antigen) or polyspecific (i.e., capable of binding two or more antigens). Binding proteins with a DVD containing two heavy polypeptide chains with DVD and two light polypeptide chains with DVD, referred to as DVD-Ig. Each half-DVD-Ig polypeptide contains a DVD heavy chain polypeptide DVD light chain and two antigenspecific center. Each binding site contains a variable domain of the heavy chain variable domain and a light chain with only 6 CDR, involved in binding to the antigen, antigennegative center.

Alkylating tools include altretamin, AMD-473, AP-5280, apaziquone, bendamustine, brostallicin, busulfan, carboquone, carmustine (BCNU), chlorambucil, CLORETAZINE® (laromustine, VPN 40101M), cyclophosphamide, dacarbazine, estramustine, fotemustine, glufosfamide, ifosfamide, KW-2170, lomustin (CCNU), mafosfamide, melphalan, mitobronitol, mitolactol, nimustine, N-oxide nitrogen mustard, RA is kustin, temozolomide, thiotepa, TREANDA® (bendamustine), treosulfan, rotspeed etc.

The angiogenesis inhibitors include inhibitors specific to the endothelial receptor tyrosine kinase (Tie-2) inhibitors of the receptor for epidermal growth factor (EGFR) inhibitors of receptor insulin-like growth factor-2 (IGFR-2) inhibitors of matrix metalloproteinase-2 (MMP-2) inhibitors of matrix metalloproteinase-9 (MMP-9) inhibitors of the receptor for platelet-derived growth factor (DERIVED), the analogues of thrombospondin, inhibitors of receptor tyrosine kinase vascular endothelial growth factor (VEGFR), etc.

Antimetabolites include ALIMTA® (pemetrexed disodium, LY231514, MTA), 5-azacytidine, XELODA® (capecitabine), carmofur, LEUSTAT® (cladribine, Clofarabine, cytarabine, cytarabine ocfosfate, cytosine arabinoside, decitabine, deferoxamine, doxifluridine, eflornithine, EICAR (5-ethinyl-1-β-D-ribofuranosylthiazole-4-carboxamide), enocitabine, utilitity, fludarabine, 5-fluorouracil alone or in combination with leucovorin, GEMZAR® (gemcitabine), hydroxyurea, ALKERAN® (melphalan, mercaptopurine, 6-mercaptopurine riboside, methotrexate, mycophenolate acid, nelarabine, nolatrexed, ocfosfate, political, pentostatin, raltitrexed, ribavirin, triapin, trimetrexate, S-1, tianfuan, tegafur, TS-1, vidarabine, UFT, etc.

Antiviral agents include ritonavir, hydroxychloroquin etc.

Inhibitors of Aurora kinase include ABT-348, AZD-1152, MLN-8054, VX-680, specific to the Aurora kinase Α inhibitors that are specific for the kinase Aurora B inhibitors and General inhibitors of Aurora kinases, etc.

Inhibitors of protein Bcl-2 include AT-101 ((-)hossipole), GENASENSE® (G3139 or oblimersen (antisense oligonucleotide targeted to Bcl-2)), IPI-194, IPI-565, N-(4-(4-((4'-chloro(1,1'-biphenyl)-2-yl)methyl)piperazine-1-yl)benzoyl)-4-(((1R)-3-(dimethylamino)-1-((phenylsulfanyl)methyl)propyl)amino)-3-nitrobenzenesulfonamide) (ABT-737), N-(4-(4-((2-(4-chlorophenyl)-5,5-dimethyl-1-cyclohex-1-EN-1-yl)methyl)piperazine-1-yl)benzoyl)-4-(((1R)-3-(morpholine-4-yl)-1-((phenylsulfanyl)methyl)propyl)amino)-3-((trifluoromethyl)sulfonyl)benzosulfimide (ABT-263), GX-070 (obatoclax), etc.

Inhibitors of kinase Bcr-Ab1 include DASATINIB® (BMS-354825), GLEEVEC® (imatinib), etc.

The CDK inhibitors include AZD-5438, BMI-1040, BMS-032, BMS-387, CVT-2584, flavopiridol, GPC-286199, MCS-5A, PD0332991, PHA-690509, seliciclib (CYC-202, R-roscovitine), ZK-304709 and so on

COX-2 inhibitors include ABT-963, ARCOXIA® (etoricoxib), BEXTRA® (valdecoxib), BMS347070, CELEBREX® (celecoxib), a COX-189 (lumiracoxib), CT-3, DERAMAXX® (deracoxib), JTE-522, 4-methyl-2-(3,4-dimetilfenil)-1-(4-sulfamoyl-1H-pyrrole), MK-663 (etoricoxib), NS-398, parecoxib, RS-57067, SC-58125, SD-8381, SVT-2016, S-2474, T-614, VIOXX® (rofecoksib), etc.

The EGFR inhibitors include ABX-EGF, immunoliposome against EGFR, EGF-vaccine, EMD-7200, ERBITUX® (cetuximab), HR3, IgA antibodies, IRESSA® (gefitinib), TARCEVA® (erlotinib or OSI-774), TP-38, merged the trees EGFR, TYKERB® (lapatinib), etc.

Inhibitors of ErbB2 receptor include CP-724-714, CI-1033 (canertinib), HERCEPTIN® (trastuzumab), TYKERB® (lapatinib), OMNITARG® (2C4, pertuzumab), TAK-165, GW-572016 (inferni), GW-282974, EKB-569, PI-166, dHER2 (HER2 vaccine), APC-8024 (HER2 vaccine), bespecifically antibody against HER/2neu, B7.her2IgG3, trifunctionally bespecifically antibodies AS HER2, mAB AR-209, mAB 2B-1, etc.

Inhibitors of histone deacetylases include depsipeptide, lunar abyss-824, MS-275, trioxin, suberoylanilide hydroxamic acid (SAHA), TSA, valproate acid, etc.,

Inhibitors of HSP-90 include 17-AAG-nab, 17-AAG, CNF-101, CNF-1010, CNF-2024, 17-DMAG, geldanamycin, IPI-504, KOS-953, MYCOGRAB® (recombinant human antibody to HSP-90), NCS-683664, PU24FC1, PU-3, radicial, SNX-2112, STA-9090 VER49009 etc.

Inhibitors of inhibitors of apoptosis proteins include HGS1029, GDC-0145, GDC-0152, LCL-161, LBW-242, etc.

Conjugates of the antibody-drug include antibody against CD22-MC-MMAF, antibody against CD22-MC-MMAE, antibody against CD22-MCC-DM1, CR-011-vcMMAE, PSMA-ADC MEDI-547, SGN-19Am SGN-35, SGN-75, etc.,

The cascade activators of death receptor include TRAIL, antibodies or other means, which are aimed at TRAIL or death receptors (e.g., DR4 and DR5), such as apomab, conatumumab, ETR2-ST01, GDC0145, (lexatumumab), HGS-1029, LBY-135, PRO-1762 and trastuzumab.

Inhibitors of kinesins include Eg5 inhibitors, such as AZD4877, ARRY-520; inhibitors CENPE, such as GSK923295A etc.

Inhibitors of JAK-2 include CEP-701 (lestaurtinib), XL019 and INCB018424 it.p.

The MEK inhibitors include ARRY-142886, ARRY-438162, PD-325901, PD-98059, etc.

The mTOR inhibitors include AP-23573, CCI-779, everolimus, RAD-001, rapamycin, temsirolimus, ATP-competitive inhibitors TORC1/TORC2, including PI-103, PP242, PP30, Thorin 1, etc.

Nonsteroidal anti-inflammatory drugs include AMIGESIC® (salsalate), DOLOBID® (diflunisal), MOTRIN® (ibuprofen), ORUDIS® (Ketoprofen), RELAFEN® (nabumetone), FELDENE® (piroxicam), ibuprofen cream, ALEVE® (naproxen) and NAPROSYN® (naproxen), VOLTAREN® (diclofenac), INDOCIN® (indomethacin), CLINORIL® (sulindac), TOLECTIN® (tolmetin), LODINE® (etodolac), TORADOL® (Ketorolac), DAYPRO® (oxaprozin) and so on

Inhibitors DERIVED include C-451, CP-673, CP-868596 etc.

Chemotherapeutic drugs based on platinum include cisplatin, ELOXATIN® (oxaliplatin) heptaplatin, lobaplatin, nedaplatin, PARAPLATIN® (carboplatin), satraplatin, picoplatin etc.

Polo-like kinase inhibitors include BI-2536, etc.

Inhibitors Phosphoinositide-3-kinase (PI3K) include wortmannin, LY294002, XL-147, CAL-120, H-21, AEZS-127, ETP-45658, PX-866, GDC-0941, BGT226, BEZ235, XL765, etc.

Analogues of thrombospondin include ABT-510, ABT-567, ABT-898, TSP-1, etc.

The VEGFR inhibitors include AVASTIN® (bevacizumab), ABT-869, AEE-788, ANGIOZYMETM(ribozyme that inhibits angiogenesis (Ribozime Pharmaceuticals (Boulder, CO.) and Chiron, (Emeryville, CA), axitinib (AG-13736), AZD-2171, CP-547,632, IM-862, MACUGEN (pegaptanib), NEXAVAR® (sorafenib, BAY43-9006), pazopanib (GW-786034), vatalanib (PTK-787, ZK-222584), SUTENT® (sunit is NIB, SU-11248), VEGF trap, ZACTIMATM(vandetanib, ZD-6474), etc.

Antibiotics include intercalating antibiotics aclarubicin, actinomycin D, amrubicin, annamycin, adriamycin, BLENOXANE® (bleomycin), daunorubicin, CAELYX® or MYOCET® (liposomal doxorubicin), elsamitrucin, airboren, parboil, ZAVEDOS® (idarubitsin), mitomycin C, nemorubicin, neocarzinostatin, peplomycin, pirarubicin, rebeccamycin, stimulater, streptozocin, VALSTAR® (valrubicin), zinostatin etc.

The topoisomerase inhibitors include aclarubicin, 9-aminocamptothecin, amonafide, amsacrine, Ekaterin, belotecan, BN-80915, CAMPTOSAR® (irinotecan hydrochloride), camptothecin, CARDIOXANE® (dexrazoxane), diflomotecan, edotecarin, ELLENCE® or PHARMORUBICIN® (epirubicin, etoposide, eksteen, 10-hydroxycamptothecin, gimatecan, lurtotecan, mitoxantrone, oracin, parabolin, pixantrone, rubitecan, sobuzoxane, SN-38, tafluprost, topotecan, etc.,

Antibodies include AVASTIN® (bevacizumab), CD40-specific antibodies, chTNT-1/B, denosumab, ERBITUX® (cetuximab), HUMAX-CD4® (zanolimumab), IGF1R-specific antibodies, lintuzumab, PANOREX® (edrecolomab), RENCAREX® (WX G250), RITUXANE® (rituximab), ticilimumab, trastuzumab, antibodies against CD20 types I and II, etc.

Hormonal drugs include ARIMIDEX® (anastrozole), AROMASIN® (exemestane), arzoxifene, CASODEX® (bikalutamid), CETROTIDE® (cetrorelix), degarelix, deslorelin, DESOPA® (trilostane), dexamethasone, DROGENIL® (flutamide), EVISTA® (raloxifene), AFEMATM(fadrozole), FARESTON® (toremifene), FASLODEX® (fulvestrant), FEMARA® (letrozol), formestane, glucocorticoids, HECTOROL® (doxercalciferol), RENAGEL® (sevelamer carbonate), lasofoxifene, leuprolide acetate MEGACE® (megestrol), MIFEPREX® (mifepristone), NILANDRONTM(nilutamide), NOLVADEX® (tamoxifen citrate), PLENAXISTM(abarelix), prednisone, PROPECIA® (finasteride), elastan, SUPREFACT® (buserelin), TRELSTAR® (hormone-releasing factor, luteinizing hormone (LHRH)), VANTAS® (implant histrelin), VETORYL® (trilostane or morestan), ZOLADEX® (forlin, goserelin), etc.

Deltoids and retinoids include seocalcitol (EB1089, CB1093), lexicality (KH1060), phenetidine, PANRETIN® (alitretinoin), ATRAGEN® (liposomal tretinoin), TARGRETIN® (bexarotene), LGD-1550, etc.

PARP inhibitors include ABT-888 (veliparib), olaparib, KU-59436, AZD-2281, AG-014699, BSI-201, BGP-15, INO-1001, ONO-2231, etc.

Plant alkaloids include, but are not limited to, vincristine, vinblastine, vindesine, vinorelbine, etc.,

The proteasome inhibitors include VELCADE® (bortezomib), MG132, NPI-0052, PR-171, etc.,

Examples of immunological tools include interferons and other amplifiers of the immune system. Interferons include interferon alpha, interferon alpha-2a, interferon alpha-2b, interferon beta, interferon gamma-1a, ACTIMMUNE® (interferon gamma-1b) or interferon gamma-n1, combinations thereof, etc., the Other is their tools include ALFAFERON® (IFN-α), BAM-002 (oxidized glutathione), BEROMUN® (tasonermin), BEXXAR® (tositumomab), CAMPΑΤΗ® (alemtuzumab), CTLA4 (cytotoxic lymphocyte antigen 4), dacarbazin, denileukin, epratuzumab, GRANOCYTE® (lenograstim), lentinan, leukocyte alpha-interferon, imiquimod, MDX-010 (antibody against CTLA-4), a vaccine against melanoma, mitooma, molgramostim, MYLOTARGTM(gemtuzumab ozogamicin), NEUPOGEN® (filgrastim), OncoVAC-CL, OVAREX® (oregovomab), pemtumomab (Y-muHMFG1), PROVENGE® (siolence-T), sargramostim, sizofiran, azelastin, THERACYS® (Bacillus of Calmet-guérin (BCG), ubenimex, VIRULIZIN® (immunotherapy tool, Lorus Pharmaceuticals), Z-100 (Specific Substance of Maruyama (SSM)), WF-10 (tetrachlorodecaoxide (TCDO)), PROLEUKIN® (aldesleukin), ZADAXIN® (thymalfasin), ZENAPAX® (daclizumab), ZEVALIN® (90Y-ibritumomab tiuxetan), etc.

The biological response modifiers are tools that modify the defense mechanisms of living organisms or biological responses, such as survival, growth or differentiation of tissue cells to direct them so that they had antitumor activity, and they include baptisms, lentinan, sizofiran, picibanil PF-3512676 (CpG 8954), ubenimex etc.

Analogues of pyrimidines include cytarabine (ara-C, or arabinoside C), cytosine arabinoside, doxifluridine, FLUDARA® (fludarabine), 5-FU (5-fluorouracil), floxuridine, GEMZAR® (gemcitabine), TOMUDEX® (raytraced), TROXATYLTM(triacetyluridine), etc.

Analogues of purines include LANVIS® (tioguanin) and PURI-NETHOL® (mercaptopurine).

Antimitoticescoy tools include batubulan, epothilone D (KOS-862), N-(2-((4-hydroxyphenyl)amino)pyridine-3-yl)-4-methoxybenzenesulfonamide, ixabepilone (BMS 247550), paclitaxel, TAXOTERE® (docetaxel), PNU100940 (109881), patupilone, XRP-9881 (larotaxel), vinflunine, ZK-EPO (synthetic epothilone), etc.

Inhibitors of ubiquitinate include MDM2 inhibitors, such as tested nutlins, inhibitors NEDD8, such as MLN4924, etc.

Compounds according to the invention can also be used as radio sensibilizators that increase the effectiveness of radiation therapy. Examples of radiation therapy include radiation therapy external beam teletherapy, brachytherapy and radiotherapy of closed and open source, etc.

In addition, the compounds of formula (I) can be combined with other chemotherapeutics, such as ABRAXANETM(ABI-007), ABT-100 (inhibitor farnesyltransferase), ADVEXIN® (vaccine Ad5CMV-p53), ALTOCOR® or MEVACOR® (lovastatin), AMPLIGEN® (poly I: poly C12U, a synthetic RNA), APTOSYN® (asialink), AREDIA® (pamidronate acid), Arglabin, L-asparaginase, atamestane (1-methyl-3,17-dione-androsta-1,4-diene), AVAGE® (tazarotene), AVE-8062 (derived combretastatin), BEC2 (mitooma), cachectin or cachectin (tumor necrosis factor), canvaxin (vaccine), CEAVAC® (vaccine against malignant tumors), CELEUK® celmoleukin), CEPLENE® (histamine dihydrochloride), CERVARIX® vaccine against human papilloma virus), CHOP® (C: CYTOXAN® (cyclophosphamide); H: ADRIAMYCIN® (hydroxydoxorubicin); O: vincristine (ONCOVIN®); P: prednisone), CYPATTM(ciproteron acetate), complestatin A4P, DAB(389)EGF (catalytic and translocation domains of diphtheria toxin fused via a linker His-Ala with epidermal growth factor) or transMID-107RTM(diphtheria toxins), dacarbazine, dactinomycin, 5,6-dimethylxanthene-4-acetic acid (DMXAA), eniluracil, EVIZONTM(squalamine lactate), DIMERICINE® (liposomal lotion T4N5), discodermolide, DX-8951f (eksteen mesilate), enzastaurin, EPO906 (epitalon B), GARDASIL® (chetyrehletija vaccine against human papillomavirus (types 6, 11, 16, 18)), GASTRIMMUNE®, GENASENSE®, GMK vaccine based on conjugate ganglioside), GVAX® vaccine for prostate cancer), halofuginone, histrelin, hydroxycarbamide, ibandronic acid, IGN-101, IL-13-PE38, IL-13-PE38QQR (cintredekin besudotox), IL-13-exotoxinpseudomonasinterferon-α, interferon-γ, JUNOVANTMor MEPACTTM(mifamurtide), lonafarnib, 5,10-methylenetetrahydrofolate, miltefosine (hexadecylphosphocholine), NEOVASTAT® (AE-941), NEUTREXIN® (trimetrexate the glucuronate), NIPENT® (pentostatin), ONCONASE® (enzyme ribonuclease), ONCOPHAGE® (vaccine to treat melanoma), ONCOVAX® (IL-2 vaccine), ORATHECINTM(rubitecan), OSIDEM® (cellular drug-based antibodies) OVAREX® MAb (monoclonal antibody mouse), paclitaxel, PANDIMEXTM(aglionby saponins from ginseng, containing 20(S)protopanaxadiol (aPPD) and 20(S)protopanaxatriol (aPPT)), panitumumab, PANVAC®-VF (passing the test vaccine against malignant tumors), pegaspargase, PEG-interferon A, phenoxodiol, procarbazine, ropemaster, REMOVAB® (catumaxomab), REVLIMID® (lenalidomide), RSR13 (efaproxiral), SOMATULINE® LA (lanreotide), SORIATANE® (acitretin), staurosporin (Streptomyces staurospores), talabostat (PT100), TARGRETIN® (bexarotene), TAXOPREXIN® (DHA-paclitaxel), TELCYTA® (infospeed, TLK286), timelife, TEMODAR® (temozolomide), tesmilifene, thalidomide, THERATOPE® (STn-KLH), thymitaq (2-amino-3,4-dihydro-6-methyl-4-oxo-5-(4-pyridylthio)hintline the dihydrochloride), TNFERADETM(adenovector: DNA carrier containing the gene for tumor necrosis factor-α), TRACLEER® or ZAVESCA® (bosentan), tretinoin (retin-A), tetrandrine, TRISENOX® (arsenic trioxide), VIRULIZIN®, Ukrain (derivative of alkaloids from plants celandine), vitaxin (antibody against alpha-v-beta-3), XCYTRIN® (motexafin gadolinium), XINLAYTM(atrasentan), XYOTAXTM(paclitaxel poliglumex), YONDELIS® (trabectedin), ZD-6126, ZINECARD® (dexrazoxane), ZOMETA® (zolendronate acid), zorubicin etc.

Data

Determine the applicability of the compounds of formula (I) as compounds that bind to and are inhibitors of antiapoptotic proteins Bcl-2, rowdily using analysis by time-of-flight study of fluorescence resonance energy transfer (TR-FRET). Antibody Tb-anti-GST were purchased Invitrogen (catalog No. PV4216).

Synthesis of probes

All reagents were used as received from the supplier, unless otherwise indicated. Reagents for peptide synthesis, including diisopropylethylamine (DIEA), dichloromethane (DCM), N-organic (NMP), hexaflurophosphate 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium (HBTU), N-hydroxybenzotriazole (HOBt) and piperidine were purchased from Applied Biosystems, Inc. (ABI), Foster City, CA or American Bioanalytical, Natick, MA. Pre-loaded cassettes from 9-Fluorenylmethoxycarbonyl (Fmoc)-amino acid (Fmoc-Ala-OH, Fmoc-Cys(Trt)-OH, Fmoc-Asp(tBu)-OH, Fmoc-Glu(tBu)-OH, Fmoc-Phe-OH, Fmoc-Gly-OH, Fmoc-His(Trt)-OH, Fmoc-Ile-OH, Fmoc-Leu-OH, Fmoc-Lys(Boc)-OH, Fmoc-Met-OH, Fmoc-Asn(Trt)-OH, Fmoc-Pro-OH, Fmor-Gln(Trt)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Ser(tBu)-OH, Fmoc-Thr(tBu)-OH, Fmoc-Val-OH, Fmoc-Trp(Boc)-OH, Fmoc-Tyr(tBu)-OH) were purchased from ABI or Anaspec, San Jose, CA. The resin for peptide synthesis (Fmoc-amide resin Rink MBHA) and Fmoc-Lys(Mtt)-OH was purchased from Novabiochem, San Diego, CA. Single isomer Succinimidyl of ester 6-carboxyfluorescein (6-FAM-NHS) was purchased from Anaspec. Triperoxonane acid (TFA) was obtained from Oakwood Products, West Columbia, SC. Thioanisole, phenol, triisopropylsilane (TIS), 3,6-dioxa-1,8-octanedithiol (DODT) and isopropanol were obtained from Aldrich Chemical Co., Milwaukee, WI. Mass spectra laser desorption-ionization in the presence of matrix (MALDI-MS) were recorded on an Applied Biosystems Voyager DE-PRO MS). Mass spectra when elektrorazpredelenie (ESI-MS) were recorded on a Finnigan SSQ7000 (Finnigan Corp., San Jose, C) in the regime of positive and negative ions.

General procedure for solid-phase peptide synthesis (PPPS).

Peptides were synthesized with at most 250 µmol pre-loaded Wang resin/capacity on the device for the synthesis of peptides ABI 433A using loops join FastmocTMat the scale of 250 µmol. Pre-loaded cassettes containing 1 mmol standard Fmoc-amino acids, except for the provisions attaching a fluorophore, where 1 mmol Fmoc-Lys(Mtt)-OH was placed on the cartridge, used with monitoring feedback for conductivity. N-terminal acetylation was carried out using 1 mmol of acetic acid in the cassette in the standard conditions of accession.

Remove 4-methyltricyclo (Mtt) of lysine

The resin from the device for synthesis were washed three times with DCM and kept moist. 150 ml of a mixture of 95:4:1 dichloromethane:triisopropylsilane:triperoxonane acid was passed through the resin for 30 minutes. The mixture became dark yellow, and then brightened to light yellow. 100 ml of DMF was passed through the layer for 15 minutes. Then the resin was washed three times with DMF and filtered. Tests with ninhydrin showed a strong signal in relation to the primary amine.

Tagging resin with 6-carboxyfluorescein-NHS (6-FAM-NHS)

The resin was treated with 2 equivalents of 6-FAM-NHS 1% DIEA/DMF and stirred or shaken at temperatures of the environment during the night. After that, the resin was drained, washed three times with DMF, three times (1× DCM and 1× with methanol and dried to obtain orange resin, which was negative in the test with ninhydrin.

General procedure for cleavage and removal of the protective group from the associated resin peptide

The peptides were tsalala from the resin by shaking for 3 hours at ambient temperature in a mixture for splitting, consisting of 80% TFA, 5% water, 5% thioanisole, 5% phenol and 2.5% TIS and 2.5% EDT (1 ml/0.1 g resin). The resin was removed by filtration and washing two times with TFA. TFA is evaporated from the filtrate and the product was besieged with simple ether (10 ml/0.1 g resin), were isolated by centrifugation, washed twice with simple ether (10 ml/0.1 g resin) and dried to obtain the crude peptide.

General procedure for the purification of peptides

The crude peptides were purified on a system for preparative HPLC Gilson, using software to analyze Unipoint® (Gilson, Inc., Middleton, WI) on radial compression column containing two segments 25 × 100 mm, filled with particles of a Delta-PakTMC18, 15 μm, pore size 100 Å and suirable one of the gradient methods listed below. Was purified from one to two milliliters of a solution of the crude peptide (10 mg/ml in 90% DMSO/water) for injection. Peaks corresponding to the product(s) from each analysis, were combined and liofilizirovanny. All drugs the positive tests were carried out at 20 ml/min with suenami as buffer A is 0.1% TFA-water, and buffer b: acetonitrile.

General procedure for analytical HPLC

Analytical HPLC was carried out on the system Hewlett-Packard 1200 series with the detector with diode array and fluorescence detector Hewlett-Packard 1046A using software 3D HPLC ChemStation version A. 03.04 (Hewlett-Packard Company. Palo Alto, CA) on a column of YMC is 4.6 × 250 mm) Packed with particles of ODS-AQ, 5 μm, pore size 120 Å and suirable one of the gradient methods listed below, after pre-equilibration to initial conditions within 7 minutes. Eluent consisted of buffer A is 0.1% TFA-water, and buffer B: acetonitrile. The flow rate for all gradient was 1 ml/min

F-Bak: The peptide probe acetyl-(SEQ ID NO: 1)GQVGRQLAIIGDK(6-FAM)-(SEQ ID NO:2)INR-NH2

Fmoc-amide resin Rink MBHA was extended using the General procedure for the synthesis of peptides with getting protected is associated with the resin peptide (1,020 g). The Mtt group was removed, marked 6-FAM-NHS and uncoupled, and the protective group was removed as described herein above, to obtain the crude product as an orange solid (0,37 g). This product was purified using RP-HPLC. The main peak fractions were tested using analytical RP-HPLC, and the purified fractions were isolated and liofilizirovanny, and the main peak gave specified in the header connection (0,0802 g) as a yellow solid; MALDI-MS m/z=2137,1 [(M+H)+

Alternative synthesis of peptide probe F-Bak: Acetyl-(SEQ ID NO: 1)GQVGRQLAIIGDK(6-FAM)-(SEQ ID NO:2)INR-NH2

The protected peptide was assembled on a 0.25-mmol Fmoc-amide resin Rink MBHA (Novabiochem) on the automatic device for the synthesis of peptides Applied Biosystems A using loops join FastmocTMusing pre-filled cartridges with 1 mmol of amino acids, except labeled with fluorescein (6-FAM) lysine where the cartridge was weighed 1 mmol Fmoc-Lys(4-methyldecyl). N-terminal acetyl group was included by placing 1 mmol of acetic acid in the cassette and attach as described herein above. Selective removal of 4-methyltricyclo groups was performed using a solution of 95:4:1 DCM:TIS:TFA (about./about./vol.), flowing over the resin for 15 minutes, followed by quenching the flow of dimethylformamide. A single isomer (6-carboxyfluorescein-NHS was subjected to reaction with the side chain of lysine in 1% DIEA in DMF and completion was confirmed using a test with ninhydrin. The peptide was tsalala from the resin and side chains were removed protective group by treatment with a mixture of 80:5:5:5:2,5:2,5 TFA/water/phenol/thioanisole/triisopropylsilane/3.6-dioxa-1,8-octanedithiol (about./about./about./about./about./vol.), and neojidanni peptide was isolated by precipitation with diethyl ether. The crude peptide was purified by reversed-phase high-performance liquid chromatography, and its clear the Tu and the authenticity was confirmed by analytical reversed-phase high-performance liquid chromatography and mass spectrometry laser desorption from the liquid matrix (m/z=2137,1 ((M+H) +)).

The analysis of fluorescence resonance energy transfer with a temporal resolution (TR-FRET)

Representative compounds were serially diluted in dimethyl sulfoxide (DMSO), starting with 50 μm (2× initial concentration; 10% DMSO) and 10 μl was transferred into a 384-well plate. Then to each well was added 10 μl of a mixture of protein/probe/antibody in the final concentrations listed in table 1. Then the samples were mixed on the device for shaking for 1 minute and incubated for an additional 3 hours at room temperature. For each analysis probe/antibody and protein/probe/antibody were included on each plate for analysis as negative and positive controls, respectively. Fluorescence was measured on an Envision (Perkin Elmer) using excitation filter 340/35 nm and emission filters 520/525 (F-Bak peptide) and 495/510 nm (labeled Tb antibody against histidine). Dissociation constants (Ki) are shown in table 2 below and they are determined using equation Wang (Wang Z.-X., An Exact Mathematical Expression For Describing Competitive Binding Of Two Different Ligands To A Protein Molecule. FEBS Lett. 1995, 360:111-4).

Table 1
Protein probe and antibody used for the analysis of TR-FRET
ProteinProbeBel is to
(nm)
Probe
(nm)
AntibodyAntibody
(nm)
GST-Bcl-2Peptide probe F-Bak: acetyl-(SEQ ID NO: 1)GQVGRQLAIIGDK(6-FAM)-(SEQ ID NO:2 INR-amide)1100Tb-anti-GST1
6-FAM = 6-carboxyfluorescein; Tb = terbium; GST = glutathione-S-transferase

Then the samples were mixed on the device for shaking for 1 minute and incubated for an additional 3 hours at room temperature. For each analysis probe/antibody and protein/probe/antibody were included on each plate for analysis as negative and positive controls, respectively. Fluorescence was measured on an Envision (Perkin Elmer) using excitation filter 340/35 nm and emission filters 520/525 (F-Bak peptide) and 495/510 nm (labeled Tb antibody against histidine).

The inhibition constants (Kifor compounds according to the invention are presented in table 2 below. When Kito connect represented as "<" (less than) a certain numerical value, imply that the magnitude of the affinity of binding (for example, in relation to Bcl-2) below detection limit used in analysis. Design the antes inhibition was determined using equation Wang (Wang Zx,. An Exact Mathematical Expression For Describing Competitive Binding Of Two Different Ligands To A Protein Molecule. FEBS Lett. 1995, 360:111-4).

The inhibition constant (Ki) represents the dissociation constant of the complex enzyme-inhibitor or complex protein/small molecule compound, where the small molecule compound inhibits the binding of one protein with another protein or peptide. Thus, a large value of Kiindicates low affinity binding, and low value of Kiindicates a high affinity of binding.

Table 2 shows the inhibition constants for the inhibition of peptide probe Bak BH3 protein Bcl-2 and indicated that the compounds according to the invention have high affinity binding in respect of the antiapoptotic protein Bcl-2. Thus, it is expected that the compounds applicable to the treatment of diseases in which is expressed anti-apoptotic protein Bcl-2.

Analysis of cell viability RS4;11

To assess activity in the cells separate anti-Bcl-2in vitroand their effectivenessin vivoas a primary cell line human used cleocinonline acute lymphoblastic leukemia (ALL) RS4; 11. In previous studies it was shown using the profile definition BH3, mitochondrial analysis, which classifies the blocks inherent in the apoptotic cascade that cells RS4;11 are highly dependent on BCL-2 for survival and sensitive to the inhibitor representatives of the family of Bcl-2 ABT-737 (Blood, 2008, Vol. 111, 2300-2309). The prevalence of Bcl-2 in complex with proapoptotic protein Bim BH3 in RS4;11 indicates that these cells are "premirovanii" or more sensitive to cell death via antagonism of antiapoptotic protein Bcl-2, from which they depend for survival.

Cells RS4;11 were cultured in RPMI-1640, supplemented with 2 mm L-glutamine, 10% FBS, 1 mm sodium pyruvate, 2 mm HEPES, 1% penicillin/streptomycin (Invitrogen), 4.5 g/l glucose and maintained at 37°C With 5% CO2. To test activity in cells compoundsin vitrothe cells were processed in the amount of 50,000 cells per well in 96-well microplate for titration in the presence of 10% human serum for 48 hours in a humidified chamber with 5% CO2. The magnitude of cellular cytotoxicity EC50was assessed using CellTiter Glo (Promega) according to the manufacturer's recommendations. Value EC50defined as the percentage of viable cells after treatment compared to untreated control cells.

Table 3 presents the applicability of the compounds of formula I for the functional inhibition of antiapoptotic protein Bcl-2 in the cellular context. Using the definition of the profile BH3, mitochondrial analysis, which classifies the blocks inherent in the apoptotic cascade that cell line lymphoblastic leukemia (ALL) RS4;11 is highly dependent on Bcl-2 for survival and is sensitive to the inhibitor representatives of the family of Bcl-2 ABT-737 (Blood, 2008, Vol. 111, 2300-2309). The ability of compounds to destroy cells RS4;11 is a direct measure of the ability of compounds to inhibit the antiapoptotic function of the protein Bcl-2. The compounds of formula I are highly effective in killing cells RS4;11, indicated by low values of EC50.

Compounds described in the patent application U.S. No. 12/631404 called "BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASE" filed December 4, 2009, applicable to the treatment of various malignant tumors and autoimmune diseases due to their activity against proteins of Bcl-2, and, more specifically, Bcl-2. These compounds are associated with Bcl-2 with high affinity in the analysis based on FRET, described is in 12/631404. The introduction of one or more of these compounds in cells, the survival of which depends on Bcl-2 or proteins of Bcl-2, such as a tumor cell line (B-cell leukemia RS4:11, leads to apoptosis, also known as programmed cell death. The level of apoptosis induced connection corresponds to the EC50 in the analysis of the viability of the cells, which is a measure of the number of living cells after the introduction of the connection.

Table 4 shows certain compounds (described below in examples 19, 20, 23 and 92 and described in more detail in 12/631404, the description of which is incorporated herein by reference) with different substituents defined as R, X and Y, as indicated. As can be seen from table 4, these compounds tend to increase the affinity of binding (Kiin relation to Bcl-2 with increasing levels of apoptosis, or cell death, dependent on Bcl-2 tumor cell line RS4;11. On this basis, the inventors expect that compounds with greater affinity in relation to Bcl-2 than the compounds shown in table 4, will show a similar trend, potentially leading to even higher levels of apoptosis when introduced into cells, the survival of which depends on Bcl-2.

Table 4
Selected the connection in the patent application U.S. No. 12/631404

In this regard, the affinity of binding and cellular activity for compounds in accordance with the present invention was compared with structurally similar indole compounds. In particular, the compounds of the present invention, in which nitrogen is contained in a specific position in heteroarenes, fused with a heteroaryl ring, compared with the corresponding indole compounds, and these latter compounds are deprived of only the specific substitution of nitrogen included in the compounds of the present invention.

As can be seen from table 5, the compounds of the present invention, specifically showing the substitution of nitrogen (i.e., the compounds of examples 1, 2, 3, 4, 5, 6, 9, 10, 11, 12, 13, 15, 16 and 17, where Ζ=N) actually achieve relatively higher levels of apoptosis when introduced into cells, the survival of which depends on Bcl-2, and have an increased affinity in relation to Bcl-2 relative to structural analogues lacking the specific substitution of nitrogen (i.e., connection examples 87, 88, 89, 90, 91, 19, 20, 21, 92, 22, 23, 93 and 94, respectively, where Ζ=C, described in 9696USL2, the contents of which are incorporated herein by reference).

In particular, in the seventh column of table 5 comparing who is the binding affinity of compounds of the present invention (connection, identified the indicated substituents in the top row in each pair of rows, separated by blank rows) with the corresponding compounds lacking described substitution of nitrogen. For each comparison, the compounds of the present application (the upper row of each pair of rows, separated by blank rows) associated with Bcl-2 with greater affinity in relation to Bcl-2 than the corresponding analogues (bottom row of each pair of rows, separated near empty).

In addition, in column 8 of table 5 compares the level-dependent apoptosis in Bcl-2 cell line RS4;11 achieved using the compounds of the present invention (again the connection identified by the indicated substituents in the upper row of each pair of rows, separated by empty rows), achieved using the compounds of examples 87, 88, 89, 90, 91, 19, 20, 21, 92, 22, 23, 93 and 94, where Ζ=C. for each comparison, the compounds of the present invention (the upper row of each pair of rows, separated by blank rows) reach a higher degree of apoptosis in dependent Bcl-2 cells RS4;11 than the corresponding analogues (bottom row of each pair of rows, separated by empty rows).

The increase in the affinity of binding between the compounds of the present invention and the corresponding analogues is in the range from 2.7× to 100×, and increased efficiency in RS4; 11 is in the range of increase of 1.65× to increase more than 10×.

As described in detail below, the specific substitution of the nitrogen atom of carbon atom leads to an unexpected increase in the affinity of binding of anti-apoptotic Bcl-2 and increase efficiency in the analysis of the viability of the cells, where the dependent apoptosis in Bcl-2 cell lines.

Thus, this invention includes a series of compounds that exhibits unexpected properties in relation to their binding and inhibiting the activity of antiapoptotic protein Bcl-2 to a much greater extent than the corresponding compounds equivalents.

Table 5
A direct comparison of the compounds of the present invention with the corresponding analogs

More specifically, the compounds of the present invention have a pattern substitution, presented at the diagramme below.

Other compounds that contain isomeric ring system relative to those shown above, such as ring systems containing nitrogen adjacent to the oxidized carbon in the ring, as shown below, are the worst due to instability.

In particular, it was revealed by the authors of the present invention when the next connection. The intermediate structure F, which immediately precedes the final product unstable compounds, obtained as described below. All intermediate compounds A-F were stable and amenable to selection using methods known to experts in this field.

The intermediate compound F, as shown in the diagram above, was subjected to the reaction with the intermediate connection of G using standard conditions of accession, which are known to experts in this field. The reaction mixture was analyzed by HPLC/MS to monitor the formation of the peak corresponding to the compound of H. Although this peak was formed within hours after start of the reaction below, this peak gradually disappeared during processing and chromatography up until then he was not present. The lack of stability of the intended soybean is inane is a consequence of the provisions of nitrogen in the system condensed rings, described above. This provision, which is adjacent to bearing the oxygen atom of carbon in 5-substituted ring system 1H-pyrrolo[2,3-c]pyridine, below and above, makes a connection Η unstable.

It is expected that the compound containing a condensed 5-substituted ring system 1H-pyrrolo[3,2-b]pyridine, is similarly unstable, because the position of the nitrogen is adjacent to bearing the oxygen atom of carbon in the ring.

Thus, compounds with 5-zalesennymi 1H-pyrrolo[2,3-b]pyridine are preferred relative isomeric compounds.

It is expected that, since the compounds of formula (I) are associated with Bcl-2, they can also be used as compounds that bind to the antiapoptotic proteins with high structural homology with Bcl-2, such as the antiapoptotic protein Bc1-XL, Bcl-w, Mcl-1 and Bfl-1/A1.

The involvement of the protein Bcl-2 in bladder cancer, malignant brain tumor, breast cancer, malignant tumor of the bone marrow, cervical cancer, chronic lymphocytic leukemia, cancer of the colon, rectum, esophagus cancer, liver cancer, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cells is knogo or B-cell origin, melanoma, myelogenous leukemia, myeloma, a malignant tumor of the oral cavity, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer, chronic lymphocytic leukemia, myeloma, prostate cancer, malignant tumor of the spleen, etc. described in belonging to the same patent PCT US 2004/36770, published as WO 2005/049593, and PCT US 2004/37911, published as WO 2005/024636.

The involvement of the protein Bcl-2 in immune and autoimmune diseases described in Current Allergy and Astmae Reports 2003, 3, 378-384; British Journal of Haematology 2000, 110(3), 584-90; Blood 2000, 95(4), 1283-92; and New England Journal of Medicine 2004, 351(14), 1409-1418.

The involvement of the protein Bcl-2 in arthritis described in belonging to the same patent provisional application U.S. serial No. 60/988479.

The involvement of the protein Bcl-2 in the rejection of bone marrow transplant are described in owned by the same patentee patent application U.S. serial No. 11/941196.

Overexpression of proteins Bcl-2 correlates with resistance to chemotherapy and clinical outcome, disease progression, General forecast or their combination in various malignant tumors and immune system disorders. Malignant tumors include, but are not limited to, hematological and solid tumor types, such as acoustic neuroma, acute leukemia, acute limpel the local leukemia, acute myelogenous leukemia (monocytic, myeloblastic, adenocarcinoma, angiosarcoma, astrocytoma, myelomonocytic and promyelocytic), acute T-cell leukemia, basal cell carcinoma, carcinoma of the bile ducts, bladder cancer, malignant brain tumor, breast cancer (including positive for estrogen receptor breast cancer), bronchogenic carcinoma, Burkitt's lymphoma, cervical cancer, chondrosarcoma, chordoma, horiokartsinoma, chronic leukemia, chronic lymphocytic leukemia, chronic miliitary (granulocytic) leukemia, chronic myelogenous leukemia, colon cancer, cancer of the colon, rectum, craniopharyngioma, cystadenocarcinoma, deproliferation changes (dysplasia and metaplasia), embryonal carcinoma, endometrial cancer, ehotelier.com, ependymoma, epithelial carcinoma, erythroleucus, esophageal cancer, positive for estrogen receptor breast cancer, essential thrombocythemia, Ewing's sarcoma, fibrosarcoma, gastric carcinoma, cancer of the reproductive cells of the testis, gestational trophoblastic disease, glioblastoma, head and neck cancer, disease, heavy chains, hemangioblastoma, hepatoma, liver cancer, hormone insensitive prostate cancer, leiomyosarcoma, liposarcoma, lung cancer (including Melk is cell lung cancer and non-small cell lung cancer), lymphangiosarcoma, lymphangiosarcoma, lymphoblastic leukemia, lymphoma (lymphoma, including both diffuse B-cell lymphoma, follicular lymphoma, Hodgkin's lymphoma and nahodkinskuju the Hodgkin's), malignancies and hyperproliferative disorders of the bladder, breast, colon, lung, ovary, pancreas, prostate, skin and uterus, lymphoid malignancies of T-cell or B-cell origin, leukemia, medullary carcinoma, medulloblastoma, melanoma, meningioma, mesothelioma, multiple myeloma, myelogenous leukemia, myeloma, myxosarcoma, neuroblastoma, oligodendroglioma, malignant tumor of the oral cavity, osteogenic sarcoma, ovarian cancer, pancreatic cancer, papillary adenocarcinomas, papillary carcinoma, lymphoma peripheral T-cells, pinealoma, polycythemia Vera, prostate cancer (including hormone-insensitive (refractory) prostate cancer), colorectal cancer, renal cell carcinoma, retinoblastoma, rhabdomyosarcoma, sarcoma, carcinoma, sebaceous glands, seminoma, skin cancer, small cell carcinoma of the lung, solid tumors (carcinomas and sarcomas), stomach cancer, squamous cell carcinoma, sinovioma, sweat gland carcinoma, testicular cancers (including cancer of the reproductive egg cells), cancer soup is aveneu gland, macroglobulinemia waldenstrom, tumors of the testis, cancer of uterine body, Wilms tumor, etc.

It is also expected that compounds of the formula (I) can inhibit the growth of cells expressing Bcl-2, originating from pediatric malignant tumors or neoplasms, including the embryonic rhabdomyosarcoma, childhood acute lymphoblastic leukemia, childhood acute myelogenous leukemia, children alveolar rhabdomyosarcoma, childhood the anaplastic ependymoma, childhood both anaplastic lymphoma, baby the anaplastic medulloblastoma, atypical children teratoid/Rathenow tumor of the Central nervous system, children's biphenotypic acute leukemia, pediatric Burkitt's lymphoma, childhood malignant tumor of the family of Ewing tumors, such as primary neuroectodermal tumors, childhood diffuse anaplastic Wilms tumor, children's tumor Wilms ' tumor with favorable histology, pediatric glioblastoma, pediatric medulloblastoma, pediatric neuroblastoma, children originating from the neuroblastoma myelocytomatosis, baby pre-B-cell malignancies such as leukemia), pediatric osteosarcoma, baby Rathenow a kidney tumor, childhood rhabdomyosarcoma and baby T-cell malignancies such as lymphoma and skin cancer, etc.,

Autoimmune disorders include the syndrome is acquired immunodeficiency syndrome (AIDS), autoimmune lymphoproliferative syndrome, hemolytic anemia, inflammatory diseases, and thrombocytopenia, acute or chronic immune disease associated with organ transplantation, Addison disease, allergic disease, alopecia, alopecia alopecia, atheromatous disease/arteriosclerosis, atherosclerosis, arthritis (including osteoarthritis, juvenile chronic arthritis, septic arthritis, Lyme arthritis, psoriatic arthritis and reactive arthritis), autoimmune bullous disease, abetalipoproteinemia, related to the acquired immunodeficiency diseases, acute immune disease associated with organ transplantation, acquired acrocyanosis, acute and chronic parasitic or infectious processes, acute pancreatitis, acute renal failure, acute rheumatic attack, acute transverse myelitis, adenocarcinoma, foliar ectopic, adult (acute) respiratory distress syndrome, AIDS-Dement complex, alcoholic cirrhosis induced by alcohol liver damage induced by alcohol-induced hepatitis, allergic conjunctivitis, allergic contact dermatitis, allergic rhinitis, allergies, asthma, allograft rejection, deficiency of alpha-1-antitrypsin deficiency, Alzheimer's disease, amyotrophic lateral sclerosis, Anh is Yu, angina associated with ankylosing spondylitis lung disease, degeneration of anterior horn cells, enciclopaedia cytotoxicity, antiphospholipid syndrome, hypersensitivity reactions against receptors, aortic and peripheral aneurysms, aortic dissection, arterial hypertension, arteriosclerosis, arteriovenous fistula, arthropathy, fatigue, asthma, ataxia, atopic allergies, atrial fibrillation (continuous or paroxysmal AF), atrial flutter, atrioventricular blockade, atrophic autoimmune hypothyroidism, autoimmune hemolytic anemia, autoimmune hepatitis, autoimmune hepatitis type 1 (classical autoimmune or anti-hepatitis), mediated by autoimmunity hypoglycemia, autoimmune neutropenia, autoimmune thrombocytopenia, autoimmune thyroid disease, b-cell lymphoma, bone graft rejection, graft rejection, bone marrow (BMT), obliterative bronchiolitis, blockade bundle branch, burns, cachexia, cardiac arrhythmia syndrome stun the heart, tumors of the heart, cardiomyopathy, inflammatory response to cardiopulmonary bypass, graft rejection of cartilage degeneration of the cerebellar cortex, disorders of the cerebellum, chaotic or multifocal atrial tachycardia, associated the with chemotherapy violations chlamydia, cholestasis, chronic alcoholism, chronic active hepatitis, chronic fatigue syndrome, chronic immune disease associated with organ transplantation, chronic eosinophilic pneumonia, chronic inflammatory pathologies, chronic mucocutaneous candidiasis, chronic obstructive pulmonary disease (COPD), chronic poisoning by salicylates, colorectal variable unclassifiable immunodeficiency (variable unclassifiable hypogammaglobulinemia), conjunctivitis, associated with disease of the connective tissue interstitial lung disease, contact dermatitis, Coombs-positive hemolytic anemia, pulmonary heart disease Creutzfeldt-Jakob disease, cryptogenic autoimmune hepatitis, cryptogenic fibrosing alveolitis, culture-negative sepsis, cystic fibrosis, associated with therapy with cytokines disorders, Crohn's disease, dementia boxers, demyelinating diseases, dengue haemorrhagic fever, dermatitis, scleroderma, with dermatitis, dermatological conditions associated with dermatomyositis/polymyositis lung disease, diabetes, diabetic arteriosclerotic disease, diabetes mellitus, diffuse disease of calves Levi, dilated cardiomyopathy, dilated C is worthy persons cardiomyopathy, discoid lupus erythematosus, disorders of the basal ganglia, disseminated intravascular coagulation, down syndrome middle age, induced by drugs interstitial lung disease induced by drugs hepatitis, motor disorders induced by drugs which block dopamine receptors in the Central nervous system, sensitivity to drugs, eczema, encephalomyelitis, endocarditis, endocrinopathy, enteropathic synovitis, epiglottitis, infection with Epstein-Barr, erythromelalgia, extrapyramidal and cerebellar disorders, family hematopoietically lymphohistiocytic, rejection of the implant embryonic thymus, ataxia, functional disorders of the peripheral arteries, female infertility, fibrosis, fibrotic lung disease, fungal sepsis, gas gangrene, gastric ulcer, giant cell arteritis diagnostics, glomerular nephritis, glomerulonephritis syndrome?, goitrous autoimmune hypothyroidism (Hashimoto's disease), gouty arthritis, graft rejection of any organ or tissue, graft-versus-host, gram-negative sepsis, gram positive sepsis, granulomas due to intracellular organisms, infection with Streptococcus group B (GBS) disease graves, associated the second with hemosiderosis disease of the lungs, hairy cell leukemia, hairy cell leukemia, a disease Hallervorden-Space, Hashimoto's thyroiditis, hay fever, graft rejection hearts, hemochromatosis, hematopoietic malignancies (leukemia and lymphoma), hemolytic anemia, hemolytic uremic syndrome/thrombolytic thrombocytopenic purple, hemorrhage, purple's disease-Seleina, hepatitis A, hepatitis B, hepatitis C, HIV infection/HIV neuropathy, Hodgkin's disease, hypoparathyroidism, horey's disease, hyperkinetic movement disorders, hypersensitivity reactions associated with hypersensitivity pneumonitis, gipertireoidizmom, hypokinetic movement disorders, examination of the hypothalamic-pituitary-adrenal system, idiopathic Addison disease, idiopathic leukopenia, idiopathic pulmonary fibrosis, idiopathic thrombocytopenia, idiosyncratic liver disease, spinal muscular atrophy infants, infectious diseases, inflammation of the aorta, inflammatory bowel disease, insulin-dependent diabetes mellitus, interstitial pneumonitis, iridocyclitis/uveitis/optic neuritis, damage during ischemia-reperfusion injury, ischemic stroke, juvenile pernicious anaemia, juvenile rheumatoid arthritis, juvenile spinal muscular atrophy, Kaposi's sarcoma, Olesen Kawasaki, transplant rejection of kidney, legionellosis, leishmaniasis, leprosy, damage kortiko-spinal system, disease, linear IgA, lipidemia, graft rejection liver, Lyme disease, lymphedema, lymphocytic infiltrative lung disease, malaria, idiopathic or NOS, male infertility, malignant histiocytosis, malignant melanoma, meningitis, meningococcemia, microscopic vasculitis of the kidneys, migraine headache, mitochondrial Multisystem violation, mixed disease of connective tissues associated with mixed connective tissue disease lung disease, the monoclonal gammopathy, multiple myeloma, Multisystem degeneration (Menzel, Dejerine-Volume, Shay-Drager and Machado-Joseph), myalgic encephalitis/disease "Royal Free", myasthenia, microscopic vasculitis of the kidneys, the intracellularmycobacterium avium,mycobacterium tuberculosis, myelodysplastic syndrome, myocardial infarction, ischemic disorders of the myocardium, carcinoma of the nasopharynx, chronic lung disease of the newborn, nephritis, nephrosis, neurodegenerative diseases, neurogenic muscular atrophy I neutropenics fever, non-alcoholic steatohepatitis, occlusion of the abdominal aorta and its branches, occlusive arterial disorders, rejection of an organ transplant, orchitis/EPI is alimit, orchitis/return procedures after the vasectomy, organomegaly, osteoarthritis, osteoporosis, ovarian failure, graft rejection of the pancreas, parasitic diseases, graft rejection parathyroid cancer, Parkinson's disease, an inflammatory disease of the pelvis, pemphigus vulgaris, the pemphigus leaf, pemphigoid, rhinitis, diseases of the pericardium, peripheral atherosclerotic disease, peripheral vascular disorders, peritonitis, pernicious anemia, phacogenic uveitis, pneumoniaPneumocystis carinii, pneumonia, POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy and skin changes syndrome), postperfusion syndrome after cardiopulmonary bypass, postcardiotomy syndrome after myocardial infarction, post-infectious interstitial lung disease, premature ovarian failure, primary biliary cirrhosis, primary sclerosing hepatitis, primary myxedema, primary pulmonary hypertension, primary sclerosing cholangitis, primary vasculitis, progressive supranuclear palsy, psoriasis, psoriasis type 1, psoriasis type 2, the psoriatic arthropathy secondary to connective tissue disease, pulmonary manifestation of polyarteritis of polyarteritis, postinflammatory intersti the territorial lung disease, radiation fibrosis, radiation therapy, phenomenon and Raynaud's disease, Raynaud's disease, a disease of Resume, regular tachycardia with a narrow QRS, disease, Reiter, renal disease NOS, renovascular hypertension, reperfusion injury, restrictive cardiomyopathy, associated with rheumatoid arthritis interstitial lung disease, rheumatoid spondylitis, sarcoidosis syndrome Schmidt, scleroderma, senile horey, senile dementia-type Taurus Levi, sepsis syndrome, septic shock, seronegative arthropathies, shock, sickle cell anemia, is associated with disease Sjogren lung disease, Sjogren syndrome, allograft rejection, skin, skin changes syndrome, graft rejection of the small intestine, autoimmunity semen, multiple sclerosis (all subtypes), spinal ataxia, cerebellar degeneration, spondyloarthropathy, spondyloarthropathy, sporadic polyglandular deficiency type I, sporadic polyglandular deficiency type II, of still's disease, streptococcal myositis, stroke, structural damage to the cerebellum, subacute sclerosing panencephalitis, sympathetic ophthalmia, syncopation, syphilis of the cardiovascular system, systemic anaphylaxis, the system inflammatory response syndrome, juvenile rheumatoid arthritis with systemic onset, the system is rasnow erythematosus, associated with systemic lupus erythematosus lung disease, systemic sclerosis associated with systemic scleroderma interstitial lung disease, T-cell or FAB ALL, disease/Takayasu's arteritis, telangiectasia, mediated Th2 type and Th1-type disease, thromboangiitis obliterans, thrombocytopenia, thyroiditis, toxicity, toxic shock syndrome, transplants, trauma/hemorrhage, autoimmune hepatitis type 2 (and hepatitis C antibodies against LKM), insulin resistance type with acanthocardia, hypersensitivity reactions type III hypersensitivity type IV, arthropathy in ulcerative colitis, ulcerative colitis, unstable angina, uremia, urosepsis, urticaria, uveitis, valvular heart disease, varicose veins, vasculitis, masculine diffuse lung disease, venous disease, venous thrombosis, ventricular fibrillation, vitiligo, acute liver disease, viral and fungal infections, fatal encephalitis/aseptic meningitis, fatal hemophagocytic syndrome, Wegener's granulomatosis syndrome Wernicke-Korsakov, Wilson disease, xenograft rejection of any organ or tissue that is associated with yersiniae or the Salmonella arthropathy, etc.

Schemes and experimental

The following abbreviations have the indicated values. ADDP means the AET 1,1'-(azodicarbon)dipiperidino; AD-mix-β means a mixture of (DHQD)2PHAL, K3Fe(CN)6, K2CO3and K2SO4; 9-BBN means 9-borabicyclo(3.3.1)nonan; Boc means tert-butoxycarbonyl; (DHQD)2PHAL means 1,4-phthalazinedione ether of hydroquinidine; DBU means 1,8-diazabicyclo[5.4.0]undec-7-ene; DIBAL means hydride diisobutylaluminum; DIEA means diisopropylethylamine; DMAP means N,N-dimethylaminopyridine; DMF means Ν,Ν-dimethylformamide; dmpe means 1,2-bis(dimethylphosphino)ethane; DMSO means dimethylsulfoxide; dppb means 1,4-bis(diphenylphosphino)butane; dppe means 1,2-bis(diphenylphosphino)ethane; dppf means 1,1'-bis(diphenylphosphino)ferrocene; dppm means 1,1-bis(diphenylphosphino)methane; EDAC·HCl means of the hydrochloride of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide; Fmoc means fluorenylmethoxycarbonyl; HATU means hexaphosphate O-(7-asobancaria-1-yl)-N,N ' N ' N'-tetramethylurea; HMPA means of hexamethylphosphoramide; IPA means isopropyl alcohol; MP-BH3means macroporous cyanoborohydride metropolitical of triethylamine; TEA means triethylamine; TFA means triperoxonane acid; THF means tetrahydrofuran; NCS means N-chlorosuccinimide; NMM means N-methylmorpholine; NMP means N-methylpyrrolidine; PPh3 means triphenylphosphine.

The following diagrams are presented to provide what is believed to be the most useful and the chorus is sho understandable procedures and conceptual aspects of this invention. Compounds according to this invention can be obtained by using synthetic chemical processes, examples of which are shown in this document. Imply that it is clear that the order of process steps may vary reagents, solvents and reaction conditions can be changed relative to those specifically mentioned, and that sensitive groups can be subjected to introduction or removal of the protective group, if necessary.

SCHEME 1

The compounds of formula (4) can be obtained, as shown in figure 1, and can be used as described in scheme 8, to obtain the compounds of formula (I), which are typical representatives of the compounds of the present invention. The compounds of formula (1), where R represents alkyl, can be converted to compounds of formula (2) using the Z3L1MgX1where X1is a halide, in a solvent such as, but not limited to, a simple ether or tetrahydrofuran. The compounds of formula (3) can be obtained from compounds of the formula (2) using a strong base such as NaH and R57X2where X2is a halide and R57is such, as described herein. The compounds of formula (3), in the processing of aqueous NaOH or LiOH, lead to compounds of the formula (4).

p> SCHEME 2

As shown in scheme 2, compounds of formula (5) can be subjected to reaction with compounds of the formula (6) and a reducing agent to obtain compounds of the formula (7). Examples of reducing agents include sodium borohydride, cyanoborohydride sodium, triacetoxyborohydride sodium associated with the polymer cyanoborohydride, etc., the Reaction is usually carried out in a solvent such as, but not limited to, methanol, tetrahydrofuran and dichloromethane, or a mixture thereof. The compounds of formula (8) can be obtained from compounds of formula (7), as indicated in figure 1, and can be used as described in scheme 8, to obtain the compounds of formula (I).

SCHEME 3

The compounds of formula (9), the reaction with the compound of the formula (10), where X is a halide or triflate, and base, will lead to the compound of formula (11). Bases suitable for the reaction include triethylamine, diisopropylethylamine, etc. of Compounds of formula (13), where Y is as described herein for substituents on Z3can be obtained from compounds of formula (11) and compounds of formula (12) with the use of combination reaction Suzuki, known to specialists in this field and is freely available in the literature. The compounds of formula (14) can be obtained from compounds of formula (13), as described n the scheme 1, and they can be used as described in scheme 8, to obtain the compounds of formula (I).

SCHEME 4

As shown in scheme 4, compounds of formula (17) can be obtained from compounds of formula (15) and compounds of formula (16), where R represents alkyl and R38is such, as described herein, using the reaction conditions of the combination Suzuki, known to specialists in this field and is freely available in the literature. The compounds of formula (17) can be restored to the compounds of formula (18) using a reducing agent, such as LiAlH4in a solvent such as, but not limited to, diethyl ether or THF. The compounds of formula (19) can be obtained from compounds of formula (18) using periodinane dess-Martin or conditions of oxidation Swarna, well-known experts in this field and is freely available in the literature. The compounds of formula (19) can be subjected to reaction with the compound of the formula (5) and a reducing agent to obtain compounds of the formula (20). Examples of reducing agents include sodium borohydride, cyanoborohydride sodium, triacetoxyborohydride sodium associated with the polymer cyanoborohydride, etc., the Reaction is usually carried out in a solvent such as, but not limited to, methanol, tetrahydrofuran, 1,2-dichloroethane and dichloromethane, or a mixture thereof. Connection is by means of formula (21) can be obtained from compounds of formula (20), as indicated in figure 1, and can be used as described in scheme 8, to obtain the compounds of formula (I).

SCHEME 5

As shown in scheme 5, compounds of formula (22), where R represents alkyl, can be converted into compounds of formula (23) by reaction of compounds of formula (22), where X1represents Cl, Br, I or CF3SO3-, and the compounds of formula R41-OH and catalyst, with the first base or without him. Examples of catalysts include complex triftoratsetata copper(I) and toluene, PdCl2Pd(OAc)2and Pd2(dba)3. Examples of the first base include triethylamine, N,N-diisopropylethylamine, Cs2CO3, Na2CO3, K3PO4and mixtures thereof.

The compounds of formula (22) can also be converted into compounds of formula (23) by reaction of compounds of formula (22), where X1represents Cl, F or NO2and compounds of the formula R41-OH with the first base. Examples of the first base include triethylamine, N,N-diisopropylethylamine, Cs2CO3, Na2CO3, K3PO4and mixtures thereof.

SCHEME 6

The compounds of formula (18) can be subjected to reaction with methylchloride and a base, such as, but not limited to, triethylamine, and then N-tert-butoxycarbonylamino, to obtain the compounds of formula (24). The compounds of formula (25) can be obtained by reaction of compounds of formula (24) with triethylsilane and triperoxonane acid. The compounds of formula (25) can be subjected to reaction with compounds of the formula (26) and HK2PO4obtaining compounds of formula (27) in a solvent such as, but not limited to, dimethyl sulfoxide. The compounds of formula (28) can be obtained from compounds of formula (27), as indicated in figure 1, and can be used as described in scheme 8, to obtain the compounds of formula (I).

SCHEME 7

As shown in scheme 7, compounds of formula (1) can be subjected to reaction with an appropriate bromide triphenylphosphine formulas (29) and a base such as, but not limited to, sodium hydride or n-utility, to obtain the compounds of formula (30). The reaction is usually carried out in a solvent such as THF or DMSO. The compounds of formula (31) can be obtained from compounds of formula (30), as indicated in figure 1, and can be used as described in scheme 8, to obtain the compounds of formula (I).

SCHEME 8

As shown in scheme 8, compounds of formula (32), which can be obtained as described herein, can be converted into compounds of formula (33) by reaction of compounds of formula (32) with ammonia. The compounds of formula (33) can be transformed into soybean is inane formula (I) by reaction of compounds of formula (33) and compounds of formula (4), (8), (14), (21), (28), (31) or (38) and the agent of combination reaction, with the first base or without him. Examples of agents of combination reaction include hydrochloride, 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide, 1,1'-carbonyldiimidazole and hexaphosphate benzotriazol-1-yl-oxtriphylline. Examples of the first base include triethylamine, Ν,Ν-diisopropylethylamine, 4-(dimethylamino)pyridine, and mixtures thereof.

SCHEME 9

The compounds of formula (33), obtained as described in scheme 8, can also be converted into compounds of formula (I) by reaction of compounds of formula (33) and compounds of formula (34) and first base. Examples of the first bases include, but are not limited to, sodium hydride, triethylamine, Ν,Ν-diisopropylethylamine, 4-(dimethylamino)pyridine, and mixtures thereof.

SCHEME 10

As shown in scheme 10, compounds of formula (35), where L is a bond, alkyl, O, S, S(O), SO2, NH, and so on, can be subjected to reaction with compounds of formula (36), with compounds of the formula (37). The reaction is typically carried out at elevated temperatures in a solvent such as, but not limited to, dimethylsulfoxide, and it may require the use of a base, such as, but not limited to, potassium phosphate, potassium carbonate, etc., the compounds of formula (38) can be obtained from the connected to the second formula (37), as described in scheme 1, and can be used as described in scheme 8, to obtain the compounds of formula (I).

SCHEME 11

The compounds of formula (39), where Y is as described herein for substituents on Z3can be obtained from compounds of formula (39A), where X is a halide or triflate, and Y-B(OH)2using the reaction conditions of the combination Suzuki, known to specialists in this field and is freely available in the literature. The compounds of formula (39) can be subjected to reaction with tert-butyl piperazine-1-carboxylate and a reducing agent, such as triacetoxyborohydride sodium, to obtain the compounds of formula (40). The reaction is usually carried out in a solvent such as, but not limited to, methylene chloride. The compounds of formula (41) can be obtained from compounds of formula (40) by reaction of compounds of formula (40) with R57X, where X is a halide, and NaH in a solvent such as Ν,Ν-dimethylformamide, and then the resulting material can be treated with triethylsilane and triperoxonane acid in dichloromethane. The compounds of formula (41) can be used as described in scheme 10, where L1-Z3is as shown in formula (41).

SCHEME 12

As shown in scheme 12, a substituted piperazine-2-he shall, where R57represents alkyl, can be reacted with compounds of the formula (6) and a reducing agent, such as triacetoxyborohydride sodium in dichloromethane to obtain compounds of formula (42). The compounds of formula (42) can be restored to the compounds of formula (43) using a reducing agent such as, but not limited to, alumoweld lithium, in a solvent such as, but not limited to, tetrahydrofuran. The compounds of formula (43) can be used as described in scheme 10, where L1-Z3is as shown in formula (43).

The following examples are presented to provide what is believed to be the most useful and well understood procedures and conceptual aspects of the present invention. Illustrated compounds were named using ACD/ChemSketch version 5.06 (05 June 2001, Advanced Chemistry Development Inc., Toronto, Ontario), ACD/ChemSketch version 12.01 (may 13, 2009, Advanced Chemistry Development Inc., Toronto, Ontario), or ChemDraw® version 9.0.5 (CambridgeSoft, Cambridge, MA). Intermediate compounds were named using ChemDraw® version 9.0.5 (CambridgeSoft, Cambridge, MA).

EXAMPLE 1

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 1A

Tert-butyl 4-((4'-chlorobiphenyl-2-yl)methyl)piperaz the n-1-carboxylate

4'-chlorobiphenyl-2-carboxaldehyde (4.1 g), tert-butyl piperazine-1-carboxylate (to 4.23 g) and triacetoxyborohydride sodium (5,61 g) in CH2Cl2(60 ml) was stirred for 24 hours. The reaction mixture was extinguished with methanol and poured into a simple ether. The solution was washed with water and brine, concentrated and subjected to chromatography on silica gel with a mixture of 2-25% ethyl acetate/hexane.

EXAMPLE 1B

1-((4'-chlorobiphenyl-2-yl)methyl)piperazine

The compound of example 1A (3.0 g) and triethylsilane (1 ml) was stirred in CH2Cl2(30 ml) and triperoxonane acid (30 ml) for 2 hours, and the reaction mixture was concentrated, and then was collected in a simple ether and again concentrated. The material was collected in dichloromethane (200 ml) and a solution of NaHCO3(100 ml), and distributed. The organic layer was dried over Na2SO4and are condensed with obtaining specified in the connection header.

EXAMPLE 1C

Tert-butyl-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazine-1-yl)-2-perbenzoate

Tert-butyl 4-bromo-2-perbenzoate (14.0 g), the compound of example 1B (of 16.05 g), Pd2(dba)3(Tris(dibenzylideneacetone)dipalladium(0)) (1.40 g), 2-(di-tert-butylphosphino)biphenyl (1,82 g) and K3PO4(16.2 g) was stirred in 1,2-dimethoxyethane (300 ml) at 80°C for 24 hours. The reaction mixture was cooled and concentrated. The crude product was subjected to chromatography on silicagel the e with a mixture of 10-20% ethyl acetate/hexane.

EXAMPLE 1D

Tert-butyl-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazine-1-yl)benzoate

1H-pyrrolo[2,3-b]pyridine-5-ol (167 mg), the compound of example 1C (500 mg) and Cs2CO3(508 mg) was stirred in dimethyl sulfoxide (5 ml) at 130°C for 24 hours. The mixture was cooled, diluted with ethyl acetate, washed three times with water and brine, and dried (Na2SO4), filtered and concentrated. The crude product was subjected to chromatography on silica gel with a mixture of 25% ethyl acetate/hexane.

EXAMPLE 1E

2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-(4-((4'-chlorobiphenyl-2-yl)methyl)piperazine-1-yl)benzoic acid

The compound of example 1D (200 mg) and triethylsilane (1 ml) was stirred in dichloromethane (15 ml) and triperoxonane acid (15 ml) for 1 hour. The mixture was concentrated, taken into ethyl acetate, washed twice NaH2PO4and brine, and dried (Na2SO4), filtered and concentrated.

EXAMPLE 1F

3-nitro-4-((tetrahydro-2H-Piran-4-yl)methylamino)benzosulfimide

4-Fluoro-3-nitrobenzenesulfonamide (2,18 g), 1-(tetrahydropyran-4-yl)methylamine (1,14 g) and triethylamine (1 g) was stirred in tetrahydrofuran (30 ml) for 24 hours. The solution was diluted with ethyl acetate, washed with a solution of NaH2PO4and brine, and dried (Na2SO4), filtered and concentrated. The product was received RA is tiranium with ethyl acetate.

EXAMPLE 1G

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

The compound of example 1E (115 mg), the compound of example 1F (67 mg), the hydrochloride of 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (82 mg) and 4-dimethylaminopyridine (26 mg) was stirred in CH2Cl2(3 ml) for 24 hours. The reaction mixture was cooled and subjected to chromatography on silica gel with a mixture of 0-5% methanol/ethyl acetate.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,48 (user.s, 1H), 8.34 per (user. s, 1H), 8,31 (m, 1H), of 7.90 (d, 1H), 7,68 (m, 1H), 7,58 (m, 2H), 7,46 (m, 4H), 7,35 (m, 2H), 7,21 (DD, 1H), 6,76 (m, 4H), 6,28 (m, 2H), to 3.02 (m, 2H), 2,89 (m, 4H), 2,80 (m, 4H), 2.40 a (m, 3H), of 1.59 (m, 2H), 1,25 (m, 4H), 0.87 (m, 2H).

EXAMPLE 2

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({4-[(3-morpholine-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 2A

4-(3-morpholinopropan)-3-nitrobenzenesulfonamide

The compound of this example was obtained by replacing 3-(N-morpholinyl)Propylamine 1-(tetrahydropyran-4-yl)methylamine in example 1F.

EXAMPLE 2B

4-{4-[(4'-chloro-1,1'-biphenyl-2-yl)methyl]piperazine-1-yl}-N-({4-[(3-morpholine-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

The compound of this example was obtained by replacing the compound of example 2A compound of example 1F in p is the iMER 1G.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,60 (user.s, 1H), at 8.60 (m, 1H), 8,43 (d, 1H), 7,94 (d, 1H), to 7.64 (m, 2H), 7,54 (d, 1H), 7,45 (m, 4H), 7,33 (m, 2H), 7.23 percent (DD, 1H), of 6.96 (d, 1H), 6,85 (m, 2H), 6,32 (d, 1H), of 6.26 (d, 1H), 3,60 (m, 4H), 3,10 (m, 4H), 3,05 (m, 10H), 2.40 a (m, 2H), 2,33 (m, 2H), 1.77 in (m, 2H).

EXAMPLE 3

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 3A

Methyl-4,4-dimethyl-2-(tripterocalyx)cyclohex-1-enecarboxylate

To the suspension is washed with hexane NaH (17 g) in dichloromethane (700 ml) drip was added 5,5-dimethyl-2-methoxycarbonylamino (38,5 g) at 0°C. After stirring for 30 minutes the mixture was cooled to -78°C and added triftormetilfullerenov anhydride (40 ml). The reaction mixture was heated to room temperature and was stirred for 24 hours. The organic layer was washed with brine, dried (Na2SO4), filtered and concentrated to obtain the product.

EXAMPLE 3B

Methyl-2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enecarboxylate

The compound of example 3A (62,15 g), 4-Chlorfenvinphos acid (32,24 g), CsF (64 g) and tetrakis(triphenylphosphine)palladium(0) (2 g) in a mixture of 2:1 dimethoxyethane/methanol (600 ml) was heated to 70°C for 24 hours. The mixture was concentrated. Added a simple ether (4× 200 ml) and the mixture Phil is travali. The combined solution in a simple ether was concentrated to obtain the product.

EXAMPLE 3C

(2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methanol

To a mixture of LiBH4(13 g), the compound of example 3B (53,8 g) and simple ether (400 ml) was slowly added to methanol (25 ml) with a syringe. The mixture was stirred at room temperature for 24 hours. The reaction mixture is extinguished 1 N HCl while cooling with ice. The mixture was diluted with water and was extracted with simple ether (3× 100 ml). The extracts were dried (Na2SO4), filtered and concentrated. The crude product was subjected to chromatography on silica gel with a mixture of 0-30% ethyl acetate/hexane.

EXAMPLE 3D

Tert-butyl 4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-carboxylate

Methylchloride (7.5 ml) was added by syringe to the compound of example 3C (29.3 g) and triethylamine (30 ml) in CH2Cl2(500 ml) at 0°C, and the mixture was stirred for 1 minute. Was added N-tert-butoxycarbonylmethyl (25 g) and the mixture was stirred at room temperature for 24 hours. The suspension was washed with brine, dried (Na2SO4), filtered and concentrated. The crude product was subjected to chromatography on silica gel with a mixture of 10-20% ethyl acetate/hexane.

EXAMPLE 3E

1-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine

The compound of example 3D (1 g) was stirred what dichloromethane (10 ml), triperoxonane acid (10 ml) and triethylsilane (1 ml) for 1 hour. The mixture was concentrated, were taken in a mixture of dichloromethane (100 ml) and saturated aqueous solution of Na2CO3(20 ml) and was stirred for 10 minutes. The layers were separated and the organic layer was dried over Na2SO4, filtered and concentrated to obtain the product.

EXAMPLE 3F

5-bromo-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine

To a mixture of 5-bromo-1H-pyrrolo[2,3-b]pyridine (15,4 g) in tetrahydrofuran (250 ml) was added 1 M hexamethyldisilazide lithium in tetrahydrofuran (86 ml) and after 10 minutes was added TIPS-Cl (triisopropylchlorosilane) (18.2 ml). The mixture was stirred at room temperature for 24 hours. The reaction mixture was diluted simple ether, and the resulting solution was washed twice with water. The extracts were dried (Na2SO4), filtered and concentrated. The crude product was subjected to chromatography on silica gel with a mixture of 10% ethyl acetate/hexane.

EXAMPLE 3G

1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine-5-ol

To a mixture of compound of example 3F (24.3 g) in tetrahydrofuran (500 ml) at -78°C was added 2.5 M BuLi (30,3 ml). After 2 minutes added trimethylboron (11.5 ml) and the mixture was allowed to warm to room temperature over 1 hour. The reaction mixture was poured into ice water, extracted three times with ethyl acetate, and the combined extracts washed is whether the brine and concentrated. The crude product was taken in tetrahydrofuran (200 ml) at 0°C, was added 1 M NaOH (69 ml), and then 30% H2O2(8,43 ml) and the solution was stirred for 1 hour. Added Na2S2O3(10 g), and the pH brought up to 4-5 with concentrated HCl and the solid NaH2PO4. The solution was extracted twice with ethyl acetate, and the combined extracts were washed with brine, dried (Na2SO4), filtered and concentrated. The crude product was subjected to chromatography on silica gel with a mixture of 5-25% ethyl acetate/hexane.

EXAMPLE 3H

Methyl-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-perbenzoate

A mixture of compound of example 3G (8.5 g), methyl-2,4-differentiate (7,05 g) and K3PO4(to 9.32 g) in diglyme (40 ml) at 115°C was stirred for 24 hours. The reaction mixture was cooled, diluted simple ether (600 ml) and washed twice with water and brine and concentrated. The crude product was subjected to chromatography on silica gel with a mixture of 2-50% ethyl acetate/hexane.

EXAMPLE 3I

Methyl-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)benzoate

A mixture of compound of example 3H (1.55 g), compound of example 3E (2,42 g) and HK2PO4(1.42 g) in dimethyl sulfoxide (20 ml) at 135°C was stirred for 24 hours. The reaction mixture was cooled, diluted simple ether (400 ml) and washed 3× 1 M aOH and brine, and concentrated. The crude product was subjected to chromatography on silica gel with a mixture of 10-50% ethyl acetate/hexane.

EXAMPLE 3J

2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)benzoic acid

The compound of example 3 (200 mg) in dioxane (10 ml) and 1 M NaOH (6 ml) at 50°C was stirred for 24 hours. The reaction mixture was cooled, was added to a solution of NaH2PO4, and was extracted three times with ethyl acetate. The combined extracts were washed with brine and concentrated to obtain pure product.

EXAMPLE 3K

Tert-butyl-1-(tetrahydro-2H-Piran-4-yl)piperidine-4-ylcarbamate

Tert-butyl piperidine-4-ylcarbamate (45,00 g, 225 mmol) and dihydro-2H-Piran-4(3H)-he (24,74 g, 247 mmol) was added to dichloromethane (1000 ml). Added triacetoxyborohydride sodium (61,90 g, 292 mmol) and the solution was stirred at room temperature for 16 hours. The solution was extracted with 1 M sodium hydroxide and dried over anhydrous sodium sulfate. The solution was filtered and concentrated and was purified column flash chromatography on silica gel with 10% methanol (in dichloromethane) to increase to 20% methanol (in dichloromethane).

EXAMPLE 3L

1-(tetrahydro-2H-Piran-4-yl)piperidine-4-unindividualized

A solution of compound of example 3K (52,57 g, 185 mmol) in dichloromethane (900 ml) was treated with 4 M of water, R is the target HCl (462 ml), and the solution is vigorously stirred at room temperature for 16 hours. The solvent was removed in vacuum to obtain the crude product as dihydrochloride salt, which was used without further purification.

EXAMPLE 3M

3-nitro-4-(1-(tetrahydro-2H-Piran-4-yl)piperidine-4-ylamino)benzosulfimide

Connection example 3L (22,12 g, 86 mmol) was added to 1,4-dioxane (300 ml) and water (43 ml). Was added triethylamine (43,6 ml, 31.6, 313 mmol) and the mixture was stirred at room temperature until complete dissolution of the compound of example 3L. Was added 4-chloro-3-nitrobenzenesulfonamide and the mixture was heated at 90°C for 16 hours. The mixture was cooled and the solvents were removed in vacuum. Added 10% methanol (in dichloromethane) and the solution was vigorously stirred at room temperature until a fine suspension. The solid was isolated by filtration under vacuum and washed with dichloromethane to obtain the pure product.

EXAMPLE 3N

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl(piperazine-1-yl)-N-({3-nitro-4-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

The compound of this example was obtained by replacing the compound of example 3J for compound of example 1E and compound of example 3M compound of example 1F in example 1G.

1H NMR (300 MHz, dimethylsulfate the d-d 6) δ 11,65 (user.s, 1H), 8,53 (user. s, 1H), 8,18 (m, 1H), 8,00 (user. s, 1H), 7,63 (m, 1H), 7,49 (m, 3H), 7,34 (d, 2H), 7,12 (m, 1H),? 7.04 baby mortality (d, 2H), to 6.67 (DD, 1H), 6,37 (d, 1H), of 6.20 (d, 1H), 3,95 (m, 2H), 3,05 (m, 10H), by 2.73 (m, 4H), 2,17 (m, 10H), of 1.95 (m, 2H), 1,80 (m, 2H), and 1.63 (m, 2H), 1.39 in (t, 2H), 0,93 (s, 6H).

EXAMPLE 4

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 4A

4-(1-methylpiperidin-4-ylamino)-3-nitrobenzenesulfonamide

The compound of this example was obtained by replacing 4-amino-N-methylpiperidine 1-(tetrahydropyran-4-yl)methylamine in example 1F.

EXAMPLE 4B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

The compound of this example was obtained by replacing the compound of example 3J for compound of example 1E and compound of example 4A compound of example 1F in example 1G.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,65 (user.s, 1H), 8,55 (user. s, 1H), 8,17 (m, 1H), 8,02 (d, 1H), a 7.85 (DD, 1H), 7,51 (m, 3H), 7,35 (m, 2H), 7,18 (DD, 1H), 7,05 (d, 2H), of 6.68 (DD, 1H), 6,38 (d, 1H), of 6.20 (d, 1H), 3,90 (m, 1H), 3,09 (m, 8H), 2,77 (m, 2H), 2,05-of 2.30 (m, 10H), of 1.95 (s, 3H), 1.39 in (t, 2H), 1,24 (m, 2H), 0,93 (s, 6H).

EXAMPLE 5

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl(piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-p is Rolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 5A

3-nitro-4-((tetrahydro-2H-Piran-4-yl)methylamino)benzosulfimide

A mixture of 4-fluoro-3-nitrobenzenesulfonamide (2,18 g), 1-(tetrahydropyran-4-yl)methylamine (1,14 g) and triethylamine (1 g) in tetrahydrofuran (30 ml) was stirred over night, neutralize with concentrated HCl and concentrated. The residue suspended in ethyl acetate and the precipitates were collected, washed with water and dried to obtain specified in the connection header.

EXAMPLE 5B

Methyl-4,4-dimethyl-2-(tripterocalyx)cyclohex-1-enecarboxylate

To the suspension is washed with hexane NaH (17 g) in dichloromethane (700 ml) drip was added 5,5-dimethyl-2-methoxycarbonylamino (38,5 g) at 0°C. After stirring for 30 minutes the mixture was cooled to -78°C and added triftormetilfullerenov anhydride (40 ml). The reaction mixture was heated to room temperature and was stirred for 24 hours. The organic layer was washed with brine, dried (Na2SO4), filtered and concentrated to obtain the product.

EXAMPLE 5S

Methyl-2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enecarboxylate

The compound of example 5B (62,15 g), 4-Chlorfenvinphos acid (32,24 g), CsF (64 g) and tetrakis(triphenylphosphine)palladium(0) (2 g) in a mixture of 2:1 dimethoxyethane/methanol (600 ml) was heated to 70°C for 24 hours. The mixture was concentrated. Added a simple ether (4×200 ml) and the mixture was filtered. The combined solution in a simple ether was concentrated to obtain the product.

EXAMPLE 5D

(2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methanol

To a mixture of LiBH4(13 g), compound of example 5C (53,8 g) and simple ether (400 ml) was added methanol (25 ml) slowly by syringe. The mixture was stirred at room temperature for 24 hours. The reaction mixture is extinguished 1 N HCl while cooling with ice. The mixture was diluted with water and was extracted with simple ether (3× 100 ml). The extracts were dried (Na2SO4), filtered and concentrated. The crude product was subjected to chromatography on silica gel with a mixture of 0-30% ethyl acetate/hexane.

EXAMPLE 5E

Tert-butyl-4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-carboxylate

Methylchloride (7.5 ml) was added by syringe to the compound of example 5D (29.3 g) and triethylamine (30 ml) in CH2Cl2(500 ml) at 0°C, and the mixture was stirred for 1 minute. Was added N-tert-butoxycarbonylmethyl (25 g) and the mixture was stirred at room temperature for 24 hours. The suspension was washed with brine, dried (Na2SO4), filtered and concentrated. The crude product was subjected to chromatography on silica gel with a mixture of 10-20% ethyl acetate/hexane.

EXAMPLE 5F

1-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine

The compound of example 5E (200 mg) and triethylsilane (1 ml) is remedial in dichloromethane (15 ml) and triperoxonane acid (15 ml) for 1 hour. The mixture was concentrated, taken into ethyl acetate, washed twice NaH2PO4and brine, and dried (Na2SO4), filtered and concentrated.

EXAMPLE 5G

5-bromo-1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine

To a mixture of 5-bromo-1H-pyrrolo[2,3-b]pyridine (15,4 g) in tetrahydrofuran (250 ml) was added 1 M hexamethyldisilazide lithium in tetrahydrofuran (86 ml) and after 10 minutes was added TIPS-Cl (triisopropylchlorosilane) (18.2 ml). The mixture was stirred at room temperature for 24 hours. The reaction mixture was diluted simple ether, and the resulting solution was washed twice with water. The extracts were dried (Na2SO4), filtered and concentrated. The crude product was subjected to chromatography on silica gel with a mixture of 10% ethyl acetate/hexane.

EXAMPLE 5H

1-(triisopropylsilyl)-1H-pyrrolo[2,3-b]pyridine-5-ol

To a mixture of compound of example 5G (24.3 g) in tetrahydrofuran (500 ml) at -78°C was added 2.5 M BuLi (30,3 ml). After 2 minutes added trimethylboron (11.5 ml), and the mixture was allowed to warm to room temperature over 1 hour. The reaction mixture was poured into ice water, extracted three times with ethyl acetate and the combined extracts were washed with brine and concentrated. The crude product was taken in tetrahydrofuran (200 ml) at 0°C, was added 1 M NaOH (69 ml), and then 30% H2O2(8,43 ml) and the solution was stirred during the s 1 hour. Added Na2S2O3(10 g), and the pH brought up to 4-5 with concentrated HCl and the solid NaH2PO4. The solution was extracted twice with ethyl acetate, and the combined extracts were washed with brine, dried (Na2SO4), filtered and concentrated. The crude product was subjected to chromatography on silica gel with a mixture of 5-25% ethyl acetate/hexane.

EXAMPLE 5I

Methyl-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-perbenzoate

A mixture of compound of example 5H (8.5 g), methyl-2,4-differentiate (7,05 g) and K3PO4(to 9.32 g) in diglyme (40 ml) at 115°C was stirred for 24 hours. The reaction mixture was cooled, diluted simple ether (600 ml) and washed twice with water and brine and concentrated. The crude product was subjected to chromatography on silica gel with a mixture of 2-50% ethyl acetate/hexane.

EXAMPLE 5J

Methyl-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)benzoate

A mixture of compound of example 5I (1.55 g), compounds of example 5F (2,42 g) and HK2PO4(1.42 g) in dimethyl sulfoxide (20 ml) at 135°C was stirred for 24 hours. The reaction mixture was cooled, diluted simple ether (400 ml) and washed 3× 1 M NaOH and brine, and concentrated. The crude product was subjected to chromatography on silica gel with a mixture of 10-50% ethyl acetate/hexane.

EXAMPLE 5K

2-(1H-Pierre is lo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)benzoic acid

The compound of example 5J (200 mg) in dioxane (10 ml) and 1 M NaOH (6 ml) at 50°C was stirred for 24 hours. The reaction mixture was cooled, was added to a solution of NaH2PO4, and was extracted three times with ethyl acetate. The combined extracts were washed with brine and concentrated to obtain pure product.

EXAMPLE 5L

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Connection example 5K (3,39 g), the compound of example 5A (1,87 g), the hydrochloride of 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (2,39 g) and 4-dimethylaminopyridine (1,09 g) was stirred in CH2Cl2(40 ml) for 24 hours. The reaction mixture was cooled and subjected to chromatography on silica gel with a mixture of 25-100% ethyl acetate/hexane, then 10% methanol/ethyl acetate with 1% acetic acid to obtain the product (1,62 g, 32%) as a white solid.

1H NMR (300 MHz, dimethylsulfoxide-d6) 11,65 (user.s, 1H), 8,55 (user. s, 1H), 8,04 (d, 1H), 7,89 (DD, 1H), 7,51 (m, 3H), 7,33 (d, 2H), was 7.08 (m, 1H),? 7.04 baby mortality (d, 2H), of 6.68 (DD, 1H), to 6.39 (d, 1H), to 6.19 (d, 1H), 3,84 (m, 1H), 3,30 (m, 4H), of 3.07 (m, 4H), by 2.73(m, 2H), 2,18 (m, 6H), of 1.95 (m, 2H), 1,61 (DD, 2H), 1,38 (m, 2H), 1,24 (m, 4H), to 0.92 (s, 6H)

EXAMPLE 6

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3 b]pyridine-5-yloxy)benzamide

EXAMPLE 6A

4-(4-methylpiperazin-1 ylamino)-3-nitrobenzenesulfonamide

In a 50 ml round bottom flask was placed 4-chloro-3-nitrobenzenesulfonamide (1 g, to 4.23 mmol), 4-methylpiperazin-1-unindividualized (1 g, 5,32 mmol) and N1N1N2N2-tetramethylene-1,2-diamine (3 ml, 20,01 mmol) in dioxane (10 ml). The reaction mixture is boiled under reflux for 12 hours. Then the reaction mixture was cooled to room temperature, the salt was filtered through a Buchner funnel, and the solvent was removed in vacuum. The crude product was added to a column of silica gel (Analogix, SF65 - 200 g) and purified by elution 0-5% methanol in dichloromethane.

EXAMPLE 6B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

The compound of this example was obtained by replacing the compound of example 3J for compound of example 1E and compound of example 6A compound of example 1F in example 1G.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,65 (user.s, 1H), which is 9.09 (user. s, 1H), of 8.47 (d, 1H), 8,24 (DD, 1H), to 7.99 (d, 1H), 7,50 (m, 4H), 7,34 (d, 2H),? 7.04 baby mortality (d, 2H), only 6.64 (DD, 1H), 6.35mm (d, 1H), of 6.20 (d, 1H), 3.04 from (m, 4H), 2,89 (m, 4H), by 2.73 (m, 2H), 2,34 (s, 3H), 2,17 (m, 6H), 1,95 (user. s, 2H), 1,38 (t, 2H), of 1.05 (m, 4H), of 0.93 (s, 6H).

EXAMPLE 7

2-(9H-carbazole-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}p is perazin-1-yl)-N-({4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide

EXAMPLE 7A

Ethyl-2-(9H-carbazole-4-yloxy)-4-perbenzoate

The compound of this example was obtained by replacement of the ethyl-2,4-differenziata methyl-2,4-differentiate and 4-hydroxycarbazole compound of example 3G in example 3H.

EXAMPLE 7B

Ethyl-2-(9H-carbazole-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)benzoate

The compound of this example was obtained by replacing the compound of example 7A compound of example 3H in example 3I.

EXAMPLE 7C

2-(9H-carbazole-4-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)benzoic acid

The compound of this example was obtained by replacing the compound of example 7B connection example 3I in example 3J, except that here after completion of the reaction was added water and 2 N HCl to bring the pH to 2, and the salt product was extracted with HCl using CHCl3/CH3OH.

EXAMPLE 7D

2-(9H-carbazole-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-methylpiperidin-4-yl)amino]-3-nitrophenyl}sulfonyl)benzamide

The compound of this example was obtained by replacing the compound of example 7C compound of example 1E and compound of example 4A compound of example 1F in example 1G, except that here the purification was performed using preparative HPLC using a C18 column, 250 × 50 mm, 10 mesh, and elwira gradient 20-100% CH 3CN vs. 0.1% triperoxonane acid in water to obtain the product as bestreferat.ru.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,82 (user. s, 1H), 11,40 (s, 1H), 9,70, 9,40 (both PTS.user. s, total 2H), 8,40 (d, 1H), 8,10 (user. d, 1H), of 7.90 (user. d, 1H), 7,72 (DD, 1H), 7,60 (d, 1H), of 7.48 (d, 1H), 7,38 (m, 3H), 7,22 (m, 2H), 7,07 (m, 4H), 6,78 (DD, 1H), gold 6.43 (DD, 1H), to 6.19 (s, 1H), 3,97 (m, 1H), 3,80 (m, 2H,), 3,60, 3,30, 3,10, 2,80 ( all of user. m, total 11H), 2,20, 2,10, 2,00 (all of user. m, total 8H), of 1.78 (m, 2H), 1,42 (m, 2H), 1,25 (m, 2H), 0,92 (s, 6H).

EXAMPLE 8

2-(9H-carbazole-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3-pyrrolidin-1-ylpropyl)amino]phenyl}sulfonyl)benzamide

EXAMPLE 8A

3-nitro-4-(3-(pyrrolidin-1-yl)propylamino)benzosulfimide

The compound of this example was obtained by replacing 3-(pyrrolidin-1-yl)propan-1-amine 1-(tetrahydropyran-4-yl)methylamine in example 1F.

EXAMPLE 8B

2-(9H-carbazole-4-yloxy)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3-pyrrolidin-1-ylpropyl)amino]phenyl}sulfonyl)benzamide

The compound of this example was obtained by replacing the compound of example 7C compound of example 1E and compound of example 8A compound of example 1F in example 1G, except that here the purification was performed preparative HPLC using a C18 column, 250 × 50 mm, 10 mesh, and elwira gradient 20-100% CH3CN vs. 0.1% trifero ssnoi acid in water to obtain the product as bestreferat.ru.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,80 (user. s, 1H), 11,42 (s, 1H), 9,50, 9,25 (both PTS.user. s, total 2H), 8,58 (user. t, 1H), 8,43 (d, 1H), to $ 7.91 (d, 1H), 7,72 (DD, 1H), 7,60 (d, 1H), 7,50 (d, 1H), 7,38 (m, 3H), of 7.23 (m, 2H), 7,07 (m, 3H), 6,93 (d, 1H), 6,78 (DD, 1H), 6,44 (DD, 1H), 6,18 (s, 1H), 3,70, 3,60, 3,20, 3,00 (all of user. m, total 18H), 2,18 (user. m, 2H), 2.00 in 180 (I. p., 8H), of 1.42 (m, 2H), 0,92 (s, 6H).

EXAMPLE 9

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 9A

TRANS-tert-butyl-4-morpholinosydnonimine

A solution of tert-butyl-4-aminocyclohexanol (20,32 g, 95 mmol), bis(2-bromatologia) simple ether (14,30 ml, 114 mmol) and triethylamine (33,0 ml, 237 mmol) in N,N-dimethylformamide (200 ml) was stirred for 16 hours at 70°C. the Reaction mixture was cooled to room temperature, concentrated and the product was extracted with ethyl acetate. The organic layer was washed with sodium carbonate solution (15%, water), dried and concentrated. The product was used in the next stage without purification.

EXAMPLE 9B

TRANS-4-morphinestrongerthanhydrocodone

To a solution of TRANS-tert-butyl-4-morpholinosydnonimine (19,2 g of 67.5 mmol) in dichloromethane (100 ml) was added HCl (100 ml, 400 mmol) (4 M in dioxane) and the reaction mixture was stirred for 16 h the V at room temperature. The reaction mixture was diluted simple ether and the solid salt was filtered, and dried in an oven.

EXAMPLE 9C

TRANS-4-(4-morpholinosydnonimine)-3-nitrobenzenesulfonamide

A solution of TRANS-4-morphinestrongerthanhydrocodone (5 g, 19,44 mmol), 4-fluoro-3-nitrobenzenesulfonamide (4,32 g, quintiles these figures were 19.63 mmol) and triethylamine (20 ml, 143 mmol) in tetrahydrofuran (60 ml) was stirred for 16 hours at room temperature. The solid product was filtered, washed with tetrahydrofuran, simple ether, dichloromethane (3 ×) and dried in vacuum.

EXAMPLE 9D

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

The compound of this example was obtained by replacing the compound of example 3J for compound of example 1E and compound of example 9C compound of example 1F in example 1G.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ of 11.61 (user.s, 1H), 8,49 (user. s, 1H), 8,12 (m, 1H), 7,99 (user. s, 1H), 7,71 (m, 1H), 7,50 (m, 3H), 7,35 (d, 2H),? 7.04 baby mortality (d, 2H), 7,01 (m, 1H), 6,65 (DD, 1H), 6,36 (d, 1H), 6,21 (d, 1H), 3,60 (m, 4H), 3.04 from (m, 4H), by 2.73 (m, 2H), 2.57 m (m, 2H), 2,42 (m, 1H), 2,18 (m, 6H), was 2.05 (m, 2H), 1,95 (m, 2H), 1,90 (m, 2H), 1,38 (m, 6H) and 1.15 (m, 3H), of 0.92 (s, 6H).

EXAMPLE 10

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-yloxy)benzamide

EXAMPLE 10A

4-(2-methoxyethylamine)-3-nitrobenzenesulfonamide

The compound of this example was obtained by replacing 2-methoxyethylamine 1-(tetrahydropyran-4-yl)methylamine in example 1F.

EXAMPLE 10B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

The compound of this example was obtained by replacing the compound of example 3J for compound of example 1E and compound of example 10A compound of example 1F in example 1G.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,65 (user.s, 1H), 8,58-8,49 (m, 1H), 8,55 (d, 1H), 8,03 (d, 1H), 7,79 (m, 1H), 7,49 (m, 3H), 7,34 (m, 2H), 7,06 (m, 1H),? 7.04 baby mortality (d, 2H), of 6.68 (DD, 1H), 6,38 (m, 1H), of 6.20 (d, 1H), 3,61-3,51 (m, 4H), and 3.31 (s, 3H), of 3.07 (m, 4H), to 2.74 (m, 2H), 2,17 (m, 6H), 1,95 (user. s, 2H), 1,38 (t, 2H), 0,92 (s, 6H).

EXAMPLE 11

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 11A

(S)-3-nitro-4-((tetrahydro-2H-Piran-3-yl)methylamino)benzosulfimide and (R)-3-nitro-4-((tetrahydro-2H-Piran-3-yl)methylamino)benzosulfimide

The compound of this example was obtained by replacing (tetrahydro-2H-Piran-3-yl)methanamine 1-(tetrahydropyran-4-yl)methylamine in example 1F.

EXAMPLE 11B

(S)-3-nitro-4-((tetrahydro-2H-Piran-3-yl)methylamino)benzolsulfonat the ID

The racemic mixture of example 11A were separated using chiral SFC on a column AD (21 mm i.d. × 250 mm) using a gradient of 10-30% 0.1% diethylamine/methanol in CO2within 15 minutes oven temperature: 40°C; flow rate: 40 ml/min) to obtain specified in the connection header.

EXAMPLE 11C

(R)-3-nitro-4-((tetrahydro-2H-Piran-3-yl)methylamino)benzosulfimide

The racemic mixture of example 11A were separated using chiral SFC on a column AD (21 mm i.d. × 250 mm) using a gradient of 10-30% 0.1% diethylamine/methanol in CO2within 15 minutes oven temperature: 40°C; flow rate: 40 ml/min) to obtain specified in the connection header.

EXAMPLE 11D

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

To a mixture of compound of example 3J (to 59.8 mg, 0,105 mmol), the compound of example 11B (33 mg, 0,105 mmol) and N,N-dimethylpyridin-4-amine (38,4 mg, 0,314 mmol) in dichloromethane (5 ml) was added the hydrochloride of 1-ethyl-3-[3-(dimethylamino)propyl]carbodiimide (24,07 mg, 0.13 mmol). The reaction mixture was stirred at room temperature overnight and concentrated. The residue was purified by reversed-phase HPLC on a C18 column using a gradient of 40-60% acetonitrile/0.1% of triperoxonane acid in water is obtaining specified in the title compounds as the salts triperoxonane acid. Salt triperoxonane acid was dissolved in dichloromethane (6 ml) and washed with 50% aqueous solution of NaHCO3. The organic layer was dried over anhydrous Na2SO4and concentrated to obtain specified in the connection header.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,68 (s, 1H), 11,40 (with, of user., 1H), 8,53-8,58 (m, 2H), of 8.04 (d, 1H), 7,80 (DD, 1H), 7,47-rate of 7.54 (m, 3H), 7,34 (d, 2H), 7,02-to 7.09 (m, 3H), to 6.67 (DD, 1H), to 6.39 (DD, 1H), to 6.19 (d, 1H), 3,79 (DD, 1H), 3,69-to 3.73 (m, 1H), 3,22-3,37 (m, 3H), 3,16-is 3.21 (m, 1H), of 3.07 (s, 4H), to 2.74 (s, 2H), 2,09-of 2.24 (m, 6H), 1,95 (s, 2H), 1,86-of 1.93 (m, 1H), 1,79-of 1.85 (m, 1H), 1,58-of 1.64 (m, 1H), 1,42-is 1.51 (m, 1H), 1,38 (t, 2H), 1,25-of 1.34 (m, 1H), 0,92 (s, 6H).

EXAMPLE 12

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 12A

4-((1,4-dioxane-2-yl)methoxy)-3-nitrobenzenesulfonamide

(1,4-dioxane-2-yl)methanol (380 mg, up 3.22 mmol) in tetrahydrofuran (30 ml) was treated with sodium hydride (60%) (245 mg, 6,13 mmol) at room temperature for 30 minutes. The reaction mixture was cooled in an ice bath was added 4-fluoro-3-nitrobenzenesulfonamide (675 mg, a 3.06 mmol). The resulting mixture was stirred at room temperature for 2 hours and added another portion of sodium hydride (60%) (245 mg, 6,13 mmol). The reaction mixture was stirred over night and extinguished with ice water (3 ml). The turbid mixture was filtered and the filtrate conc who was narrowly. The residue triturated with methanol to obtain specified in the connection header.

EXAMPLE 12V

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 11D using the compounds of example 12A instead of the compound of example 11B.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,67 (s, 1H), 11,42 (with, of user., 1H), a 8.34 (s, 1H), 8,03 (d, 2H), of 7.48-of 7.55 (m, 3H), 7,41 (d, 1H), 7,35 (d, 2H),? 7.04 baby mortality (d, 2H), to 6.67 (DD, 1H), to 6.39 (DD, 1H), 6,21 (d, 1H), 4,20-to 4.28 (m, 2H), 3,85-3,91 (m, 1H), 3,82 (DD, 1H), 3,74-of 3.78 (m, 1H), 3,59 at 3.69 (m, 2H), 3,41-3,51 (m, 2H), 3,05-3,17 (m, 4H), 2,83 (with, of user., 2H), and 2.27 (s, user., 4H), of 2.15 (s, 2H), 1,96 (s, 2H), 1.39 in (t, 2H), 0,93 (s, 6H).

EXAMPLE 13

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(3-nitro-4-{[(3R)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 11D using the compound of example 11C instead of the compound of example 11B. Spectra proton NMR of the compound of example 13 and the connection of example 11D are identical.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,68 (s, 1H), 11,40 (with, of user., 1H), 8,53-8,58 (m, 2H), of 8.04 (d, 1H), 7,80 (DD, 1H), 7,47-rate of 7.54 (m, 3H), 7,34 (d, 2H), 7,02-to 7.09 (m, 3H), to 6.67 (DD, 1H), to 6.39 (DD, 1H), to 6.19 (d, 1H), 3,79 (DD, 1H), 3,69-to 3.73 (m, 1H), 3,22-3,37 (m, 3H), 3,16-is 3.21 (m, 1H), ,07 (s, 4H), to 2.74 (s, 2H), 2,09-of 2.24 (m, 6H), 1,95 (s, 2H), 1,86-of 1.93 (m, 1H), 1,79-of 1.85 (m, 1H), 1,58-of 1.64 (m, 1H), 1,42-is 1.51 (m, 1H), 1,38 (t, 2H), 1,25-of 1.34 (m, 1H), 0,92 (s, 6H).

EXAMPLE 14

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-(2-naphthylmethyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 11D, using naphthalene-2-sulfonamida (47 mg, 0,227 mmol) instead of the compound of example 11B.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,82 (s, 1H), of 11.69 (s, 1H), 8,51 (s, 1H), 8,08 (d, 1H), with 8.05 (d, 1H), of 7.97 (DD, 2H), 7,82 (DD, 1H), 7,66-7,71 (m, 1H), 7,63 (t, 1H), 7,54 (d, 1H), 7,47-7,52 (m, 2H), 7,34 (d, 2H),? 7.04 baby mortality (d, 2H), of 6.65 (DD, 1H), to 6.39 (DD, 1H), 6,18 (s, 1H), 3.04 from (s, 4H), of 2.72 (s, 2H), 2,10-of 2.20 (m, 6H), 1,95 (s, 2H), 1,38 (t, 2H), 0,92 (s, 6H).

EXAMPLE 15

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 15A

Methyl-6,6-dimethyl-4-exoterica-2H-Piran-3-carboxylate

To the suspension is washed with hexane NaH (0,72 g, 60% in mineral oil) in tetrahydrofuran (30 ml) was added a solution of 2,2-dimethylbicyclo-2H-Piran-4(3H)-she (2.0 g) in tetrahydrofuran (20 ml). The suspension was stirred at room temperature for 30 minutes. Drip was added dimethylcarbonate (of 6.31 ml) by syringe. The mixture was heated to the boiling temperature under reflux for 4 hours LC/MS p is Casali expected product as the main product. The mixture was acidified with 5% HCl and was extracted with dichloromethane (100 ml × 3) and washed with water, brine and dried over Na2SO4. After evaporation the crude product was applied on the column and was suirable 10% ethyl acetate in hexane to obtain the product.

EXAMPLE 15B

Methyl-6,6-dimethyl-4-(tripterocalyx)-5,6-dihydro-2H-Piran-3-carboxylate

To a cooled (0°C) stirred suspension of NaH (0,983 g, 60% in mineral oil) in a simple ether (50 ml) was added the compound of example 15A (3.2 g). The mixture was stirred at 0°C for 30 minutes and then added Tf2O (4,2 ml). Then the mixture was stirred at room temperature overnight. The mixture was diluted simple ether (200 ml) and washed with 5% HCl, water and brine. After drying over Na2SO4the evaporation of the solvent gave the crude product, which was used in the next stage without further purification.

EXAMPLE 15C

Methyl-4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-carboxylate

To a solution of compound of example 15B (2,88 g), 4-Chlorfenvinphos acid (1.88 g) and Pd(Ph3P)4(0,578 g) in toluene (40 ml) and ethanol (10 ml) was added 2 N Na2CO3(10 ml). The mixture was stirred while boiling under reflux overnight. The mixture was diluted simple ether (300 ml) and washed with water, brine and dried over Na2SO4. After evaporation of the races is varicela, the residue was applied on the column and was suirable 3% ethyl acetate in hexane to obtain the product.

EXAMPLE 15D

(4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl)methanol

To a solution of compound of example 15C (1.6 g) in a simple ether (20 ml) was added LiAlH4(1.2 g). The mixture was stirred for 4 hours. The mixture was carefully acidified with 5% HCl and was extracted with ethyl acetate (100 ml × 3) and washed with water, brine and dried over Na2SO4. After concentration the crude product was applied on the column and was suirable 10% ethyl acetate in hexane to obtain the product.

EXAMPLE 15E

4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-carbaldehyde

To a solution of oxalicacid (1.1 g) in dichloromethane (30 ml) at -78°C was added dimethyl sulfoxide (6,12 ml). The mixture was stirred at this temperature for 30 minutes and then added to the solution of compound of example 15D (1.2 g) in dichloromethane (10 ml). The mixture was stirred at -78°C for 2 hours, and then was added triethylamine (10 ml). The mixture was stirred overnight and the temperature was allowed to rise to room temperature. The mixture was diluted simple ether (300 ml) and washed with water, brine and dried over Na2SO4. Concentration of the solvent and purification on column (5% ethyl acetate in hexane) gave the product.

EXAMPLE 15F

Methyl-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-(piperazine-1-yl)benzo is at

A mixture of compound of example 3H (20.5 g) and piperazine (37,0 g) in dimethyl sulfoxide (200 ml) was heated to 110°C for 24 hours, and the mixture was allowed to cool to room temperature. The mixture was poured into water (1 l) was extracted three times with dichloromethane, and the combined extracts were washed 2× with water and brine and was filtered and concentrated to obtain pure product.

EXAMPLE 15G

Methyl-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl)methyl)piperazine-1-yl)benzoate

To a solution of compound of example 15E (100 mg) and the compound of example 15F (177 mg) in dichloromethane (10 ml) was added triacetoxyborohydride sodium (154 mg). The mixture was stirred over night. The mixture was diluted with ethyl acetate (200 ml) and washed with 2% NaOH, water and brine. After drying over Na2SO4the mixture was filtered and the solvent evaporated in vacuum. The residue was applied on the column and was suirable 30% ethyl acetate in hexane to obtain the pure product.

EXAMPLE 15H

2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl)methyl)piperazine-1-yl)benzoic acid

To a solution of compound of example 15G (254 mg) in tetrahydrofuran (4 ml), methanol (2 ml) and water (2 ml) was added LiOH·H2O (126 mg). The mixture was stirred over night. The mixture is then neutralize with 5% HCl and was diluted with ethyl acetate (200 ml). Polypropylene brine, it was dried over Na2SO4. Filtration and evaporation of the solvent gave the product.

EXAMPLE 15I

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 1G, substituting the compound of example 1E connection example 15H.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,68 (user. s, 1H), 11,42 (s, 1H), at 8.60 (m, 1H), to 8.57 (d, 1H), with 8.05(d, 1H), 7,80 (DD, 1H), of 7.48-rate of 7.54 (m, 3H), 7,38 (d, 2H), 7,12 (m, 3H), of 6.68 (DD, 1H), 6,40 (DD, 1H), of 6.20 (s, 1H), 4,11(s, 2H), 3,85(m, 2H), of 3.27(m, 6H), of 3.07 (m, 2H), 2,84 (m, 2H), and 2.14 (m, 5H), of 1.92(m, 1H), 1,42 (m, 2H), 1,24(m, 2H), 1,10 (s, 6H).

EXAMPLE 16

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 16A

4-(2-methoxyethylamine)-3-(trifloromethyl)benzosulfimide

4-fluoro-3-(trifloromethyl)benzosulfimide (1,536 g, 5 mmol), 2-methoxyethylamine (0,376 g, 5 mmol) and triethylamine (1,939 g, 15 mmol) in anhydrous solution of tetrahydrofuran (30 ml) was heated at 55°C for 3 hours. The solution was diluted with ethyl acetate, washed with water and brine and dried (Na2SO2), filtered and the filtrate was concentrated. The crude material was used in the next stage without further purification.

EXAMPLE 16B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-methoxyethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

The compound of this example was obtained by replacing the compound of example 3J for compound of example 1E and compound of example 16A compound of example 1F in example 1G.

1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11,67 (user.s, 1H), 8,14 (m, 1H), 8,03 (d, 1H), to $ 7.91 (d, 1H), 7,50 (m, 3H), 7,34 (d, 2H), 7,19 (s, 1H),? 7.04 baby mortality (m, 3H), to 6.67 (DD, 1H), 6,39 (m, 1H), to 6.19 (d, 1H), 3,51 (m, 4H), of 3.28 (s, 3H), 3,06 (m, 4H), to 2.75 (m, 2H), 2,17 (m, 6H), of 1.95 (m, 2H), 1.39 in (t, 2H), 0,93 (s, 6H).

EXAMPLE 17

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide

EXAMPLE 17A

4-((tetrahydro-2H-Piran-4-yl)methylamino)-3-(trifloromethyl)benzosulfimide

The compound of this example was obtained by replacing 1-(tetrahydropyran-4-yl)methylamine 2-methoxyethylamine in example 16A.

EXAMPLE 17B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide

The compound of this example was obtained by replacing the compound of example 3J for compound of example 1E and compound the example 17A compound of example 1F in example 1G.

1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11,70 (user.s, 1H), 8,15 (m, 1H), 8,04 (d, 1H), 7,92 (d, 1H), 7,51 (m, 3H), 7,34 (d, 2H), 7,19 (s, 1H), 7,05 (m, 3H), of 6.68 (DD, 1H), 6,40 (m, 1H), 6,18 (d, 1H), 3,85 (m, 2H), 3,25 (m, 4H), of 3.07 (m, 4H), 2,77 (m, 2H), 2,17 (m, 6H), of 1.95 (m, 2H), of 1.84 (m,lH), and 1.54 (m, 2H), 1.39 in(t, 2H), 1,24 (m, 2H), 0,93 (s, 6H).

EXAMPLE 18

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide

EXAMPLE 18A

Methyl-2-(1H-indol-5-yloxy)-4-perbenzoate

A mixture of 5-hydroxyindole (8.5 g), methyl-2,4-differentiate (7,05 g) and K3PO4(to 9.32 g) in diglyme (40 ml) at 115°C was stirred for 24 hours. The reaction mixture was cooled, diluted simple ether (600 ml) and washed twice with water and brine and concentrated. The crude product was subjected to chromatography on silica gel with a mixture of 2-50% ethyl acetate/hexane.

EXAMPLE 18B

Methyl-2-(1H-indol-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)benzoate

A mixture of compound of example 18A (1.7 g), compound of example 3E (1.8 g) and HK2PO4(1,21 g) in dimethyl sulfoxide (20 ml) at 135°C was stirred for 24 hours. The reaction mixture was cooled, diluted simple ether (400 ml) and washed 3× 1 M NaOH and brine, and concentrated. The crude product was subjected to chromatography on silica gel with a mixture of 10-50% ethyl acetate/GE the San.

EXAMPLE 18C

2-(1H-indol-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)benzoic acid

The compound of example 18B (200 mg) in dioxane (10 ml) and 1 M NaOH (6 ml) at 50°C was stirred for 24 hours. The reaction mixture was cooled, was added to a solution of NaH2PO4, and was extracted three times with ethyl acetate. The combined extracts were washed with brine and concentrated to obtain pure product.

EXAMPLE 18D

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide

Specified in the title compound was obtained as described in example 11D, replacing soedinenie example 3J for compound of example 18C, and the compound of example 1F compound of example 11B.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,18 (s, 2H), 8,59-8,64 (m, 2H), 7,80 (DD, 1H), 7,52 (d, 1H), 7,39-7,42 (m, 2H), 7,33 (d, 2H), 7,16 (d, 1H), 7,10 (d,lH), 7,03 (d, 2H), 6,8 (DD, 1H), 6,65 (DD, 1H), 6,40 (s, 1H), 6,14 (d, 1H), of 3.85 (DD, 2H), 3,24-of 3.32 (m, 4H), 3,03 (s, 3H), 2,73 (s, 2H), 2,12-2,17 (m, 5H), 1,68-of 1.94 (m, 3H), of 1.61 (d, 2H), 1,37 (t, 2H), 1,24-of 1.27 (m, 2H), 0,92 (s, 6H).

EXAMPLE 19

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-indol-5-yloxy)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)benzamide

Specified in the title compound was obtained as described in example 11D, replacing the connection is of example 11B compound of example 9B and the compound of example 3J for compound of example 18C.

1H NMR (500 MHz, pyridine-d5) δ 12,29 (s, 1H), 9,29 (d, J=2.1 Hz, 1H), of 8.37 (d, J=7,6 Hz, 1H), 8,32 (DD, J=9,3, 2.3 Hz, 1H), 8,18 (d, J=8,8 Hz, 1H), 7,52-EUR 7.57 (m, 2H), 7,39-7,47 (m, 3H), 7,10 (DD, J=8,7, 2.3 Hz, 1H), 7,05-was 7.08 (m, 2H), make 6.90 (d, J=9.5 Hz, 1H), 6,74 (DD, J=9,0, 2.3 Hz, 1H), 6,59-6,63 (m, 1H), 6,55 (d, J=2.4 Hz, 1H), 3.72 points-of 3.78 (m, 4H), 3.33 and-of 3.43 (m, 1H), 2,99-to 3.09 (m, 4H), was 2.76 (s, 2H), 2,46-of 2.54 (m, 4H), 2,16-to 2.29 (m, 3H), 2,09 with 2.14 (m, 4H), of 2.05 (d, J=11,9 Hz, 2H), 1,97 (d, J=1.8 Hz, 2H), 1,87 (d, J=11,6 Hz, 2H), 1,19-of 1.42 (m, 6H), of 0.93 (s, 6H).

EXAMPLE 20

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-indol-5-yloxy)-N-({4-[(2-methoxyethyl)amino]-3-nitrophenyl}sulfonyl)benzamide

Specified in the title compound was obtained as described in example 11D, replacing the compound of example 11B compound of example 10A and the compound of example 3J for compound of example 18C.

1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11,20 (user., s, 1H) of 11.15 (s, 1H) 8,59 (m, 2H) 7,81 (DD, 1H) 7,50 (d, 1H) of 7.36 (m, 4H) was 7.08 (m, 4H) 6,85 (DD, 1H) 6,65 (DD, 1H) 6,38 (m, 1H) 6,14 (m, 1H) to 3.58 (m, 4H) 3,30 (s, 3H) 3,03 (m, 4H) 2,73 (s, 2H) 2,15 (m, 6H) a 1.96 (s, 2H) to 1.38 (t, 2H) to 0.92 (s, 6H).

EXAMPLE 21

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H - indol-5-yloxy)-N-[(3-nitro-4-{[(3S)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]benzamide

Specified in the title compound was obtained as described in example 11D, replacing the compound of example 3J for compound of example 18C.

1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11,17 (s, 2H), 8,53-8,65 (m, 2H), 7,80 (d, 1H), 7,51 (d 1H), 7,38-7,44 (m, 2H), 7,33 (d, 2H), 7,15 (s, 1H), 7,02-to 7.09 (m, 3H), 6,82-6,92 (m, 1H), 6,65 (d, 1H), to 6.39 (s, 1H), 6,14 (s, 1H), 3,68-3,82 (m, 2H), 3,22-of 3.32 (m, 2H), 3,13-up 3.22 (m, 1H), 3,03 (s, 4H), of 2.72 (s, 2H), 2,09-of 2.23 (m, 6H), 1,78-to 1.98 (m, 4H), 1.56 to of 1.66 (m, 1H), 1,43-is 1.51 (m, 1H), 1,37 (t, 2H), 1,22-of 1.33 (m, 1H), 0,92 (s, 6H).

EXAMPLE 22

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-indol-5-yloxy)-N-[(3-nitro-4-{[(3R)-tetrahydro-2H-Piran-3-ylmethyl]amino}phenyl)sulfonyl]benzamide

Specified in the title compound was obtained as described in example 11D using the compound of example 11C instead of the compound of example 11B, and the compound of example 18C instead of the compound of example 3J.

1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11,17 (s, 2H), 8,53-8,65 (m, 2H), 7,80 (d, 1H), 7,51 (d, 1H), 7,38-7,44 (m, 2H), 7,33 (d, 2H), 7,15 (s, 1H), 7,02-to 7.09 (m, 3H), 6,82-6,92 (m, 1H), 6,65 (d, 1H), to 6.39 (s, 1H), 6,14 (s, 1H), 3,68-3,82 (m, 2H), 3,22-of 3.32 (m, 2H), 3,13-up 3.22 (m, 1H), 3,03 (s, 4H), of 2.72 (s, 2H), 2,09-of 2.23 (m, 6H), 1,78-to 1.98 (m, 4H), 1.56 to of 1.66 (m, 1H), 1,43-is 1.51 (m, 1H), 1,37 (t, 2H), 1,22-of 1.33 (m, 1H), 0,92 (s, 6H).

EXAMPLE 23

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-2-(1H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide

EXAMPLE 23A

Methyl-2-(1H-indol-5-yloxy)-4-(piperazine-1-yl)benzoate

Specified in the title compound was obtained as described in example 15F, replacing the compound of example 3H compound of example 18A.

EXAMPLE 23B

Methyl-2-(1H-indol-5-yloxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-di is Idro-2H-Piran-3-yl)methyl)piperazine-1-yl)benzoate

Specified in the title compound was obtained as described in example 15G, replacing the compound of example 15F compound of example 23A.

EXAMPLE 23C

2-(1H-indol-5-yloxy)-4-(4-((4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl)methyl)piperazine-1-yl)benzoic acid

Specified in the title compound was obtained as described in example 15H, replacing the compound of example 15G compound of example 23B.

EXAMPLE 23D

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-2-(1H-indol-5-yloxy)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)benzamide

Specified in the title compound was obtained as described in example 11D, replacing the compound of example 11B compound of example 1F, and the compound of example 3J for compound of example 23C.

1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11,20 (user. s, 1H), 11,17(s, 1H), 8,63 (t, 1H), 8,59 (d, 1H), 7,79 (DD, 1H), 7,51 (d, 1H), was 7.36 (m, 3H), 7,13 (m, 2H), 6,86 (DD, 1H), 6,66 (DD, 1H), to 6.39 (s, 1H), x 6.15 (d, 1H), 4,10 (s, 2H), 3,85 (m, 3H), 3,50 (m, 2H), 3,42 (m, 2H), 3,24 (m, 4H), to 3.02 (m, 4H), 2,82 (m, 2H), 2,16 (m, 2H), 1.61 of (m, 3H), 1,25 (m, 4H), of 1.17 (s, 6H).

EXAMPLE 24

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl) - N-{[3-nitro-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 24A

3-nitro-4-((tetrahydro-2H-Piran-4-yl)methoxy)benzosulfimide

(Tetrahydro-2H-Piran-4-yl)methanol (2.0 g) in tetrahedr is the furan (20 ml) was treated with 60% NaH (1,377 g). The solution was stirred for 20 minutes at room temperature. To this solution was added in portions with 4-fluoro-3-nitrobenzenesulfonamide (2,84 g). The reaction mixture was stirred for additional 2 hours. The mixture was poured into water, neutralize with 10% HCl, and was extracted with ethyl acetate three times. The combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated. The residue was purified column flash chromatography on silica gel, elwira 20-60% ethyl acetate in hexane.

EXAMPLE 24B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[3-nitro-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 24A compound of example 11B in example 11D.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,67 (s, 1H), with 8.33 (s, 1H), 8,00-8,02 (m, 2H), 7,50-7,53 (m, 3H), 7,34 and 7.36 (m, 3H),? 7.04 baby mortality (d, 2H), to 6.67 (DD, 1H), 6,38 (d, 1H), 6,21 (s, 1H), 4,06 (d, 2H), 3,88 (DD, 2H), is 3.08 (s, 4H), 2,80 (s, 2H), of 2.25 (s, 4H), of 2.15 (s, 2H), 1,96 (s, 2H), 1,63-of 1.66 (m, 2H), of 1.52-1.55V (m, 1H), 1,33-of 1.40 (m, 4H), to 0.92 (s, 6H).

EXAMPLE 25

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 25A

4-((1,4-dioxane-2-yl)methylamino)-3-nitrobenzenesulfonamide

Pointed to by the e in the title compound was obtained, as described in example 1F using (1,4-dioxane-2-yl)methanamine instead (tetrahydropyran-4-yl)methanamine.

EXAMPLE 25B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 11D, using the compound of example 25A instead of the compound of example 11B.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,66 (s, 1H), 11,38 (s, 1H), 8,53-8,59 (m, 2H), 8,03 (d, 1H), 7,81 (DD, 1H), 7,46-rate of 7.54 (m, 3H), 7,34 (d, 2H), to 7.09 (d, 1H),? 7.04 baby mortality (d, 2H), of 6.68 (DD, 1H), 6,38 (DD, 1H), to 6.19 (d, 1H), 3.75 to 3,86 (m, 3H), to 3.58-3,68 (m, 2H), 3.45 points-to 3.52 (m, 2H), 3,35-of 3.43 (m, 2H), of 3.07 (s, 4H), to 2.75 (s, 2H), 2,17 (d, 6H), 1,95 (s, 2H), 1,38 (t, 2H), 0,92 (s, 6H).

EXAMPLE 26

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(2,2,2-triptorelin)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 26A

3-nitro-4-(2,2,2-triptoreline)benzosulfimide

Specified in the title compound was obtained by replacing 2,2,2-triptoreline (tetrahydropyran-4-yl)methylamine in example 1F.

EXAMPLE 26B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(2,2,2-triptorelin)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing connected to the eating of example 26A compound of example 11B in example 11D.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ of $ 11.48 (s, 1H), 8,40 (m, 2H), of 7.90 (d, 1H), 7,71 (DD, 1H), to 7.59 (d, 1H), 7,40 (t, 1H), 7,34 (d, 2H), 7,25 (d, 1H), 7,06 (m, 3H), of 6.61 (DD, 1H), 6,26 (m, 2H), 4,32 (m, 2H), 3,00 (m, 4H), 2,73 (s, 2H), are 2.19 (m, 6H), to 1.96 (s, 2H), 1.39 in (t, 2H), 0,93 (s, 6H).

EXAMPLE 27

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl(piperazine-1-yl)-N-({3-nitro-4-[(3,3,3-cryptochromes)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 27A

3-nitro-4-(3,3,3-triptoreline)benzosulfimide

Specified in the title compound was obtained by replacing 3,3,3-cryptochrome-1-amine (tetrahydropyran-4-yl)methylamine in example 1F.

EXAMPLE 27B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(3,3,3-cryptochromes)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 27A compound of example 11B in example 11D.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,47 (s, 1H), of 8.37 (d, 1H), 8,29 (m, 1H), 7,89 (d, 1H), to 7.61 (m, 2H), 7,39 (t, 1H), 7,35 (d, 2H), 7,22 (d, 1H), 7,05 (d, 2H), 6.75 in (d, 1H), 6,62 (DD, 1H), 6,27 (m, 2H), 3,59 (square, 2H), 3,00 (m, 4H), by 2.73 (s, 2H), 2,66 (m, 2H), 2,18 (m, 6H), to 1.96 (s, 2H), 1.39 in (t, 2H), 0,93 (m, 6H).

EXAMPLE 28

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2S)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 28A

(S)-4-((1,4-dioxane-2-yl)methoxy)-3-nitrobenzenesulfonamide

The racemic mixture of the compound of example 12A was separated on chiral SFC-column AD for obtaining specified in the connection header.

EXAMPLE 28B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2S)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 11D using the compound of example 28A instead of the compound of example 11B.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,67 (s, 2H), 8,35 (s, 1H), 8,03 (d, 2H), of 7.48-EUR 7.57 (m, 3H), 7,42 (d, 1H), 7,35 (d, 2H), 7,05 (d, 2H), of 6.68 (DD, 1H), to 6.39 (DD, 1H), 6,21 (s, 1H), 4,19-4,30 (m, 2H), 3,85-to 3.92 (m, 1H), of 3.73-of 3.85 (m, 2H), to 3.58-3,70 (m, 2H), 3,40-to 3.52 (m, 2H), 3,10 (s, 4H), 2,85 (s, 2H), 2,18-2,39 (m, 3H), of 2.15 (s, 2H), 1,96 (s, 2H), 1.39 in (t, 2H), 0,93 (s, 6H).

EXAMPLE 29

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 29A

CIS-4-((4-methoxycyclohexyl)methylamino)-3-nitrobenzenesulfonamide

4-Fluoro-3-nitrobenzenesulfonamide (1,098 g) and compound 34A (1 g) in tetrahydrofuran (20 ml) was treated with Ν,Ν-diisopropylethylamine (0,871 ml) over night. The reaction mixture was concentrated and the residue was purified by reversed-phase chromatography, elwira 40-55% acetonitrile is 0.1% triperoxonane acid in water for 25 min to obtain the CIS isomer of the compound of example 29A and the TRANS-isomer of the compound of example 34B.

EXAMPLE 29B

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 11D, using the compound of example 29A instead of the compound of example 11B.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ of 11.69 (s, 1H), 11,36 (s, 1H), 8,53-8,63 (m, 2H), of 8.04 (d, 1H), 7,79 (DD, 1H), 7,47-7,56 (m, 3H), 7,34 (d, 2H), 7,00 for 7.12 (m, 3H), of 6.68 (DD, 1H), to 6.39 (DD, 1H), to 6.19 (d, 1H), 3,37 (s, 1H), 3,26 (t, 2H), 3,20 (s, 3H), of 3.07 (s, 4H), to 2.75 (s, 2H), 2,17 (d, 6H), 1,95 (s, 2H), 1,81 (DD, 2H), 1,64-of 1.74 (m, 1H), 1,48 (DD, 2H), 1,23-of 1.42 (m, 6H), to 0.92 (s, 6H).

EXAMPLE 30

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2R)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 30A

(R)-4-((1,4-dioxane-2-yl)methoxy)-3-nitrobenzenesulfonamide

The racemic mixture of the compound of example 12A was separated on chiral SFC-column AD with obtaining specified in the connection header.

EXAMPLE 30B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2R)-1,4-dioxane-2-ylethoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 11D, using the compound of example 30A instead of the compound of example 11B.

p> 1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,67 (s, 2H), 8,35 (s, 1H), 8,03 (d, 2H), of 7.48-EUR 7.57 (m, 3H), 7,42 (d, 1H), 7,35 (d, 2H), 7,05 (d, 2H), of 6.68 (DD, 1H), to 6.39 (DD, 1H), 6,21 (s, 1H), 4,19-4,30 (m, 2H), 3,85-to 3.92 (m, 1H), of 3.73-of 3.85 (m, 2H), to 3.58-3,70 (m, 2H), 3,40-to 3.52 (m, 2H), 3,10 (s, 4H), 2,85 (s, 2H), 2,18-2,39 (m, 3H), of 2.15 (s, 2H), 1,96 (s, 2H), 1.39 in (t, 2H), 0,93 (s, 6H).

EXAMPLE 31

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(1,4-dioxane-2-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 1G, substituting the compound of example 1E and compound of example 1F connection example 15H and the compound of example 25A, respectively.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,66 (s, 1H), 11,46 (m, 1H), 8,54 (m, 2H), 8,45 (m, 1H), 8,03 (d, 1H), 7,83 (m, 2H), 7,50 (m, 3H), 7,34 (m, 3H), 7,12 (m, 2H), of 6.68 (DD, 1H), 6,38 (DD, 1H), of 6.20 (d, 1H), 4,11 (s, 2H), 3,79 (m, 4H), 3,51 (m, 6H), was 3.05 (m, 4H), 2,17 (m, 3H), of 1.17 (s, 6H).

EXAMPLE 32

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[4-(1,4-dioxane-2-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 1G, substituting the compound of example 1E and compound of example 1F connection example 15H and the compound of example 12A, respectively.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,67 (s, 1H), of 8.37 (d, 1H), 8,03 (m, 2H), 7,50 (m, 3H), 7,37 (d, 2H), 7,13(d, 2H), of 6.68 (DD, 1H), 6,40 (DD, 1H), of 6.20 (d, 1H), 4,25 (m, 2H), 4,12 (s, 2H), 3,84 (m, 3H), 3,63 (m, 2H), of 3.45 (m, 2H), 3,06 (m, 4H), of 2.86 (m, 2H), 2,24 (m, 6H), of 1.20 (m, 6H).

EXAMPLE 33

TRANS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 1G, substituting the compound of example 1E and compound of example 1F connection example 15H and the compound of example 9C, respectively.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,63 (s, 1H), 8,51 (d, 1H), 8,15 (d, 1H), 8,01 (d, 1H), 7,76 (DD, 1H), of 7.48 (m, 3H), 7,38 (d, 2H), 7,13 (d, 2H), 7,06 (d, 1H), 6,66 (DD, 1H), 6,36 (DD, 1H), 6,21 (d, 1H), 4,11 (s, 2H), 3,63 (m, 5H), of 3.05 (m, 4H), and 2.83 (s, 2H), 2,64 (m, 4H), 2,17 (m, 6H), was 2.05 (m, 2H), 1.91 a (s, 2H), USD 1.43 (m, 6H), 1,17 (m, 6H).

EXAMPLE 34

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 34A

(4-methoxycyclohexyl)methanamine

(4-methoxyphenyl)methanamine (1 g, 1,29 mmol) in ethanol (10 ml) was treated with 5% Rh-Al2O3(and 99.8 mg, 0,048 mmol) in an atmosphere of H2(500 psi (3.5 MPa)) at 50°C for 16 hours. Added an additional 5% Rh-Al2O3(0.4 g). The resulting mixture was stirred in an atmosphere of H2(500 psi (3.5 MPa)) at 60°C during the 2 hours. Insoluble material was filtered and the filtrate was concentrated to obtain a mixture of CIS - and TRANS-product in the form of oil, which was used in the next stage without further purification.

EXAMPLE 34B

TRANS-4-((4-methoxycyclohexyl)methylamino)-3-nitrobenzenesulfonamide

4-fluoro-3-nitrobenzenesulfonamide (1,098 g) and the compound of example 34A (1 g) in tetrahydrofuran (20 ml) was treated with Ν,Ν-diisopropylethylamine (0,871 ml) over night. The reaction mixture was concentrated and the residue was purified by reversed-phase chromatography, and was suirable 40-55% acetonitrile in 0.1% triperoxonane acid in water for 25 minutes.

EXAMPLE 34C

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 11D, using the compound of example 34B instead of the compound of example 11B.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ of 11.69 (s, 1H), 11,37 (s, 1H), charged 8.52-to 8.62 (m, 2H), of 8.04 (d, 1H), 7,79 (DD, 1H), 7,47-of 7.55 (m, 3H), 7,34 (d, 2H), 7,02-to 7.09 (m, 3H), of 6.68 (DD, 1H), to 6.39 (DD, 1H), to 6.19 (d, 1H), 3,21-of 3.27 (m, 5H), 3,02-of 3.12 (m, 5H), a 2.75 (s, 2H), measuring 2.20 (s, 4H), and 2.14 (s, 2H), 1.93 and-2,04 (m, 4H), to 1.79 (d, 2H), 1,55-1,65 (m, 1H), 1,38 (t, 2H), 0,97 by 1.12 (m, 4H), to 0.92 (s, 6H).

EXAMPLE 35

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[5-cyano--(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 1G, substituting the compound of example 1E and compound of example 1F connection example 15H and the compound of example 36C, respectively.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,65 (s, 1H), 8,78 (s, 1H), 8,58 (s, 1H), 8,00 (d, 1H), 7,51 (m, 3H), 7,38 (d, 2H), 7,14 (d, 2H), of 6.68 (DD, 1H), 6,37 (DD, 1H), 6,23 (d, 1H), or 4.31 (d, 2H), 4,13 (s, 2H), 3,88 (DD, 2H), 3,11 (m, 5H), of 2.16 (m, 6H), of 1.65 (m, 2H), 1,35 (m, 2H), 1,19 (s, 6H).

EXAMPLE 36

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 36A

5-bromo-6-chloropyridin-3-sulfonyl chloride (8.2 g) in methanol (20 ml) was cooled to 0°C. To this solution was added 7 N NH3in methanol (80 ml). The reaction mixture was stirred over night. The solvent was removed at low temperature, and the residue was distributed between ethyl acetate and water. The aqueous layer was extracted with ethyl acetate three times. The combined organic layers were washed with brine, dried (MgSO4), filtered and concentrated. The solid was purified column flash chromatography on silica gel using 20-100% ethyl acetate in hexane to obtain specified in the connection header.

EXAMPLE 36B

Specified in the title compound was obtained by replacing the compound of example 36A 4-fluoro-3-neither is robinsonslainedc in example 24A.

EXAMPLE 36C

A mixture of compound of example 36B (0,702 g), dilantine (0,129 g) and tetrakis(triphenylphosphine)palladium(0) (0,231 g) in N,N-dimethylformamide (2 ml) was degirolami cycle vacuum/nitrogen three times. The reaction mixture was heated at 120°C for 3 hours. After cooling, it was poured into water and was extracted with ethyl acetate three times. The combined organic layers were washed with brine, dried over MgSO4, filtered and concentrated. The residue was purified column flash chromatography on silica gel, elwira 20%-60% ethyl acetate in hexane to obtain specified in the connection header.

EXAMPLE 36D

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing soedinenie of example 36C compound of example 11B in example 11D.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ to 11.56 (s, 1H), 8,66 (s, 1H), 8,44 (s, 1H), 7,94 (d, 1H), 7,55 (d, 1H), 7,44 (t, 1H), 7,34-7,35 (m, 3H),? 7.04 baby mortality (d, 2H), of 6.65 (DD, 1H), 6,32 (s, 1H), 6,24 (s, 1H), 4.26 deaths (d, 2H), 3,86 (DD, 2H), 3,10 (s, 4H), a 2.75 (s, 2H), 2,31 to 2.35 (m, 2H), 2,01-2,05 (m, 1H), 2,15 (s, 2H), 1,96 (s, 2H), 1,63-of 1.66 (m, 2H), 1,33-of 1.40 (m, 4H), to 0.92 (s, 6H).

EXAMPLE 37

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]PI is one-5-yloxy)benzamide

EXAMPLE 37A

1,6-dioxaspiro[2.5]octane-2-carbonitrile

The mixture tetrahydropyran-4-it (10 ml) and chloroacetonitrile (6.4 ml) in tert-butanol (10 ml) was stirred for 10 minutes. To this solution was added a solution of tert-butoxide potassium (12,11 g) in 200 ml of tert-butanol at room temperature for 40 minutes. The reaction mixture was stirred for 16 hours, diluted with water and slowly extinguished 1 N HCl. The solvent chastichno was removed with rotary evaporation. Then the mixture was extracted with simple ether (5× 200 ml). The combined extracts were washed with brine, dried over MgSO4was filtered and the filtrate was concentrated and purified flash chromatography on silica gel with a mixture of 3:7 to 1:1 ethyl acetate:hexane to obtain specified in the connection header.

EXAMPLE 37B

2-(4-Porterage-2H-Piran-4-yl)-2-hydroxyacetate

The compound of example 37A (11.5g) in dichloromethane (40 ml) in a polypropylene bottle drip was treated with 70% gidroftoridakh pyridine (10.4 ml) at 0°C. the Solution was allowed to warm to room temperature for 3 hours, and stirred for an additional 1.5 hours. The reaction mixture was diluted with ethyl acetate (200 ml) and poured into saturated aqueous NaHCO3. Gently used additional solid NaHCO3before the termination of pozerania. The organic layer was isolated and the aqueous layer was extra the listed additional ethyl acetate three times (each time in a 150 ml). The combined organic layers washed with 5% HCl (each time 50 ml, twice), brine, dried over MgSO4, filtered and concentrated to give the desired product which was used directly in the next stage.

EXAMPLE 37C

(4 Porterage-2H-Piran-4-yl)methanol

The compound of example 37B (11,7 g, 74 mmol) in 2-propanol (150 ml) and water (37.5 ml) was cooled to 0°C. To this solution was added NaBH4(4,20 g, 111 mmol). The solution was stirred and allowed him to warm to room temperature for 3 hours. It snuffed out the acetone and stirred for an additional 1 hour. Clear liquid separated from the solids by transfusion. Additional ethyl acetate (2× 100 ml) used for washing the solids and the mixture is poured. The combined organic solutions were concentrated. The residue was purified flash chromatography, elwira a mixture of 1:1 ethyl acetate:hexane to obtain specified in the connection header.

EXAMPLE 37D

4-((4-Porterage-2H-Piran-4-yl)methoxy)-3-nitrobenzenesulfonamide

Specified in the title compound was obtained by replacing the compound of example 37C (tetrahydro-2H-Piran-4-yl)methanol in example 24A.

EXAMPLE 37E

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-yloxy)benzamide

Specified in the title compound was obtained as described in example 11D, using the compound of example 37D instead of the compound of example 11B.

1H NMR (dimethylsulfoxide-d6), 11,64 (s, 2H), with 8.33 (s, 1H), 8,00 shed 8.01 (m, 2H), 7,39-EUR 7.57 (m, 4H), 7,33 (d, J=8,24 Hz, 2H), 7,03 (d, J=8.54 in Hz, 2H), 6,65 (DD, J=9, to 1.98 Hz, 1H), 6,37-6,38 (m, 1H), to 6.19 (d, J=1,53 Hz, 1H), 4,35 (d, J=20,75 Hz, 2H), 3,74-of 3.78 (m, 2H), 3,55-of 3.60 (m, 2H), 3,07 (user., 4H), 2,80 (user., 2H), 2,25 (user., 4H), 2.13 and (OSiR., 2H), 1,81-of 1.94 (m, 6H), to 1.38 (t, J=6,26 Hz, 2H), of 0.91 (s, 6H).

EXAMPLE 38

N-{[3-(aminocarbonyl)-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 38A

3-cyano-4-((tetrahydro-2H-Piran-4-yl)methoxy)benzosulfimide

Specified in the title compound was obtained by replacing 3-cyano-4-fermentalization 4-fluoro-3-nitrobenzenesulfonamide in example 24A.

EXAMPLE 38B

5-sulfamoyl-2-((tetrahydro-2H-Piran-4-yl)methoxy)benzamide

To a solution of compound of example 38A (0,455 g) in ethanol (3 ml) and tetrahydrofuran (1 ml) was added hydrogen peroxide (30% in water, 2 ml), and then 1 N aqueous NaOH (1,024 ml) and was heated to 35°C for 3 hours. The reaction mixture was poured into dichloromethane (50 ml) and 1 N aqueous HCl (25 ml). The aqueous layer was extracted with dichloromethane (3 × 50 ml). The sediment contained in the combined organic layers were collected by filtration receipt the m specified in the connection header.

EXAMPLE 38C

N-{[3-(aminocarbonyl)-4-(tetrahydro-2H-Piran-4-ylethoxy)phenyl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 38B compound of example 1F and the compound of example 3J for compound of example 1E in example 1G.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ to 11.79-11,70 (m, 1H), 11,66-11,54 (m, 1H), 9,29-remaining 9.08 (m, 1H), 8,27 (d, 1H), 8,08 (d, 1H), 7,97-of 7.90 (m, 1H), 7,76-7,72 (m, 1H), 7.62mm (s, 1H), 7,54 (s, 1H), 7,50 (d, 1H), 7,39 (d, 1H), 7.23 percent (d, 1H), was 7.08 (d, 1H), 6,74 is 6.67 (m, 1H), 6,44 (s, 1H), from 6.22 (s, 1H), 4,03 (d, 6H), 3,74-to 3.52 (m, 4H), to 3.33 (s, 4H), 3,11-2,90 (m, 2H), 2,01 (s, 4H), 1,79 is 1.58 (m, 2H), 1,24 (s, 5H), were 0.94 (s, 6H).

EXAMPLE 39

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 39A

CIS-tert-butyl-4-morpholinosydnonimine

To a solution of the research (4,08 g) and tert-butyl-4-oxocyclohexanecarboxylate (10 g), stirred for 24 hours at room temperature in isopropoxide titanium (IV) (27.5 ml), was added methanol (10 ml), and then carefully added sodium borohydride (3.55 g). The reaction mixture was extinguished with water/NaOH solution was extracted with simple ether, dried over magnesium sulfate, filtered and concentrated. The product was separated from the TRANS-isome is a and was purified flash chromatography (silica gel, 50%-100% acetone in hexane) to obtain specified in the connection header.

EXAMPLE 39B

Bis(2,2,2-triptorelin) CIS-4-morpholinosydnonimine

To a solution of compound of example 39A (2,43 g) in dichloromethane (15 ml) was added triperoxonane acid (5 ml) and the reaction mixture was stirred for 16 hours at room temperature. The reaction mixture was concentrated and the crude product used without purification.

EXAMPLE 39C

4-(CIS-4-morpholinosydnonimine)-3-nitrobenzenesulfonamide

A solution of compound of example 39B (0.40 g), 4-fluoro-3-nitrobenzenesulfonamide (0,478 g) and triethylamine (2 ml) in tetrahydrofuran (10 ml) was stirred for 3 days at room temperature. The reaction mixture was concentrated and purified flash chromatography (silica gel, 0-30% methanol/dichloromethane) to give the product.

EXAMPLE 39D

CIS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 39C compound of example 11B in example 11D.

1H NMR (500 MHz, pyridine-d5) δ 13,07 (s, 1H), of 9.30 (d, 1H), 8,64 (d, 1H), 8,43 (d, 1H), scored 8.38 (DD, 1H), 8,11 (d, 1H), to 7.67 (t, 2H), 7,44 (d, 2H), 7,06 (d, 2H), 6,91 (d, 1H), 6,74 (DD, 1H), 6.48 in-6,55 (m, 2H), 3,65-to 3.73 (m, 5H), 3,02-to 3.09 (m, 4H), was 2.76 (s, 2H), 2,41-2,48 (m, 4H), of 2.25 (t, 2H), ,09-2,16 (m, 5H), of 1.97 (s, 2H), 1.77 in is 1.86 (m, 2H), 1,55-to 1.63 (m, 6H), 1.39 in (t, 2H), 0,93 (s, 6H).

EXAMPLE 40

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 40A

5,6-dichloropyridine-3-sulfonamide

Specified in the title compound was obtained by replacing 5,6-dichloropyridine-3-sulphonylchloride 5-bromo-6-chloropyridin-3-sulphonylchloride in example 36A.

EXAMPLE 40B

5-chloro-6-((tetrahydro-2H-Piran-4-yl)methoxy)pyridine-3-sulfonamide

Specified in the title compound was obtained by replacing the compound of example 40A 4-fluoro-3-nitrobenzenesulfonamide in example 24A.

EXAMPLE 40C

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 40B compound of example 11B in example 11D.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,67 (s, 1H), charged 8.52 (s, 1H), 8,39 (d, 1H), 8,03 (d, 1H), 7,54 (d, 1H), 7,52 (d, 1H), 7,50 (DD, 1H), 7,35 (d, 2H),? 7.04 baby mortality (d, 2H), to 6.67 (DD, 1H), 6,39 (m, 1H), 6,21 (d, 1H), 4,25 (d, 2H), a 3.87 (DD, 2H), 3,30 (m, 2H), 3,10 (PTS.user. s, 4H), 2,90 (PTS.user. s, 2H), 2,35 (PTS.user. s, 4H), 2,17 (user. m, 2H), 2.05 is (m, 1H), 1,96 (s, 2H), 1,64 (d, 2H), 1,40 (t, 2H), 1,35 (DDD, 2H), 0,93 (s, 6H).

EXAMPLE 41

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-Digi the ro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-{[5-chloro-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 15H compound of example 3J and compound of example 40B compound of example 11B in example 11D.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,68 (s, 1H), 8,55 (d, 1H), to 8.41 (d, 1H), 8,04 (d, 1H), 7,54 (m, 2H), 7,50 (DD, 1H), 7,38 (d, 2H), 7,14 (d, 2H), of 6.68 (DD, 1H), 6,40 (m, 1H), of 6.20 (d, 1H), 4,25 (d, 2H), 4,12 (s, 2H), a 3.87 (DD, 2H), 3,30 (m, 2H), 3,10 (PTS. user. s, 4H), 2,90 (PTS.user. s, 2H), and 2.27 (PTS.user. s, 4H), 2,17 (user. m, 2H), 2.05 is (m, 1H), 1,96 (s, 2H), 1,64 (d, 2H), 1,35 (DDD, 2H), 0,97 (s, 6H).

EXAMPLE 42

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-{[4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-(trifluoromethyl)phenyl]sulfonyl}benzamide

EXAMPLE 42A

4-((tetrahydro-2H-Piran-4-yl)methylamino)-3-(trifluoromethyl)benzosulfimide

A mixture of 4-fluoro-3-(trifluoromethyl)benzosulfimide (1,056 g), (tetrahydro-2H-Piran-4-yl)methanamine (0.5 g) and Ν,Ν-diisopropylethylamine (1.68 g) in anhydrous solution of dimethyl sulfoxide (15 ml) was heated at 90°C during the night. The reaction mixture was cooled to room temperature and was diluted with ethyl acetate. The organic phase is washed with water, brine, dried over anhydrous sodium sulfate, filtered and concentrated to obtain specified in the connection header.

EXAMPLE 42B

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b-5-yloxy)-N-{[4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-(trifluoromethyl)phenyl]sulfonyl}benzamide

Specified in the title compound was obtained as described in example 1G, substituting the compound of example 1E and compound of example 1F connection example 15H and the compound of example 42A, respectively.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,73 (s, 1H), 11,25 (s, 1H), 8,08 (d, 1H), 7,89 (d, 1H), to 7.77 (m, 1H), to 7.61 (d, 1H), 7,51 (m, 2H), 7,37 (d, 2H), 7,13 (d, 2H), to 6.88 (d, 1H), to 6.67 (DD, 1H), 6,53 (m, 1H), gold 6.43 (m, 1H), x 6.15 (d, 1H), of 4.11 (s, 2H), 3,82 (DD, 2H), 3,19 (m, 5H), was 3.05 (m, 4H), 2,82 (s, 2H), measuring 2.20 (m, 7H), of 1.85 (m, 1H), and 1.56 (m, 2H), of 1.18 (s, 6H).

EXAMPLE 43

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-({4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)benzamide

Specified in the title compound was obtained as described in example 1G, substituting the compound of example 1E and compound of example 1F connection example 15H and the compound of example 17A, respectively.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ of 11.69 (s, 1H), 11,48 (m, 1H), 8,16 (d, 1H), with 8.05 (d, 1H), 7,92 (DD, 1H), 7,52 (m, 3H), 7,37 (d, 2H), 7,27 (m, 1H), 7,11 (m, 3H), of 6.68 (DD, 1H), 6,41 (DD, 1H), 6,18 (d, 1H), 4,11 (s, 2H), 3,84 (DD, 2H), of 3.25 (m, 4H), of 3.07 (m, 4H), 2,84 (m, 2H), 2,23 (m, 5H), of 1.84 (m, 1H), 1.55V (m, 2H), 1,25 (m, 3H), of 1.18 (s, 6H).

EXAMPLE 44

TRANS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

P the EMER 44A

TRANS-4-(4-morpholinosydnonimine)-3-(trifloromethyl)benzosulfimide

Specified in the title compound was obtained as described in example 16A, replacing 2-methoxyethylamine compound of example 9B.

EXAMPLE 44B

TRANS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 1G, substituting the compound of example 1E and compound of example 1F connection example 15H and the compound of example 44A, respectively.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ are 11.62 (s, 1H), 8,08 (s, 1H), 8,00 (d, 1H), a 7.85 (d, 1H), 7,47 (m, 3H), 7,38 (d, 2H), 7,14 (d, 2H), 6,98 (d, 1H), 6,65 (DD, 1H), 6,55 (m, 1H), 6,37 (m, 1H), 6,21 (d, 1H), 4,12 (s, 2H), 3,54 (m, 6H), totaling 3.04 (m, 4H), and 2.83 (s, 2H), 2.57 m (m, 3H), 2,24 (m, 6H), 1.91 a (m, 5H), of 1.34 (m, 4H), of 1.20 (s, 6H).

EXAMPLE 45

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(1-methylpiperidin-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 45A

4-(1-methylpiperidin-4-ylamino)-3-(trifloromethyl)benzosulfimide

Specified in the title compound was obtained as described in example 16A, replacing 2-methoxyethylamine 1-methyl-4-aminopiperidine.

EXAMPLE 45B

4-(4-{[4-(4-PI is henyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(1-methylpiperidin-4-yl)amino]-3-[(trifluoromethyl)sulfonyl]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 1G, substituting the compound of example 1E and compound of example 1F connection example 15H and the compound of example 45A, respectively.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,59 (s, 1H), 8,10 (s, 1H), 7,98 (d, 1H), of 7.90 (DD, 1H), 7,49 (m, 3H), 7,39 (m, 3H), 7,14 (d, 2H), 7,02 (d, 1H), 6,65 (DD, 2H), 6,36 (DD, 1H), from 6.22 (d, 1H), 4,12 (s, 2H, in), 3.75 (m, 1H), and 3.16 (m, 4H), 2,98 (m, 5H), is 2.88 (m, 5H), to 2.67 (s, 2H), 2,22 (m, 6H), by 1.68 (m, 1H), 1,18 (s, 6H).

EXAMPLE 46

5-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-(tetrahydro-2H-Piran-4-ylethoxy)nicotinamide

5-sulfamoyl-2-((tetrahydro-2H-Piran-4-yl)methoxy)nicotinamide

To the compound of example 36C (0.025 g) in ethanol (1 ml) and tetrahydrofuran (1 ml) was added hydrogen peroxide (30% in water, 0.5 ml) and then 1 M aqueous sodium hydroxide solution (0,056 ml), and then an additional 1 ml of tetrahydrofuran. The reaction mixture was heated to 45°C for 2 hours, cooled and extinguished 1 N aqueous HCl (5 ml), and the product was extracted in dichloromethane (10 ml). The organic layer was dried over magnesium sulfate, filtered and concentrated to obtain specified in the connection header.

EXAMPLE 46B

5-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-(tetrahydro-2H-PI is an-4-ylethoxy)nicotinamide

Specified in the title compound was obtained by replacing the compound of example 46A compound of example 1F and the compound of example 3J for compound of example 1E in example 1G.

1H NMR (300 MHz, CDC13) δ 10,31-to 10.09 (m, 1H), which is 9.09 (s, 2H), 8,93-8,81 (m, 1H), 8,28-8,18 (m, 1H), 8,03-7,87 (m, 1H), to 7.77-to 7.68 (m, 1H), to 7.59-7,51 (m, 1H), of 7.48-7,41 (m, 1H), 6,91 (d, 2H), 6,59-6.48 in (m, 2H), 5,97 (s, 2H), 4,50 (d, 2H), 4,08-3,98 (m, 2H), 3.45 points (s, 4H), 3,13-to 2.99 (m, 4H), 2,82 of 2.68 (m, 2H), 2,19 (s, 4H), to 1.86 (s, 5H), 1,61-of 1.35 (m, 4H), were 0.94 (s, 6H).

EXAMPLE 47

N-({5-bromo-6-[(1-methylpiperidin-4-yl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 47A

5-bromo-6-((1-methylpiperidin-4-yl)methoxy)pyridine-3-sulfonamide

To (1 methylpiperidin-4-yl)methanol (0,109 g) in tetrahydrofuran (2 ml) was added sodium hydride (0,136 g). After 30 minutes, was added the compound of example 36A (0,230 g) as a solution in tetrahydrofuran (1 ml) and the reaction mixture was heated to 50°C. After 4 hours the reaction mixture was cooled, poured into water (10 ml) and dichloromethane (50 ml) and the pH was brought to pH~8. The aqueous layer was extracted with dichloromethane (3 × 50 ml) and the organic layers were combined, washed with brine (30 ml), dried over magnesium sulfate, filtered and concentrated to obtain specified in the connection header.

EXAMPLE 47B

N-({5-bromo-6-[(1-methylpiperidin-4-yl)methoxy]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-�lorgeril)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 47A compound of example 1F and the compound of example 3J for compound of example 1E in example 1G.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,51 (s, 1H), 8,35 (d, 1H), 8,17 (d, 1H), to 7.93 (d, 1H), 7,60 (d, 1H), 7,44-7,40 (m, 1H), 7,33 (DD, 3H), 7,05 (d, 2H), is 6.61 (d, 1H), of 6.31 (DD, 1H), 6,24 (s, 1H), 4,25 (d, 2H), 3,40 (s, 4H), 3,01 (s, 4H), 2,73 (d, J=8,2, 5H), of 2.20 (s, 6H), 1.93 and (d, 4H), and 1.54 (s, 1H), 1.39 in (s, 2H), 1,24 (s, 2H), 0,93 (s, 6H).

EXAMPLE 48

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-methylpiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 48A

4-((1-methylpiperidin-4-yl)methoxy)-3-nitrobenzenesulfonamide

Specified in the title compound was obtained by replacing (1-methylpiperidin-4-yl)methanol (tetrahydro-2H-Piran-4-yl)methanol in example 24A.

EXAMPLE 48B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(1-methylpiperidin-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 48A compound of example 1F and the compound of example 3J for compound of example 1E in example 1G.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,54 (s, 1H), 8,17 (s, 1H), 7,92 (s, 1H), 7,87-to 7.77 (m, 1H), 7,58 (d, 1H), 7,43 (s, 1H), 7,40-7,00 (m, 7H), 6,70-6,56 (m, 1H), of 6.31 (s, 1H), 6,24 (s, 1H), of 4.05 (s, 2H), 3.46 in-to 3.33 (m, 2H), to 3.02 (s, 6H) of 2.72 (d, 5H), of 2.21 (s, 6H), to 1.96 (s, 5H), 1.70 to to 1.48 (m, 2H), 1.39 in (s, 2H), 0,93 (s, 6H).

EXAMPLE 49

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(1,4-dioxane-2-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 49A

6-((1,4-dioxane-2-yl)methoxy)-5-bromopyridin-3-sulfonamide

Specified in the title compound was obtained by replacing (1,4-dioxane-2-yl)methanol (tetrahydro-2H-Piran-4-yl)methanol and the compound of example 36A 4-fluoro-3-nitrobenzenesulfonamide in example 24A.

EXAMPLE 49B

6-((1,4-dioxane-2-yl)methoxy)-5-cyano-3-sulfonamide

Specified in the title compound was obtained by replacing the compound of example 49A connection example in example 36B 36C.

EXAMPLE 49C

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(1,4-dioxane-2-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 49B compound of example 11B in example 11D.

1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11,50 (s, 1H), at 8.60 (s, 1H), 8,40 (s, 1H), to $ 7.91 (d, 1H), 7,58 (d, 1H), 7,42 (t, 1H), 7,35 (d, 2H), 7,28 (s, 1H), 7,06 (d, 2H), only 6.64 (DD, 1H), 6,29 (m, 2H), and 4.40 (d, 2H), 3,90 (m, 1H), 3,79 (m, 2H), 3,63 (m, 2H), 3.46 in (m, 4H), of 3.07 (s, 4H), 2,85 (m, 2H), 2,34 (m, 4H), of 2.16 (m, 2H), 1,40 (t, 2H), 0,93 (s, 6H).

EXAMPLE 50

N-{[5-bromo-6-(1,4-dioxane-2-ylethoxy)pyridine-3-yl]sulfonyl}-4-(4-{[2-(4-chlorphen is)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 49A compound of example 11B in example 11D.

1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11,60 (s, 1H), 8,46 (s, 1H), of 8.27 (s, 1H), to 7.99 (d, 1H), 7,56 (d, 1H), 7,46 (m, 2H), 7,35 (d, 2H), 7,05 (d, 2H), of 6.65 (DD, 1H), 6,36 (DD, 1H), from 6.22 (d, 1H), 4,34 (m, 2H), 3,88 (m, 1H), 3,79 (m, 2H), 3,63 (m, 2H), 3.46 in (m, 2H), 3,06 (s, 4H), of 2.81 (s, 2H), and 2.26 (m, 4H), of 2.15 (s, 2H), 1,96 (s, 2H), 1,38 (m, 2H), 0,93 (s, 6H).

EXAMPLE 51

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2,2-dimethylether-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 51A

Specified in the title compound was obtained as described in example 12A, replacing (1,4-dioxane-2-yl)methanol (2,2-dimethylether-2H-Piran-4-yl)methanol.

EXAMPLE 51B report

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2,2-dimethylether-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 11D using the compounds of example 51A instead of the compound of example 11B.

1H NMR (400 MHz, dimethylsulfoxide-d6) δ of 11.69 (s, 2H), 8,35 (s, 2H), 8,03 (d, 4H), 7,47-7,58 (m, 6H), 7,31-7,42 (m, 6H),? 7.04 baby mortality (d, 4H), of 6.68 (DD, 2H), 6,40 (s, 2H), 6,20 (d, 2H), 3.96 points-4.09 to (m, 2H), 3,54-3,68 (m, 2H), to 3.09 (s, 4H), and 2.83 (s, 2H), 2,09-is 2.37 (m, 7H), to 1.96 (s, 2H), 1,55 was 1.69 (m, 2H), 1.39 in (t, 2H), 1,19 (m, 8H), to 0.92 (s, 6H).

EXAMPLE 52

N-({3-chloro-5-cyano-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 52A

3-cyano-4-forbindelsesfaneblad

3-cyano-4-torbenson-1-sulphonylchloride (1.1 g) in 1,4-dioxane (10 ml) at 0°C drip was treated with 7 N ammonia solution in methanol (3,57 ml) and was stirred for 30 minutes. A small amount of solid was removed by filtration and discarded. The filtrate was concentrated, diluted with ethyl acetate, washed with water and brine, dried (MgSO4), filtered, concentrated and triturated with diethyl ether to obtain the product.

EXAMPLE 52B

3-cyano-4-((tetrahydro-2H-Piran-4-yl)methylamino)benzosulfimide

Specified in the title compound was obtained by replacing the compound of example 52A 4-chloro-3-nitrobenzenesulfonamide and (tetrahydro-2H-Piran-4-yl)methanamine dihydrochloride 4-methylpiperazin-1-amine in example 6A.

EXAMPLE 52C

3-chloro-5-cyano-4-((tetrahydro-2H-Piran-4-yl)methylamino)benzosulfimide

Connection example V (0,148 g) in acetonitrile (5 ml) was treated with N-chlorosuccinimide (0,080 g), was heated at 60°C for 3 hours and filtered to remove small amounts of solids. The filtrate was concentrated and subjected to chromatography on silica gel with 3-15% this is lacerata in dichloromethane as eluent. The obtained solid is suspended in water, filtered, washed with additional water and dried in vacuum to obtain the product.

EXAMPLE 52D

N-({3-chloro-5-cyano-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 52C compound of example 11B in example 11D.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,70 (s, 1H), 11,41 (user. s, 1H), 8,07 (d, 1H), 7,89 (s, 2H), to 7.61 (m, 1H), 7,53 (m, 2H), 7,35 (d, 2H), 7,18 (m, 1H), 7,05 (d, 2H), 6,69 (m, 1H), 6.42 per (DD, 1H), 6,18 (DD, 1H), 3,83 (m, 2H), 3,55 (t, 2H), 3,23 (m, 3H), 3,06 (m, 4H), of 2.15 (m, 4H), of 1.92 (m, 4H), to 1.60 (m, 2H), 1,40 (m, 2H), 1,19 (m, 4H), of 0.93 (s, 6H).

EXAMPLE 53

N-({4-[(1-acetylpiperidine-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 53A

N-[(4-chloro-3-nitrophenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 3J for compound of example 1E and 4-chloro-3-nitrobenzenesulfonamide compound of example 1F in example 1G.

EXAMPLE 53B

N-({4-[(1-acetylpiperidine-4-yl)amino]-3-nitrophenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-immiscibles-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

A 5-ml round-bottom flask were placed compound of example 53A (120 mg), 1-acetylpiperidine-4-amine (28 mg), and triethylamine (0,064 ml) in dioxane (2 ml). The reaction mixture was heated to 90°C for 24 hours. The reaction mixture was cooled to room temperature and added to a column of silica gel and purified, elwira 0-5% methanol in dichloromethane.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,66 (user. s, 1H), 8,65 (d, 1H), 8,24 (d, 1H), 8,03 (d, 1H), 7,83 (DD, 1H), 7,54-7,46 (m, 3H), 7,35 (d, 2H), 7,19 (d, 1H),? 7.04 baby mortality (d, 2H), of 6.68 (DD, 1H), 6,39 (m, 1H), of 6.20 (d, 1H), 4,28 (d, 1H), 3,97 of 3.75 (m, 2H), 3,07 (user. s, 4H), 2,87-2,70 (m, 4H), 2,29 is 2.10 (m, 6H), 2,02 (s, 3H), 2.00 in 1,89 (m, 4H), 1,66-and 1.54 (m, 2H), 1.39 in (t, 2H), 0,92 (s, 6H).

EXAMPLE 54

N-({2-chloro-5-fluoro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 54A

2-chloro-5-fluoro-4-((tetrahydro-2H-Piran-4-yl)methylamino)benzosulfimide

Specified in the title compound was obtained by replacing 2-chloro-4,5-differentlanguages 4-chloro-3-nitrobenzenesulfonamide and (tetrahydro-2H-Piran-4-yl)methanamine dihydrochloride 4-methylpiperazin-1-amine in example 6A.

EXAMPLE 54

N-({2-chloro-5-fluoro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in C is the cylinder compound was obtained by replacing the compound of example 54A compound of example 11B in example 11D.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,76 (s, 1H), 11,31 (s, 1H), 8,08 (d, 1H), 7,69 (d, 1H), 7,60 (d, 1H), 7,55 (m, 2H), 7,34 (d, 2H),? 7.04 baby mortality (d, 2H), 6.90 to (s, 1H), at 6.84 (d, 1H), 6,69 (DD, 1H), 6,45 (DD, 1H), 6,13 (d, 1H), 3,82 (DD, 2H), 3,24 (t, 2H), 3,05 (m, 6H), 2,73 (s, 2H), and 2.14 (m, 6H), 1,95 (s, 2H), is 1.81 (m, 1H), 1,61 (m, 2H), 1,38 (t, 2H), 1,17 (m, 2H), 0,92 (s, 6H).

EXAMPLE 55

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(3-morpholine-4-ylpropyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 3J for compound of example 1E and compound of example 2A compound of example 1F in example 1G.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,66 (user. s, 1H), up 8.75 (t, 1H), 8,54 (d, 1H), 8,03 (d, 1H), 7,79 (DD, 1H), 7,54-of 7.48 (m, 3H), 7,35 (d, 2H), 7,08-7,02 (m, 3H), to 6.67 (DD, 1H), 6,38 (m, 1H), of 6.20 (d, 1H), 3,61 (t, 4H), 3.43 points (square, 2H), 3,29 (m, 2H), 3,06 (user. s, 4H), 2,73 (user. s, 2H), 2,47 (user. s, 4H), to 2.18 (m, 6H), 1,95 (user. s, 2H), 1,80 (m, 2H), 1,38 (t, 2H), 0,92 (s, 6H).

EXAMPLE 56

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 56A

5-bromo-6-((4-Porterage-2H-Piran-4-yl)methoxy)pyridine-3-sulfonamide

Specified in the title compound was obtained by replacing the compound of example 37C tetrahydro-2H-Piran-4-yl)methanol and the compound of example 36A 4-fluoro-3-neither is robinsonslainedc in example 24A.

EXAMPLE 56B

Specified in the title compound was obtained by replacing the compound of example 56A connection example in example 36B 36C.

EXAMPLE 56C

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({5-cyano-6-[(4-Porterage-2H-Piran-4-yl)methoxy]pyridine-3-yl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 56B compound of example 11B in example 11D.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,58 (s, 1H), to 8.70 (s, 1H), 8,51 (s, 1H), of 7.96 (d, 1H), EUR 7.57 (d, 1H), 7,45 (t, 1H), 7,35-7,37 (m, 3H), 7,06 (d, 2H), to 6.67 (DD, 1H), 6,33 (d, 1H), of 6.26 (s, 1H), 4,56 (d, 2H), 3,76-of 3.80 (s, 2H), 3,56-3,62 (m, 2H), 3,01-3,10 (m, 4H), 2,14-to 2.18 (m, 2H), 1,96 (s, 2H), 1,80-to 1.87 (m, 4H), of 1.41 (t, 2H), 0,93 (s, 6H).

EXAMPLE 57

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(2-morpholine-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 57A

5-bromo-6-(2-morpholinoethoxy)pyridine-3-sulfonamide

Specified in the title compound was obtained by replacing 2-morpholinoethyl tetrahydro-2H-Piran-4-yl)methanol and the compound of example 36A 4-fluoro-3-nitrobenzenesulfonamide in example 24A.

EXAMPLE 57B

5-cyano-6-(2-morpholinoethoxy)pyridine-3-sulfonamide

Specified in the title compound was obtained by replacing the compound of example 57A compound of example 36A in example 36B.

WHEN THE EP 57C

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(2-morpholine-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 57B compound of example 11B in example 11D.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ to 11.56 (s, 1H), 8,64 (s, 1H), to 8.41 (s, 1H), 7,92 (d, 1H), 7,58 (d, 1H), 7,44 (t, 1H), was 7.36 (d, 2H), 7,31 (s, 1H), 7,06 (d, 2H), of 6.65 (DD, 1H), of 6.31 (d, 1H), 6,27 (d, 1H), 4,59 (t, 2H) and 3.59 (s, 4H), is 3.08 (s, 4H), 2,89 (s, 2H), 2,65 (s, 4H), 2,16-to 2.18 (m, 2H), 1,97 (s, 2H), 1,41 (t, 2H), 0,93 (s, 6H).

EXAMPLE 58

Ν-[(3-chloro-4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 58A

3-chloro-4-(2-(2-methoxyethoxy)ethylthio)benzosulfimide

A 25-ml test tube for processing microwave radiation was added sodium hydride (0.6 g) in tetrahydrofuran (10 ml) to give a suspension. Was slowly added 2-(2-methoxyethoxy)ethanthiol (1 g). After stirring for 30 minutes was slowly added 3-chloro-4-forbindelsesfaneblad (1.54 g), dissolved in 10 ml of tetrahydrofuran. The mixture was heated at 110°C for 30 minutes in a microwave reactor Biotage Initiator. Added water, the product was extracted with simple ether (20 ml ×3), dried over Na2SO4was filtered and the solvent was removed PR is the reduced pressure. The crude product was purified flash chromatography on silica gel, elwira 0-25% ethyl acetate in hexane.

EXAMPLE 58B

3-chloro-4-(2-(2-methoxyethoxy)ethylsulfonyl)benzosulfimide

The compound of example 58A (0.15 g) suspended in acetic acid (3 ml). Was slowly added peracetic acid (0.4 ml). The mixture was stirred at room temperature overnight, then poured into a solution of Na2S2O3and the product was besieged. After filtration and washing with water the product was dried in vacuum.

EXAMPLE 58C trainers

N-[(3-chloro-4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}phenyl)sulfonyl]-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 58B compound of example 11B in example 11D.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ to 11.52 (s, 1H), 7,92 (d, 1H), to 7.84 (m, 2H), 7,68 (m, 1H), 7.62mm (d, 1H), 7,42 (t, 1H), 7,35 (d, 2H), 7,29 (m, 1H), 7,05 (d, 2H), 6,62 (DD, 1H), 6,32 (m, 1H), of 6.26 (d, 1H), 3,74 (t, 2H), 3,68 (t, 2H), 3,24 (m, 2H), 3,06 (m, 5H), 3,01 (m, 4H), to 2.74 (s, 2H), 2,19 (m, 6H), to 1.96 (s, 2H), 1.39 in (t, 2H), 0,93 (s, 6H).

EXAMPLE 59

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 59A

4-(2-(2-methoxyethoxy)ethylthio)-3-nitrobenzenesulfonamide

The decree is Noah in the title compound was obtained by replacing 4-fluoro-3-nitrobenzenesulfonamide 3-chloro-4-forbindelsesfaneblad in example 58A.

EXAMPLE 59B

4-(2-(2-methoxyethoxy)ethylsulfonyl)-3-nitrobenzenesulfonamide

Specified in the title compound was obtained by replacing the compound of example 59A compound of example 58A in example 58B.

EXAMPLE 59C

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[2-(2-methoxyethoxy)ethyl]sulfonyl}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 59B compound of example 11B in example 11D.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,51 (s, 1H), 8,17 (m, 1H), 7,94 (m, 3H), of 7.64 (d, 1H), 7,42 (m, 1H), 7,35 (d, 2H), 7,28 (d, 1H), 7,05 (d, 2H), 6,62 (m, 1H), 6,28 (m, 2H), 3,83 (m, 4H), and 3.16 (m, 2H), is 3.08 (s, 3H), 3,01 (m, 4H), by 2.73 (s, 2H), 2,18 (m, 6H), to 1.96 (m, 4H), 1.39 in (t, 2H), 0,93 (s, 6H).

EXAMPLE 60

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)oxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 60A

TRANS-4-(4-aminocyclohexane)-3-nitrobenzenesulfonamide

To a solution of tert-butyl-4-hydroxycyclohexanecarboxylate (0,250 g) in tetrahydrofuran (5 ml) was added sodium hydride (0,186 g). After stirring for 15 minutes was added 4-fluoro-3-nitrobenzenesulfonamide (0,256 g) as a solution in tetrahydrofuran (1 ml). The reaction mixture was heated to 60°C for 1.5 hours, cooled and the water flow is in a mixture of dichloromethane (100 ml) and water (25 ml). The aqueous layer was brought to pH 4 with 1 N aqueous HCl and the organic layer was separated, washed with brine (50 ml), dried over magnesium sulfate, filtered and concentrated. The residue was applied on silica gel (GraceResolv 40 g) and was suirable with a gradient of 0.5% to 7.5% methanol/dichloromethane over 30 minutes. This solid was treated with HCl (4.0m in dioxane, 5 ml) at room temperature for 1 hour and then concentrated to obtain specified in the connection header.

EXAMPLE 60B

4-(TRANS-4-morpholinoethoxy)-3-nitrobenzenesulfonamide

To the compound of example 60A (0,220 g) and 1-bromo-2-(2-bromoethoxy)ethane (0,177 g) in N,N-dimethylformamide (3 ml) was added triethylamine (0,338 ml) and the reaction mixture was heated to 70°C for 5 hours. The reaction mixture was cooled and the precipitate was removed by filtration. The reaction mixture was concentrated and applied to silica gel and was suirable with a gradient of 0.5% to 7.5% methanol/dichloromethane to obtain specified in the connection header.

EXAMPLE 60C

TRANS-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)oxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 60B compound of example 1F and the compound of example 3J for compound use is and 1E in example 1G.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ are 11.62 (s, 1H), 8,23 (s, 1H), to 7.99 (s, 1H), of 7.96-7,88 (m, 1H), 7,54 (d, 1H), of 7.48 (s, 2H), 7,34 (d, 3H),? 7.04 baby mortality (d, 2H), 6,72 return of 6.58 (m, 1H), 6,37 (s, 1H), 6,21 (s, 1H), 4,69-4,47 (m, 1H), 3,66 (s, 4H), of 3.05 (s, 4H), was 2.76 (s, 6H), 2,22 (s, 9H), to 1.96 (s, 4H), of 1.39 (s, 6H), to 0.92 (s, 6H).

EXAMPLE 61

N-({5-bromo-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 61A

5-bromo-6-(1-(tetrahydro-2H-Piran-4-yl)piperidine-4-ylamino)pyridine-3-sulfonamide

A mixture of compound of example 36A (1.0 g), compounds of example 3L (0.95 g) and triethylamine (is 3.08 ml) in anhydrous dioxane (20 ml) was heated at 110°C over night. The organic solvent was removed in vacuum. The residue was purified column flash chromatography on silica gel, elwira a mixture of 2%-8% methanol/dichloromethane to obtain specified in the connection header.

EXAMPLE 61B

N-({5-bromo-6-[(1-tetrahydro-2H-Piran-4-reparacin-4-yl)amino]pyridine-3-yl}sulfonyl)-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 61A compound of example 11B in example 11D.

1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11,59 (s, 1H), 8,35 (s, 1H), 8,00 (s, 2H), 7,55 (d, 1H), 7,46 (m, 2H), 7,34 (d, 2H),? 7.04 baby mortality (d, 2H), 6,63 (DD, 1H), of 6.49 (m, 1 is), 6,36 (s, 1H), of 6.20 (s, 1H), of 4.05 (m, 1H), 3,94 (d, 2H), or 3.28 (m, 6H), 3,01 (s, 4H), of 2.72 (s, 2H), 2,16 (m, 6H), 1.93 and (m, 4H), of 1.80 (m, 4H), of 1.57 (m, 2H), 1,38 (t, 2H), 1,17 (t, 2H), 0,90 (s, 6H).

EXAMPLE 62

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-cyanoethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 62A

4-(2-cyanoethylidene)-3-nitrobenzenesulfonamide

Specified in the title compound was obtained by replacing the 3-aminopropionitrile connection example in example 39B 39C.

EXAMPLE 62B

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(2-cyanoethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 62A compound of example 11B in example 11D.

1H NMR (501 MHz, pyridine-d5) δ 13,04 (s, 1H), 9,24 (d, 1H), 9,04 (t, 1H), 8,43 (d, 1H), scored 8.38 (DD, 1H), 8,13 (d, 1H), of 7.64-to 7.68 (m, 2H), 7,44 (DDD, 2H), 7,07 (DDD, 2H), 7,02 (d, 1H), 6,76 (DD, 1H), 6,55 (d, 1H), 6.48 in (DD, 1H), 3,83 (square, 2H), of 3.07 (d, 4H), 2,98 (t, 2H), 2,77 (s, 2H), and 2.26 (s, 2H), 2,11-2,17 (m, 4H), of 1.97 (s, 2H), 1.39 in (t, 2H), 0,93 (s, 6H).

EXAMPLE 63

CIS-4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 15H compound of example 3J and connect the receiving of example 39C compound of example 11B in example 11D.

1H NMR (501 MHz, pyridine-d5) δ to 13.09 (s, 1H), of 9.30 (d, 1H), 8,64 (d, 1H), 8,43 (d, 1H), scored 8.38 (DD, 1H), 8,10 (d, 1H), 7,68 (dt, 2H), 7,46 (DDD, 2H), 7,12 (DDD, 2H), 6,91 (d, 1H), 6,72 (DD, 1H), 6,51 (DD, 1H), of 6.49 (d, 1H), 5,69 (s, 2H), however, 4.40 (s, 2H), 3,69-to 3.73 (m, 4H), 3,68 (s, 1H), 2,95-to 3.02 (m, 4H), 2,84 (s, 2H), 2.40 a is 2.46 (m, 4H), of 2.21 (s, 2H), 2,08-of 2.15 (m, 5H), 1,76-of 1.84 (m, 2H), 1,55-to 1.63 (m, 6H), of 1.29 (s, 6H).

EXAMPLE 64

TRANS-N-{[4-({4-[bis(cyclopropylmethyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 64A

Tert-butyl(TRANS)-4-(bis(cyclopropylmethyl)amino)cyclohexylcarbamate

Specified in the title compound was obtained by replacing cyclopropanecarboxaldehyde 4'-chlorobiphenyl-2-carboxaldehyde and tert-butyl(TRANS)-4-aminocyclohexanecarboxylic tert-butyl piperazine-1-carboxylate in example 1A.

EXAMPLE 64B

The dihydrochloride (TRANS)-N1N1bis(cyclopropylmethyl)cyclohexane-1,4-diamine

To a solution of compound of example 64A (1.4 g) in dichloromethane (10 ml) was added hydrochloric acid (10 ml, 4 M in dioxane) and the reaction mixture was stirred for 16 hours at room temperature. The reaction mixture was diluted simple ether and pure product was filtered.

EXAMPLE 64C

TRANS-4-(4-(bis(cyclopropylmethyl)amino)cyclohexylamino)-3-nitrobenzenesulfonamide

Specified in reception is e compound was obtained by replacing the compound of example 64B connection example in example 39B 39C.

EXAMPLE 64D

TRANS-N-{[4-({4-[bis(cyclopropylmethyl)amino]cyclohexyl}amino)-3-nitrophenyl]sulfonyl}-4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 64C compound of example 11B in example 11D.

1H NMR (500 MHz, pyridine-d5) δ 13,06 (s, 1H), of 9.30 (d, 1H), 8,44 (d, 1H), to 8.41 (DD, 1H), of 8.37 (d, 1H), 8,12 (d, 1H), to 7.67 (d, 2H), 7,44 (d, 2H), 7,07 (d, 2H), 7,00 (d, 1H), 6.75 in (DD, 1H), 6,53 (d, 1H), of 6.49 (DD, 1H), 3,36-of 3.43 (m, 1H), 3,02-to 3.09 (m, 4H), 2,87-to 2.94 (m, 1H), 2,77 (s, 2H), 2,47 (d, 4H), of 2.25 (t, 2H), 2,11-of 2.16 (m, 4H), 2,08 (d, 2H), 1,97 (s, 2H), 1,84 (d, 2H), 1.39 in (t, 2H), 1,26-of 1.35 (m, 4H), 0,90-0,98 (m, 8H), from 0.50 to 0.56 (m, 4H), 0,18-0,23 (m, 4H).

EXAMPLE 65

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-methylpiperidin-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 65A

4-((1-methylpiperidin-4-yl)methylamino)-3-nitrobenzenesulfonamide

Specified in the title compound was obtained by replacing 4-aminomethyl-1-methylpiperidine (tetrahydropyran-4-yl)methylamine in example 1F.

EXAMPLE V

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[(1-methylpiperidin-4-yl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 65A of the program of example 130C in example 130D.

1H NMR (500 MHz, dichloromethane-d2) to 9.57 δ (user.s, 1H), 8,78 (d, 1H), to 8.41 (d, 1H), 8,14 (d, 1H), of 7.90 (m, 2H), to 7.64 (d, 1H), 7,45 (d, 1H), 7.23 percent (d, 2H), 6,95 (d, 2H), 6,76 (d, 1H), 6,59 (DD, 1H), 6,51 (d, 1H), 6,09 (d, 1H), 3,21 (m, 2H), is 3.08 (m, 4H), to 3.02 (m, 2H), 2,74 (s, 2H), 2,33 (s, 3H), 2.21 are 2,17 (m, 6H), 2,16-2,02 (m, 3H), 1,97 (user.,s, 2H), 1,78 (m, 4H), of 1.41 (t, 2H), were 0.94 (s, 6H).

EXAMPLE 66

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(morpholine-3-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 66A

Tert-butyl 3-((2-nitro-4-sulfhemoglobinemia)methyl)morpholine-4-carboxylate

Specified in the title compound was obtained by replacing tert-butyl-3-(aminomethyl)morpholine-4-carboxylate (tetrahydropyran-4-yl)methylamine in example 1F.

EXAMPLE 66B

Tert-butyl 3-((4-(N-(2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)benzoyl)sulfamoyl)-2-nitrophenylamino)methyl)morpholine-4-carboxylate

Specified in the title compound was obtained by replacing the compound of example 66A compound of example 1F and the compound of example 3J for compound of example 1E in example 1F, except that the product was purified on a column of silica gel, elwira 4% methanol in dichloromethane.

EXAMPLE 66C

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(morpholine-3-ylmethyl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b] is iridin-5-yloxy)benzamide

A solution of compound of example 66B in a mixture of 50% triperoxonane acid and dichloromethane was stirred at ambient temperature for 2 hours. The solvents are evaporated and the residue was purified by reversed-phase HPLC using a gradient of 20-80% acetonitrile in water containing 10 mm ammonium acetate.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ of 11.61 (s, 1H), charged 8.52 (user.s, 1H), 8,49 (d, 1H), 7,98 (d, 1H), 7,78 (d, 1H), 7,54 (d, 1H), 7,46 (s, 1H), 7,42 (s, 1H), 7,34 (d, 2H),? 7.04 baby mortality (m, 3H), of 6.65 (DD, 1H), 6,34 (s, 1H), 6,21 (d, 1H), 3,89 (d, 1H), 3,76 (d, 1H), 3,55-of 3.46 (m, 2H), 3,40-to 3.35 (m, 4H), 3.04 from (m, 4H), 2.91 in (t, 1H), 2,73 (s, 2H), 2,20-2,12 (m, 6H), 1,95 (s, 2H), 1,38 (t, 2H), 0,92 (s, 6H).

EXAMPLE 67

4-(4-{[4-(4-chlorophenyl)-6,6-dimethyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-({4-[(4-methylpiperazin-1-yl)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 1G, substituting the compound of example 1E and compound of example 1F connection example 15H and the compound of example 6A, respectively.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ 11,58 (s, 1H), 9,04 (s, 1H), 8,44 (d, 1H), of 7.97 (d, 1H), 7,76 (DD, 1H), 7,49 (m, 4H), 7,38 (d, 2H), 7,14 (d, 2H), only 6.64 (DD, 1H), 6,34 (d, 1H), 6,21 (d, 1H), 4,12 (s, 2H), 3,03 (m, 6H), 2,85 (m, 5H), to 2.29 (m, 4H), to 2.18 (m, 6H), of 1.20 (s, 6H).

EXAMPLE 68

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-albut-2-inyl)oxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]p is ridin-5-yloxy)benzamide

EXAMPLE 68A

4-morpholino-2-in-1-ol

To a solution of the research (4,36 g) in toluene (15 ml) was added 4-harbut-2-in-1-ol (2,09 g) in toluene (5 ml). The solution was stirred at 85°C for 3 hours. After cooling, the solid was filtered. The filtrate was subjected to vacuum distillation to obtain pure specified in the connection header.

EXAMPLE V

4-(4-morpholino-2-ynyloxy)-3-nitrobenzenesulfonamide

Specified in the title compound was obtained by replacing the compound of example 68A (tetrahydro-2H-Piran-4-yl)methanol in example 24A.

EXAMPLE 68

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-albut-2-inyl)oxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 68B compound of example 11B in example 11D.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,68 (s, 1H), at 8.36 (s, 1H), 8,08 (d, 1H), 8,03 (d, 1H), 7,47-7,53 (m, 4H), 7,35 (d, 2H),? 7.04 baby mortality (d, 2H), to 6.67 (DD, 1H), 6,40 (DD, 1H), of 6.20 (d, 1H), further 5.15 (s, 2H), 3,52-3,55 (m, 4H), to 3.09 (s, 4H), 2,84 (user. s, 2H), 2,23-to 2.40 (m, 6H), 2,12-to 2.18 (m, 2H), 1,96 (s, 2H), 1.39 in (t, 2H), 0,92 (s, 6H).

EXAMPLE 69

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-ethinyl-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 69A

6-((tetrahydro-2H-Piran-4-the l)methoxy)-5-((triisopropylsilyl)ethinyl)pyridine-3-sulfonamide

The compound of example 36B (0,176 g) chloride bis(triphenylphosphine)palladium(II) (0,176 g), copper iodide(I) (0,010 g), N,N-dimethylacetamide (2.5 ml) and triethylamine (0,105 ml) were combined, and treated with a stream of nitrogen and was stirred for 2 minutes. Added (triisopropylsilyl)acetylene (is 0.135 ml) and the reaction mixture was again treated with a stream of nitrogen, was heated at 60°C overnight, diluted with ethyl acetate, washed with water and brine, dried (MgSO4), filtered, concentrated and subjected to chromatography on silica gel with 10-30% ethyl acetate in hexane as eluent to obtain the product.

EXAMPLE 69B

5-ethinyl-6-((tetrahydro-2H-Piran-4-yl)methoxy)pyridine-3-sulfonamide

Compound 69A (0,205 g) in tetrahydrofuran (3 ml) at ambient temperature was treated with tetrabutylammonium fluoride (1 M in tetrahydrofuran, 0,906 ml) and stirred at ambient temperature for 4 hours. Was added tetrabutylammonium fluoride (1 M in tetrahydrofuran, 1.8 ml) and the mixture was heated at 40°C for 45 minutes. Added solid tetrabutylammonium fluoride (0,253 g) and heating was continued for 30 minutes. The reaction mixture was concentrated, and then subjected to chromatography on silica gel using 0-2% methanol in dichloromethane as eluent to obtain the product.

EXAMPLE 69

4-(4-{[2-(4-chlorophenyl)-4,4-dimetallic ohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[5-ethinyl-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing the compound of example 69B compound of example 11B in example 11D.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ of 11.69 (s, 1H), 11,41 (s, 1H), 8,58 (d, 1H), 8,19 (d, 1H), with 8.05 (d, 1H), 7,53 (m, 3H), 7,35 (d, 2H),? 7.04 baby mortality (d, 2H), to 6.67 (DD, 1H), 6,41 (DD, 1H), 6,18 (d, 1H), 4,56 (s, 1H), 4,24 (d, 2H), a 3.87 (DD, 2H), to 3.38 (m, 3H), of 3.07 (m, 4H), of 2.86 (m, 2H), to 2.29 (m, 5H), 2,04 (m, 3H), 1,64 (DD, 2H), of 1.34 (m, 4H), of 0.93 (s, 6H).

EXAMPLE 70

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-oxo-3,4-dihydroquinazolin-6-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 70A

4-amino-3-cyanobenzenesulfonyl

3-cyano-4-torbenson-1-sulfonyl chloride (1.1 g) was dissolved in dioxane (4 ml). The solution was cooled to 0°C and was added 7 ml of a solution of ammonia (7 N in methanol). After complete addition, the ice bath was removed and the reaction mixture was stirred at room temperature for 24 hours. After concentration of the reaction mixture, the crude material was purified flash chromatography, elwira gradient of 30-100% ethyl acetate/hexane.

EXAMPLE 70B

2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-(4-amino-3-cyanobenzylidene)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)benzamid

Specified in the title compound was obtained by replacing the compound of example 70A compound of example 1F and the compound of example 3J for compound of example 1E in example is 1G.

EXAMPLE 70C

2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-N-(4-amino-3-carbamoylmethyl)-4-(4-((2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)benzamid

To a solution of compound of example 70B (90 mg) in ethanol (2 ml) was added tetrahydrofuran (2 ml), hydrogen peroxide (30%, 1 ml) and 1 M sodium hydroxide solution (of 0.48 ml), and then an additional 2 ml of tetrahydrofuran. The reaction mixture was heated to 45°C for 30 minutes, cooled, and then extinguished 5% HCl solution and was extracted twice with dichloromethane. The extracts were combined and concentrated to obtain the product.

EXAMPLE 70D

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-oxo-3,4-dihydroquinazolin-6-yl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

The compound of example 70C (80 mg) was combined with triethylorthoformate (2.3 ml) and triperoxonane acid (0,03 ml) and the resulting solution was stirred at room temperature for 4 hours. The mixture was purified flash chromatography, elwira gradient of 3-10% methanol/dichloromethane.

1H NMR (300 MHz, dimethylsulfoxide-d6) δ was 12.61 (s, 1H), 11,71 (s, 1H), 8,65 (d, 1H), 8,24 (s, 1H), 8,17 (DD, 1H), 8,04 (m, 1H), 7,73 (d, 1H), EUR 7.57 (d, 1H), 7,51 (m, 2H), 7,39 (d, 2H), 7,07 (d, 2H), 6,70 (DD, 1H), 6,40 (m, 1H), 6,24 (user. s, 1H), 3,61 (m, 6H), 3,03 (m, 2H), 2,75 (m, 2H), 2,17 (m, 2H), 2,01 (m, 2H), 1,44 (m, 2H), were 0.94 (s, 6H).

EXAMPLE 71

TRANS-4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}Pipa is Azin-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 71A

8 harsper[4.5]Dec-7-EN-7-carbaldehyde

To a solution of Ν,Ν-dimethylformamide (2,81 ml) in dichloromethane (40 ml) drip was added POCl3(2,78 ml) at 0°C. the Reaction mixture was heated to room temperature and drip added Spiro[4.5]Decan-8-he (3,95 g) in dichloromethane (5 ml). The mixture was stirred over night. The reaction mixture was extinguished cold aqueous solution of sodium acetate and the resulting mixture was extracted with simple ether and the organic layer was dried over Na2SO4, filtered and concentrated to obtain specified in the connection header.

EXAMPLE 71B

8-(4-chlorophenyl)Spiro[4.5]Dec-7-ene-7-carbaldehyde

To a suspension of compound of example 71A (3 g) in water (50 ml) was added 4-Chlorfenvinphos acid (2.83 g), tetrabutylammonium (4,87 g), potassium carbonate (6,26 g) and palladium(II) acetate (0,169 g). The reaction mixture was stirred at 45°C for 5 hours and was extracted with dichloromethane. The organic layer was concentrated and the residue was applied onto a column of silica gel, and was suirable 5-20% ethyl acetate in hexane to obtain specified in the connection header.

EXAMPLE 71C

Methyl-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-(4-((8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl)methyl)piperazine-1-yl)benzoate

To a solution of compound of example 71B (274 mg) in dichloroethane (3.5 ml) was added the compound of example 15F (387 mg) and triacetoxy the reed sodium (317 mg). The reaction mixture was stirred over night. Added cyanoborohydride sodium (37.6 mg) and the resulting mixture was stirred over night. The reaction mixture was extinguished with water and diluted with dichloromethane. The mixture was thoroughly washed with water and the organic layer was dried over Na2SO4, filtered and concentrated to obtain specified in the connection header.

EXAMPLE 71D

2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-(4-((8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl)methyl)piperazine-1-yl)benzoic acid

Specified in the title compound was obtained as described in example 3J, using the compound of example 71C instead of the compound of example 3I.

EXAMPLE 71E

TRANS-4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-({4-[(4-morpholine-4-illlogical)amino]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 11D, using the compound of example 71D and the compound of example 9C instead of the compound of example 3J and compound of example 11B, respectively.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,64 (s, 1H), 8,51 (s, 1H), 8,15 (d, 1H), 8,01 (d, 1H), 7,76 (d, 1H), 7,44-7,53 (m, 3H), 7,34 (d, 2H), 7,07 (d, 3H), of 6.66 (DD, 1H), 6,37 (DD, 1H), of 6.20 (d, 1H), 3,50-3,70 (m, 5H), 3.04 from (s, 4H), 2,55 was 2.76 (m, 5H), 2,34-2,39 (m, 1H), 2,20 (d, 6H), 2,03 (s, 4H), 1.91 a (s, 2H), 1,61 (square, 4H) and 1.51 (t, 2H), 1,36 of 1.46 (m, 8H).

EXAMPLE 72

CIS-4-(4-{[4-(4-chlorophenyl)-6,6-d is methyl-5,6-dihydro-2H-Piran-3-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 11D, using the compound of example 15H and 29A instead of the compound of example 3J and compound of example 11B, respectively.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ of 11.69 (s, 1H), of 11.45 (s, 1H), 8,59 (t, 1H), 8,56 (d, 1H), 8,04 (d, 1H), 7,79 (DD, 1H), 7,54 (d, 1H), 7,47-7,52 (m, 2H), 7,37 (d, 2H), 7,13 (d, 2H), was 7.08 (d, 1H), of 6.68 (DD, 1H), 6,35-6.42 per (m, 1H), to 6.19 (d, 1H), 4,11 (s, 2H), 3,37 (s, 1H), 3,26 (t, 2H), 3,20 (s, 3H), of 3.07 (s, 4H), and 2.83 (s, 2H), 2,17 (d, 6H), is 1.81 (DD, 2H), 1,64-of 1.73 (m, 1H), 1,48 (DD, 2H), 1,23-of 1.41 (m, 4H), of 1.18 (s, 6H).

EXAMPLE 73

4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-({4-[(4-Porterage-2H-Piran-4-yl)methoxy]-3-nitrophenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 11D, using the compound of example 7ID compounds of example 37D instead of the compound of example 3J and compound of example 11B, respectively.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ 11,68 (s, 1H), of 8.37 (s, 1H), 7,98-8,11 (m, 2H), to 4.38 (d, 2H), 3,74-3,82 (m, 2H), 3,54-to 3.64 (m, 2H), 3,44 (s, 1H), is 3.08 (s, 3H), 2,58-2,89 (m, 2H), 2.13 and to 2.35 (m, 4H), 2,04 (s, 2H), 1,78-of 1.93 (m, 4H), 1,57-of 1.65 (m, 4H), of 1.52 (t, 2H), about 1.36 to 1.47 (m, 4H).

EXAMPLE 74

TRANS-4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-[(4-{[(4-methoxycyclohexyl)methyl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in the application is e 11D, using the compounds of example 71D and compounds of example 34B instead of the compound of example 3J and compound of example 11B, respectively.

1H NMR (500 MHz, dimethylsulfoxide-d6) δ of 11.69 (s, 1H), is 11.39 (s, 1H), 8,58 (t, 1H), 8,56 (d, 1H), 8,04 (d, 1H), 7,79 (DD, 1H), 7,47-of 7.55 (m, 3H), 7,34 (d, 2H), 7,07 (d, 3H), of 6.68 (DD, 1H), to 6.39 (DD, 1H), to 6.19 (d, 1H), 3,25 (t, 2H), up 3.22 (s, 3H), 3,06 (s, 5H), 2,71 (s, 2H), of 2.21 (s, 6H), 1,94-to 2.06 (m, 4H), to 1.79 (d, 2H), 1,57-of 1.65 (m, 5H) and 1.51 (t, 2H), 1.39 in (t, 4H), 0.95 to-1,11 (m, 4H).

EXAMPLE 75

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

EXAMPLE 75A

Methyl-5,5-dimethyl-2-(tripterocalyx)cyclohex-1-enecarboxylate

Specified in the title compound was obtained by replacing 4,4-dimethyl-2-methoxycarbonylamino 5,5-dimethyl-2-methoxycarbonylamino in example 3A.

EXAMPLE 75B

Methyl-2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enecarboxylate

Specified in the title compound was obtained by replacing the compound of example 75A compound of example 3A example 3B.

EXAMPLE 75S

(2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enyl)methanol

Specified in the title compound was obtained by replacing the compound of example 75B compound of example 3B example 3C.

EXAMPLE 75D

2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-interbanded

The solution is connected to the I example 75S (2.8 g) in dichloromethane (50 ml) was added periodinane dess-Martin (of 5.68 g). The reaction mixture was stirred at room temperature for 3 hours and diluted simple ether and promille 5% NaOH and brine. The organic layer was dried over Na2SO4, filtered and concentrated. The residue was purified flash chromatography using 20% ethyl acetate in hexane to obtain specified in the connection header.

EXAMPLE 75E

Methyl-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)benzoate

Specified in the title compound was obtained by replacing 4'-chlorobiphenyl-2-carboxaldehyde connection example 75D and tert-butyl piperazine-1-carboxylate compound of example 15F in example 1A.

EXAMPLE 75F

2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)-4-(4-((2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-enyl)methyl)piperazine-1-yl)benzoic acid

Specified in the title compound was obtained as described in example 15H, replacing the compound of example 15G connection example 75E.

EXAMPLE 75G

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 11D, using the compound of example 75F and compounds of example 1F instead of the compound of example 3J and compound of example 11B, sootvetstvenno is.

1H NMR (400 MHz, dimethylsulfoxide-d6) δ of 11.69 (s, 1H), 11,38 (s, 1H), at 8.60 (t, 1H), 8,56 (d, 1H), 8,04 (d, 1H), 7,80 (DD, 1H), 7,47-of 7.55 (m, 3H), 7,31 and 7.36 (m, 2H), 7,05-7,13 (m, 3H), of 6.68 (DD, 1H), to 6.39 (DD, 1H), 6,18 (d, 1H), 3,85 (DD, 2H), 3,22-of 3.31 (m, 4H), of 3.07 (s, 4H), 2,67-2,78 (m, 2H), 2,19 (s, 6H), 1,82-to 1.98 (m, 3H), 1.56 to of 1.66 (m, 2H), 1.39 in (t, 2H), by 1.17 and 1.33 (m, 3H), of 0.93 (s, 6H).

EXAMPLE 76

4-(4-{[2-(4-chlorophenyl)-5,5-dimethylcyclohex-1-EN-yl]methyl}piperazine-1-yl)-N-{[5-cyano-6-(tetrahydro-2H-Piran-4-ylethoxy)pyridine-3-yl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 11D, using the compound of example 75F and compounds of example 36C instead of the compound of example 3J and compound of example 11B, respectively.

1H NMR (400 MHz, dimethylsulfoxide-d6) δ are 11.62 (s, 1H), 8,73 (s, 1H), charged 8.52 (s, 1H), 7,98 (d, 1H), 7,56 (d, 1H), 7,45-7,51 (m, 1H), 7,43 (s, 1H), 7,37 (d, 2H), 7,10 (d, 2H), of 6.68 (DD, 1H), 6.35mm (DD, 1H), and 6.25 (s, 1H), 4,29 (d, 2H), 3,88 (DD, 2H), 3,12 (d, 4H), of 2.21 (s, 2H), 2,00-2,11 (m, 1H), 1,95 (s, 2H), 1,64 (DD, 2H), 1,27 of 1.46 (m, 4H), of 0.95 (s, 6H).

EXAMPLE 77

Tert-butyl-3-{[4-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-nitrophenoxy]methyl}morpholine-4-carboxylate

EXAMPLE 77A

Tert-butyl 3-((2-nitro-4-sulfamoylbenzoic)methyl)morpholine-4-carboxylate

Specified in the title compound was obtained as described in example 12A, replacing (1,4-dioxane-2-yl)methanol tert-bout the l-3-(hydroxymethyl)morpholine-4-carboxylate.

EXAMPLE 77B

Tert-butyl-3-{[4-({[4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzoyl]amino}sulfonyl)-2-nitrophenoxy]methyl}morpholine-4-carboxylate

Specified in the title compound was obtained as described in example 11D, using the compound of example 77A instead of the compound of example 11B.

1H NMR (400 MHz, dimethylsulfoxide-d6) δ 11,67 (s, 1H), at 8.36 (s, 1H), 8,01-8,11 (m, 2H), 7,47-to 7.61 (m, 4H), 7,35 (d, 2H),? 7.04 baby mortality (d, 2H), of 6.68 (DD, 1H), to 6.39 (d, 1H), of 6.20 (s, 1H), to 4.41-to 4.52 (m, 2H), 4,15-to 4.28 (m, 1H), 3,59-3,95 (m, 3H), 3,51 (d, 1H), 3,34-of 3.43 (m, 1H), 3,10 (s, 5H), 2,84 (s, 2H), 2,28 (s, 4H), of 2.15 (s, 2H), 1,96 (s, 2H), 1,20-of 1.45 (m, 12H), to 0.92 (s, 6H).

EXAMPLE 78

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-{[4-(morpholine-3-ylethoxy)-3-nitrophenyl]sulfonyl}-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

The compound of example 77B (100 mg) in dichloromethane (10 ml) at 0°C was treated triperoxonane acid (5 ml) for 20 minutes. The reaction mixture was concentrated. The residue was purified by reversed-phase HPLC on a C18 column using a gradient of 35% to 60% acetonitrile in 0.1% triperoxonane acid in water to obtain specified in the title compounds as the salts triperoxonane acid. Salt triperoxonane acid was dissolved in dichloromethane (10 ml) and washed with 50% aqueous solution of NaHCO3. The organic layer was dried over anhydrous Na2O 4and concentrated to obtain specified in the connection header.

1H NMR (400 MHz, dimethylsulfoxide-d6) δ to 11.56 (s, 1H), 8,23 (d, 1H), 7,94 (d, 1H), of 7.90 (DD, 1H), EUR 7.57 (d, 1H), 7,42-7,46 (m, 1H), 7,31-7,37 (m, 3H), 7,25 (d, 1H), 7,01-to 7.09 (m, 2H), only 6.64 (DD, 1H), 6,29-6,37 (m, 1H), 6,24 (d, 1H), 4,17-or 4.31 (m, 2H), 3,90-of 4.05 (m, 1H), of 3.77-of 3.85 (m, 1H), 3,45-3,59 (m, 4H), 2,94-3,13 (m, 6H), was 2.76 (s, 2H), 2,18 (d, 6H), to 1.96 (s, 2H), 1.39 in (t, 2H), 0,93 (s, 6H).

EXAMPLE 79

4-(4-{[8-(4-chlorophenyl)Spiro[4.5]Dec-7-EN-7-yl]methyl}piperazine-1-yl)-N-({3-nitro-4-[(tetrahydro-2H-Piran-4-ylmethyl)amino]phenyl}sulfonyl)-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained as described in example 11D, using the compound of example 71D and the compound of example 1F instead of the compound of example 3J and compound of example 11B, respectively.

1H NMR (400 MHz, dimethylsulfoxide-d6) δ of 11.69 (s, 1H), 11,38 (s, 1H), at 8.60 (t, 1H), 8,56 (d, 1H), 8,04 (d, 1H), to 7.77-to 7.84 (m, 1H), 7,45-7,56 (m, 3H), 7,34 (d, 2H),? 7.04 baby mortality-7,13 (m, 3H), of 6.68 (DD, 1H), to 6.39 (d, 1H), to 6.19 (d, 1H), 3,85 (DD, 2H), 3,22-of 3.31 (m, 4H), of 3.07 (s, 4H), 2,71 (s, 2H), of 2.21 (s, 6H), 2,03 (s, 2H), 1,81-of 1.94 (m, 1H), 1.56 to its 1.68 (m, 6H) and 1.51 (t, 2H), 1,34-of 1.45 (m, 4H), of 1.20 and 1.33 (m, 2H).

EXAMPLE 80

4-(4-{[2-(4-chlorophenyl)-4,4-dimethylcyclohex-1-EN-1-yl]methyl}piperazine-1-yl)-N-[(4-{[1-(methylsulphonyl)piperidine-4-yl]amino}-3-nitrophenyl)sulfonyl]-2-(1H-pyrrolo[2,3-b]pyridine-5-yloxy)benzamide

Specified in the title compound was obtained by replacing 1-(met